<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">

 <title>TmmGeek</title>
 <link href="http://lanyon.getpoole.com/atom.xml" rel="self"/>
 <link href="http://lanyon.getpoole.com/"/>
 <updated>2015-11-02T17:20:34-06:00</updated>
 <id>http://lanyon.getpoole.com</id>
 <author>
   <name>TmmGeek</name>
   <email>davidliangtmm@gmail.com</email>
 </author>

 
 <entry>
   <title>Bleeding and Thrombotic Disorders</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/10/30/laboratory-medicine-text-chapter11/"/>
   <updated>2015-10-30T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/10/30/laboratory-medicine-text-chapter11</id>
   <content type="html">&lt;p id=&quot;beginning&quot;&gt;&lt;/p&gt;

&lt;p&gt;Chapter 11: Bleeding and Thrombotic Disorders&lt;/p&gt;

&lt;p&gt;Elizabeth M. Van Cott; Michael Laposata&lt;/p&gt;

&lt;p&gt;Learning Objectives&lt;/p&gt;

&lt;p&gt;1.Learn the basic molecular events in clot formation and fibrinolysis.&lt;/p&gt;

&lt;p&gt;2.Understand the basic classification of disorders in hemostasis.&lt;/p&gt;

&lt;p&gt;3.Identify the appropriate laboratory tests for evaluation of the bleeding patient and the thrombotic patient.&lt;/p&gt;

&lt;p&gt;4.Learn the prominent clinical and laboratory features of the individual disorders of hemostasis.&lt;/p&gt;

&lt;p&gt;The coagulopathies are grouped into disorders of bleeding and thrombosis. The hemorrhagic diseases are further subdivided into the 2 major categories of coagulation factor disorders and platelet disorders. To understand the diseases with abnormal coagulation that follow, a brief introduction to normal hemostasis precedes the discussions of the diseases.&lt;/p&gt;

&lt;h2 id=&quot;introduction-to-hemostasis&quot;&gt;Introduction to Hemostasis&lt;/h2&gt;

&lt;p&gt;Normal hemostasis is the controlled activation of coagulation factors and platelets leading to clot formation, with subsequent clot lysis, in a process that stops hemorrhage without excess clotting (thrombosis). Effective hemostasis is a rapid and localized response to an interruption in vascular integrity (vessel wall injury), such that clots are formed only when and where they are needed.&lt;/p&gt;

&lt;h3 id=&quot;clot-formation&quot;&gt;Clot Formation&lt;/h3&gt;

&lt;p&gt;Clot formation involves platelet activation and the subsequent generation of fibrin via the coagulation cascade. The 2 processes are discussed separately in the sections that follow.&lt;/p&gt;

&lt;h3 id=&quot;platelet-plug-formation&quot;&gt;Platelet Plug Formation&lt;/h3&gt;

&lt;p&gt;Platelet plug formation is initiated in vivo by exposure of platelets to vascular subendothelium when a vessel is injured. The platelets adhere to the subendothelium, spread out along the surface, and release substances that promote the aggregation of other platelets at that site. The platelets also accelerate fibrin clot formation by providing a reactive surface for several steps in the coagulation cascade.&lt;/p&gt;

&lt;p&gt;Clot formation involves platelet activation and the subsequent generation of fibrin via the coagulation cascade.&lt;/p&gt;

&lt;p&gt;Adhesion of platelets to the subendothelial surface is facilitated by a plasma protein, von Willebrand factor (vWF), especially in vessels with high shear forces (eg, the fast blood flow in arteries has a higher shear force than slow blood flow in veins). vWF binds to a specific receptor on the platelet surface. Deficiency of vWF results in poor adherence of platelets to subendothelium. The severity of bleeding in von Willebrand disease (vWD) varies widely among patients. Another related platelet adhesion defect occurs in patients whose platelets lack the receptor for vWF. This bleeding disorder, known as Bernard–Soulier disease, results from an inability of platelets to bind vWF.&lt;/p&gt;

&lt;p&gt;Platelet activation occurs from interaction of platelet agonists, most of which are soluble, with specific receptors on the platelet membrane. Physiologically important agonists include adenosine diphosphate (ADP), thrombin, epinephrine, collagen, and thromboxane A2, which is derived from arachidonic acid. A sequence of membrane and cytoplasmic events is initiated by the agonist–receptor interaction, involving an increase in cytoplasmic calcium ion concentration and a platelet shape change from a disc to a spiny sphere. The change in cytoplasmic calcium concentration leads to contractile events in the platelet, causing alpha and delta granules (also known as dense bodies) to fuse with the platelet plasma membrane and release their granule contents into the extracellular space. Successful granule release requires the formation of thromboxane A2 from endogenous arachidonate via the enzyme cyclooxygenase. This enzyme is inhibited irreversibly by aspirin and inhibited reversibly by a number of other anti-inflammatory agents. Treatment with aspirin can cause a platelet secretion defect (reduced release of granule contents) that is often clinically significant in patients with underlying coagulopathies. Alpha granules contain vWF, fibrinogen, Factor V, 2 platelet-specific proteins—platelet factor 4 (PF4) and beta–thromboglobulin—as well as a number of other proteins. Delta granules contain serotonin, adenosine triphosphate (ATP), ADP, pyrophosphate, polyphosphate, and calcium. The release of some of these substances, in particular ADP, activates unstimulated platelets nearby. Absence or deficiency of alpha or delta granules occurs as a feature of several congenital and acquired platelet function disorders, collectively known as storage pool disorders. Individuals whose platelets possess appropriate numbers of intact granules that cannot be released on appropriate stimulation have a platelet release defect, and on that basis also may have a bleeding tendency. Aspirin is a common cause of a platelet release defect, because it impairs thromboxane production.&lt;/p&gt;

&lt;p&gt;Release of platelet granule contents is followed by platelet aggregation, that is, the binding of platelets to one another to form the platelet plug. Normal aggregation requires fibrinogen binding to platelets via the fibrinogen receptor, which is the glycoprotein IIb/IIIa complex (GP IIb/IIIa), on the platelet surface. Congenital absence of GP IIb/IIIa results in a bleeding diathesis known as Glanzmann thrombasthenia (GT).&lt;/p&gt;

&lt;p&gt;The platelet surface serves as a site for certain coagulation pathway enzyme reactions (see below). For example, the platelet membrane can bind the Factor Xa/Factor Va complex that activates prothrombin to thrombin. Thus, platelet activation and fibrin formation via the coagulation cascade are interactive biological processes.&lt;/p&gt;

&lt;h3 id=&quot;fibrin-clot-formation&quot;&gt;Fibrin Clot Formation&lt;/h3&gt;

&lt;p&gt;The coagulation factor pathway is an enzymatic cascade with sequential conversion of proenzymes (zymogens) to fully activated enzymes, which then convert other zymogens to their activated forms (Figure 11–1). The final steps directly preceding fibrin formation can be activated through both the intrinsic and extrinsic pathways; hence, this part of the pathway is called the common pathway. Numerous positive and negative feedback mechanisms exist in the coagulation pathways so that the cascades do not proceed in an uncontrolled fashion. The pathways are now known to be extremely complex, with multiple interactions between factors in the intrinsic, extrinsic, and common pathways. The following description is a version of coagulation factor interactions that highlights the fundamental reactions.&lt;/p&gt;

&lt;p&gt;Figure 11–1&lt;/p&gt;

&lt;p&gt;The coagulation cascade. α-KAL, alpha-Kallikrein; PK, prekallikrein; HK, high-molecular-weight kininogen; PL, phospholipid.&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t1.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;The coagulation cascade is activated by the appearance of tissue factor (also historically known as Factor III), which is not normally exposed. Tissue factor is presented when a blood vessel is injured. It binds with Factor VII and small amounts of circulating active Factor VII (Factor VIIa), resulting in a complex of Factor VII or VIIa and tissue factor. The Factor VII in the complex can be autoconverted to Factor VIIa, resulting in a greater number of Factor VIIa–tissue factor complexes. This complex activates Factor IX to Factor IXa in the intrinsic pathway, with some activation of Factor X to Factor Xa in the common pathway. Factor IXa, with support from Factor VIII as a cofactor (or Factor VIIIa, which is a much more effective cofactor), activates Factor X to Factor Xa. Factor Xa with the assistance of Factor V or, more effectively Factor Va, converts prothrombin (Factor II) to thrombin (Factor IIa). At this point, the coagulation cascade is markedly amplified because thrombin activates Factor VIII to Factor VIIIa, a more effective cofactor, and activates Factor V to its more effective Factor Va form. In addition, thrombin activates Factor XI to Factor XIa, which, like Factor VIIa and tissue factor, activates Factor IX to Factor IXa. Thrombin catalyzes the conversion of fibrinogen to fibrin, which is then cross-linked by Factor XIII to create a stabilized form of fibrin (clot). Factor XIII is also activated to Factor XIIIa by thrombin.&lt;/p&gt;

&lt;p&gt;Factor XII, prekallikrein (PK), and high-molecular-weight kininogen (HMWK, shown as HK in Figure 11–1) are not required for the generation of fibrin in vivo because even when they are completely absent, there is no increased risk for bleeding. Nevertheless, the intrinsic pathway is activated when Factor XII contacts collagen (exposed by vessel injury) or polyphosphate (released from activated platelets).&lt;/p&gt;

&lt;p&gt;This cascade, as it is currently understood and described above, explains 2 long-standing clinical observations. First, it explains the significant bleeding tendency associated with Factors VIII and IX deficiencies because these factors are important in the early stages of cascade amplification. Factor VIIa and tissue factor activate Factor IX to Factor IXa, and Factor IXa requires Factor VIII to convert Factor X to Factor Xa. Second, this scheme provides an explanation for the clinical observation that deficiencies of Factor XII, PK, and HMWK are not associated with an increased risk for bleeding because Factor VIIa/TF activates Factor IX, and thrombin activates Factor XI, bypassing the need for Factor XII.&lt;/p&gt;

&lt;p&gt;Two of the coagulation cascade reactions occur on the platelet surface. The first of these is the activation of Factor X to Factor Xa, which is produced by platelet-bound Factor IXa and platelet-bound Factor VIIIa. In the second, platelet-bound Factor Xa and platelet-bound Factor Va convert prothrombin (Factor II) to thrombin (Factor IIa) in a subsequent step in the coagulation sequence. As noted below, single factor deficiency states, most of which are congenital, exist for all of the factors, but multiple factor deficiencies, which are usually not congenital, are much more commonly encountered. Inhibitors, as antibodies directed against a specific coagulation factor, can arise to any of the individual factors to create deficiency states. With some exceptions, most factor inhibitors are rare.&lt;/p&gt;

&lt;p&gt;There are 2 major inhibitory pathways that determine the rate at which the cascade is amplified. One of these is the protein C–protein S anticoagulant pathway. An additional mechanism for control of the coagulation cascade involves the inhibitory action of antithrombin.&lt;/p&gt;

&lt;p&gt;There are 2 major inhibitory pathways that determine the rate at which the cascade is amplified. One of these is the protein C–protein S anticoagulant pathway (Figure 11–2). As shown in the figure, excess thrombin, which is generated through the activation of the coagulation cascade, provides the signal to shut off the coagulation cascade by binding to a protein on the endothelial surface known as thrombomodulin. The thrombin/thrombomodulin complex converts protein C into its activated form. The activated protein C then binds free protein S as a cofactor. Protein S may be bound to C4b-binding protein and to a limited number of other proteins, in which case protein S becomes inactive. Once free (unbound) protein S binds to activated protein C, the activated protein C/protein S complex then proteolytically degrades Factors Va and VIIIa, reducing the flux through the coagulation cascade by removing these 2 activated cofactors. A mutation in the Factor V molecule, known as the Factor V Leiden mutation, makes Factor V resistant to proteolytic degradation by the activated protein C/protein S complex. This condition is known as activated protein C resistance. This permits the prothrombotic action of Factor Va to persist and contribute to a hypercoagulable state.&lt;/p&gt;

&lt;p&gt;Figure 11–2&lt;/p&gt;

&lt;p&gt;The protein C–protein S anticoagulant pathway. TM, thrombomodulin. (Redrawn with permission from Van Cott EM, Laposata M. Laboratory evaluation of hypercoagulable states.Hematol Oncol Clin North Am. 1998;12:1141–1166.)&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;View Full Size&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Favorite Figure&lt;/td&gt;
      &lt;td&gt;Download Slide (.ppt)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;An additional mechanism for control of the coagulation cascade involves the inhibitory action of antithrombin (formerly known as antithrombin III) (Figure 11–3). Antithrombin has a limited anticoagulant effect on its own, but in the presence of heparin or selected other negatively charged heparin-like molecules, antithrombin adopts a new conformation that increases its inhibitory activity 1000-fold, permitting it to inhibit most of the activated coagulation factors in complexes where both antithrombin and heparin bind to the activated coagulation factor. Inhibition of Factor Xa, however, does not require the direct binding of the activated coagulation factor by heparin. Factor Xa can be neutralized when it is bound only to antithrombin, after antithrombin has been activated by heparin or related molecule. The antithrombotic action of short chains of heparin (low-molecular-weight heparin) is directed primarily against Factor Xa because short heparin chains inhibit predominantly only Factor Xa (longer chains are required for Factor IIa inhibition). Fondaparinux, a synthetic heparin-related pentasaccharide, inhibits Factor Xa exclusively.&lt;/p&gt;

&lt;p&gt;Figure 11–3&lt;/p&gt;

&lt;p&gt;The anticoagulant action of antithrombin. AT, antithrombin. (Modified with permission from Kabakibi A, et al. The hypercoagulable state.Turnaround Times [a newsletter for physicians at the Massachusetts General Hospital, Boston]. 1994;3:1:1.)&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;View Full Size&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Favorite Figure&lt;/td&gt;
      &lt;td&gt;Download Slide (.ppt)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;It should be noted that all of the coagulation factors in the coagulation cascade are synthesized in the liver, and that the activity of Factors II, VII, IX, and X is vitamin K-dependent. Tissue factor is constitutively expressed on some cell types, and in other cell types, such as endothelial cells, it is not normally expressed. There is little (if any) tissue factor in the circulating plasma under normal conditions. It is not exclusively synthesized in the liver. Tissue factor in the subendothelium is exposed to blood when blood vessels are injured, triggering the extrinsic pathway of the coagulation cascade. The half-lives of the coagulation factors in the blood vary markedly, with Factor VII showing the shortest half-life of approximately 5 hours and Factor XIII having the longest half-life of more than 120 hours. There is also a wide range of plasma concentrations for the coagulation factors. Factor VII is in the lowest concentration of the circulating coagulation factors at 100 to 500 ng/mL. The highest concentration is found for fibrinogen at 200 to 400 mg/dL.&lt;/p&gt;

&lt;p&gt;Fibrinolysis&lt;/p&gt;

&lt;p&gt;Fibrinolysis is the controlled dissolution of the formed clot. It occurs when the injured vessel begins to heal, and is initiated to a limited extent when clot formation begins. In this way, fibrinolysis serves as a regulatory mechanism to limit excess clot formation.&lt;/p&gt;

&lt;p&gt;Fibrinolysis is the controlled dissolution of the formed clot. It occurs when the injured vessel begins to heal, and is initiated to a limited extent when clot formation begins. In this way, fibrinolysis serves as a regulatory mechanism to limit excess clot formation.&lt;/p&gt;

&lt;p&gt;The principal enzyme involved in fibrinolysis is plasmin, which exists in a zymogen form known as plasminogen (Figure 11–4). Plasminogen is converted into plasmin by tissue plasminogen activator (tPA). Plasmin degrades the fibrin clot. A recombinant form of tPA is used as a pharmacologic agent to produce thrombolysis (breakdown of a thrombus), in patients with myocardial infarction or stroke, and clots elsewhere in the body. Clinically effective derivatives of tPA from genetic manipulation are also used for thrombolysis. tPA is released by endothelial cells, and its secretion into the plasma is increased by thrombin. Plasminogen activator inhibitors are secreted by platelets and endothelial cells, particularly when they are activated. Plasminogen activator inhibitors stabilize a newly formed clot by blocking the action of tPA, thereby preventing premature dissolution of the clot. Plasmin degrades fibrin polymers, and, to a limited degree, fibrinogen as well, by specific and sequential proteolytic cleavages, generating fibrin degradation products (FDP). These FDP (fragments X, Y, D, D-dimer, and E) may be detected in the plasma of patients experiencing fibrinolysis. Deficiency of plasminogen may predispose to thrombosis, and deficiency of plasminogen activator inhibitor may increase the risk for bleeding. Antiplasmin inhibits plasmin, but only when it is circulating and not when it is clot-bound. This prevents the circulation of a proteolytically active form of plasmin, while permitting clot lysis to proceed by plasmin within the clot. Deficiency of antiplasmin may result in a hemorrhagic tendency.&lt;/p&gt;

&lt;p&gt;Figure 11–4&lt;/p&gt;

&lt;p&gt;The fibrinolytic pathway. A plus sign indicates that tissue plasminogen activator converts plasminogen into plasmin. A minus sign indicates inhibitory action. (Redrawn with permission from Kabakibi, A et al. The hypercoagulable state.Turnaround Times [a newsletter for physicians at the Massachusetts General Hospital, Boston]. 1994;3:1:1.)&lt;/p&gt;

&lt;h2 id=&quot;bleeding-disorders&quot;&gt;Bleeding Disorders&lt;/h2&gt;

&lt;p&gt;Figure 11–5 provides a classification of coagulation disorders. The major division in the classification is between disorders associated with bleeding and disorders associated with thrombosis. There are 2 major subdivisions of bleeding disorders—those associated with coagulation factor and fibrinolytic pathway factor deficiencies, and those associated with an abnormal platelet count or impaired platelet function. Isolated factor deficiencies are usually congenital, although occasionally an isolated acquired factor deficiency develops. An example of an acquired isolated coagulation factor deficiency is the Factor X deficiency associated with amyloidosis. The deficiency of antiplasmin is listed in this section because its absence permits increased plasmin activity and overactive clot dissolution, resulting in a bleeding tendency. Another major category of coagulation factor abnormalities is multiple coagulation factor deficiencies. There are several commonly encountered situations associated with multiple factor deficiencies. These include vitamin K deficiency or warfarin intake (which results in a reduced amount of functional Factors II, VII, IX, and X as well as protein C and protein S); disseminated intravascular coagulation (DIC), which results in the consumption of multiple coagulation factors; and liver disease that results in decreased synthesis of coagulation factors. Several activated coagulation factors are inhibited by heparin. Heparin administration results in inactivation of most of the activated coagulation factors.&lt;/p&gt;

&lt;p&gt;Quantitative platelet disorders include thrombocytopenia and thrombocytosis. Qualitative platelet disorders are characterized by abnormal platelet function in the presence of a normal platelet count.&lt;/p&gt;

&lt;p&gt;Figure 11– 
A classification of coagulation disorders 
View Full Size  | 
Favorite Figure  |  Download Slide (.pp)&lt;/p&gt;

&lt;h3 id=&quot;quantitative-platelet-disorders-and-qualitative-platelet-disorders&quot;&gt;quantitative platelet disorders and qualitative platelet disorders&lt;/h3&gt;

&lt;p&gt;The group of disorders associated with platelets is divided first into quantitative platelet disorders and qualitative platelet disorders. Quantitative platelet disorders include thrombocytopenia and thrombocytosis. Thrombocytopenia can be produced as a result of increased platelet destruction, from a variety of immune or nonimmune causes, or decreased platelet production. Common causes of decreased platelet production include tumor infiltration of bone marrow from metastases or a hematologic malignancy, and drug-induced thrombocytopenia as occurs with chemotherapy. Thrombocytopenia can also occur as a result of increased sequestration of platelets in the spleen, usually in patients with splenomegaly. Thrombocytosis is much less common than thrombocytopenia. Thrombocytosis can be divided into reactive thrombocytosis, in which there is a transiently increased number of platelets froma stimulus to increase platelet production, or neoplastic thrombocytosis, as seen in myeloproliferative disease and, less commonly, myelodysplastic disorders.&lt;/p&gt;

&lt;p&gt;Qualitative platelet disorders are characterized by abnormal platelet function in the presence of a normal platelet count. vWD is a disorder in which there is defective platelet function, but from a defect originating outside the platelet, since vWF is generated primariy in endothelial cells. vWF coats the surface of the activated platelet to allow it to adhere to the cut vessel surface and initiate platelet plug formation.&lt;/p&gt;

&lt;p&gt;Other causes of defective platelet function result from abnormalities within the platelet. These disorders may be congenital or acquired. The congenital ones are extremely rare, and the acquired ones are very frequently encountered. Congenital platelet abnormalities associated with defective function include GT, Bernard–Soulier disease, and storage pool disease (SPD). The much more common acquired qualitative platelet disorders include drug-induced platelet dysfunctin, such as produced by aspirin and clopidogrel (Plavix), and uremia-induced platelet dysfunction, which occurs in patients with impaired renal function.&lt;/p&gt;

&lt;h3 id=&quot;fibrinogen-deficiencies&quot;&gt;Fibrinogen Deficiencies&lt;/h3&gt;

&lt;p&gt;Description&lt;/p&gt;

&lt;p&gt;Fibrinogen is produced in the liver by hepatocytes. Abnormalities of fibrinogen production may be congenital or acquired and, in general, involve either decreased production of a normal molecule (afibrinogenemia and hypofibrinogenemia) or production of an abnormal molecule (dysfibrinogenemia) (see Table 11–1).&lt;/p&gt;

&lt;p&gt;Table 11–1   Laboratory Evaluation for Fibrinogen Deficiencies&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t6.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;h4 id=&quot;congenital-afibrinogenemia-and-hypofibrinogenemia&quot;&gt;congenital afibrinogenemia and hypofibrinogenemia&lt;/h4&gt;

&lt;p&gt;In congenital afibrinogenemia and hypofibrinogenemia, there is a reduced (hypofibrinogenemia) or absent (afibrinogenemia) production of a normal fibrinogen molecule. In general, the homozygous deficiency results in afibrinogenemia, and the heterozygous state results in hypofibrinogenemia. Both disorders are rare. Homozygotes suffer a mild-to-moderate spontaneous bleeding tendency. Manifestations include umbilical stump hemorrhage and bleeding from mucous membranes, among many other possible signs and symptoms related to blood loss. Severe bleeding may occur with trauma or surgery. Hypofibrinogenemic patients are usually asymptomatic, but may bleed significantly with surgery or trauma.&lt;/p&gt;

&lt;p&gt;Congenital dysfibrinogenemia is a result of inheritance of a gene for an abnormal fibrinogen molecule, which is produced in normal or near-normal quantities. All the fibrinogen produced by a homozygote for dysfibrinogenemia is abnormal, and approximately half of the fibrinogen in a heterozygote is abnormal. Hundreds of abnormal fibrinogens have been described. The true incidence of dysfibrinogenemia is not known because many forms of the disorder are asymptomatic. Homozygotes may have a mild bleeding tendency, perhaps because the fibrinogen molecule is cleaved too slowly to form fibrin monomers or because abnormal fibrin monomers polymerize too slowly. The bleeding tendency is characterized by easy or spontaneous bruising, menorrhagia, and prolonged or severe bleeding with surgery or trauma. Heterozygotes are usually asymptomatic, but may show excessive bleeding with surgery or trauma. Several types of dysfibrinogenemia (approximately 10%-15% of cases) are associated with an increased risk of thrombosis rather than bleeding. A few types of congenital dysfibrinogenemia are associated with both bleeding and thrombosis.&lt;/p&gt;

&lt;p&gt;Acquired hypofibrinogenemia is observed predominantly in patients with advanced liver disease, in patients with a consumptive coagulation disorder such as DIC, and in those treated with thrombolytic therapy.&lt;/p&gt;

&lt;p&gt;Acquired dysfibrinogenemia represents the acquired production of an abnormal fibrinogen molecule in normal or near-normal quantities, most often in patients with acute or chronic liver disease, especially those with primary or metastatic hepatic malignancies. The patient may or may not be symptomatic, depending on 1) whether there is simultaneous production of normal fibrinogen in amounts sufficient to allow normal hemostasis and 2) whether the abnormal fibrinogen can polymerize like a normal fibrinogen molecule (see the section “Hemostatic Abnormalities in Liver Disease”).&lt;/p&gt;

&lt;h5 id=&quot;diagnosis&quot;&gt;Diagnosis&lt;/h5&gt;

&lt;p&gt;See Table 11–1 for the laboratory evaluation of the patient with a fibrinogen deficiency.&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t6.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;h3 id=&quot;prothrombin-factor-ii-deficiency&quot;&gt;Prothrombin (Factor II) Deficiency&lt;/h3&gt;

&lt;h5 id=&quot;description&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Prothrombin (Factor II) is the precursor to thrombin (Factor IIa), which converts fibrinogen into fibrin in the common pathway of the coagulation cascade. Deficiency of prothrombin, either inherited or acquired, may result in a hemorrhagic diathesis. Inherited abnormalities of prothrombin are rare. As with fibrinogen, abnormalities occur in 2 major forms. The first is reduced or absent production of a normal prothrombin molecule. The second is production of normal amounts of an abnormal prothrombin molecule with decreased activity (dysfunctional form or dysprothrombinemia). Heterozygotes usually have approximately 50% of normal activity and may be asymptomatic or have a bleeding tendency. In 1 study, 83% of a small cohort of heterozygotes had bleeding, with Factor II levels ranging from 21% to 35%. Homozygotes usually have 1% to 25% of normal activity and have a mild-to-severe hemorrhagic tendency. Acquired hypoprothrombinemia occurs most often along with deficiencies of Factors VII, IX, and X in vitamin K deficiency and with warfarin (Coumadin) therapy; with deficiencies of multiple coagulation factors in liver disease or DIC; as an isolated coagulation factor deficiency in some patients with lupus anticoagulant (LA); and in patients exposed to topical bovine thrombin who develop antibodies to prothrombin (and not uncommonly to Factor V also). Bleeding manifestations depend on the level of prothrombin activity; usually no bleeding occurs with a prothrombin level &amp;gt;50% of normal.&lt;/p&gt;

&lt;p&gt;Abnormalities occur in 2 major forms. The first is reduced or absent production of a normal prothrombin molecule. The second is production of normal amounts of an abnormal prothrombin molecule with decreased activity (dysfunctional form or dysprothrombinemia).&lt;/p&gt;

&lt;h4 id=&quot;diagnosis-1&quot;&gt;Diagnosis&lt;/h4&gt;

&lt;p&gt;See Table 11–2 for the laboratory evaluation of the patient with a prothrombin (Factor II) deficiency.&lt;/p&gt;

&lt;p&gt;Table 11–2   Laboratory Evaluation for Coagulation Factor Deficiencies 
View Large |&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t7.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t8.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;h3 id=&quot;factor-v-deficiency&quot;&gt;Factor V Deficiency&lt;/h3&gt;

&lt;h5 id=&quot;description-1&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Factor V is a high-molecular-weight protein (approximately 300,000 Da) that acts as an accelerating cofactor for the enzymatic conversion of prothrombin to thrombin by Factor Xa. When Factor V is cleaved to Factor Va by thrombin, its cofactor activity is significantly increased. Factors Va and VIIIa are degraded by activated protein C. An isolated deficiency of Factor V is a rare cause of bleeding.&lt;/p&gt;

&lt;p&gt;Apparent heterozygous and homozygous deficient states have been observed. Heterozygotes usually have levels of approximately 50% of normal and can experience bleeding or may be asymptomatic. In a cohort of 19 heterozygous patients, 50% had bleeding, with Factor V levels ranging from 21% to 55%. Homozygotes have variable levels below 50%; they are most likely to be symptomatic if the level is 10% or less.&lt;/p&gt;

&lt;h6 id=&quot;combined-deficiency-of-factors-v-and-viii&quot;&gt;combined deficiency of Factors V and VIII&lt;/h6&gt;

&lt;p&gt;As with the other coagulation factors, 2 major forms of the inherited deficiency are described: reduced or absent production of a normal Factor V molecule (absence form) and production of an abnormal molecule with reduced activity in normal amounts (dysfunctional form). A rare combined deficiency of Factors V and VIII is due to a genetic defect in intracellular transport of Factors V and VIII. Acquired deficiencies of Factor V occur with liver dysfunction or DIC.&lt;/p&gt;

&lt;h5 id=&quot;diagnosis-2&quot;&gt;Diagnosis&lt;/h5&gt;

&lt;p&gt;See Table 11–2 for the laboratory evaluation of the patient with a Factor V deficiency.&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t7.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t8.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;h3 id=&quot;factor-vii-deficiency&quot;&gt;Factor VII Deficiency&lt;/h3&gt;

&lt;h5 id=&quot;description-2&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Factor VII is a vitamin K-dependent coagulation factor precursor that, when activated by thrombin, Factor Xa, or Factor IXa, is converted to Factor VIIa. This activated factor then converts phospholipid-bound Factor X into Factor Xa in the presence of calcium and tissue factor. It also converts Factor IX to Factor IXa. Factor VII deficiency may occur as an inherited or acquired disorder.&lt;/p&gt;

&lt;p&gt;The inherited deficiency state, which is rare, may be present as reduced or absent production of a normal molecule (absence form) or production of an abnormal molecule with decreased activity in normal amounts (dysfunctional form). An inherited isolated deficiency of Factor VII in heterozygotes is usually associated with a Factor VII activity level of approximately 50%. In a cohort of 88 heterozygous patients, 36% had a bleeding tendency, with Factor VII levels ranging from 21% to 69%. In homozygotes, there are variable Factor VII activity levels below 50%. The bleeding risk is difficult to predict in these patients because the factor activity level correlates poorly with the patient’s tendency to hemorrhage, but in general values &amp;lt;10% can be associated with major spontaneous bleeding. A large proportion of patients with less than 2% Factor VII do not bleed. Acquired Factor VII deficiency occurs in vitamin K deficiency and with warfarin therapy along with deficiencies of Factors II, IX, and X; and in DIC or liver disease along with multiple other coagulation factor deficiencies.&lt;/p&gt;

&lt;p&gt;The bleeding risk is difficult to predict because the factor VII activity level correlates poorly with the patient’s tendency to hemorrhage. A large proportion of patients with less than 2% Factor VII do not bleed.&lt;/p&gt;

&lt;p&gt;Intracranial hemorrhage has been reported in Factor VII-deficient patients, most often occurring in infants &amp;lt;1 year of age. Elevated Factor VII levels have been associated with an increased risk of cardiovascular disease.&lt;/p&gt;

&lt;h5 id=&quot;diagnosis-3&quot;&gt;Diagnosis&lt;/h5&gt;

&lt;p&gt;See Table 11–2 for the laboratory evaluation of the patient with a Factor VII deficiency.&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t7.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t8.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;h3 id=&quot;hemophilia-a-factor-viii-deficiency&quot;&gt;Hemophilia A (Factor VIII Deficiency)&lt;/h3&gt;

&lt;h5 id=&quot;description-3&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Hemophilia A is a bleeding disorder resulting from a deficiency of Factor VIII procoagulant activity. Factor VIII circulates in the plasma bound to vWF. Approximately 90% of patients with hemophilia A synthesize low amounts of normal Factor VIII molecules, and 10% of patients with hemophilia A synthesize normal amounts of an abnormal (nonfunctional) Factor VIII. Hemophilia A is inherited as an X-linked trait, and 65% to 75% of patients have a positive family history. Disease prevalence in the United States is 1 in 10,000 males; the carrier state in females is rarely symptomatic. Hemophilia A and hemophilia B (Factor IX deficiency, see below) are clinically indistinguishable. The likelihood of hemorrhage depends on the amount of Factor VIII present; the majority of patients (approximately 50%-70% of hemophilia A patients) have severe disease. The severity of disease is categorized as follows:&lt;/p&gt;

&lt;p&gt;*In mild disease: the VIII level is 6% to 20% of normal, with rare spontaneous bleeding&lt;/p&gt;

&lt;p&gt;*In moderate disease: the VIII level is 1% to 5% of normal, with occasional spontaneous bleeding&lt;/p&gt;

&lt;p&gt;*In severe disease: the VIII level is &amp;lt;1% of normal, with frequent spontaneous bleeding.&lt;/p&gt;

&lt;p&gt;Hemophilia A is a bleeding disorder resulting from a deficiency of Factor VIII procoagulant activity. Factor VIII inhibitors are antibodies, usually IgG, that bind to Factor VIII and inhibit its coagulant activity.&lt;/p&gt;

&lt;p&gt;All hemophilia patients (A and B) may experience severe hemorrhage following trauma or surgery if there is no prior treatment to elevate the factor level. Bleeding that is characteristic of hemophilia (A and B) includes intra-articular (joint), intracranial, and intramuscular hemorrhage. The latter can produce a compartment compression syndrome. Easy bruising and prolonged bleeding after minor cuts and abrasions are also characteristic. The onset of hemorrhage is typically delayed following injury, and pathologic bleeding may occur hours after injury. Primary hemostasis (dependent on platelet plug formation) is intact, but secondary hemostasis (dependent on the fibrin clot generated by the coagulation cascade) is defective. Up to 15% of hemophilia A patients develop an inhibitor to Factor VIII at some time during the course of their disease (ie, an antibody against Factor VIII). The inhibitor develops only in those transfused with Factor VIII-containing products, and most often in patients with &amp;lt;1% Factor VIII. Factor VIII inhibitors may also spontaneously occur rarely in nonhemophiliacs (see the section “Factor VIII Inhibitors”).&lt;/p&gt;

&lt;h5 id=&quot;diagnosis-4&quot;&gt;Diagnosis&lt;/h5&gt;

&lt;p&gt;See Table 11–2 for information regarding the laboratory evaluation for Factor VIII deficiency.&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t7.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t8.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Factor VIII Inhibitors&lt;/p&gt;

&lt;h5 id=&quot;description-4&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Factor VIII inhibitors are antibodies, usually IgG, that bind to Factor VIII and inhibit its coagulant activity.&lt;/p&gt;

&lt;p&gt;Factor VIII inhibitors have been found in several clinical situations.&lt;/p&gt;

&lt;p&gt;*Inhibitors are diagnosed most commonly in patients with hemophilia A. Inhibitors occur in 10% to 15% of these patients and make the treatment of hemorrhage much more difficult. The vast majority of cases of Factor VIII inhibitors in hemophilia A patients occur in those with severe hemophilia A (&amp;lt;1% Factor VIII activity). Inhibitor formation is related to transfusion of exogenous Factor VIII, and usually develops before 100 treatment days if it appears. Two immune response patterns have been observed in hemophilia A patients. The first is a high response pattern. Inhibitors rise to a high titer in response to exposure to Factor VIII. The titer may not decline for months to years, even without further exposure to Factor VIII. Rapid anamnestic responses are often seen within 3 to 7 days of reexposure in these patients. In the second pattern, there is a low response. In addition, inhibitors usually remain at a low titer despite reexposure. They may occasionally disappear and reappear spontaneously. Little, if any, anamnestic response is likely found in a low responder.&lt;/p&gt;

&lt;p&gt;*Spontaneous inhibitors to Factor VIII can occur in the postpartum patient. Usually they are recognized 2 to 5 months after the birth of the first child and disappear spontaneously after 12 to 18 months. However, the course is variable, and there are reports of death from hemorrhage in some patients. Antigenic differences between mother and fetus do not sufficiently explain the development of a Factor VIII inhibitor, and its cause remains unknown.&lt;/p&gt;

&lt;p&gt;Inhibitors may occur in those with allergic and enhanced immunologic reactions, including patients with:&lt;/p&gt;

&lt;p&gt;(a) Rheumatoid arthritis&lt;/p&gt;

&lt;p&gt;(b) Systemic lupus erythematosus&lt;/p&gt;

&lt;p&gt;(c) Reactions to drugs, such as penicillin, chloramphenicol, sulfonamides, and phenytoin&lt;/p&gt;

&lt;p&gt;(d) Malignancy&lt;/p&gt;

&lt;p&gt;(e) Asthma&lt;/p&gt;

&lt;p&gt;(f) Crohn disease&lt;/p&gt;

&lt;p&gt;(g) Ulcerative colitis&lt;/p&gt;

&lt;p&gt;(h) Pemphigus&lt;/p&gt;

&lt;p&gt;(i) Multiple myeloma&lt;/p&gt;

&lt;p&gt;*Inhibitors may appear in patients without any obvious underlying disorder. These are usually older individuals, and the inhibitor may remit in several months, persist for years, or disappear with immunosuppressive therapy.&lt;/p&gt;

&lt;p&gt;In a hemophilia A patient, a poor response to treatment with Factor VIII concentrate may be the first indication that an inhibitor is present, or there may be an increased frequency of bleeding episodes. In nonhemophiliacs, development of a new hemorrhagic tendency is usually the presenting feature of a spontaneous Factor VIII inhibitor. The most favorable prognoses are for patients with low titer inhibitors, peripartum women, and patients without an underlying disorder.&lt;/p&gt;

&lt;p&gt;Hemophilia B is an inherited hemorrhagic disorder resulting from a lack of procoagulant activity of Factor IX.&lt;/p&gt;

&lt;h5 id=&quot;diagnosis-5&quot;&gt;Diagnosis&lt;/h5&gt;

&lt;p&gt;See Table 11–3 for information regarding the laboratory evaluation for a Factor VIII inhibitor.&lt;/p&gt;

&lt;p&gt;Table 11–3   Laboratory Evaluation for Factor VIII Inhibitor 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;h3 id=&quot;hemophilia-b-factor-ix-deficiency&quot;&gt;Hemophilia B (Factor IX Deficiency)&lt;/h3&gt;

&lt;h5 id=&quot;description-5&quot;&gt;Description&lt;/h5&gt;

&lt;h6 id=&quot;inheritance-is-sex-linked-with-affected-males-and-female-carriers&quot;&gt;Inheritance is sex-linked, with affected males, and female carriers&lt;/h6&gt;

&lt;p&gt;Hemophilia B is an inherited hemorrhagic disorder resulting from a lack of procoagulant activity of Factor IX. Factor IX is a vitamin K-dependent factor that, in its active form (Factor IXa), is a serine protease of the intrinsic pathway of the coagulation cascade. Approximately 70% to 90% of hemophilia B patients have a deficiency of a normal coagulant protein, and 10% to 30% produce an abnormal Factor IX that is nonfunctional. Inheritance is sex-linked, with affected males, and female carriers. Of hemophilia B patients, 60% to 70% have a positive family history for bleeding. The prevalence of hemophilia B is much less than that of hemophilia A. Approximately 1 in 50,000 males in the United States has hemophilia B versus 1 in 10,000 males with hemophilia A. The hemophilia B carrier state in the female is usually asymptomatic, as is the case with hemophilia A. Acquired Factor IX deficiency may occur along with deficiencies of Factors II, VII, and X in patients with vitamin K deficiency or those receiving warfarin therapy, and with deficiencies of other coagulation factors in patients with liver disease, DIC, or nephrotic syndrome.&lt;/p&gt;

&lt;p&gt;As previously noted, hemophilia B is clinically indistinguishable from hemophilia A. The severity of hemorrhage depends on the amount of Factor IX activity present:&lt;/p&gt;

&lt;p&gt;*In mild disease: 6% to 20% of normal IX activity is present, with rare spontaneous bleeding.&lt;/p&gt;

&lt;p&gt;*In moderate disease: 1% to 5% of normal IX activity is present, with occasional spontaneous bleeding.&lt;/p&gt;

&lt;p&gt;*In severe disease: &amp;lt;1% of normal activity is present, with frequent spontaneous bleeding.&lt;/p&gt;

&lt;p&gt;Profuse bleeding may occur in any hemophilia B patient with trauma or surgery if there is no prior treatment to elevate the factor level. Bleeding in hemophilia B resembles that found in hemophilia A and includes deep tissue bleeding, intra-articular bleeding (hemarthrosis), intracranial bleeding (which may be lethal), and intramuscular bleeding with potential compartment compression syndrome. Severe mucosal membrane bleeding can occur in hemophilia, particularly after dental surgery.&lt;/p&gt;

&lt;p&gt;Inhibitors develop to Factor IX in 1% to 5% of hemophilia B cases. These antibodies often occur in high titer and frequently present a major bleeding problem despite treatment.&lt;/p&gt;

&lt;h5 id=&quot;diagnosis-6&quot;&gt;Diagnosis&lt;/h5&gt;

&lt;p&gt;See Table 11–2 for information regarding the laboratory evaluation for patients with hemophilia B.&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t7.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t8.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;h3 id=&quot;factor-x-deficiency&quot;&gt;Factor X Deficiency&lt;/h3&gt;

&lt;h5 id=&quot;description-6&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;An inherited isolated deficiency of Factor X is a rare disorder. Homozygotes and heterozygotes have been identified. Homozygotes usually possess &amp;lt;2% of normal activity. Heterozygotes usually possess 40% to 70% of normal activity. In a cohort of 15 heterozygous patients, 33% had a bleeding tendency, with Factor X levels ranging from 23% to 47%. Patients with Factor X values &amp;lt;10% can have a high risk of spontaneous major bleeding, and those with &amp;gt;40% are usually asymptomatic. Inherited Factor X deficiency, like the other factor deficiency states, occurs in 2 major forms: reduced or absent synthesis of a normal molecule (absence form) and synthesis of an abnormal molecule in normal amounts (dysfunctional form).&lt;/p&gt;

&lt;p&gt;Acquired Factor X deficiency may result from warfarin or vitamin K deficiency (in the presence of deficiencies of Factors II, VII, and IX), from liver disease (with deficiencies of other factors synthesized in the liver), with DIC, or as an isolated deficiency in cases of amyloidosis. In amyloidosis, Factor X becomes irreversibly bound to amyloid fibrils in the extracellular space, and is thereby removed from the circulation.&lt;/p&gt;

&lt;h5 id=&quot;diagnosis-7&quot;&gt;Diagnosis&lt;/h5&gt;

&lt;p&gt;See Table 11–2 for information regarding the laboratory evaluation of patients with Factor X deficiency.&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t7.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t8.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Factor XI Deficiency&lt;/p&gt;

&lt;h5 id=&quot;description-7&quot;&gt;Description&lt;/h5&gt;

&lt;h6 id=&quot;reduced-or-absent-production-of-a-normal-molecule-is-the-main-cause&quot;&gt;reduced or absent production of a normal molecule is the main cause&lt;/h6&gt;

&lt;p&gt;Factor XI deficiency is a commonly encountered disorder. Homozygotes typically have less than 20% of normal Factor XI activity. Heterozygotes have 20% to 70% of normal Factor XI activity. The deficiency in almost all cases appears to be a reduced or absent production of a normal molecule, rather than production of an abnormal or dysfunctional molecule.&lt;/p&gt;

&lt;h5 id=&quot;jewish-descent&quot;&gt;Jewish descent&lt;/h5&gt;

&lt;p&gt;The vast majority of the cases of Factor XI deficiency are in people of Jewish descent, particularly those of Ashkenazi origin. The frequency of the homozygous deficient state is 0.2% to 0.3% in the Ashkenazi population, and the frequency of the heterozygous state is extremely high, at approximately 5.5% to 11.0%.&lt;/p&gt;

&lt;p&gt;The hemorrhagic tendency is variable for both heterozygotes and homozygotes. Patients with Factor XI levels &amp;lt;15% to 20% uncommonly have spontaneous bleeding but frequently have postoperative bleeding, and patients with levels between 20% and 65% tend to be asymptomatic or have low rates of postoperative bleeding. Bleeding does not correlate well with the level of Factor XI activity. Some homozygotes have an abnormal partial thromboplastin time (PTT), a very low Factor XI level of less than 10%, and no bleeding, even with surgery. The bleeding tendency of a particular individual is more closely related to the bleeding tendency of the patient’s kindred than to the measured Factor XI level. The explanation, which is true for all mutations affecting coagulation factors, is that certain mutations produce a low level of Factor XI and a prolonged PTT but are not clinically significant in vivo. This is because they only affect the activity of the factor in the in vitro clotting factor assays, which are not exact replicas of clot formation in vivo. Acquired decreases in Factor XI can occur with pregnancy, proteinuria, liver dysfunction, and DIC.&lt;/p&gt;

&lt;h5 id=&quot;diagnosis-8&quot;&gt;Diagnosis&lt;/h5&gt;

&lt;p&gt;See Table 11–2 for information regarding the laboratory evaluation of patients with Factor XI deficiency.&lt;/p&gt;

&lt;h3 id=&quot;deficiencies-of-the-contact-factors&quot;&gt;Deficiencies of the Contact Factors&lt;/h3&gt;

&lt;h5 id=&quot;description-8&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;The contact coagulation factors (so named because they were originally thought to activate the coagulation cascade by contacting the cut surface of the vessel wall) include Factor XII, PK, and HMWK. A deficiency of any of the contact factors prolongs the PTT because the PTT assay is constructed to involve these factors, even though the coagulation cascade in vivo does not depend on these factors. Bleeding diatheses have not been reported in patients with deficiencies at any level of Factor XII, PK, or HMWK. Factor XII deficiency is fairly common, with many thousands affected, especially individuals of Asian descent and children with tonsillitis. HMWK deficiency and PK deficiency are rare.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–2 for information regarding the laboratory evaluation for contact factor abnormalities.&lt;/p&gt;

&lt;h3 id=&quot;factor-xiii-deficiency&quot;&gt;Factor XIII Deficiency&lt;/h3&gt;

&lt;h5 id=&quot;description-9&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Factor XIII circulates in plasma as a zymogen and is converted to its active form (Factor XIIIa) by thrombin. Factor XIIIa catalyzes the formation of covalent bonds between chains of adjacent fibrin monomers. This stabilizes the fibrin clot, making it rigid and more resistant to the action of plasmin. Congenital deficiency of Factor XIII is rare. The bleeding tendency in homozygotes is characterized by umbilical stump bleeding in newborns (&amp;gt;90% of patients with clinically significant Factor XIII deficiency have this finding), intracranial hemorrhage, miscarriages, and posttraumatic hematomas, with bleeding often delayed hours to days after the trauma. Patients with mild or moderate deficiencies might have mucocutaneous bleeding or be asymptomatic. Patients with Factor XIII levels above 30% are usually always asymptomatic.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–2 for information regarding the laboratory evaluation for Factor XIII deficiency.&lt;/p&gt;

&lt;h3 id=&quot;antiplasmin-deficiency&quot;&gt;Antiplasmin Deficiency&lt;/h3&gt;

&lt;h5 id=&quot;description-10&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Antiplasmin or plasmin inhibitor (formerly known as alpha-2 antiplasmin) is a glycoprotein (GP) that serves as a regulator of fibrinolysis in several ways (see Figure 11–4). It blocks the enzymatic activity of plasmin (the major fibrinolytic enzyme) and other serine proteases, some of which are coagulation factors, and it inhibits the binding of plasminogen to fibrin. A bleeding diathesis is associated with the congenital deficiency of plasmin inhibitor. It is an extremely rare disorder and only homozygotes with &amp;lt;10% of normal plasmin inhibitor activity appear to be clinically affected. Those who do bleed may experience mucosal membrane bleeding (particularly in the genitourinary tract), subcutaneous hematomas, spontaneous bruising, and severe bleeding with trauma. Most heterozygotes are asymptomatic, but those few who are symptomatic have only a mild bleeding tendency. Acquired deficiency of plasmin inhibitor can occur in liver disease, nephrotic syndrome, amyloidosis, DIC, and, most notably, following thrombolytic therapy. In thrombolytic therapy, plasminogen is purposefully converted to plasmin, which results in the formation of plasmin–antiplasmin complexes, thereby reducing the amount of available antiplasmin.&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/textbook/laboratory\ medicine/chapter\ 11/t4.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;h5 id=&quot;diagnosis-9&quot;&gt;Diagnosis&lt;/h5&gt;

&lt;p&gt;See Table 11–4 for information on the laboratory evaluation of plasmin inhibitor deficiency.&lt;/p&gt;

&lt;p&gt;Table 11–4   Laboratory Evaluation for Antiplasmin Deficiency 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;h3 id=&quot;vitamin-k-deficiency&quot;&gt;Vitamin K Deficiency&lt;/h3&gt;

&lt;h5 id=&quot;description-11&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;In adults, vitamin K deficiency most often occurs secondary to disease or drug therapy; it rarely occurs as a dietary deficiency. Causes of vitamin K deficiency include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Warfarin therapy (reduces the amount of active vitamin K)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Antibiotic therapy (capable of suppressing bowel flora that synthesize vitamin K)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Malabsorption syndromes: cystic fibrosis, sprue, ulcerative colitis, Crohn disease, parasitic infections, short bowel syndrome, and ileojejunostomy for morbid obesity)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dietary restriction with incidental decrease in vitamin K intake&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Long-term total parenteral nutrition&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Biliary obstruction&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;In adults, vitamin K deficiency most often occurs secondary to disease or drug therapy; it rarely occurs as a dietary deficiency.&lt;/p&gt;

&lt;p&gt;Vitamin K depletion can occur in as little as 2 weeks if both intake (enteral and parenteral) and endogenous production of vitamin K are eliminated. In early deficiency, Factor VII only, or Factors VII and IX only, may be decreased due to their shorter half-lives. Vitamin K deficiency may present as an asymptomatic prolongation of the PT in mild cases or as a major spontaneous hemorrhage in severe deficiencies. The degree of prolongation of the PT does not accurately predict the risk of hemorrhage.&lt;/p&gt;

&lt;h5 id=&quot;certain-cephalosporins-produce-vitamin-k-deficiency-much-more-rapidly-than-other-antibiotics&quot;&gt;certain cephalosporins produce vitamin K deficiency much more rapidly than other antibiotics&lt;/h5&gt;

&lt;h5 id=&quot;cephalosporins-with-an-n-methylthiotetrazole-mtt-group-in-position-3-directly-inhibit-the-vitamin-k-dependent-carboxylase-that-is-responsible-for-converting-factors-ii-vii-ix-and-x-to-their-active-form&quot;&gt;Cephalosporins with an N-methylthiotetrazole (MTT) group in position 3 directly inhibit the vitamin K-dependent carboxylase that is responsible for converting Factors II, VII, IX, and X to their active form.&lt;/h5&gt;

&lt;p&gt;Most antibiotics destroy bacterial flora and must be considered as a possible cause of vitamin K deficiency in the bleeding patient. However, certain cephalosporins produce vitamin K deficiency much more rapidly than other antibiotics. Cephalosporins with an N-methylthiotetrazole (MTT) group in position 3 directly inhibit the vitamin K-dependent carboxylase that is responsible for converting Factors II, VII, IX, and X to their active form. Cephalosporins in the MTT group include cefamandole, cefoperazone, cefotetan, moxalactam, cefmetazole, and cefmenoxime. Weekly prophylaxis with vitamin K has been recommended when MTT-cephalosporins are given to patients at high risk for vitamin K deficiency.&lt;/p&gt;

&lt;h5 id=&quot;diagnosis-10&quot;&gt;Diagnosis&lt;/h5&gt;

&lt;p&gt;See Table 11–5 for information on the laboratory evaluation for vitamin K deficiency.&lt;/p&gt;

&lt;p&gt;Table 11–5   Laboratory Evaluation for Vitamin K Deficiency 
View Large |&lt;/p&gt;

&lt;h3 id=&quot;disseminated-intravascular-coagulation&quot;&gt;Disseminated Intravascular Coagulation&lt;/h3&gt;

&lt;h5 id=&quot;description-12&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;DIC is a common acquired coagulation disorder that occurs secondary to a variety of underlying disorders. The most common cause is infection; 10% to 20% of patients with gram-negative sepsis develop DIC. Other causes of DIC include obstetrical complications (retained dead fetus, placental abruption, amniotic fluid embolism, hypertonic saline-induced abortion, and septic abortion), extensive tissue injury (including trauma, ischemia, infarction, and burns), liver disease, transfusion of ABO-incompatible blood, and adult respiratory distress syndrome. The clinical presentation varies from an asymptomatic condition, detectable only by laboratory abnormalities, to a severe coagulopathy with a mortality of up to 80%.&lt;/p&gt;

&lt;p&gt;The major events in acute DIC, independent of the cause, are microvascular thrombosis with consumption of platelets and coagulation factors, and then hemorrhage as a result of low levels of platelets and coagulation factors and overactivation of the fibrinolytic system to remove the thrombi. Hemorrhagic symptoms can include any of the following—petechiae, ecchymoses, mucosal oozing, hematuria, gastrointestinal tract bleeding, bleeding into surgical wounds, and prolonged bleeding at venous access sites. Severe bleeding may contribute to hypotensive shock.&lt;/p&gt;

&lt;p&gt;DIC may present as a more chronic, low-grade condition in patients with malignancy. These patients are at risk for macrovascular (large vessel) thrombosis as well, most likely as a deep vein thrombosis.&lt;/p&gt;

&lt;p&gt;The prolongations of the PT and the PTT reflect a decrease in fibrinogen and other coagulation factors that are consumed by clotting. In addition, fibrinogen is degraded by excess plasmin activation in the fibrinolytic system. Platelets are also consumed, and, therefore, the platelet count is typically low. The presence of FDP(fibrin degradation product), 1 of which is the D-dimer, indicates that fibrin clots have been formed and subsequently degraded. There is no single laboratory test that can diagnose or exclude DIC, and the diagnosis is made when the characteristic laboratory abnormalities are present along with a known stimulus for DIC. A practical approach to diagnosis of DIC is to perform the PT, the PTT, and a D-dimer assay, with serial measurements of fibrinogen and platelets. In severe acute DIC, most of the laboratory test results will be abnormal, although fibrinogen may be normal or even elevated. In chronic DIC, the laboratory abnormalities may be less pronounced or even absent because the liver and bone marrow can increase production of coagulation factors and platelets, respectively, to offset the losses from consumption.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–6 for information on the laboratory evaluation for DIC.&lt;/p&gt;

&lt;p&gt;Table 11–6   Commonly Used Assays in the Laboratory Evaluation for Disseminated Intravascular Coagulation (DIC) 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;h3 id=&quot;hemostatic-abnormalities-in-liver-disease&quot;&gt;Hemostatic Abnormalities in Liver Disease&lt;/h3&gt;

&lt;h5 id=&quot;description-13&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Patients with acute and chronic liver disease often have laboratory evidence of a hemostatic abnormality. These patients may be asymptomatic or have only mild bleeding problems, but those with advanced liver disease may experience a severe hemorrhage.&lt;/p&gt;

&lt;p&gt;Hemorrhage in patients with liver disease may be due to 1 or more of the following:&lt;/p&gt;

&lt;p&gt;*Coagulation factor abnormalities: These are caused by decreased hepatic synthesis of vitamin K-dependent factors (II, VII, IX, and X) and non-vitamin K-dependent factors. Decreased fibrinogen is usually found only in patients with severe hepatic failure; in fact, patients with acute hepatitis without hepatic failure usually have an increased fibrinogen level&lt;/p&gt;

&lt;p&gt;*Thrombocytopenia: This frequently occurs as a consequence of sequestration in the spleen, impaired platelet production, or increased platelet destruction. 
It is not usually a severe decrease in platelet number&lt;/p&gt;

&lt;p&gt;*Platelet dysfunction: The dysfunction is usually mild and its clinical significance is uncertain; platelet dysfunction may be clinically important only in 
liver disease patients with severe thrombocytopenia or severe renal failure, which can result in uremia-induced platelet dysfunction&lt;/p&gt;

&lt;p&gt;*DIC or a DIC-like syndrome: There is no general agreement as to whether the coagulation abnormalities that occur in patients with liver disease are due to DIC, liver disease alone, or a combination of these and other mechanisms. A DIC-like syndrome occurs frequently in patients with acute hepatic failure.
Laboratory abnormalities in these cases include hypofibrinogenemia, thrombocytopenia, increased FDP such as D-dimer, and decreased levels of Factors V and 
VIII&lt;/p&gt;

&lt;p&gt;*Acquired dysfibrinogenemia (in patients with selected liver diseases [see the section “Fibrinogen Deficiencies”]): Impaired fibrin polymerization may result 
and thereby predispose the patient to bleeding&lt;/p&gt;

&lt;p&gt;*Increased fibrinolysis: Hemostatic abnormalities in patients with cirrhosis may be due to increased fibrinolysis. This may occur as a result of decreased 
hepatic clearance of plasminogen activators and decreased synthesis of inhibitors of fibrinolysis (see Figure 11–4).&lt;/p&gt;

&lt;p&gt;*Patients with acute and chronic liver disease often have laboratory evidence of a hemostatic abnormality. These patients may be asymptomatic or have only mild bleeding problems, but those with advanced liver disease may experience a severe hemorrhage.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;The laboratory evaluation for hemostatic defects from liver disease is shown in Table 11–7.&lt;/p&gt;

&lt;p&gt;Table 11–7   Laboratory Evaluation for Hemostatic Defects in Liver Disease 
View Large |&lt;/p&gt;

&lt;h3 id=&quot;immune-thrombocytopenic-purpura-itp&quot;&gt;Immune Thrombocytopenic Purpura (ITP)&lt;/h3&gt;

&lt;h5 id=&quot;description-14&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;ITP (where the I formerly stood for idiopathic) exists in both an acute and a chronic form. The disorder is one in which accelerated platelet destruction occurs in the absence of other causes such as DIC, thrombotic thrombocytopenic purpura (TTP), drug-induced thrombocytopenia, and neonatal thrombocytopenia. Platelet production is also often reduced.&lt;/p&gt;

&lt;p&gt;The destruction of platelets in ITP is antibody-mediated. The amount of platelet-associated IgG is increased in the majority of patients with acute and chronic ITP. Many patients with chronic ITP have increased levels of antiplatelet antibodies in the serum, as well as on the platelet surface. It should be noted that there are a host of disorders unrelated to immune thrombocytopenias, which are associated with increased IgG on the platelet surface. Helicobacter pylori infection has been associated with ITP.&lt;/p&gt;

&lt;p&gt;In acute ITP, the platelet may be an innocent target of an antipathogen antibody that cross-reacts with an epitope on the platelet membrane. Chronic ITP appears to be more of a classic autoimmune illness in which the target antigens for platelet autoantibodies are platelet GPs. Sequestration and destruction of antibody-coated platelets occur predominantly in the spleen.&lt;/p&gt;

&lt;p&gt;Acute ITP usually presents as a childhood illness with peak incidence between 2 and 9 years. It is heralded by a prodromal illness, such as a viral respiratory infection, in 60% to 80% of cases. The infection occurs 2 to 21 days prior to onset of thrombocytopenia. The risk of hemorrhage is greatest during the first 1 to 2 weeks after the onset of acute ITP. Intracranial hemorrhage is the most feared complication of ITP. The majority of patients experience a spontaneous resolution of acute ITP 3 weeks to 3 months after onset. A small percentage of patients do not recover fully after 12 months, and advance to a diagnosis of chronic ITP.&lt;/p&gt;

&lt;p&gt;Acute ITP usually presents as a childhood illness with peak incidence between 2 and 9 years. Chronic ITP occurs most commonly between the ages of 20 and 50 years, and in females more often than males.&lt;/p&gt;

&lt;p&gt;Chronic ITP occurs most commonly between the ages of 20 and 50 years, and in females more often than in males (ratio of 2:1 to 3:1). It is characterized by the absence of a prodromal illness and the presence of mild bleeding that may continue for months before medical attention is sought. Manifestations include scattered petechiae or purpura, mostly on distal extremities, mild mucosal bleeding, easy bruising, epistaxis, and menorrhagia. ITP is often discovered in an asymptomatic patient found to have a low platelet count as part of a complete blood count (CBC). The diagnosis of ITP is made only after ruling out other causes for an isolated thrombocytopenia by history, physical examination, and laboratory studies.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–8 for information on the laboratory evaluation for ITP.&lt;/p&gt;

&lt;p&gt;Table 11–8   Laboratory Evaluation for Immune Thrombocytopenic Purpura (ITP) 
View Large |&lt;/p&gt;

&lt;h3 id=&quot;drug-induced-immunologic-thrombocytopenia&quot;&gt;Drug-induced Immunologic Thrombocytopenia&lt;/h3&gt;

&lt;h5 id=&quot;description-15&quot;&gt;Description&lt;/h5&gt;

&lt;h6 id=&quot;innocent-bystander-effect&quot;&gt;innocent bystander” effect&lt;/h6&gt;

&lt;p&gt;Many drugs have been implicated in drug-induced immune thrombocytopenia. However, most cases can be attributed to relatively few drugs, notably heparin, quinidine/quinine, gold salts, and sulfonamides. Exposure to most of these compounds is readily ascertained. However, when obtaining the patient’s history, one should include inquiries regarding consumption of over-the-counter medications and topical medications, as well as soft drinks, mixers, and aperitifs to rule out exposure to quinine. The pathogenesis of thrombocytopenia for most drugs involves both the drug and IgG (as the predominant class of antibody involved). A plasma protein bound to the drug serves as the antigen; the antigen combines with a specific antibody, and this complex binds to the platelet membrane. This is known as an “innocent bystander” effect. The antibody-coated platelet is then sequestered and destroyed. Certain other drugs (eg, protamine, bleomycin, and ristocetin) can cause destruction of platelets by a direct toxic effect that is nonimmune. In heparin-induced thrombocytopenia (HIT), a complex of heparin and a circulating protein derived from the platelet, known as platelet factor 4 (PF4), acts as the antigen. The complex, along with bound antibody, binds to the platelet surface, causing platelet activation, and unlike other drug-induced thrombocytopenias, an increased risk for thrombosis.&lt;/p&gt;

&lt;p&gt;The true incidence of drug-induced immunologic thrombocytopenia is not known. The incidence varies with the drug in question and the clinical condition or treatment of the patient. It may be as high as 1% to 3% of people exposed to the drug, as is the case with unfractionated (standard) heparin. Of quinidine users, approximately 1 in 1000 develop symptomatic thrombocytopenia. Drug-induced immunologic thrombocytopenia occurs most commonly in patients more than 50 years old, but it also has been reported in infants less than 1 year old. It is not possible to predict that patients will develop thrombocytopenia from drug treatment.&lt;/p&gt;

&lt;p&gt;Ingestion of a drug that induces thrombocytopenia may produce flushing, fever, headache, and chills prior to onset of thrombocytopenia. The onset of thrombocytopenia may be abrupt following drug exposure or, if it requires antibody generation to lower the platelet count, it may be delayed for 4 to 15 days. Anamnestic responses may occur and if they arise, the delay is shorter. Bleeding may occur as early as 6 to 12 hours after exposure to the drug in highly responsive patients. Bleeding manifestations may include 1 or more of the following: petechiae, purpura (usually the first symptom), mucosal hemorrhagic bullae, gastrointestinal or genitourinary hemorrhage, intrapulmonary hemorrhage, and, lastly, intracranial hemorrhage, which is rare, but often lethal. HIT(heparin-induced thrombocytopenia) is unique in that bleeding is uncommon, and, as noted above, HIT patients are at risk for thrombosis rather than bleeding.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–9 for information on the laboratory evaluation for drug-induced immunologic thrombocytopenia. Laboratory tests for drug-induced thrombocytopenia are not routinely available, with the exception of testing for HIT. If HIT is considered, a platelet count should be performed first. If the platelet count decreases to 50% or less of its apparent baseline value, a test for antibodies to the heparin–PF4 complex or a functional test that shows platelet activation in the presence of heparin and the patient’s plasma should be performed.&lt;/p&gt;

&lt;p&gt;Table 11–9   Laboratory Evaluation for Drug-induced Immunologic Thrombocytopenia 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;h3 id=&quot;posttransfusion-purpura&quot;&gt;Posttransfusion Purpura&lt;/h3&gt;

&lt;h5 id=&quot;description-16&quot;&gt;Description&lt;/h5&gt;

&lt;h6 id=&quot;antigen-hpa-1a&quot;&gt;antigen HPA-1a&lt;/h6&gt;

&lt;p&gt;Posttransfusion purpura (PTP) is a rare syndrome characterized by the sudden onset of thrombocytopenia 7 to 10 days following transfusion of blood or blood products containing platelets or platelet material. The thrombocytopenia appears to be due to antibody-mediated destruction of autologous as well as transfused platelets. In over 90% of cases, the antibody that develops in the affected individuals is directed against the antigen HPA-1a, formerly known as P1A1, on platelet membrane GP IIIa. In these cases, the recipient’s own platelets are HPA-1a negative. It is not known why there is destruction of the patient’s own HPA-1a-negative platelets following platelet transfusion with HPA-1a-positive platelets. Only 2% to 3% of the population in the United States lacks this antigen. Antibodies against other platelet-specific antigens have been reported in PTP, but they are much less commonly encountered. In almost all cases, the development of anti-HPA-1a antibody is thought to be an anamnestic response, with prior sensitization occurring through previous transfusion or pregnancy.&lt;/p&gt;

&lt;p&gt;PTP occurs predominantly in females, perhaps due to the likelihood of sensitization through pregnancy. The interval between the first exposure to the HPA-1a antigen and the transfusion that incites the thrombocytopenia is greater than 3 years in most cases in which the information has been reported. The onset of thrombocytopenia is fulminant in most cases, with the platelet count decreasing to &amp;lt;10,000/μL. Hemorrhage usually begins with purpura and mucocutaneous bleeding, and may progress to gastrointestinal and genitourinary bleeding, epistaxis, oozing from intravenous access sites, and intracranial hemorrhage. In severely affected patients sustained with supportive therapy of red blood cells and/or platelets, the thrombocytopenia usually begins to resolve in 14 days (mean value with a range 1-35 days). Cases with less severe thrombocytopenia apparently require a longer recovery period (24 days average, range 6-70 days). The outcome is fatal in approximately 10% of cases, usually due to hemorrhage. The risk of fatal hemorrhage appears to be greatest at the onset of the disease. Recurrent PTP has been documented, with the recurrence appearing no sooner than 3 years after the first episode, even though antibody may persist in the patient’s blood during the intervening time and there may be repeated challenges with exogenous platelets.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–10 for information on the laboratory evaluation for PTP.&lt;/p&gt;

&lt;p&gt;Table 11–10   Laboratory Evaluation for Posttransfusion Purpura 
View Large |&lt;/p&gt;

&lt;h3 id=&quot;neonatal-alloimmune-thrombocytopenia-nait&quot;&gt;Neonatal Alloimmune Thrombocytopenia (NAIT)&lt;/h3&gt;

&lt;h5 id=&quot;description-17&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;NAIT is a disorder in which there is destruction of platelets in the fetus and newborn. The destruction occurs following transplacental passage of maternal IgG antibodies directed against a platelet-specific antigen present on fetal platelets and absent from the mother’s platelets. The antibody-coated platelets are removed from the circulation by the neonate’s reticuloendothelial system around the time of birth. The estimated incidence ranges from 1 in 5000 to 1 in 2000 births, with an increasingly higher incidence in recent years attributed to improved surveillance and serologic testing for the disorder. The platelet-specific antigen implicated in 80% to 90% of all cases (and 95% of symptomatic cases) of NAIT is HPA-1a. As previously noted, this antigen is present on the platelets of 97% to 98% of the general population. In approximately 50% of cases, NAIT occurs during the first pregnancy; when it does occur, there is a 97% chance that the next pregnancy will be affected.&lt;/p&gt;

&lt;p&gt;Affected newborns are usually the product of an otherwise uncomplicated pregnancy and delivery. Within hours after birth, petechiae and ecchymoses appear in a generalized distribution. Other clinical signs include neurologic abnormalities if intracranial hemorrhage occurs, and pallor from anemia, if the bleeding is severe. Intracranial hemorrhage is the leading cause of death in NAIT, with a 50% mortality. Overall mortality from NAIT is approximately 5% to 10%. Thrombocytopenia usually persists for approximately 2 weeks in untreated cases (range of 1 week to 2 months), and 1 week in treated cases.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–11 for information on the laboratory evaluation for NAIT.&lt;/p&gt;

&lt;p&gt;Table 11–11   Laboratory Evaluation for Neonatal Alloimmune Thrombocytopenia (NAIT) 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;p&gt;Discussions of TTP and hemolytic–uremic syndrome (HUS), which are thrombocytopenias associated with thrombosis, are presented among the thrombotic disorders.&lt;/p&gt;

&lt;h3 id=&quot;essential-thrombocythemia&quot;&gt;Essential Thrombocythemia&lt;/h3&gt;

&lt;h5 id=&quot;description-18&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Essential thrombocythemia is a chronic myeloproliferative disorder, characterized by thrombocytosis arising from the clonal proliferation of a neoplastic multipotent stem cell. Life expectancy can be essentially normal with a median survival of 10 to 15 years, but the disease course is frequently complicated by both hemorrhage and thrombosis. A small percentage (&amp;lt;5%) of patients progress to acute leukemia, predominantly those patients previously treated with radioactive phosphorus or alkylating agents to reduce their platelet counts. At the time of diagnosis using older criteria, mild splenomegaly occurs in 30% to 50% of patients, and hepatomegaly in 15% to 20%. Using 2008 WHO diagnostic criteria, splenomegaly is present in only a minority of patients at diagnosis. The incidence of the disorder is higher in older age groups.&lt;/p&gt;

&lt;p&gt;The principal diagnostic feature of essential thrombocythemia is a persistently elevated platelet count with bone marrow megakaryocyte hyperplasia. Patients with this disorder can progress to a “spent” phase, characterized by myelofibrosis and a low platelet count. The purpose of the laboratory testing is to eliminate other possible etiologies for the thrombocytosis. Other entities in the differential diagnosis of an elevated platelet count include reactive thrombocytosis and other myeloproliferative disorders—myelofibrosis, polycythemia vera, and chronic myelogenous leukemia.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–12 for information on the laboratory evaluation for essential thrombocythemia.&lt;/p&gt;

&lt;p&gt;Table 11–12   Laboratory Evaluation for Essential Thrombocythemia (ET) 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;h3 id=&quot;von-willebrand-disease&quot;&gt;von Willebrand Disease&lt;/h3&gt;

&lt;h5 id=&quot;description-19&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;vWD is caused by a quantitative deficiency of normal vWF in the majority of cases and a qualitatively abnormal vWF in the remainder of cases. vWF normally polymerizes to form multimers, which are aggregates of a single vWF polypeptide; in normal plasma, the multimers have a range of sizes. vWF has 2 major roles:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Platelet adhesion: Large multimers of vWF (ie, those with many units of the single polypeptide) effectively promote platelet adhesion to the subendothelium in injured vessels; if only small multimers are present, platelet plugs form poorly.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Binding of Factor VIII: vWF circulates in the plasma with Factor VIII, the coagulant protein that is lacking in hemophilia A. vWF prolongs the half-life of Factor VIII by protecting it from rapid degradation. If vWF is reduced, Factor VIII coagulant activity is often reduced as well.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;vWD prevalence estimates vary, with reported values as high as 1% of the general population. Unlike hemophilia A and B, vWD affects both men and women. It is likely to be the most common inherited bleeding disorder. There are 3 major types of vWD. The types were reorganized and renumbered with Arabic numerals in the 1990s (see Table 11–13). The most common type (type 1) is usually a mild bleeding disorder; it accounts for the majority of all cases of vWD. Type 2 vWD includes patients with qualitative vWF defects. Type 3 is rare and inherited as an autosomal recessive trait. It is associated with severe bleeding and very low to absent vWF levels. The types are distinguished from each other by laboratory testing.&lt;/p&gt;

&lt;p&gt;vWD prevalence estimates vary, with reported values as high as 1% of the general population. Unlike hemophilia A and B, vWD affects both men and women.&lt;/p&gt;

&lt;p&gt;Table 11–13   Classification of von Willebrand Disease (vWD) 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;p&gt;It should also be noted that the mean vWF levels vary with blood type as shown in the second portion of Table 11–14.&lt;/p&gt;

&lt;p&gt;Table 11–14   Laboratory Evaluation for von Willebrand Disease (vWD) 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;p&gt;More than 65% of patients with vWD have type O, presumably because patients with this blood type start from a lower baseline value for vWF.&lt;/p&gt;

&lt;p&gt;The severity of bleeding is highly variable among patients, even within the same subtype of vWD, and even within an individual patient over time. Typically, bleeding manifestations such as easy bruising or epistaxis begin in early childhood. Other manifestations include menorrhagia and mucous membrane bleeding (from the gingiva, oropharynx, and gastrointestinal and genitourinary tracts). Profuse hemorrhage may occur with a significant hemostatic challenge such as trauma or surgery.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;Laboratory test results vary with the type and subtype of vWD. Like the severity of bleeding, the laboratory values can also vary widely over time for an individual patient, and may sometimes be normal. Normal results from a single determination do not rule out the diagnosis. If the patient history strongly suggests vWD, and the test results are normal, the tests should be repeated at a later time because plasma levels for vWF are increased during pregnancy, stress, while receiving oral contraceptives, and during an acute illness or injury. Therefore, values obtained at these times may be unreliable for diagnosis. It is also not yet clear if the absolute level of vWF or the level relative to the mean vWF for the blood type of the patient is more important in establishing the diagnosis.&lt;/p&gt;

&lt;h6 id=&quot;current-guidelines-note-that-the-absolute-level-of-vwf-seems-to-be-more-important-than-the-level-relative-to-blood-type&quot;&gt;Current guidelines note that the absolute level of vWF seems to be more important than the level relative to blood type.&lt;/h6&gt;

&lt;p&gt;See Table 11–14 for information on the laboratory evaluation for vWD.&lt;/p&gt;

&lt;p&gt;von Willebrand Disease Types, Subtypes, and Their Expected Test Results&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Type 1: vWF multimers of all sizes are decreased due to a defect in synthesis or release of vWF from the endothelium, the site of most vWF synthesis. Functional (ristocetin cofactor or vWF:RCo) and antigenic (vWF antigen or vWF:Ag) levels of vWF are usually proportionately decreased. Factor VIII activitty might also be low. The vWF multimer pattern shows a normal distribution of multimers&lt;/li&gt;
&lt;/ul&gt;

&lt;h6 id=&quot;vwfrco--vwfag--factor-viii-is-the-most-commonly-observed-pattern-in-type-2a&quot;&gt;vWF:RCo &amp;lt; vWF:Ag &amp;lt; Factor VIII is the most commonly observed pattern in type 2A&lt;/h6&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Type 2A: Absence of large and intermediate-size vWF multimers from the plasma and platelet surface, due to a defect in the synthesis or polymerization of multimers, or from increased proteolysis of multimers. Functional activity (vWF:RCo) is decreased compared with antigenic levels (vWF:Ag). Therefore, vWF:RCo &amp;lt; vWF:Ag &amp;lt; Factor VIII is the most commonly observed pattern in type 2A. The vWF multimer pattern shows an abnormal distribution of multimers, with thabsence of large and intermediate-size multimers&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Type 2B: Marked deficiency of large vWF multimers from plasma. Intermediate-size and small multimers are present. Large multimers are present on the patient’s platelets, due to increased affinity of the abnormal vWF molecule for the platelet surface. Functional and antigenic levels in plasma samples are similar to those in type 2A (vWF:RCo &amp;lt; vWF:Ag &amp;lt; Factor VIII). The vWF multimer pattern shows the absence of large multimers from plasma. The patient’s platelets show increased aggregation at low concentrations of ristocetin that do not cause normal platelets to aggregate. The patient’s platelets aggregate at low concentrations of ristocetin because they are coated with large vWF multimers&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Types 2M and 2N are uncommon and are briefly described in Table 11–13&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Type 3: Severe deficiency of all vWF multimers, due to a marked defect in synthesis. Factor VIII activity is less severely affected than vWF activity. Both functional and antigenic vWF levels are markedly reduced. The vWF multimer pattern shows a virtual absence of all-size multimers&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Platelet-type Willebrand disease: vWF is qualitatively normal, but abnormal platelets have an increased affinity for large multimers of vWF due to a defecinent platelet GP Ib. The laboratory test values are similar to those in type 2B&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Acquired vWD: This disorder has been found in patients with systemic lupus erythematosus, multiple myeloma, Waldenström macroglobulinemia, lymphoproliferative disorders, and other diseases. Patients have no congenital or familial history of bleeding. Causes of the decrease in circulating vWF include adsorption of large multimers onto cells (eg, lymphocytes or tumor cells) or the presence of antibodies to vWF. Acquired vWD resolves when thunderlying disorder is effectively treated.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;bernardsoulier-disease-and-glanzmann-thrombasthenia&quot;&gt;Bernard–Soulier Disease and Glanzmann Thrombasthenia&lt;/h3&gt;

&lt;h5 id=&quot;description-20&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Bernard–Soulier syndrome (BS) and GT are rare congenital hemorrhagic disorders that result from absent or defective specific platelet membrane GPs, impairing platelet function. BS is characterized by a decrease of functional GP Ib/IX/V, the platelet receptor for vWF. GT is characterized by a decrease of functional GP IIb/IIIa, the complex that mediates platelet aggregation by binding fibrinogen to the platelet surface when platelets are activated.&lt;/p&gt;

&lt;p&gt;GT often decreases in severity with age. Manifestations include easy bruising, epistaxis, mucous membrane bleeding—particularly in the gastrointestinal tract—and menorrhagia. The amount of hemorrhage is highly variable among affected patients.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–15 for information on the laboratory evaluation for BS and GT.&lt;/p&gt;

&lt;p&gt;Table 11–15   Laboratory Evaluation for Bernard–Soulier Disease and Glanzmann Thrombasthenia 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;h3 id=&quot;platelet-storage-pool-disease&quot;&gt;Platelet Storage Pool Disease&lt;/h3&gt;

&lt;h5 id=&quot;description-21&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Platelet SPD represents a group of disorders in which there is a deficiency of platelet granules. Decreased secretion of platelet granular contents at the time of platelet activation makes the platelets less hemostatically effective. The congenital forms of SPD include:&lt;/p&gt;

&lt;p&gt;*Delta SPD: platelets have a decreased number of delta (dense) granules; these secretory granules contain ADP, polyphosphate, serotonin, and calcium&lt;/p&gt;

&lt;p&gt;*Alpha-delta or alpha-partial delta SPD: decreased number of delta granules with either a complete or partial deficiency of alpha granules; alpha 
granulescontain many proteins including fibrinogen, PF4, platelet-derived growth factor, and beta-thromboglobulin&lt;/p&gt;

&lt;p&gt;*Alpha SPD (“gray platelet syndrome”): decreased number of alpha granules, and a normal number of delta granules; platelets appear gray, large, andvacuolated 
on a peripheral blood smear.&lt;/p&gt;

&lt;p&gt;SPD also may occur as an acquired abnormality, acutely in patients who have been supported on a cardiopulmonary bypass device and chronically in some cases of acute leukemia and myeloproliferative disorders. The molecular basis of most types of congenital SPD is unknown. It may result from abnormal granule morphogenesis or abnormal granule maturation in megakaryocytes. SPD may be a manifestation of a global defect in granule formation as in the Hermansky–Pudlak syndrome (see below). Hereditary SPD is the most common congenital qualitative platelet disorder, but it is still quite rare.&lt;/p&gt;

&lt;p&gt;Most patients with storage pool disease have mild bleeding symptoms. Bleeding manifestations of SPD include mild mucous membrane bleeding, easy bruising, menorrhagia, and excessive bleeding following dental or general surgery.&lt;/p&gt;

&lt;p&gt;Most patients with SPD have mild bleeding symptoms. Bleeding manifestations of SPD include mild mucous membrane bleeding, easy bruising, menorrhagia, and excessive bleeding following dental or general surgery. SPD may also occur as a component of the following syndromes:&lt;/p&gt;

&lt;p&gt;*Hermansky–Pudlak syndrome: Features include delta SPD, oculocutaneous albinism, pulmonary fibrosis, and the accumulation of ceroid-like material in cells of the reticuloendothelial system. One subtype is due to a defective gene (called HSP1) on chromosome 10&lt;/p&gt;

&lt;h6 id=&quot;defective-gene-called-hsp1-on-chromosome-10&quot;&gt;defective gene (called HSP1) on chromosome 10&lt;/h6&gt;

&lt;p&gt;*Chediak–Higashi syndrome: Features include delta SPD with giant platelet granules, photophobia, nystagmus, pseudoalbinism, lymphadenopathy, splenomegaly, and increased susceptibility to infection. It is attributed to defects in a gene called CHS1 on chromosome 1, affecting protein trafficking&lt;/p&gt;

&lt;h6 id=&quot;chs1-on-chromosome-1-affecting-protein-trafficking&quot;&gt;CHS1 on chromosome 1, affecting protein trafficking&lt;/h6&gt;

&lt;p&gt;*Thrombocytopenia with absent radius: Features include alpha SPD and absence of the radius bone&lt;/p&gt;

&lt;p&gt;*Wiskott–Aldrich syndrome: Features of this X-linked recessive disorder include delta SPD with other metabolic platelet defects, recurrent infections, eczema, lymphocytopenia, multiple cellular and humoral immunologic defects, and thrombocytopenia with microplatelets (small platelets); the thrombocytopenia may resolve following splenectomy. It is attributed to a genetic defect in a gene called WASP on the X chromosome, affecting signal transduction and other functions.&lt;/p&gt;

&lt;h6 id=&quot;wasp-on-the-x-chromosome-affecting-signal-transduction-and-other-functions&quot;&gt;WASP on the X chromosome, affecting signal transduction and other functions.&lt;/h6&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–16 for information on the laboratory evaluation for storage pool deficiency.&lt;/p&gt;

&lt;p&gt;Table 11–16   Laboratory Evaluation for Storage Pool Deficiency 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;h3 id=&quot;hemostatic-defects-in-uremia&quot;&gt;Hemostatic Defects in Uremia&lt;/h3&gt;

&lt;h5 id=&quot;description-22&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;The bleeding tendency in uremia-induced hemorrhage is attributed to platelet dysfunction and endothelial cell dysfunction.&lt;/p&gt;

&lt;p&gt;Bleeding manifestations may be mild or severe and can include petechiae, ecchymoses, epistaxis, and purpura. Paradoxically, chronic renal failure is also associated with an increased incidence of arterial and venous thrombosis, and, therefore, can influence hemostasis toward bleeding or clotting.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–17 for information on the laboratory evaluation for hemostatic defects in uremia.&lt;/p&gt;

&lt;p&gt;Table 11–17   Laboratory Evaluation for Hemostatic Defects in Uremia 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;h3 id=&quot;drug-induced-qualitative-platelet-dysfunction&quot;&gt;Drug-induced Qualitative Platelet Dysfunction&lt;/h3&gt;

&lt;h5 id=&quot;description-23&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Platelet dysfunction may occur on ingestion of a wide variety of drugs, particularly aspirin and clopidogrel (Plavix). Due to the ubiquity of aspirin in over-the-counter medications, many medications are implicated in platelet dysfunction. Some patients consume multiple drugs, such as aspirin and clopidogrel, with different and additive antiplatelet effects and thereby inhibit platelet function by more than 1 mechanism. Drug-induced platelet dysfunction can present a high bleeding risk in patients with existing hemostatic defects, but typically does not result in clinically significant bleeding in normal individuals. When hemorrhage does occur, there is usually an underlying hemostatic disorder affecting either the platelets or coagulation factors, or an anatomic lesion, such as an ulcer, that predisposes the patient to bleeding.&lt;/p&gt;

&lt;p&gt;Commonly encountered coagulopathies that place patients at risk for bleeding when there is a superimposed drug-induced platelet defect include vWD, thrombocytopenia of any cause, and anticoagulation therapy. Hemorrhagic manifestations can include petechiae and purpura, ecchymoses, mucosal membrane bleeding, hematuria, epistaxis, and oozing from intravenous access sites and surgical incisions.&lt;/p&gt;

&lt;h5 id=&quot;diagnosis-11&quot;&gt;Diagnosis&lt;/h5&gt;

&lt;p&gt;Laboratory tests are of little value in predicting the clinical significance of drug-induced platelet defects. They can confirm the presence of abnormal platelet function, but cannot assess the risk of bleeding. Furthermore, laboratory abnormalities in platelet function are not specific for a particular drug. See Table 11–18 for information on the laboratory evaluation for drug-induced platelet defects.&lt;/p&gt;

&lt;p&gt;Table 11–18   Drug-induced Qualitative Platelet Dysfunction 
View Large |&lt;/p&gt;

&lt;h2 id=&quot;thrombotic-disorders&quot;&gt;Thrombotic Disorders&lt;/h2&gt;

&lt;h6 id=&quot;factor-v-leiden-mutation&quot;&gt;Factor V Leiden mutation&lt;/h6&gt;

&lt;h6 id=&quot;prothrombin-g20210a-mutation&quot;&gt;prothrombin G20210A mutation&lt;/h6&gt;

&lt;h6 id=&quot;antiphospholipid-antibody-syndrome&quot;&gt;antiphospholipid antibody syndrome&lt;/h6&gt;

&lt;p&gt;In this chapter, the disorders associated with thrombosis (Figure 11–5) are grouped into those with a relatively higher prevalence and those with a relatively lower prevalence. Among those with a higher prevalence is activated protein C resistance, which is produced by the Factor V Leiden mutation. This mutation is present in 3% to 5% of Caucasian populations. Other thrombotic disorders with a high prevalence are the prothrombin G20210A mutation, and the antiphospholipid antibody syndrome (an acquired disorder). The thrombotic disorders with a lower prevalence include protein C deficiency, protein S deficiency, and antithrombin deficiency. Elevated plasma homocysteine levels may also increase the risk for thrombosis. Plasminogen deficiency is also rare, and its association with thrombosis is controversial. Two other rare conditions, dysfibrinogenemia of certain types and essential thrombocythemia, can produce either thrombosis or bleeding. Also rare are TTP and HUS.&lt;/p&gt;

&lt;h3 id=&quot;hypercoagulable-states&quot;&gt;Hypercoagulable States&lt;/h3&gt;

&lt;h5 id=&quot;description-24&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Hypercoagulable states are associated with an increased risk for thrombosis (Table 11–19). There are both hereditary and acquired hypercoagulable states. Hereditary forms may arise from a quantitative or qualitative deficiency of a regulatory anticoagulant protein, such as protein C, protein S, or antithrombin (see Figures 11–2 and 11–3). Activated protein C resistance is caused by a mutation in the Factor V molecule (nearly always the Factor V Leiden mutation), which prevents activated protein C-mediated inactivation of Factor Va. The prothrombin G20210A mutation is prevalent in Caucasian populations, similar to Factor V Leiden. Prothrombin G20210A is a mutation in the promoter of the prothrombin gene, causing increased synthesis of prothrombin (Factor II). Hyperhomocysteinemia, a disorder in which there is an abnormally high level of plasma homocysteine, can be hereditary or acquired. Hyperhomocysteinemic individuals are at increased risk for coronary artery disease and deep venous thrombosis. However, studies have not yet shown that reducing slightly or moderately elevated homocysteine with vitamin therapy reduces the thrombotic risk. A block in the pathway at any 1 of the several steps results in the accumulation of homocysteine. When the homocysteine level is manyfold higher than the upper limit of normal, this very high value may contribute to the damaging effects on the blood vessel wall. Acquired hypercoagulable states arise from a diverse array of clinical conditions. They include malignancy, immobilization, surgery, trauma, obesity, smoking, infection, prolonged travel, and the use of oral contraceptives, estrogen replacement therapy, and progesterone, among many others. An acquired hypercoagulable state for which specific coagulation testing is available is the antiphospholipid antibody syndrome.&lt;/p&gt;

&lt;p&gt;Table 11–19   Laboratory Evaluation for Hypercoagulable States 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;p&gt;The presence of 1 hypercoagulable condition alone is not usually sufficient to initiate thrombosis. The presence of a second (or more), superimposed hypercoagulable condition (often called a “second hit”) appears to be required to provoke a thrombotic event. For example, a person with activated protein C resistance may not experience a thrombotic event until suffering major trauma as a “second hit.”&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;h6 id=&quot;warfarin---protein-c-----anticoagulant-heparin---antithormbin-----anticoagulant-oral-contraceptives---protein-s-----anticoagulant&quot;&gt;warfarin -&amp;gt; protein C (-) -&amp;gt; anticoagulant; heparin -&amp;gt; antithormbin (-) -&amp;gt; anticoagulant; oral contraceptives -&amp;gt; protein S (-) -&amp;gt; anticoagulant.&lt;/h6&gt;

&lt;p&gt;Laboratory testing for hypercoagulable states is most often performed for patients presenting with a personal or family history of thrombosis. The laboratory evaluation for hereditary hypercoagulable states is best performed as a panel of test results. The most common disorders are activated protein C resistance (caused nearly always by Factor V Leiden) and prothrombin G20210A, and the less common are deficiencies of protein C, protein S, and antithrombin. Frequently, antiphospholipid antibody testing is performed in conjunction with the tests for hereditary hypercoagulable disorders. If all of these tests are negative and the clinical suspicion for a congenital hypercoagulable state remains high, additional testing for the more rare hypercoagulable disorders can be performed. There are many acquired conditions or treatments that reduce the level of protein C, protein S, and antithrombin in the test panel for hypercoagulability, but despite this, the risk for thrombosis is not significantly increased on that basis. For example, warfarin reduces the levels of protein C and protein S but reduces thrombotic risk. Antithrombin is lowered by heparin therapy. Pregnancy, oral contraceptives, and estrogen therapy can all decrease the activity of protein S, although they can induce a hypercoagulable state by other mechanisms. Active clot formation, liver dysfunction, or DIC can lower protein C, protein S, and antithrombin. In situations where such a confounding variable exists that alters the level of protein C, protein S, or antithrombin, the tests should be repeated (if possible) when the variable is no longer present to obtain the patient’s true baseline values. This should allow determination of whether a heritable deficiency of any of these 3 proteins truly exists:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Activated protein C resistance: Usually, the first assay performed is a functional assay for activated protein C resistance. If the result is abnormal, genetic analysis is performed, to confirm whether Factor V Leiden is present in the heterozygous state, present in the homozygous state, or absent&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Prothrombin G20210A: This mutation is identified by genetic analysis that can specifically identify heterozygous and homozygous states&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hyperhomocysteinemia: Plasma homocysteine levels are measured by a variety of automated methods&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h6 id=&quot;sequence-of-test--1st---2nd-----3rd--functional---antigenic-assay&quot;&gt;sequence of test = (1st -&amp;gt; 2nd -&amp;gt; -&amp;gt; 3rd = functional -&amp;gt; antigenic assay)&lt;/h6&gt;

&lt;ul&gt;
  &lt;li&gt;Protein C, protein S, and antithrombin deficiencies: Individual functional assays to measure the activity of these endogenous anticoagulant proteins detect both qualitative (normal number of abnormally functioning molecules) and quantitative (low number of normally functioning molecules) deficiencies. In contrast, an antigenic (immunologic) assay, which measures only the quantity of protein present, can detect quantitative but not qualitative deficiencies. Therefore, the first assay performed should be a functional assay. If the result is abnormal, an antigenic assay can be performed to determine if the cause of the decreased activity is a quantitative or qualitative deficiency of the protein&lt;/li&gt;
&lt;/ul&gt;

&lt;h6 id=&quot;la-an-antiphospholipid-antibody&quot;&gt;LA (an antiphospholipid antibody)&lt;/h6&gt;

&lt;h6 id=&quot;ptt-based-or-dilute-russell-viper-venom-time-drvvt-assays&quot;&gt;PTT-based or dilute Russell viper venom time (DRVVT) assays&lt;/h6&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;LA (an antiphospholipid antibody): A variety of tests can be used to detect an LA. This antibody interferes with the cofactor action of phospholipid in the coagulation cascade in laboratory assays only (see the section “Antiphospholipid Antibodies: The Lupus Anticoagulant, Anticardiolipin Antibodies, and Beta-2 Glycoprotein I Antibodies” [Beta-2 GP I antibodies]). Various phospholipid-dependent coagulation test times, especially PTT-based or dilute Russell viper venom time (DRVVT) assays, can be used. The DRVVT is the clotting time obtained using Russell viper venom, which contains a Factor X activator&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anticardiolipin antibody or beta-2 GP I antibody (both are antiphospholipid antibodies): These antiphospholipid antibodies may or may not be associated with the presence of an LA (see the section “Antiphospholipid Antibodies: The Lupus Anticoagulant, Anticardiolipin Antibodies, and Beta-2 Glycoprotein I Antibodies”), and they are detected by enzyme-linked immunoassays.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;See Table 11–19 for characteristics of the hypercoagulable states.&lt;/p&gt;

&lt;p&gt;Antiphospholipid Antibodies: The Lupus Anticoagulant, Anticardiolipin Antibodies, and Beta-2 Glycoprotein I Antibodies&lt;/p&gt;

&lt;h5 id=&quot;description-25&quot;&gt;Description&lt;/h5&gt;

&lt;p&gt;Antiphospholipid antibodies recognize specific phospholipid–protein complexes rather than phospholipid alone. They can be immunoglobulin type IgG or IgM, or, less commonly, IgA. The LA is an immunoglobulin that can interfere with phospholipid-dependent coagulation reactions in laboratory assays without inhibiting the activity of any specific coagulation factor. It targets phospholipids bound to prothrombin, beta-2 GP I, protein C, protein S, or other proteins bound to phospholipids. Anticardiolipin antibodies are another type of antiphospholipid antibody, which target beta-2 GP I bound to a particular phospholipid, cardiolipin; these can be detected by anticardiolipin antibody immunoassays. Anti-beta-2 GP I antibodies also target beta-2 GP I.&lt;/p&gt;

&lt;p&gt;An antiphospholipid antibody may occur in apparently healthy individuals with no detectable illness. It also occurs in patients with a variety of clinical conditions or disorders including:&lt;/p&gt;

&lt;p&gt;*Systemic lupus erythematosus and other autoimmune disorder&lt;/p&gt;

&lt;p&gt;*Malignancy&lt;/p&gt;

&lt;p&gt;*Following ingestion of selected drugs (procainamide, quinidine, phenytoin, chlorpromazine, valproic acid, amoxicillin, augmentin, hydralazine,&lt;/p&gt;

&lt;p&gt;*streptomycin,and propranolol have all been reported to induce an LA&lt;/p&gt;

&lt;p&gt;*Infectious diseases—bacterial (including spirochetal and mycobacterial), viral, fungal, and protozoal infection&lt;/p&gt;

&lt;p&gt;*Following vaccination&lt;/p&gt;

&lt;h5 id=&quot;of-patients-with-a-prolonged-ptt-will-have-an-la-as-the-cause-of-the-prolongation&quot;&gt;2% of patients with a prolonged PTT will have an LA as the cause of the prolongation&lt;/h5&gt;

&lt;p&gt;Estimates of prevalence have been highly variable because results are completely dependent on the test(s) used for detection of antiphospholipid antibodies, and some methods are more sensitive than others. Approximately 2% of patients with a prolonged PTT will have an LA as the cause of the prolongation. LA is the most common cause of a prolonged PTT that remains prolonged in a PTT mixing study (a PTT performed on a sample of mixed patient and normal plasma). It is estimated that 1% to 5% of the general population has an antiphospholipid antibody. The frequency of antiphospholipid antibody in systemic lupus erythematosus patients is in the 30% to 40% range. Antiphospholipid antibodies due to infections are typically transient and asymptomatic.&lt;/p&gt;

&lt;p&gt;A lupus anticoagulant is the most common cause of a prolonged PTT that remains prolonged in a PTT mixing study (a PTT performed on a sample of mixed patient and normal plasma).&lt;/p&gt;

&lt;p&gt;Although the LA acts as an anticoagulant in vitro, it does not appear to be associated with hemorrhage, even with surgical challenge. Rare cases of bleeding in patients with the LA can almost always be attributed to specific abnormalities in hemostasis that happen to be present along with the LA. Decreased prothrombin (Factor II) is occasionally found with the LA. The LA can bind directly to prothrombin, but typically the LA does not neutralize the procoagulant activity of prothrombin even when it does bind to it. In an occasional patient, however, antibody binding does reduce the prothrombin concentration by accelerated clearance of prothrombin/antiprothrombin complexes, and these patients can have hemorrhagic complications. Concomitant thrombocytopenia is not infrequently found in patients with the LA, and this also may be a cause for hemorrhage.&lt;/p&gt;

&lt;h6 id=&quot;antiphospholipid-antibodies---venous--arterial-thrombosis&quot;&gt;antiphospholipid antibodies -&amp;gt; venous &amp;amp; arterial thrombosis(+)&lt;/h6&gt;

&lt;h6 id=&quot;if-abnormal--3-3cigganticardiolipin-anti-b-2-gp-i-higher-risk&quot;&gt;if abnormal &amp;gt; 3; 3=c(IgG,anticardiolipin, anti-b-2 GP I); higher risk.&lt;/h6&gt;

&lt;p&gt;Antiphospholipid antibodies are associated with an increased risk for venous and arterial thrombosis. The role of the antiphospholipid antibody in thrombosis is not clear, although several mechanisms for thrombosis have been proposed. The incidence of clinically apparent thromboembolism in patients with the LA, with or without systemic lupus erythematosus, is difficult to determine because of the variety of tests used to detect the LA. However, data suggest that the percentage of patients with the LA who will develop thrombosis is 1% per year if there is no history of thrombosis and 5.5% per year if there has been at least 1 prior thrombotic event. High titers of anticardiolipin or anti-beta-2 GP I antibodies present a higher risk for complications than low titers, and IgG is thought to be higher risk than IgM or IgA. There is a greater risk for thrombosis if more than 1 of the 3 antiphospholipid antibody tests (LA, anticardiolipin antibodies, and anti-beta-2 GP I antibodies) are abnormal.&lt;/p&gt;

&lt;p&gt;Recurrent spontaneous abortion has been reported to be increased in patients with antiphospholipid antibodies. There is evidence suggesting that thrombosis and infarction in the placenta mediate antiphospholipid antibody-associated spontaneous abortion in a significant number of women experiencing recurrent fetal loss or premature birth.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;There are no “gold standard” tests that unequivocally establish the presence of antiphospholipid antibodies:&lt;/p&gt;

&lt;h6 id=&quot;drvvt--dilute-russells-viper-venom-time&quot;&gt;DRVVT = “Dilute Russell’s Viper Venom Time”&lt;/h6&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;For the LA: A prolonged PTT and a PTT mixing study that does not correct into the normal range are clues to the presence of the LA, although some PTT reagents are not sensitive to the LA. Therefore, it should be noted that the routine PTT is not an appropriate screening test for the LA. A PTT- or DRVVT-based test with a reduced amount of phospholipid can be used as a screening test for the LA. If it is prolonged, a 1:1 mixing study and a confirmatory assay should be performed. In the presence of an LA, the PTT or DRVVT usually remains prolonged when equal portions of patient plasma and normal plasma are mixed. Confirmatory assays demonstrate that the clotting time shortens toward normal when excess phospholipid is added, overcoming the LA effect. The PT is not typically increased by the LA, unless the patient has an associated hypoprothrombinemia or the thromboplastin used in the PT is one that is particularly sensitive to inhibition by the LA.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;For anticardiolipin or anti-beta-2 GP I antibodies: An enzyme-linked immunosorbent assay (ELISA) is used that quantitates IgG and IgM antibody levels in arbitrary units. IgA is also measured in some kits.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h6 id=&quot;patients-with-antiphospholipid-antibodies-may-have-a-false-positive-serologic-test-result-for-syphilis-such-as-venereal-disease-research-laboratories-vdrl-and-rapid-plasma-reagin-rpr&quot;&gt;Patients with antiphospholipid antibodies may have a false-positive serologic test result for syphilis (such as Venereal Disease Research Laboratories [VDRL] and rapid plasma reagin [RPR]).&lt;/h6&gt;

&lt;p&gt;See Table 11–19 for information on the laboratory diagnosis of antiphospholipid antibodies.&lt;/p&gt;

&lt;p&gt;Thrombotic Thrombocytopenic Purpura&lt;/p&gt;

&lt;p&gt;Description&lt;/p&gt;

&lt;p&gt;TTP(Thrombotic thrombocytopenic purpura) is a clinical syndrome that is characterized by a triad (1-3 below, more commonly) or pentad (1-5 below, less commonly) of signs and symptoms:&lt;/p&gt;

&lt;p&gt;1.Thrombocytopenia with generalized purpura, and mucous membrane bleeding&lt;/p&gt;

&lt;p&gt;2.Hemolytic anemia (microangiopathic) sufficient to cause jaundice or pallor&lt;/p&gt;

&lt;p&gt;3.Neurologic abnormalities, which may include fluctuating weakness, dysphagia, headache, dementia/behavioral changes, obtundation, seizures, diplopia,paresthesias, and coma&lt;/p&gt;

&lt;p&gt;4.Fever&lt;/p&gt;

&lt;p&gt;5.Renal dysfunction, which may include hematuria, proteinuria, or renal insufficiency&lt;/p&gt;

&lt;p&gt;The characteristic, but not pathognomonic, pathology includes platelet and fibrin “hyaline” thrombi in the small arteries, arterioles, and capillaries in a widespread organ distribution. Organ ischemia and infarction that arise from these thrombi are thought to give rise to the observed fever and organ dysfunction. The etiology for TTP has been shown to be a deficiency of vWF-cleaving protease. Nonfamilial cases of TTP are a result of an inhibitor to the vWF-cleaving protease; the familial form of TTP is apparently caused by a constitutional deficiency of the protease. The unusually large forms of vWF in the plasma of patients with TTP promote the aggregation of platelets in vivo, which accounts for most of the clinical findings.&lt;/p&gt;

&lt;p&gt;TTP can occur at any age but is most common between the ages of 20 and 50 years. Peak incidence is in the third decade. There is a female to male ratio of 3:2.TTP usually occurs as an acute, fulminant disease, but may also occur in a chronic form or in an acute relapsing form. The acute and acute relapsing types are often preceded by a viral prodrome. Nonspecific signs such as malaise, weakness, fatigue, and anorexia may predominate at first, until the above triad or pentad develops in days to weeks. The chronic type usually pursues an indolent, low-grade course, with ongoing disease activity for months.&lt;/p&gt;

&lt;p&gt;Nonspecific manifestations in other organ systems resulting from ischemia may include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Cardiac: conduction defects, sudden death, and heart failure&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Pulmonary: lung infiltrates and acute respiratory failure&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Gastrointestinal: abdominal pain due to visceral ischemia, pancreatitis, and gastrointestinal mucosal hemorrhage&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hemolytic–uremic syndrome is a clinical syndrome with presentation and manifestations similar to TTP. Despite the clinical similarity, evidence has shown that the low levels of vWF-cleaving protease found in TTP are not found in HUS.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–20 for information on the laboratory evaluation for TTP.&lt;/p&gt;

&lt;p&gt;Table 11–20   Laboratory Evaluation for Thrombotic Thrombocytopenic Purpura 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;h3 id=&quot;hemolyticuremic-syndrome&quot;&gt;Hemolytic–Uremic Syndrome&lt;/h3&gt;

&lt;h5 id=&quot;description-26&quot;&gt;Description&lt;/h5&gt;

&lt;h6 id=&quot;hus---ttp&quot;&gt;HUS -&amp;gt; (TTP)&lt;/h6&gt;

&lt;p&gt;HUS is a clinical syndrome with presentation and manifestations similar to TTP. Despite the clinical similarity, evidence has shown that the low levels of vWF-cleaving protease found in TTP are not found in HUS. Thus, the pathogenesis of these 2 disorders is apparently completely different. HUS is characterized by fever, microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. It differs clinically from TTP in the following ways: neurologic symptoms are less pronounced or absent in HUS; renal function is usually more impaired in HUS than in TTP; HUS occurs in a younger population than TTP with a peak incidence between 6 months and 4 years, with males and females equally affected; HUS is a more common entity than TTP; as with TTP, hyaline thrombi may be found, but in most cases they tend to be confined to the glomerular capillaries and afferent arterioles.&lt;/p&gt;

&lt;p&gt;HUS occasionally occurs in adults, and is often distinguished from childhood HUS because of its strong association in adults with obstetrical complications such as eclampsia. The prognosis is worse in adults than in affected children, with an adult mortality as high as 60%.&lt;/p&gt;

&lt;h6 id=&quot;shiga-toxin-producing-e-coli&quot;&gt;Shiga-toxin-producing E. coli&lt;/h6&gt;

&lt;p&gt;Acute HUS occurs in nonfamilial and familial forms, which may have different causes. Nonfamilial forms are most often associated with a diarrheal illness caused by a Shiga-toxin-producing E. coli (in particular, E. coli O157:H7). Familial forms have been linked to abnormalities in complement factor H and factor I. The majority of childhood cases resolve without sequelae, if children with acute renal failure receive dialysis when necessary. The prognosis depends on the duration of renal failure and the severity of the neurologic disturbance. Renal function returns to normal in approximately 90% of childhood cases.&lt;/p&gt;

&lt;p&gt;Diagnosis&lt;/p&gt;

&lt;p&gt;See Table 11–21 for information on the laboratory evaluation for HUS.&lt;/p&gt;

&lt;p&gt;Table 11–21   Laboratory Evaluation for Hemolytic–Uremic Syndrome 
View Large |&lt;/p&gt;

&lt;h3 id=&quot;anticoagulant-therapies&quot;&gt;Anticoagulant Therapies&lt;/h3&gt;

&lt;p&gt;Thrombosis can be treated and/or prevented with anticoagulant therapies, which are therapies that inhibit the coagulation cascade, thereby inhibiting fibrin clot formation. Since too little anticoagulation might allow new thrombosis to occur while too much anticoagulant can cause bleeding, laboratory tests can be used to determine how much anticoagulation is present in the patient, so that the dose can be adjusted if needed. For decades, heparin and warfarin were the only anticoagulants available for use. Heparin is given intravenously or subcutaneously, and warfarin is taken orally. As described previously, heparin inhibits multiple coagulation factors, and the effect of this inhibition is that heparin prolongs the PTT. Most PT reagents contain a heparin neutralizer that largely prevents significant PT prolongations for patients on heparin. Warfarin decreases the synthesis of active forms of Factors II, VII, IX, and X, which prolongs the PT. Different PT methods can demonstrate different degrees of prolongation with warfarin. Therefore, a formula is used to convert the PT into a more standardized number that takes into account the relative sensitivity of the PT reagent. This calculation is called the international normalized ratio (INR), and it is meant to provide similar results no matter what method is in use by the laboratory. To be sure the correct amount of anticoagulation is present, heparin is closely monitored with the PTT, and warfarin is closely monitored with INR measurements.&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;http://labmed.ascpjournals.org/content/42/3/176/F1.large.jpg&quot; alt=&quot;INR&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Newer anticoagulants have emerged that do not routinely need monitoring with laboratory tests. Nevertheless, laboratory monitoring may still be occasionally indicated. Low-molecular-weight heparin, fondaparinux, rivaroxaban and apixaban inhibit Factor Xa. Therefore, these anticoagulants can be monitored with anti-Factor Xa assays. These are assays that can measure the concentration of the anticoagulant based on how much inhibition of Factor Xa is detected. Direct thrombin inhibitors (argatroban, bivalirudin, and dabigatran) inhibit thrombin, which prolongs the PTT and to a lesser extent the PT. A dilute thrombin time assay has been shown to have a linear relationship to therapeutic doses of dabigatran. The PTT can be useful to monitor argatroban. Bivalirudin is specifically approved for use during percutaneous coronary intervention (PCI), a cardiac catheterization procedure that requires anticoagulation that is monitored with a rapid, bedside whole blood clotting time test called the activated clotting time (ACT). If a patient has PCI with bivalirudin, the ACT is used.&lt;/p&gt;

&lt;p&gt;Only warfarin, rivaroxaban, dabigatran and apixaban are administered orally. The other anticoagulants are administered parenterally.&lt;/p&gt;

&lt;p&gt;See Table 11–22 for a summary of the mechanisms of action and the laboratory tests to measure the anticoagulation effect of these various anticoagulant therapies.&lt;/p&gt;

&lt;p&gt;Table 11–22   Laboratory Monitoring of Anticoagulant Therapies 
View Large |&lt;/p&gt;

&lt;p&gt;Favorite Table&lt;/p&gt;

&lt;h3 id=&quot;antiplatelet-therapies&quot;&gt;Antiplatelet Therapies&lt;/h3&gt;

&lt;p&gt;Patients with arterial thrombosis, in particular myocardial infarction or ischemic stroke, are usually treated with antiplatelet therapy, to inhibit platelet activation. Unlike many anticoagulant therapies, laboratory testing is not yet routinely used to monitor antiplatelet therapy. Studies are ongoing to determine if laboratory monitoring of platelet therapy is beneficial. A variety of platelet-inhibiting medications are available. Aspirin irreversibly inhibits cyclooxygenase in platelets, which prevents the generation of thromboxane A2 from arachidonic acid. This inhibits platelet aggregation because thromboxane A2 triggers the release of platelet granules and activates other platelets. Several GP IIb/IIIa inhibitors are available (abciximab, eptifibatide, or tirofiban). These agents inhibit platelet aggregation because GP IIb/IIIa on the platelet surface mediates platelet aggregation. Clopidogrel, prasugrel, and ticagrelor all inhibit an ADP receptor on the platelet surface, which ultimately inhibits activation of platelet GP IIb/IIIa. Dipyridamole inhibits platelets through multiple mechanisms.&lt;/p&gt;

&lt;p&gt;A portion of this chapter, primarily the material in the section “Introduction to Hemostasis,” was adapted with permission with modifications from Laposata M, Connor AM, Hicks, DG, Phillips DK. The Clinical Hemostasis Handbook. Chicago: Year Book Medical Publishers; 1989.&lt;/p&gt;

&lt;p&gt;31.71.2&lt;/p&gt;

&lt;p&gt;Silverchair&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>correlation study</title>
   <link href="http://lanyon.getpoole.com/statistics/2015/10/30/correlation-study/"/>
   <updated>2015-10-30T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/statistics/2015/10/30/correlation-study</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;https://cran.r-project.org/web/packages/corrplot/vignettes/corrplot-intro.html&quot;&gt;An Introduction to corrplot package&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Ipython and Jupyter study</title>
   <link href="http://lanyon.getpoole.com/python/2015/10/30/Ipython-Jupyter-study/"/>
   <updated>2015-10-30T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/python/2015/10/30/Ipython-Jupyter-study</id>
   <content type="html">&lt;p&gt;video resource&lt;/p&gt;

&lt;p&gt;IPython &amp;amp; Jupyter in depth: high productivity interactive and parallel python - PyCon 2015&lt;/p&gt;

&lt;iframe width=&quot;560&quot; height=&quot;315&quot; src=&quot;https://www.youtube.com/embed/05fA_DXgW-Y&quot; frameborder=&quot;0&quot; allowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;
</content>
 </entry>
 
 <entry>
   <title>exam2 review note from textbooks and others</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/10/13/exam2-review-textbook/"/>
   <updated>2015-10-13T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/10/13/exam2-review-textbook</id>
   <content type="html">&lt;h2 id=&quot;wbc-and-lymphoid&quot;&gt;WBC and Lymphoid&lt;/h2&gt;

&lt;h3 id=&quot;keywords&quot;&gt;keywords&lt;/h3&gt;

&lt;p&gt;&lt;a href=&quot;https://en.wikipedia.org/wiki/Emperipolesis#/media/File:Emperipolesis_-_very_high_mag.jpg&quot;&gt;emperipolesis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;an intact cell within the cytoplasm of another cell&lt;/p&gt;

&lt;h2 id=&quot;note-from-books&quot;&gt;note from books&lt;/h2&gt;

&lt;h3 id=&quot;acute-leukemias-in-general&quot;&gt;Acute Leukemias in general&lt;/h3&gt;

&lt;p&gt;oncogenic tyrosine kinases activate RAS and its two downstream signaling arms, the PI3K/AKT and MAPK pathways&lt;/p&gt;

&lt;p&gt;B-ALL and CML -&amp;gt; BCR-ABL fusion gene (9,22) translocation, philiadelphia chromosome.&lt;/p&gt;

&lt;p&gt;some T-ALLs -&amp;gt; NUP214-ABL (similar to BCR-ABL)&lt;/p&gt;

&lt;p&gt;Acute leukemias have the following characteristics:&lt;/p&gt;

&lt;p&gt;a lack of CD7 expression could insinuate mycosis fungoides (MF) or Sezary syndrome (SS).&lt;/p&gt;

&lt;h4 id=&quot;laboratory-findings-in-acute-leukemias&quot;&gt;Laboratory Findings in Acute Leukemias&lt;/h4&gt;

&lt;p&gt;(WBC count) variable; maybe &amp;gt; 100,000 cells/μL, in 50% of patient, &amp;lt; 10,000 cells/μL.&lt;/p&gt;

&lt;p&gt;Anemia is almost always present&lt;/p&gt;

&lt;p&gt;platelet count 00,000/μL&lt;/p&gt;

&lt;p&gt;Neutropenia&lt;/p&gt;

&lt;h4 id=&quot;all-immunophenotypic-features&quot;&gt;ALL Immunophenotypic Features&lt;/h4&gt;

&lt;p&gt;Terminal deoxynucleotidyl transferase (TdT) -&amp;gt; pre-B and pre-T cells&lt;/p&gt;

&lt;p&gt;Further subtyping of ALL -&amp;gt; lineage-specific markers, such as CD19 (B cell) and CD3 (T cell).&lt;/p&gt;

&lt;h4 id=&quot;b-lymphoblastic-leukemialymphoma-immunophenotype&quot;&gt;B lymphoblastic leukemia/lymphoma: Immunophenotype&lt;/h4&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;CD19 – pan-B-cell marker&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD10  - Common Acute Lymphoblastic Leukemia Antigen (CALLA), most cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD34 – stem cell marker, most cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;TdT – nearly all cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cytoplasmic IgM heavy chain (μ chain)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Only in the more mature “late pre-B” cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Otherwise, ALL are negative for Ig&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Distinguishes ALL from mature B-cell leukemia/lymphoma&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;t-lymphoblastic-leukemialymphoma-immunophenotype&quot;&gt;T lymphoblastic leukemia/lymphoma: Immunophenotype&lt;/h4&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;TdT – many cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Most T-cell antigens positive: CD1a, CD2, cytoplasmic CD3, CD5, and CD7&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD1a - T-cell markers often negative: surface CD3, CD4 and CD8&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 and CD8 often negative in more immature forms&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 and CD8 often positive in more mature forms&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;b-lymphoblastic-leukemialymphoma-genetics&quot;&gt;B lymphoblastic leukemia/lymphoma: genetics&lt;/h4&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Abnormality&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Frequency&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Prognosis&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(v;11q23), MLL, early precursor&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2-3%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;strong&gt;unfavorable&lt;/strong&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(9;22), Ph1, BCR-ABL1&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;3-4%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;strong&gt;unfavorable&lt;/strong&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(25% adults)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(12;21) TEL/AML1&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;16-19%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;favorable&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Hyperdiploid &amp;gt; 50&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;20-25%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;favorable&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Hypodiploid&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;5%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;strong&gt;unfavorable&lt;/strong&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Antigen  Designation&lt;/th&gt;
      &lt;th style=&quot;text-align: left&quot;&gt;Normal Cellular Distribution&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily T-Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD1&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Thymocytes and Langerhans cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD3&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Thymocytes, mature T cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD4&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Helper T cells, subset of thymocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD5&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;T cells and a small subset of B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD8&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Cytotoxic T cells, subset of thymocytes, and some NK cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily B-Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;BCL6&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;a transcription factor required for the generation of germinal center B cells.&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD10&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pre-B cells and germinal-center B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD19&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pre-B cells and mature B cells but not plasma cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD20&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pre-B cells after C19 and mature B cells but not plasma  cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD21&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;EBV receptor; mature B cells and follicular dendritic cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD23&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Activated mature B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD79a&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Marrow pre-B cells and mature B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily Monocyte or Macrophage Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD11c&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Granulocytes, monocytes, and macrophages; also  expressed by hairy cell leukemias&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD13&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Immature and mature monocytes and granulocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD14&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Monocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD15&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Granulocytes; Reed-Sternberg cells and variants&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD33&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Myeloid progenitors and monocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD64&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Mature myeloid cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily NK-Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD16&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;NK cells and granulocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD56&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;NK cells and a subset of T cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily Stem Cell and Progenitor Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD34&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pluripotent hematopoietic stem cells and progenitor cells  of many lineages&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Activation Markers&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD30&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Activated B cells, T cells, and monocytes; Reed-Sternberg  cells and variants&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Present on All Leukocytes&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD45&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;All leukocytes; also known as leukocyte common antigen  (LCA)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Diagnosis&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Cell of Origin&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Genotype&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Salient Clinical Features&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Neoplasms of Immature B and T Cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;B-cell acute lymphoblastic  leukemia/lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Bone marrow precursor  B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse chromosomal translocations;  t(12;21) involving RUNX1 and ETV6  present in 25%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Predominantly children; symptoms relating to marrow  replacement and pancytopenia; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;T-cell acute lymphoblastic  leukemia/lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Precursor T cell (often  of thymic origin)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse chromosomal translocations,  NOTCH1 mutations (50%-70%)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Predominantly adolescent males; thymic masses and  variable bone marrow involvement; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Neoplasms of Mature B Cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Burkitt lymphoma*&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Germinal-center B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Translocations involving MYC and lg loci,  usually t(8;14); subset EBV-associated&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adolescents or young adults with extranodal masses;  uncommonly presents as “leukemia”; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diffuse large B-cell  lymphoma†&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Germinal-center or  postgerminal center  B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse chromosomal rearrangements,  most often of BCL6 (30%), BCL2 (10%),  or MYC (5%)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;All ages, but most common in older adults; often appears  as a rapidly growing mass; 30% extranodal; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Extranodal marginal zone  lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Memory B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(11;18), t(1;14), and t(14;18) creating  MALT1-IAP2, BCL10-IgH, and  MALT1-IgH fusion genes, respectively&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Arises at extranodal sites in adults with chronic  inflammatory diseases; may remain localized; indolent&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Follicular lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Germinal-center B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(14;18) creating BCL2-IgH fusion gene&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older adults with generalized lymphadenopathy and  marrow involvement; indolent&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Hairy cell leukemia&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Memory B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Activating BRAF mutations&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older males with pancytopenia and splenomegaly; indolent&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mantle cell lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Naive B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(11;14) creating CyclinD1-IgH fusion gene&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older males with disseminated disease; moderately  aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Multiple myeloma/solitary  plasmacytoma†&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Post-germinal-center  bone marrow homing  plasma cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse rearrangements involving IgH; 13q  deletions&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Myeloma: older adults with lytic bone lesions, pathologic  fractures, hypercalcemia, and renal failure; moderately  aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Plasmacytoma: isolated plasma cell masses in bone or  soft tissue; indolent&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Small lymphocytic  lymphoma/chronic  lymphocytic leukemia&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Naive B cell or memory  B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Trisomy 12, deletions of 11q, 13q, and  17p&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older adults with bone marrow, lymph node, spleen, and  liver disease; autoimmune hemolysis and  thrombocytopenia in a minority; indolent&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Neoplasms of Mature T Cells or NK Cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adult T-cell leukemia/ lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Helper T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;HTLV-1 provirus present in tumor cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adults with cutaneous lesions, marrow involvement, and  hypercalcemia; occurs mainly in Japan, West Africa,  and the Caribbean; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Peripheral T-cell lymphoma,  unspecified&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Helper or cytotoxic   T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;No specific chromosomal abnormality&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mainly older adults; usually presents with  lymphadenopathy; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Anaplastic large-cell  lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Cytotoxic T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Rearrangements of ALK (anaplastic large  cell lymphoma kinase) in a subset&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Children and young adults, usually with lymph node and  soft-tissue disease; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Extranodal NK/T-cell  lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;NK-cell (common) or  cytotoxic T cell (rare)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;EBV-associated; no specific chromosomal  abnormality&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adults with destructive extranodal masses, most  commonly sinonasal; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mycosis fungoides/Sézary  syndrome&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Helper T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;No specific chromosomal abnormality&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adult patients with cutaneous patches, plaques, nodules,  or generalized erythema; indolent&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Large granular lymphocytic  leukemia&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Two types: cytotoxic T  cell and NK cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Point mutations in STAT3&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adult patients with splenomegaly, neutropenia, and  anemia, sometimes, accompanied by autoimmune  disease&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;*Most common tumors in children&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;†Most common tumors in adults.&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; Ig, immunoglobulin; NK, natural killer.&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;Immunophenotype of chronic B-cell neoplasms&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;neoplasm&lt;/td&gt;
      &lt;td&gt;CD19CD20&lt;/td&gt;
      &lt;td&gt;CD5&lt;/td&gt;
      &lt;td&gt;CD10&lt;/td&gt;
      &lt;td&gt;CD23&lt;/td&gt;
      &lt;td&gt;sIg&lt;/td&gt;
      &lt;td&gt;CD103&lt;/td&gt;
      &lt;td&gt;Cyclin D1&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;CLL/SLL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-/+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;FL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;++&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MZL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+++&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;HCL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+++&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;+/-&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h4 id=&quot;leukocyte-alkaline-phosphatase&quot;&gt;Leukocyte alkaline phosphatase&lt;/h4&gt;

&lt;p&gt;Leukocyte alkaline phosphatase (LAP) is found within mature white blood cells. White blood cell levels of LAP can help in the diagnosis of certain conditions.&lt;/p&gt;

&lt;p&gt;Higher levels are seen in polycythemia vera (PV), essential thrombocytosis (ET), primary myelofibrosis (PM), and the leukemoid reaction.
Lower levels are found in chronic myelogenous leukemia(CML), paroxysmal nocturnal hemoglobinuria (PNH) and acute myelogenous leukaemia (AML).&lt;/p&gt;

&lt;h4 id=&quot;cllsll&quot;&gt;CLL/SLL&lt;/h4&gt;

&lt;p&gt;circulating  nucleated  red  cells  could  stem  from  premature  release  of  progenitors  in  the  face  of  severe anemia&lt;/p&gt;

&lt;p&gt;The most promising new therapy is BTK inhibitors, described earlier.&lt;/p&gt;

&lt;h3 id=&quot;blood-count-note&quot;&gt;blood count note&lt;/h3&gt;

&lt;p&gt;observing CBC and blood count&lt;/p&gt;

&lt;p&gt;platlet count -&amp;gt; thrombocytopenia&lt;/p&gt;

&lt;p&gt;Normal bone marrow -&amp;gt; exclude acute lymphoid or myeloid leukemia&lt;/p&gt;

&lt;p&gt;reduction in RBCs, WBCs, and platelet production -&amp;gt; aplastic anemia&lt;/p&gt;

&lt;p&gt;band neutrophil -&amp;gt; left shift -&amp;gt; inflammatory condition&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Hemodynamics Supplimentary Material</title>
   <link href="http://lanyon.getpoole.com/2015/10/12/hemodynamics-supplimentary-material/"/>
   <updated>2015-10-12T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/10/12/hemodynamics-supplimentary-material</id>
   <content type="html">
&lt;hr /&gt;
&lt;p&gt;layout: post
comments: True
title: Bleeding and Thrombotic Disorders
category: Pathology
tags: [pathology, diseases, textbook, Lab Med]
—&lt;/p&gt;

&lt;h2 id=&quot;hemodynamics-and-bleeding-disorders&quot;&gt;Hemodynamics and bleeding disorders&lt;/h2&gt;

&lt;p&gt;TABLE 2.-Causes of Pleural Effusions&lt;/p&gt;

&lt;h3 id=&quot;transudates&quot;&gt;Transudates&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Congestive heart failure&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cirrhosis with ascites&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Nephrotic syndrome Hypoalbuminemia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Peritoneal dialysis Atelectasis,acute&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Superior vena cava obstruction Subclavian catheter misplacement Early mediastinal malignancy&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;exudates&quot;&gt;Exudates&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Parapneumonic effusion (bacterial pneumonia) Pulmonary infarction&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Malignancy (direct pleural involvement, late mediasti-&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;nalinvolvement)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Viral disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Connective tissue disease (lupus, rheumatoid, mixed) Tuberculosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Fungal disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Parasitic disease (Entamoeba histolytica, Paragonimus&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;westermani)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Gastrpintestinal disease (pancreatitis, esophageal rup-&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ture, subphrenic abscess)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Drug reaction (nitrofurantoin, methysergide) Asbestos&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Meigs’ syndrome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Postmyocardial infarction and postcardiac surgical&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;operation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Trapped lung Lymphatic abnormality Uremic pleurisy Atelectasis,chronic Chylothorax Sarcoidosis&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;
</content>
 </entry>
 
 <entry>
   <title>Assignment 4 Creating graphs for your data</title>
   <link href="http://lanyon.getpoole.com/data%20science/2015/10/11/assignment4-creating-graph/"/>
   <updated>2015-10-11T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/data%20science/2015/10/11/assignment4-creating-graph</id>
   <content type="html">&lt;p&gt;to download my python code &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/Assignment%204.py&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;to download the dataset &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/gapminder.csv&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;to download the ipython notebook file &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/Assignment%204.ipynb.json&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;To visit my assignment result, please &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/Assignment%204.html&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;to visit my previous assignments for reference, &lt;a href=&quot;http://jizongl.github.io/DataManagement/&quot;&gt;please click here&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;instructions&quot;&gt;instructions&lt;/h3&gt;

&lt;p&gt;Continue with the program you’ve successfully run.&lt;/p&gt;

&lt;p&gt;STEP 1: Create graphs of your variables one at a time (univariate graphs).&lt;/p&gt;

&lt;p&gt;Examine both their center and spread.&lt;/p&gt;

&lt;p&gt;STEP 2: Create a graph showing the association between your explanatory and response variables (bivariate graph).&lt;/p&gt;

&lt;p&gt;Your output should be interpretable (i.e. organized and labeled).&lt;/p&gt;

&lt;h3 id=&quot;review-criteria-less&quot;&gt;Review Criteria less&lt;/h3&gt;

&lt;p&gt;Your assessment will be based on the evidence you provide that you have completed all of the steps. When relevant, gradients in the scoring will be available to reward clarity (for example, you will get one point for submitting graphs that do not accurately represent your data, but two points if the data is accurately represented). In all cases, consider that the peer assessing your work is likely not an expert in the field you are analyzing. You will be assessed equally on your description of your frequency distributions.&lt;/p&gt;

&lt;p&gt;Specific rubric items, and their point values, are as follows:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Was a univariate graph created for each of the selected variables? (2 points)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Was a bivariate graph created for the selected variables? (2 points)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Did the summary describe what the graphs revealed in terms of the individual&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;variables and the relationship between them? (2 points)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

</content>
 </entry>
 
 <entry>
   <title>Coagulation Small Group</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/10/05/small-group2-coagulation/"/>
   <updated>2015-10-05T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/10/05/small-group2-coagulation</id>
   <content type="html">&lt;p&gt;This post is written for the small group presentation on WBC, which is from the pathology course I take at UMMC&lt;/p&gt;

&lt;!--break--&gt;

&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#case-1&quot; id=&quot;markdown-toc-case-1&quot;&gt;Case 1&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#background-info&quot; id=&quot;markdown-toc-background-info&quot;&gt;background info&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#for-each-of-the-following-patient-signs-give-a-brief-description-of-possible-etiologies&quot; id=&quot;markdown-toc-for-each-of-the-following-patient-signs-give-a-brief-description-of-possible-etiologies&quot;&gt;1. For each of the following patient signs, give a brief description of possible etiologies:&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-coagulation-laboratory-tests-would-you-order-and-why&quot; id=&quot;markdown-toc-what-coagulation-laboratory-tests-would-you-order-and-why&quot;&gt;2. What coagulation laboratory tests would you order and why?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-your-interpretation-of-the-complete-blood-count-next-slide&quot; id=&quot;markdown-toc-what-is-your-interpretation-of-the-complete-blood-count-next-slide&quot;&gt;3. What is your interpretation of the complete blood count? (next slide)&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#cbc-count&quot; id=&quot;markdown-toc-cbc-count&quot;&gt;CBC count&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#wbc-differential&quot; id=&quot;markdown-toc-wbc-differential&quot;&gt;WBC differential&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-your-interpretation-of-the-following-coagulation-tests-what-do-these-results-rule-in-and-rule-out&quot; id=&quot;markdown-toc-what-is-your-interpretation-of-the-following-coagulation-tests-what-do-these-results-rule-in-and-rule-out&quot;&gt;￼4.  What is your interpretation of the following coagulation tests? What do these results rule-in and rule-out?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#based-on-these-initial-findings-mixing-studies-and-certain-factor-levels-next-question-are-performed-what-is-a-mixing-study-and-how-is-it-performed-what-information-does-a-mixing-study-provide-interpret-the-following-mixing-study-information&quot; id=&quot;markdown-toc-based-on-these-initial-findings-mixing-studies-and-certain-factor-levels-next-question-are-performed-what-is-a-mixing-study-and-how-is-it-performed-what-information-does-a-mixing-study-provide-interpret-the-following-mixing-study-information&quot;&gt;￼5. Based on these initial findings, mixing studies and certain factor levels (next question) are performed. What is a mixing study and how is it performed? What information does a mixing study provide? Interpret the following mixing study information:&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#how-would-you-correct-this-coagulation-problem&quot; id=&quot;markdown-toc-how-would-you-correct-this-coagulation-problem&quot;&gt;7. How would you correct this coagulation problem?&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#case-2&quot; id=&quot;markdown-toc-case-2&quot;&gt;Case 2&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#background-information&quot; id=&quot;markdown-toc-background-information&quot;&gt;background information&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-your-interpretation-of-the-complete-blood-count-next-slide-1&quot; id=&quot;markdown-toc-what-is-your-interpretation-of-the-complete-blood-count-next-slide-1&quot;&gt;8. What is your interpretation of the complete blood count (next slide)?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#cbc-count-1&quot; id=&quot;markdown-toc-cbc-count-1&quot;&gt;CBC count&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#wbc-differential-count&quot; id=&quot;markdown-toc-wbc-differential-count&quot;&gt;WBC differential count&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-coagulation-tests-would-you-order-and-why-look-at-the-test-results-what-is-your-interpretation-of-these-coagulation-tests-what-do-the-pfa-100-results-indicate&quot; id=&quot;markdown-toc-what-coagulation-tests-would-you-order-and-why-look-at-the-test-results-what-is-your-interpretation-of-these-coagulation-tests-what-do-the-pfa-100-results-indicate&quot;&gt;9. What coagulation tests would you order and why? Look at the test results. What is your interpretation of these coagulation tests? What do the PFA-100 results indicate?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#based-on-the-clinical-presentation-family-history-and-preliminary-laboratory-results-generate-a-differential-diagnosis-what-is-the-apparent-mode-of-inheritance&quot; id=&quot;markdown-toc-based-on-the-clinical-presentation-family-history-and-preliminary-laboratory-results-generate-a-differential-diagnosis-what-is-the-apparent-mode-of-inheritance&quot;&gt;10. Based on the clinical presentation, family history, and preliminary laboratory results, generate a differential diagnosis. What is the apparent mode of inheritance?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#a-mixing-study-is-performed-what-information-do-you-glean-from-the-results-do-you-have-a-working-diagnosis-how-do-you-explain-the-factor-viii-level&quot; id=&quot;markdown-toc-a-mixing-study-is-performed-what-information-do-you-glean-from-the-results-do-you-have-a-working-diagnosis-how-do-you-explain-the-factor-viii-level&quot;&gt;11. A mixing study is performed. What information do you glean from the results. Do you have a working diagnosis? How do you explain the factor VIII level?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#von-willebrand-disease-manifests-in-several-different-types-discuss-the-three-main-types-and-decide-what-type-of-von-willebrand-disease-this-patient-has&quot; id=&quot;markdown-toc-von-willebrand-disease-manifests-in-several-different-types-discuss-the-three-main-types-and-decide-what-type-of-von-willebrand-disease-this-patient-has&quot;&gt;13. Von Willebrand disease manifests in several different types. Discuss the three main types and decide what type of von Willebrand disease this patient has.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#how-would-you-manage-this-patients-current-excessive-bleeding-what-choices-are-available-if-surgery-is-required-in-the-future&quot; id=&quot;markdown-toc-how-would-you-manage-this-patients-current-excessive-bleeding-what-choices-are-available-if-surgery-is-required-in-the-future&quot;&gt;15. How would you manage this patient’s current excessive bleeding? What choices are available if surgery is required in the future?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#as-this-young-girl-reaches-the-age-of-60-her-bruising-may-decrease-why&quot; id=&quot;markdown-toc-as-this-young-girl-reaches-the-age-of-60-her-bruising-may-decrease-why&quot;&gt;16. As this young girl reaches the age of 60 her bruising may decrease. Why?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#why-is-the-blood-type-important-in-assessing-a-patient-for-von-willebrand-disease&quot; id=&quot;markdown-toc-why-is-the-blood-type-important-in-assessing-a-patient-for-von-willebrand-disease&quot;&gt;17. Why is the blood type important in assessing a patient for von Willebrand disease?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#briefly-describe-the-subtypes-of-type-2-von-willebrand-disease&quot; id=&quot;markdown-toc-briefly-describe-the-subtypes-of-type-2-von-willebrand-disease&quot;&gt;18.  Briefly describe the subtypes of type 2 von Willebrand disease.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-platelet-type-or-pseudo-vwd&quot; id=&quot;markdown-toc-what-is-platelet-type-or-pseudo-vwd&quot;&gt;19.  What is “platelet type” or “pseudo –vWD”?&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;case-1&quot;&gt;Case 1&lt;/h2&gt;

&lt;h3 id=&quot;background-info&quot;&gt;background info&lt;/h3&gt;

&lt;p&gt;An 89 year-old man is admitted to the hospital from a local nursing home with generalized weakness, nausea, vomiting, fever, mild hypertension, and right lower lobe crepitant rales. Additional findings include a pale, cachexic, edentulous, and extremely agitated elderly man who is mildly disoriented to time and place. Examination of the skin reveals numerous small bruises and ecchymoses on arms, forearms, thighs, and the dorsal aspect of both hands. The bruises are of different sizes and various ages. The larger bruises are the more recent bruises and are painful. Blood is noted to extravasate at the phlebotomy sites and bright red blood is noted peri-rectally. The chest x-ray reveals right, lower lobe pneumonia, and the EKG is normal.&lt;/p&gt;

&lt;p&gt;Family History: There is no family history of bleeding problems or bleeding disorders.&lt;/p&gt;

&lt;h3 id=&quot;for-each-of-the-following-patient-signs-give-a-brief-description-of-possible-etiologies&quot;&gt;1. For each of the following patient signs, give a brief description of possible etiologies:&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Bruising&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ecchymoses&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Extravasation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Rectal Bleeding&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-coagulation-laboratory-tests-would-you-order-and-why&quot;&gt;2. What coagulation laboratory tests would you order and why?&lt;/h3&gt;

&lt;h3 id=&quot;what-is-your-interpretation-of-the-complete-blood-count-next-slide&quot;&gt;3. What is your interpretation of the complete blood count? (next slide)&lt;/h3&gt;

&lt;h3 id=&quot;cbc-count&quot;&gt;CBC count&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;WBC:&lt;/td&gt;
      &lt;td&gt;15,000/mm3&lt;/td&gt;
      &lt;td&gt;(3.0-10.0X103)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Hgb:&lt;/td&gt;
      &lt;td&gt;10.1 mg/dl&lt;/td&gt;
      &lt;td&gt;(12.0-14.0)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Hct:&lt;/td&gt;
      &lt;td&gt;30.5%&lt;/td&gt;
      &lt;td&gt;(39.0-45.0)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;RBC:&lt;/td&gt;
      &lt;td&gt;2.90 m/mm3&lt;/td&gt;
      &lt;td&gt;(4.5-5.9)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCV:&lt;/td&gt;
      &lt;td&gt;89 fl&lt;/td&gt;
      &lt;td&gt;(85-99)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCH:&lt;/td&gt;
      &lt;td&gt;28 pg&lt;/td&gt;
      &lt;td&gt;(26-34)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCHC:&lt;/td&gt;
      &lt;td&gt;34%&lt;/td&gt;
      &lt;td&gt;(31-37)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;RDW:&lt;/td&gt;
      &lt;td&gt;13.0&lt;/td&gt;
      &lt;td&gt;(11.5-14.5)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Platelet Count:&lt;/td&gt;
      &lt;td&gt;200,000/mm3&lt;/td&gt;
      &lt;td&gt;(170-500,000/mm3)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;wbc-differential&quot;&gt;WBC differential&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Neutrophils&lt;/td&gt;
      &lt;td&gt;60%&lt;/td&gt;
      &lt;td&gt;(44-65)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Bands&lt;/td&gt;
      &lt;td&gt;25%&lt;/td&gt;
      &lt;td&gt;(0-10)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Eosinophils&lt;/td&gt;
      &lt;td&gt;2%&lt;/td&gt;
      &lt;td&gt;(0-9)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Basophils&lt;/td&gt;
      &lt;td&gt;1%&lt;/td&gt;
      &lt;td&gt;(0-4)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Monocytes&lt;/td&gt;
      &lt;td&gt;2%&lt;/td&gt;
      &lt;td&gt;(1-10)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Lymphocytes&lt;/td&gt;
      &lt;td&gt;10%&lt;/td&gt;
      &lt;td&gt;(25-46)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;what-is-your-interpretation-of-the-following-coagulation-tests-what-do-these-results-rule-in-and-rule-out&quot;&gt;￼4.  What is your interpretation of the following coagulation tests? What do these results rule-in and rule-out?&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Prothrombin time: 21.4 sec&lt;/td&gt;
      &lt;td&gt;(10.5-13.5 sec)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Partial thromboplastin time: 42 sec&lt;/td&gt;
      &lt;td&gt;(25.0-36.0 sec)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Fibrinogen: 310 mg/dl&lt;/td&gt;
      &lt;td&gt;(150-500 mg/dl)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;PFA-100:&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;ADP=110 sec closure&lt;/td&gt;
      &lt;td&gt;(70-120 sec closure)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Epinephrine=98 sec closure&lt;/td&gt;
      &lt;td&gt;(89-189 sec closure)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;based-on-these-initial-findings-mixing-studies-and-certain-factor-levels-next-question-are-performed-what-is-a-mixing-study-and-how-is-it-performed-what-information-does-a-mixing-study-provide-interpret-the-following-mixing-study-information&quot;&gt;￼5. Based on these initial findings, mixing studies and certain factor levels (next question) are performed. What is a mixing study and how is it performed? What information does a mixing study provide? Interpret the following mixing study information:&lt;/h3&gt;

&lt;p&gt;Mixing Study with PT:&lt;/p&gt;

&lt;p&gt;| :—: | :—: |
|Dilutions |   Results |
|1:1, 4:1  |  11, 12 seconds |
￼￼
### 6.  Interpret these factor levels. What factors are vitamin K dependent? (hint). What is the diagnosis?&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Factor&lt;/td&gt;
      &lt;td&gt;VII 20%&lt;/td&gt;
      &lt;td&gt;(50-150%)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Factor&lt;/td&gt;
      &lt;td&gt;V 110%&lt;/td&gt;
      &lt;td&gt;(50-150%)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;how-would-you-correct-this-coagulation-problem&quot;&gt;7. How would you correct this coagulation problem?&lt;/h3&gt;

&lt;h2 id=&quot;case-2&quot;&gt;Case 2&lt;/h2&gt;

&lt;h3 id=&quot;background-information&quot;&gt;background information&lt;/h3&gt;

&lt;p&gt;A pale but pleasant twelve year-old seventh grader began menses 14 months ago, and has had severe menorrhagia. She has had frequent nosebleeds since the age of four. An endocrine work-up is negative for anovulatory cycles. A careful history reveals her older sister, mother, and maternal aunt had similar menorrhagia. Her older brother and maternal uncle bruise easily and have frequent nosebleeds. All the members of her family are blood type 0 positive.&lt;/p&gt;

&lt;h3 id=&quot;what-is-your-interpretation-of-the-complete-blood-count-next-slide-1&quot;&gt;8. What is your interpretation of the complete blood count (next slide)?&lt;/h3&gt;

&lt;h3 id=&quot;cbc-count-1&quot;&gt;CBC count&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;WBC:&lt;/td&gt;
      &lt;td&gt;5400/mm3&lt;/td&gt;
      &lt;td&gt;(3.0-10.0X103)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Hgb:&lt;/td&gt;
      &lt;td&gt;10.1 mg/dl&lt;/td&gt;
      &lt;td&gt;(12.0-14.0)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Hct:&lt;/td&gt;
      &lt;td&gt;29.5%&lt;/td&gt;
      &lt;td&gt;(39.0-45.0)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;RBC:&lt;/td&gt;
      &lt;td&gt;2.89 m/mm3&lt;/td&gt;
      &lt;td&gt;(4.5-5.9)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCV:&lt;/td&gt;
      &lt;td&gt;72 fl&lt;/td&gt;
      &lt;td&gt;(85-99)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCH:&lt;/td&gt;
      &lt;td&gt;25 pg&lt;/td&gt;
      &lt;td&gt;(26-34)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCHC:&lt;/td&gt;
      &lt;td&gt;29%&lt;/td&gt;
      &lt;td&gt;(31-37)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;RDW:&lt;/td&gt;
      &lt;td&gt;16.0&lt;/td&gt;
      &lt;td&gt;(11.5-14.5)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Platelet Count:&lt;/td&gt;
      &lt;td&gt;210,000/mm3&lt;/td&gt;
      &lt;td&gt;(170-500,000/mm3)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;wbc-differential-count&quot;&gt;WBC differential count&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Neutrophils&lt;/td&gt;
      &lt;td&gt;46%&lt;/td&gt;
      &lt;td&gt;(44-65)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Bands&lt;/td&gt;
      &lt;td&gt;4%&lt;/td&gt;
      &lt;td&gt;(0-10)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Eosinophils&lt;/td&gt;
      &lt;td&gt;5%&lt;/td&gt;
      &lt;td&gt;(0-9)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Basophils&lt;/td&gt;
      &lt;td&gt;1%&lt;/td&gt;
      &lt;td&gt;(0-4)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Monocytes&lt;/td&gt;
      &lt;td&gt;9%&lt;/td&gt;
      &lt;td&gt;(1-10)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Lymphocytes&lt;/td&gt;
      &lt;td&gt;35%&lt;/td&gt;
      &lt;td&gt;(25-46)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;what-coagulation-tests-would-you-order-and-why-look-at-the-test-results-what-is-your-interpretation-of-these-coagulation-tests-what-do-the-pfa-100-results-indicate&quot;&gt;9. What coagulation tests would you order and why? Look at the test results. What is your interpretation of these coagulation tests? What do the PFA-100 results indicate?&lt;/h3&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Prothrombin time: 10.7 sec&lt;/td&gt;
      &lt;td&gt;(10.5-13.5 sec)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Partial thromboplastin time: 73 sec&lt;/td&gt;
      &lt;td&gt;(25.0-36.0 sec)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Bleeding time: &amp;gt;15.0 min&lt;/td&gt;
      &lt;td&gt;(2-9 min)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;PFA-100:&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;ADP=170 sec closure&lt;/td&gt;
      &lt;td&gt;(70-120 sec closure)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Epinephrine=270 sec closure&lt;/td&gt;
      &lt;td&gt;(89-189 sec closure)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;based-on-the-clinical-presentation-family-history-and-preliminary-laboratory-results-generate-a-differential-diagnosis-what-is-the-apparent-mode-of-inheritance&quot;&gt;10. Based on the clinical presentation, family history, and preliminary laboratory results, generate a differential diagnosis. What is the apparent mode of inheritance?&lt;/h3&gt;

&lt;h3 id=&quot;a-mixing-study-is-performed-what-information-do-you-glean-from-the-results-do-you-have-a-working-diagnosis-how-do-you-explain-the-factor-viii-level&quot;&gt;11. A mixing study is performed. What information do you glean from the results. Do you have a working diagnosis? How do you explain the factor VIII level?&lt;/h3&gt;

&lt;p&gt;Mixing study with PTT:&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Dilution&lt;/td&gt;
      &lt;td&gt;Results&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;1:1, 1:4&lt;/td&gt;
      &lt;td&gt;29, 32 sec&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Factor VIII&lt;/td&gt;
      &lt;td&gt;35%&lt;/td&gt;
      &lt;td&gt;[50-150%]&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;￼￼
### 12. Explain the following test results. Is the defect primarily of vWF quantity or quality? State the diagnosis.&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;von Willebrand cofactor assay&lt;/td&gt;
      &lt;td&gt;20%&lt;/td&gt;
      &lt;td&gt;[40-140%]&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;von Willebrand assay&lt;/td&gt;
      &lt;td&gt;15%&lt;/td&gt;
      &lt;td&gt;[45-180%]&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Multimer assay&lt;/td&gt;
      &lt;td&gt;Normal pattern&lt;/td&gt;
      &lt;td&gt; &lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;&lt;strong&gt;Hints:&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;von Willebrand cofactor assay=functional test 
von Willebrand assay=quantitative test&lt;/p&gt;

&lt;h3 id=&quot;von-willebrand-disease-manifests-in-several-different-types-discuss-the-three-main-types-and-decide-what-type-of-von-willebrand-disease-this-patient-has&quot;&gt;13. Von Willebrand disease manifests in several different types. Discuss the three main types and decide what type of von Willebrand disease this patient has.&lt;/h3&gt;
&lt;p&gt;￼
### 14. Describe acquired von Willebrand disease. What are the disease associations and proposed mechanisms?&lt;/p&gt;

&lt;h3 id=&quot;how-would-you-manage-this-patients-current-excessive-bleeding-what-choices-are-available-if-surgery-is-required-in-the-future&quot;&gt;15. How would you manage this patient’s current excessive bleeding? What choices are available if surgery is required in the future?&lt;/h3&gt;

&lt;h3 id=&quot;as-this-young-girl-reaches-the-age-of-60-her-bruising-may-decrease-why&quot;&gt;16. As this young girl reaches the age of 60 her bruising may decrease. Why?&lt;/h3&gt;

&lt;h3 id=&quot;why-is-the-blood-type-important-in-assessing-a-patient-for-von-willebrand-disease&quot;&gt;17. Why is the blood type important in assessing a patient for von Willebrand disease?&lt;/h3&gt;

&lt;h3 id=&quot;briefly-describe-the-subtypes-of-type-2-von-willebrand-disease&quot;&gt;18.  Briefly describe the subtypes of type 2 von Willebrand disease.&lt;/h3&gt;

&lt;h3 id=&quot;what-is-platelet-type-or-pseudo-vwd&quot;&gt;19.  What is “platelet type” or “pseudo –vWD”?&lt;/h3&gt;
</content>
 </entry>
 
 <entry>
   <title>WBC small group</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/10/05/small-group-wbc/"/>
   <updated>2015-10-05T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/10/05/small-group-wbc</id>
   <content type="html">&lt;p&gt;This post is written for the small group presentation on WBC, which is from the pathology course I take at UMMC&lt;/p&gt;

&lt;!--break--&gt;

&lt;p id=&quot;beginning&quot;&gt;&lt;/p&gt;

&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#case-1&quot; id=&quot;markdown-toc-case-1&quot;&gt;Case 1&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-your-differential-diagnosis-after-physical-examination&quot; id=&quot;markdown-toc-what-is-your-differential-diagnosis-after-physical-examination&quot;&gt;1. What is your differential diagnosis after physical examination?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-are-some-causes-of-bone-marrow-failure&quot; id=&quot;markdown-toc-what-are-some-causes-of-bone-marrow-failure&quot;&gt;2. What are some causes of bone marrow failure?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#cbc-results&quot; id=&quot;markdown-toc-cbc-results&quot;&gt;CBC Results:&lt;/a&gt;        &lt;ul&gt;
          &lt;li&gt;&lt;a href=&quot;#differential-&quot; id=&quot;markdown-toc-differential-&quot;&gt;Differential (%)&lt;/a&gt;&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#describe-the-findings-in-the-complete-blood-count--is-the-patient-anemic-and-if-so-how-would-you-describe-the-anemia--is-the-patient-neutropenic--explain-how-the-absolute-neutrophil-count-is-calculated--what-is-the-significance-of-neutropenia&quot; id=&quot;markdown-toc-describe-the-findings-in-the-complete-blood-count--is-the-patient-anemic-and-if-so-how-would-you-describe-the-anemia--is-the-patient-neutropenic--explain-how-the-absolute-neutrophil-count-is-calculated--what-is-the-significance-of-neutropenia&quot;&gt;3. Describe the findings in the complete blood count.  Is the patient anemic, and if so, how would you describe the anemia?  Is the patient neutropenic?  Explain how the absolute neutrophil count is calculated.  What is the significance of neutropenia?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#examine-the-peripheral-smear-and-describe-the-cells--what-are-these-cells-and-what-do-they-indicate&quot; id=&quot;markdown-toc-examine-the-peripheral-smear-and-describe-the-cells--what-are-these-cells-and-what-do-they-indicate&quot;&gt;4. Examine the peripheral smear and describe the cells.  What are these cells and what do they indicate?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-are-common-leukemias-that-afflict-children&quot; id=&quot;markdown-toc-what-are-common-leukemias-that-afflict-children&quot;&gt;5. What are common leukemias that afflict children?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-information-do-you-glean-from-these-cytochemical-stains&quot; id=&quot;markdown-toc-what-information-do-you-glean-from-these-cytochemical-stains&quot;&gt;6. What information do you glean from these cytochemical stains?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#more-description-for-patient&quot; id=&quot;markdown-toc-more-description-for-patient&quot;&gt;more description for patient&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#explain-the-flow-cytometry-results--how-do-immunophenotyping-studies-flow-cytometry-help-determine-the-diagnosis--refer-to-the-chart-of-lymphocyte-maturation-next-slide-for-a-reference&quot; id=&quot;markdown-toc-explain-the-flow-cytometry-results--how-do-immunophenotyping-studies-flow-cytometry-help-determine-the-diagnosis--refer-to-the-chart-of-lymphocyte-maturation-next-slide-for-a-reference&quot;&gt;7. Explain the flow cytometry results.  How do immunophenotyping studies (flow cytometry) help determine the diagnosis?  Refer to the chart of lymphocyte maturation (next slide) for a reference.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-do-you-see-in-the-bone-marrow-biopsy&quot; id=&quot;markdown-toc-what-do-you-see-in-the-bone-marrow-biopsy&quot;&gt;8. What do you see in the bone marrow biopsy?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-the-prognosis-for-this-patient-based-on-wbc-age-and-gender--describe-favorable-and-unfavorable-cytogenetic-findings-for-patients-with-all&quot; id=&quot;markdown-toc-what-is-the-prognosis-for-this-patient-based-on-wbc-age-and-gender--describe-favorable-and-unfavorable-cytogenetic-findings-for-patients-with-all&quot;&gt;9.  What is the prognosis for this patient based on WBC, age, and gender?  Describe favorable and unfavorable cytogenetic findings for patients with ALL.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#the-patient-is-treated-with-chemotherapy-including-vincristine-prednisone-and-l-asparaginase-with-intrathecal-methotrexate-mtx--why-is-intrathecal-treatment-indicated&quot; id=&quot;markdown-toc-the-patient-is-treated-with-chemotherapy-including-vincristine-prednisone-and-l-asparaginase-with-intrathecal-methotrexate-mtx--why-is-intrathecal-treatment-indicated&quot;&gt;10. The patient is treated with chemotherapy including vincristine, prednisone, and L-asparaginase with intrathecal methotrexate (MTX).  Why is intrathecal treatment indicated?&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#case-2&quot; id=&quot;markdown-toc-case-2&quot;&gt;Case 2&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#case-history&quot; id=&quot;markdown-toc-case-history&quot;&gt;Case History&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#cbc-results-1&quot; id=&quot;markdown-toc-cbc-results-1&quot;&gt;CBC Results:&lt;/a&gt;        &lt;ul&gt;
          &lt;li&gt;&lt;a href=&quot;#wbc-differential-&quot; id=&quot;markdown-toc-wbc-differential-&quot;&gt;WBC Differential (%)&lt;/a&gt;&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#questions&quot; id=&quot;markdown-toc-questions&quot;&gt;QUESTIONS&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-does-the-cbc-reveal&quot; id=&quot;markdown-toc-what-does-the-cbc-reveal&quot;&gt;11. What does the CBC reveal?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#examine-the-peripheral-smear--describe-your-findings-particularly-the-nuclear-features-of-the-neutrophils--what-is-this-phenomenon-called-and-when-may-it-be-seen&quot; id=&quot;markdown-toc-examine-the-peripheral-smear--describe-your-findings-particularly-the-nuclear-features-of-the-neutrophils--what-is-this-phenomenon-called-and-when-may-it-be-seen&quot;&gt;12. Examine the peripheral smear.  Describe your findings, particularly the nuclear features of the neutrophils.  What is this phenomenon called and when may it be seen?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-your-differential-diagnosis&quot; id=&quot;markdown-toc-what-is-your-differential-diagnosis&quot;&gt;13. What is your differential diagnosis?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-the-next-diagnostic-test-which-should-be-performed-and-why&quot; id=&quot;markdown-toc-what-is-the-next-diagnostic-test-which-should-be-performed-and-why&quot;&gt;14. What is the next diagnostic test which should be performed and why?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#examine-the-bone-marrow-aspirate-and-biopsy-slides-2-5--describe-your-findings--what-are-typical-marrow-findings-in-myelodysplastic-syndromes&quot; id=&quot;markdown-toc-examine-the-bone-marrow-aspirate-and-biopsy-slides-2-5--describe-your-findings--what-are-typical-marrow-findings-in-myelodysplastic-syndromes&quot;&gt;15. Examine the bone marrow aspirate and biopsy (slides 2-5).  Describe your findings.  What are typical marrow findings in myelodysplastic syndromes?&lt;/a&gt;        &lt;ul&gt;
          &lt;li&gt;&lt;a href=&quot;#bone-marrow-aspirate-and-biopsy-slides-2-5-for-case-2&quot; id=&quot;markdown-toc-bone-marrow-aspirate-and-biopsy-slides-2-5-for-case-2&quot;&gt;bone marrow aspirate and biopsy (slides 2-5) for case 2&lt;/a&gt;&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#describe-low-and-high-grade-myelodysplastic-syndromes-in-terms-of-marrow-cellularity&quot; id=&quot;markdown-toc-describe-low-and-high-grade-myelodysplastic-syndromes-in-terms-of-marrow-cellularity&quot;&gt;16. Describe low and high-grade myelodysplastic syndromes in terms of marrow cellularity.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-aleukemic-leukemia&quot; id=&quot;markdown-toc-what-is-aleukemic-leukemia&quot;&gt;17. What is aleukemic leukemia?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-findings-might-you-expect-on-a-karyotyping-study-of-the-marrow-in-mds--what-is-the-most-common-cytogenetic-abnormality-in-acute-myeloid-leukemia&quot; id=&quot;markdown-toc-what-findings-might-you-expect-on-a-karyotyping-study-of-the-marrow-in-mds--what-is-the-most-common-cytogenetic-abnormality-in-acute-myeloid-leukemia&quot;&gt;18. What findings might you expect on a karyotyping study of the marrow in MDS?  What is the most common cytogenetic abnormality in acute myeloid leukemia?&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#what-is-the-prognosis-for-mds--describe-treatments-for-myelodysplastic-syndrome--what-are-causes-of-death-in-myelodysplastic-syndrome&quot; id=&quot;markdown-toc-what-is-the-prognosis-for-mds--describe-treatments-for-myelodysplastic-syndrome--what-are-causes-of-death-in-myelodysplastic-syndrome&quot;&gt;19. What is the prognosis for MDS?  Describe treatments for myelodysplastic syndrome.  What are causes of death in myelodysplastic syndrome?&lt;/a&gt;        &lt;ul&gt;
          &lt;li&gt;&lt;a href=&quot;#prognosis&quot; id=&quot;markdown-toc-prognosis&quot;&gt;prognosis&lt;/a&gt;&lt;/li&gt;
          &lt;li&gt;&lt;a href=&quot;#cause-of-death&quot; id=&quot;markdown-toc-cause-of-death&quot;&gt;cause of death&lt;/a&gt;&lt;/li&gt;
          &lt;li&gt;&lt;a href=&quot;#treatment&quot; id=&quot;markdown-toc-treatment&quot;&gt;treatment&lt;/a&gt;&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;case-1&quot;&gt;Case 1&lt;/h2&gt;

&lt;h3 id=&quot;what-is-your-differential-diagnosis-after-physical-examination&quot;&gt;1. What is your differential diagnosis after physical examination?&lt;/h3&gt;

&lt;h3 id=&quot;what-are-some-causes-of-bone-marrow-failure&quot;&gt;2. What are some causes of bone marrow failure?&lt;/h3&gt;

&lt;h3 id=&quot;cbc-results&quot;&gt;CBC Results:&lt;/h3&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;patient&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Reference Interval&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;WBC=9,000/mm3&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(4000-11,000/mm3)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;HGB=9 g/dL&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(12-15 g/dL)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;HCT=27%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(31-43%)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;MCV=86 fL&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(80-99 fL)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;MCHC=32%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(31-37%)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;RDW=13.0&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(11.5-14.5)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;PLATELETS=55,000/mm3&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(130-400,000/mm3)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h4 id=&quot;differential-&quot;&gt;Differential (%)&lt;/h4&gt;

&lt;p&gt;5 segmented neutrophils, 15 lymphocytes, 5 monocytes, 75 blasts.&lt;/p&gt;

&lt;h3 id=&quot;describe-the-findings-in-the-complete-blood-count--is-the-patient-anemic-and-if-so-how-would-you-describe-the-anemia--is-the-patient-neutropenic--explain-how-the-absolute-neutrophil-count-is-calculated--what-is-the-significance-of-neutropenia&quot;&gt;3. Describe the findings in the complete blood count.  Is the patient anemic, and if so, how would you describe the anemia?  Is the patient neutropenic?  Explain how the absolute neutrophil count is calculated.  What is the significance of neutropenia?&lt;/h3&gt;

&lt;h3 id=&quot;examine-the-peripheral-smear-and-describe-the-cells--what-are-these-cells-and-what-do-they-indicate&quot;&gt;4. Examine the peripheral smear and describe the cells.  What are these cells and what do they indicate?&lt;/h3&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/1.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/1.jpeg&quot; alt=&quot;slide1&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Peripheral blood smear with lymphoblasts  &lt;/div&gt;
&lt;/div&gt;

&lt;h3 id=&quot;what-are-common-leukemias-that-afflict-children&quot;&gt;5. What are common leukemias that afflict children?&lt;/h3&gt;

&lt;h3 id=&quot;what-information-do-you-glean-from-these-cytochemical-stains&quot;&gt;6. What information do you glean from these cytochemical stains?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Sudan black B and myeloperoxidase - negative in blasts, positive in normal neutrophils&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;PAS - block positivity in blasts (see figure below)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Specific and non-specific esterases - negative in blasts&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/2.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/2.jpeg&quot; alt=&quot;slide2&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Lymphoblasts with characteristic “block” or globular PAS positivity &lt;/div&gt;
&lt;/div&gt;

&lt;h3 id=&quot;more-description-for-patient&quot;&gt;more description for patient&lt;/h3&gt;

&lt;p&gt;The lab calls you with the CBC results as the patient is being taken to Radiology.  At this point, you decide a bone marrow biopsy is more important than the X-ray and call the patient back for a marrow biopsy, sending an aspirate to the Immunopathology Lab for flow cytometry immunophenotyping of the blasts.&lt;/p&gt;

&lt;h3 id=&quot;explain-the-flow-cytometry-results--how-do-immunophenotyping-studies-flow-cytometry-help-determine-the-diagnosis--refer-to-the-chart-of-lymphocyte-maturation-next-slide-for-a-reference&quot;&gt;7. Explain the flow cytometry results.  How do immunophenotyping studies (flow cytometry) help determine the diagnosis?  Refer to the chart of lymphocyte maturation (next slide) for a reference.&lt;/h3&gt;

&lt;p&gt;CD45  leukocyte common antigen (LCA)
CD34  CD117 - blast/stem cell marker
HLA-DR  (early myeloid and B-cells)
TdT (lymphoid)
CD 10,19,20 are positive, indicates lymphoid (B-lineage) 
CD2,3,5 are negatives, rule out peripheral T-cell lymphomas -lymphoid (T-lineage)&lt;/p&gt;

&lt;p&gt;kappa and lambda are negative - rule out Plasma Cell Neoplasms and Related Disorders&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;CD45&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
      &lt;td&gt;Surface kappa&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;CD34&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
      &lt;td&gt;Surface lambda&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;HLA-DR&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
      &lt;td&gt;CD2&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;TdT&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
      &lt;td&gt;CD3&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;CD20&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
      &lt;td&gt;CD5&lt;/td&gt;
      &lt;td&gt;negative&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;CD19&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
      &lt;td&gt;CD10&lt;/td&gt;
      &lt;td&gt;positive&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/3.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/3.jpeg&quot; alt=&quot;slide3&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Lymphocyte development (B and T)&lt;/div&gt;
&lt;/div&gt;

&lt;h3 id=&quot;what-do-you-see-in-the-bone-marrow-biopsy&quot;&gt;8. What do you see in the bone marrow biopsy?&lt;/h3&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/4.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/4.jpeg&quot; alt=&quot;slide4&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;
		normal &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/5.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/5.jpeg&quot; alt=&quot;slide4&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;
	 acute leukemia &lt;/div&gt;
&lt;/div&gt;

&lt;h3 id=&quot;what-is-the-prognosis-for-this-patient-based-on-wbc-age-and-gender--describe-favorable-and-unfavorable-cytogenetic-findings-for-patients-with-all&quot;&gt;9.  What is the prognosis for this patient based on WBC, age, and gender?  Describe favorable and unfavorable cytogenetic findings for patients with ALL.&lt;/h3&gt;

&lt;p&gt;B-ALL
Children: 95% remission; 80% appear to be cured.&lt;/p&gt;

&lt;p&gt;11 q23&lt;/p&gt;

&lt;p&gt;Adults: 60-85% remission. Genetics not as well characterized as in children (25% have Ph1 chromosome.
B-LBL
High remission rate. Median survival 5 years&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;#beginning&quot;&gt;back to the top&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;the-patient-is-treated-with-chemotherapy-including-vincristine-prednisone-and-l-asparaginase-with-intrathecal-methotrexate-mtx--why-is-intrathecal-treatment-indicated&quot;&gt;10. The patient is treated with chemotherapy including vincristine, prednisone, and L-asparaginase with intrathecal methotrexate (MTX).  Why is intrathecal treatment indicated?&lt;/h3&gt;

&lt;p&gt;a lot of chemo drugs don’t pass the brain blood barrior. so it needs Intrathecal therapy&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a. What is the mechanism of the chemotherapeutic agents in general?&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;targeting rapidly deviding cells&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;b. With what enzyme does methotrexate (MTX) interfere?&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;dihydrofolate reductase&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;c. What is complete remission (CR)?&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;dispearance of signs of cancer cells&lt;/p&gt;

&lt;p&gt;the blast number should be at 5% or less&lt;/p&gt;

&lt;h2 id=&quot;case-2&quot;&gt;Case 2&lt;/h2&gt;

&lt;h3 id=&quot;case-history&quot;&gt;Case History&lt;/h3&gt;

&lt;p&gt;The patient is a 77 year-old man with &lt;strong&gt;extreme fatigue and malaise&lt;/strong&gt;.  He saw a doctor at a walk-in clinic seven months ago for similar complaints.  He shows you the prescription given to him then, which he has faithfully taken.  It is a &lt;strong&gt;multivitamin with iron&lt;/strong&gt;.  He is on no other medications.  He is thin, but not cachectic and he appears tired.&lt;/p&gt;

&lt;p&gt;No abnormalities are found on physical exam except for &lt;strong&gt;petechiae&lt;/strong&gt;, a few &lt;strong&gt;bruises&lt;/strong&gt; on his lower legs, &lt;strong&gt;pallor and pale mucous membranes&lt;/strong&gt;.  The digital rectal exam shows no enlargement of the prostate gland and the stool guaiac test is negative for occult blood.  You send a blood sample in a purple top (EDTA) tube for a CBC with reticulocyte count.&lt;/p&gt;

&lt;h3 id=&quot;cbc-results-1&quot;&gt;CBC Results:&lt;/h3&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;patient&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Reference Interval&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;WBC=1,180/mm&lt;sup&gt;3&lt;/sup&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(4000-11,000/mm&lt;sup&gt;3&lt;/sup&gt;)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;HGB=10 g/dL&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(14-18 g/dL)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;HCT=30%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(42-49%)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;MCV=103 fL&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(80-99 fL)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;MCHC=33 g/dL&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(31-37 g/dL)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;RDW=20&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(11.5-14.5)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;PLATELETS=50,000/mm3&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(130,-400,000/mm3)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;RETICULOCYTE (%)=0.1 %&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(0.5-1.5%, manual)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h4 id=&quot;wbc-differential-&quot;&gt;WBC Differential (%)&lt;/h4&gt;

&lt;p&gt;65 segs, 30 lymphocytes, 5 monocytes&lt;/p&gt;

&lt;h3 id=&quot;questions&quot;&gt;QUESTIONS&lt;/h3&gt;

&lt;h3 id=&quot;what-does-the-cbc-reveal&quot;&gt;11. What does the CBC reveal?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;low htc (anemia), low WBC(pan-cytopenias),low platelets indicates haematopoiesis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;high MCV &amp;gt;100fL (macrocytosis), the multivitamin given previously was for B12 deficiency.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Abnormal RBC maturation (eg, myelodysplastic syndrome, acute leukemia, LGL leukemia)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;low reticulocyte (either it is not produced, the &lt;strong&gt;bone marrow&lt;/strong&gt; is not functioning)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;WEB differential does not mention any blast.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;examine-the-peripheral-smear--describe-your-findings-particularly-the-nuclear-features-of-the-neutrophils--what-is-this-phenomenon-called-and-when-may-it-be-seen&quot;&gt;12. Examine the peripheral smear.  Describe your findings, particularly the nuclear features of the neutrophils.  What is this phenomenon called and when may it be seen?&lt;/h3&gt;

&lt;p&gt;neutrophils appear bilobed, indicative of Pelger-Huet anomaly. It may be seen in Myelodysplastic Syndromes&lt;/p&gt;

&lt;p&gt;note: when seeing hypersegmented nutrophils, think of B12 deficiency&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/pathology/smallGroup/WBC/6.jpeg&quot; alt=&quot;Peripheral blood film&quot; /&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-your-differential-diagnosis&quot;&gt;13. What is your differential diagnosis?&lt;/h3&gt;

&lt;p&gt;old age, fatigue, anemia , pallor and pale mucous membranes,&lt;/p&gt;

&lt;p&gt;bruise and petechiae assoicated with low platelets count (thrombocytopenia.)&lt;/p&gt;

&lt;p&gt;Pelger-Huet anomaly&lt;/p&gt;

&lt;p&gt;low htc, low WBC(pan-cytopenias),low platelets indicates haematopoiesis&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;note&lt;/strong&gt; patient previous was given iron treatment, and he did not response to it.&lt;/p&gt;

&lt;p&gt;also consider drug toxicity&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-next-diagnostic-test-which-should-be-performed-and-why&quot;&gt;14. What is the next diagnostic test which should be performed and why?&lt;/h3&gt;

&lt;p&gt;&lt;a href=&quot;http://www.cancer.org/cancer/myelodysplasticsyndrome/detailedguide/myelodysplastic-syndromes-diagnosis&quot;&gt;Bone marrow tests&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;trilineage of the cells&lt;/p&gt;

&lt;p&gt;aspirate provides morphological features and architecture of the cells.&lt;/p&gt;

&lt;p&gt;adjust cellularity&lt;/p&gt;

&lt;p&gt;send to cytogenetic for abnormality&lt;/p&gt;

&lt;p&gt;and float cytometry&lt;/p&gt;

&lt;p&gt;These tests are used first for diagnosis and classification and may be repeated later to tell if the MDS is responding to therapy or is transforming into an acute leukemia.&lt;/p&gt;

&lt;h3 id=&quot;examine-the-bone-marrow-aspirate-and-biopsy-slides-2-5--describe-your-findings--what-are-typical-marrow-findings-in-myelodysplastic-syndromes&quot;&gt;15. Examine the bone marrow aspirate and biopsy (slides 2-5).  Describe your findings.  What are typical marrow findings in myelodysplastic syndromes?&lt;/h3&gt;

&lt;p&gt;1 Bone marrow biopsy showed 100% cellularity (hypercellularity) with erythroid predominance and granulocytic and megakaryocytic dyspoiesis&lt;/p&gt;

&lt;p&gt;2 dysplastic red cell precursors manifested by abnormal nuclear contours, nuclear budding, and other abnormalities of nuclei&lt;/p&gt;

&lt;p&gt;dysmegakaryopoiesis, erythoroid precursor.&lt;/p&gt;

&lt;p&gt;3 Significant erythroid predominance with dyserythropoiesis and with &lt;strong&gt;Auer rod&lt;/strong&gt;. (confirmed it is AML)&lt;/p&gt;

&lt;p&gt;large N/C ratio. has large cytoplasm.&lt;/p&gt;

&lt;p&gt;4 Hypercellular bone marrow with dysmegakaryopoiesis.&lt;/p&gt;

&lt;h4 id=&quot;bone-marrow-aspirate-and-biopsy-slides-2-5-for-case-2&quot;&gt;bone marrow aspirate and biopsy (slides 2-5) for case 2&lt;/h4&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/7.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/7.jpeg&quot; alt=&quot;slide2&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Bone marrow biopsy with predominance of blasts &lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/8.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/8.jpeg&quot; alt=&quot;slide3&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Marked dyserythropoiesis in marrow&lt;/div&gt;
&lt;/div&gt;

&lt;p&gt;Prominent erythroid dysplasia and rare dysplastic granulocytic precursors&lt;/p&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/9.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/9.jpeg&quot; alt=&quot;slide4&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
   &lt;div class=&quot;desc&quot;&gt;Cluster of myeloblasts—one has an Auer rod&lt;/div&gt;



&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/smallGroup/WBC/10.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/smallGroup/WBC/10.jpeg&quot; alt=&quot;slide5&quot; width=&quot;180&quot; height=&quot;150&quot; /&gt;
  &lt;/a&gt;
    &lt;div class=&quot;desc&quot;&gt;Marrow depicting abnormal localization of immature precursors&lt;/div&gt;
&lt;/div&gt;
&lt;p&gt;Lymphoid aggregate in a background of hypercellular bone marrow.&lt;/p&gt;

&lt;h3 id=&quot;describe-low-and-high-grade-myelodysplastic-syndromes-in-terms-of-marrow-cellularity&quot;&gt;16. Describe low and high-grade myelodysplastic syndromes in terms of marrow cellularity.&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;progress slowly and may cause mild to moderate anemia (a low number of red cells), or decrements to other types of cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;higher blast counts and more severe cytopenias, as well as the presence of multiple clonal chromosomal abnormalities.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;em&gt;additional information&lt;/em&gt; (see &lt;a href=&quot;http://www.hopkinsmedicine.org/kimmel_cancer_center/types_cancer/myelodysplastic_syndrome.html&quot;&gt;source here&lt;/a&gt;)&lt;/p&gt;

&lt;p&gt;grade 1&lt;/p&gt;

&lt;p&gt;5%  to 9%&lt;/p&gt;

&lt;p&gt;grade 2
10% to 19%&lt;/p&gt;

&lt;p&gt;if auer rod is present, it is considered grade 2&lt;/p&gt;

&lt;p&gt;&lt;em&gt;immature cells called blast cells make up more than 5 percent of the cells in the marrow.&lt;/em&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;When MDS patients develop more than 20 percent blast cells, they are reclassified as having acute myelogenous leukemia (AML)*&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-is-aleukemic-leukemia&quot;&gt;17. What is aleukemic leukemia?&lt;/h3&gt;

&lt;p&gt;blasts are entirely absent from the blood (aleukemic leukemia).&lt;/p&gt;

&lt;p&gt;can happen in any of the 4 major leukemias.&lt;/p&gt;

&lt;h3 id=&quot;what-findings-might-you-expect-on-a-karyotyping-study-of-the-marrow-in-mds--what-is-the-most-common-cytogenetic-abnormality-in-acute-myeloid-leukemia&quot;&gt;18. What findings might you expect on a karyotyping study of the marrow in MDS?  What is the most common cytogenetic abnormality in acute myeloid leukemia?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Monosomies 5 and 7&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Deletions of 5q, 7q, and 20q&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Trisomy 8&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;deletion 5q isolation, has better pronosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;7 q is worse&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-is-the-prognosis-for-mds--describe-treatments-for-myelodysplastic-syndrome--what-are-causes-of-death-in-myelodysplastic-syndrome&quot;&gt;19. What is the prognosis for MDS?  Describe treatments for myelodysplastic syndrome.  What are causes of death in myelodysplastic syndrome?&lt;/h3&gt;

&lt;h4 id=&quot;prognosis&quot;&gt;prognosis&lt;/h4&gt;

&lt;p&gt;The median survival in primary MDS varies from 9 to 29 months, but some individuals in good prognostic groups may live for 5 years or more.&lt;/p&gt;

&lt;p&gt;Overall, progression to AML occurs in 10% to 40% of individuals and is usually accompanied by the appearance of additional cytogenetic abnormalities.&lt;/p&gt;

&lt;h4 id=&quot;cause-of-death&quot;&gt;cause of death&lt;/h4&gt;

&lt;p&gt;Patients often succumb to the complications of thrombocytopenia (bleeding) and neutropenia (infection). The outlook is even grimmer in t-MDS, which has a median survival of only 4 to 8 months. &lt;strong&gt;bleeding is the major cause&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In t-MDS, cytopenias tend to be more severe and progression to AML is often rapid.&lt;/p&gt;

&lt;h4 id=&quot;treatment&quot;&gt;treatment&lt;/h4&gt;

&lt;ul&gt;
  &lt;li&gt;In younger patients&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;allogeneic hematopoietic stem cell transplantation offers hope for reconstitution of normal hematopoiesis and possible cure.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Older patients&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Supportively with antibiotics and blood product transfusions.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Thalidomide-like drugs&lt;/strong&gt; and DNA methylation inhibitors improve the effectiveness of hematopoiesis and the peripheral blood counts in a subset of patients. (no longer use)&lt;/p&gt;

&lt;p&gt;The presence of isolated 5q- is correlated with a hematologic response to thalidomide-like drugs, but as yet response to DNA methylation inhibitors is unpredictable.&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Assignment 3 Data Management and EDA</title>
   <link href="http://lanyon.getpoole.com/data%20science/2015/10/04/Data-Management-Assignment3/"/>
   <updated>2015-10-04T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/data%20science/2015/10/04/Data-Management-Assignment3</id>
   <content type="html">&lt;h2 id=&quot;instructions&quot;&gt;Instructions&lt;/h2&gt;

&lt;p&gt;This week, you will be making and implementing decisions about data management for the variables that you have chosen to examine based on the steps reviewed in the videos and supplemental materials. This assignment is important because it offers you the opportunity to practice making sound data management decisions and think about how these decisions will impact your research.&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;You can download my python code file &lt;a href=&quot;/assets/couseraAssignment/DataManagement/week3/week3assignment.py&quot;&gt;here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;And you can download the gapminder dataset &lt;a href=&quot;/assets/couseraAssignment/DataManagement/week3/gapminder.csv&quot;&gt;csv file here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;And you can review my Assignment for the codebook &lt;a href=&quot;http://jizongl.github.io/data%20science/2015/09/19/Data-Management-Assignment1/&quot;&gt;here&lt;/a&gt;&lt;/p&gt;

&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#instructions&quot; id=&quot;markdown-toc-instructions&quot;&gt;Instructions&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#import-the-entire-dataset-to-memory&quot; id=&quot;markdown-toc-import-the-entire-dataset-to-memory&quot;&gt;import the entire dataset to memory&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#some-house-keeping-to-the-dataset&quot; id=&quot;markdown-toc-some-house-keeping-to-the-dataset&quot;&gt;some house keeping to the dataset&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#i-am-interested-to-divided-urbanrate-into-4-percentiles-so-i-coded-with-both-methods-introduced-from-the-video-as-follow&quot; id=&quot;markdown-toc-i-am-interested-to-divided-urbanrate-into-4-percentiles-so-i-coded-with-both-methods-introduced-from-the-video-as-follow&quot;&gt;I am interested to divided urbanrate into 4 percentiles, so I coded with both methods introduced from the video as follow&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#result&quot; id=&quot;markdown-toc-result&quot;&gt;result&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#use-crosstab-function-to-make-cross-counts-for-both-newly-created-variables-urbanratenew--urbanratenew2-and-the-original-variable-urbanrate&quot; id=&quot;markdown-toc-use-crosstab-function-to-make-cross-counts-for-both-newly-created-variables-urbanratenew--urbanratenew2-and-the-original-variable-urbanrate&quot;&gt;Use &lt;strong&gt;crosstab()&lt;/strong&gt; function to make cross counts for both newly created variables (urbanrateNew &amp;amp; urbanrateNew2) and the original variable urbanrate.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#result-of-crosstable-count-for-both-methods&quot; id=&quot;markdown-toc-result-of-crosstable-count-for-both-methods&quot;&gt;result of crosstable count for both methods&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#review-criteria&quot; id=&quot;markdown-toc-review-criteria&quot;&gt;Review Criteria&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;import-the-entire-dataset-to-memory&quot;&gt;import the entire dataset to memory&lt;/h3&gt;
&lt;pre&gt;
pre&lt;code&gt;
import pandas
import numpy
&lt;/code&gt;
&lt;/pre&gt;

&lt;h3 id=&quot;some-house-keeping-to-the-dataset&quot;&gt;some house keeping to the dataset&lt;/h3&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;	
print(&quot;Import the entire dataset to memory&quot;)
data = pandas.read_csv(&quot;gapminder.csv&quot;, low_memory = False)

print(&quot;upper case all DataFrame column names&quot;)
data.columns = map(str.lower, data.columns)

print(&quot;avoid run time error message&quot;)
pandas.set_option(&#39;display.float_format&#39;, lambda x:&#39;%f&#39;%x)

print(&quot;convert strings to numerics&quot;)
data[&#39;alcconsumption&#39;] = data[&#39;alcconsumption&#39;].convert_objects(convert_numeric=True)
data[&#39;alcconsumption&#39;] = data[&#39;alcconsumption&#39;].convert_objects(convert_numeric=True)
data[&#39;relectricperperson&#39;] = data[&#39;relectricperperson&#39;].convert_objects(convert_numeric=True)
data[&#39;urbanrate&#39;] = data[&#39;urbanrate&#39;].convert_objects(convert_numeric=True)
data[&#39;internetuserate&#39;] = data[&#39;internetuserate&#39;].convert_objects(convert_numeric=True)
data[&#39;hivrate&#39;] = data[&#39;hivrate&#39;].convert_objects(convert_numeric=True)

print(&quot;Set mission data to NAN&quot;)
data[&#39;alcconsumption&#39;] = data[&#39;alcconsumption&#39;].replace(0, numpy.nan)
data[&quot;lifeexpectancy&quot;] = data[&quot;lifeexpectancy&quot;].replace(0, numpy.nan)
data[&quot;relectricperperson&quot;] = data[&quot;relectricperperson&quot;].replace(0, numpy.nan)
data[&#39;urbanrate&#39;] = data[&#39;urbanrate&#39;].replace(0, numpy.nan)
data[&quot;internetuserate&quot;] = data[&quot;internetuserate&quot;].replace(0, numpy.nan)
data[&#39;hivrate&#39;] = data[&#39;hivrate&#39;].replace(0, numpy.nan)
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;	
print(&#39;create sub2 dataset to include only variables of interest.&#39;)
sub2 = data[[&#39;alcconsumption&#39;,&#39;lifeexpectancy&#39;,&#39;relectricperperson&#39;,&#39;urbanrate&#39;, &#39;internetuserate&#39;,&#39;hivrate&#39;]]

print(&#39;preview dataset&#39;)
print(sub2.head(n=10))

   alcconsumption lifeexpectancy  relectricperperson  urbanrate  \
0        0.030000         48.673                 nan  24.040000   
1        7.290000         76.918          636.341383  46.720000   
2        0.690000         73.131          590.509814  65.220000   
3       10.170000                                nan  88.920000   
4        5.570000         51.093          172.999227  56.700000   
5        8.170000                                nan  30.460000   
6        9.350000         75.901          768.428300  92.000000   
7       13.660000         74.241          603.763058  63.860000   
8             nan         75.246                 nan  46.780000   
9       10.210000         81.907         2825.391095  88.740000   

   internetuserate  hivrate  
0         3.654122      nan  
1        44.989947      nan  
2        12.500073 0.100000  
3        81.000000      nan  
4         9.999954 2.000000  
5        80.645455      nan  
6        36.000335 0.500000  
7        44.001025 0.100000  
8        41.800889      nan  
9        75.895654 0.100000  
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;h3 id=&quot;i-am-interested-to-divided-urbanrate-into-4-percentiles-so-i-coded-with-both-methods-introduced-from-the-video-as-follow&quot;&gt;I am interested to divided urbanrate into 4 percentiles, so I coded with both methods introduced from the video as follow&lt;/h3&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;	
print(&#39;create new variable urbanrateNew2 to cut urbanrate into 4 percentile&#39;)
sub2[&#39;urbanrateNew&#39;]= pandas.qcut(sub2.urbanrate, 4, labels = [&quot;1=25%tile&quot;,&quot;2=50%tile&quot;, &quot;3=75%tile&quot;, &quot;4=100%tile&quot;])
print(&#39;create new variable urbanrateNew2 to cut urbanrate into 4 categories&#39;)
sub2[&quot;urbanrateNew2&quot;] = pandas.cut(sub2.urbanrate,[10,40,70,100])

print(&#39;frequency count for method 1&#39;)
c1 = sub2[&quot;urbanrateNew&quot;].value_counts(sort=False,dropna=True)
print(c1)
print(&quot;percentage count for method 1&quot;)
p1 = sub2[&quot;urbanrateNew&quot;].value_counts(sort=False, normalize=True)
print(p1)

print(&#39;frequency count for method 2&#39;)
c2 = sub2[&quot;urbanrateNew2&quot;].value_counts(sort=False,dropna=True)
print(c2)
print(&quot;percentage count for method 2&quot;)
p2 = sub2[&quot;urbanrateNew2&quot;].value_counts(sort=False, normalize=True)
print(p2)
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;h3 id=&quot;result&quot;&gt;result&lt;/h3&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;	
frequency count for method 2
1=25%tile     51
2=50%tile     51
3=75%tile     50
4=100%tile    51
dtype: int64
percentage count for method 1
1=25%tile    0.239437
2=50%tile    0.239437
3=75%tile    0.234742
4=100%tile   0.239437
dtype: float64
frequency count for method 2
(10, 40]     59
(40, 70]     80
(70, 100]    64
dtype: int64
percentage count for method 2
(10, 40]    0.276995
(40, 70]    0.375587
(70, 100]   0.300469
dtype: float64
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;h3 id=&quot;use-crosstab-function-to-make-cross-counts-for-both-newly-created-variables-urbanratenew--urbanratenew2-and-the-original-variable-urbanrate&quot;&gt;Use &lt;strong&gt;crosstab()&lt;/strong&gt; function to make cross counts for both newly created variables (urbanrateNew &amp;amp; urbanrateNew2) and the original variable urbanrate.&lt;/h3&gt;

&lt;pre&gt;
&lt;code&gt;	
print(&#39;crosstable function for count of oberservation within each category&#39;)
print(pandas.crosstab(sub2[&quot;urbanrateNew&quot;], sub2[&quot;urbanrate&quot;]))
print(pandas.crosstab(sub2[&quot;urbanrateNew2&quot;], sub2[&quot;urbanrate&quot;]))

&lt;/code&gt;
&lt;/pre&gt;

&lt;h3 id=&quot;result-of-crosstable-count-for-both-methods&quot;&gt;result of crosstable count for both methods&lt;/h3&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;	
crosstable function for count of oberservation within each category
urbanrate     10.400000   12.540000   12.980000   13.220000   14.320000   \
urbanrateNew                                                               
1=25%tile              1           1           1           1           1   
2=50%tile              0           0           0           0           0   
3=75%tile              0           0           0           0           0   
4=100%tile             0           0           0           0           0   

urbanrate     15.100000   16.540000   17.000000   17.240000   17.960000   \
urbanrateNew                                                               
1=25%tile              1           1           1           1           1   
2=50%tile              0           0           0           0           0   
3=75%tile              0           0           0           0           0   
4=100%tile             0           0           0           0           0   

urbanrate        ...      92.680000   93.160000   93.320000   94.220000   \
urbanrateNew     ...                                                       
1=25%tile        ...               0           0           0           0   
2=50%tile        ...               0           0           0           0   
3=75%tile        ...               0           0           0           0   
4=100%tile       ...               1           1           1           1   

urbanrate     94.260000   95.640000   97.360000   98.320000   98.360000   \
urbanrateNew                                                               
1=25%tile              0           0           0           0           0   
2=50%tile              0           0           0           0           0   
3=75%tile              0           0           0           0           0   
4=100%tile             1           1           1           1           1   

urbanrate     100.000000  
urbanrateNew              
1=25%tile              0  
2=50%tile              0  
3=75%tile              0  
4=100%tile             6  

[4 rows x 194 columns]
urbanrate      10.400000   12.540000   12.980000   13.220000   14.320000   \
urbanrateNew2                                                               
(10, 40]                1           1           1           1           1   
(40, 70]                0           0           0           0           0   
(70, 100]               0           0           0           0           0   

urbanrate      15.100000   16.540000   17.000000   17.240000   17.960000   \
urbanrateNew2                                                               
(10, 40]                1           1           1           1           1   
(40, 70]                0           0           0           0           0   
(70, 100]               0           0           0           0           0   

urbanrate         ...      92.680000   93.160000   93.320000   94.220000   \
urbanrateNew2     ...                                                       
(10, 40]          ...               0           0           0           0   
(40, 70]          ...               0           0           0           0   
(70, 100]         ...               1           1           1           1   

urbanrate      94.260000   95.640000   97.360000   98.320000   98.360000   \
urbanrateNew2                                                               
(10, 40]                0           0           0           0           0   
(40, 70]                0           0           0           0           0   
(70, 100]               1           1           1           1           1   

urbanrate      100.000000  
urbanrateNew2              
(10, 40]                0  
(40, 70]                0  
(70, 100]               6  

[3 rows x 194 columns]

Process finished with exit code 0


&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;h3 id=&quot;review-criteria&quot;&gt;Review Criteria&lt;/h3&gt;

&lt;p&gt;Your assessment will be based on the evidence you provide that you have completed all of the steps. When relevant, gradients in the scoring will be available to reward clarity (for example, you will get one point for submitting output that is not understandable, but two points if it is understandable). In all cases, consider that the peer assessing your work is likely not an expert in the field you are analyzing. You will be assessed equally on your description of your frequency distributions.&lt;/p&gt;

&lt;p&gt;Specific rubric items, and their point values, are as follows:&lt;/p&gt;

&lt;pre&gt;&lt;code&gt;Was the program output interpretable (i.e. organized and labeled)? (1 point)
Does the program output display three data managed variables as frequency tables? (1 point)
Did the summary describe the frequency distributions in terms of the values the variables take, how often they take them, the presence of missing data, etc.? (2 points)
&lt;/code&gt;&lt;/pre&gt;
</content>
 </entry>
 
 <entry>
   <title>keywords and figures</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/10/02/pathology-exam-2-keywords-review/"/>
   <updated>2015-10-02T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/10/02/pathology-exam-2-keywords-review</id>
   <content type="html">&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#multiple-myeloma&quot; id=&quot;markdown-toc-multiple-myeloma&quot;&gt;Multiple Myeloma&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#monoclonal-gammopathy-of-undetermined-significance-mgus&quot; id=&quot;markdown-toc-monoclonal-gammopathy-of-undetermined-significance-mgus&quot;&gt;Monoclonal gammopathy of undetermined significance (MGUS)&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;multiple-myeloma&quot;&gt;Multiple Myeloma&lt;/h4&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a plasma cell neoplasm commonly associated with lytic bone lesions, hypercalcemia, renal failure, and acquired immune abnormalities.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;It principally involves the bone marrow and usually is associated with lytic lesions throughout the skeletal system.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;M protein produced by myeloma cells is IgG (60%), followed by IgA (20% to 25%); only rarely are IgM, IgD, or IgE M proteins observed. In the remaining 15% to 20% of cases, the plasma cells produce only κ or λ light chains.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;monoclonal-gammopathy-of-undetermined-significance-mgus&quot;&gt;Monoclonal gammopathy of undetermined significance (MGUS)&lt;/h4&gt;

&lt;p&gt;bone marrow
lymph nodes
hepatomegaly&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Regression indepth study</title>
   <link href="http://lanyon.getpoole.com/statistics/2015/09/29/regression-study/"/>
   <updated>2015-09-29T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/statistics/2015/09/29/regression-study</id>
   <content type="html">&lt;p&gt;Some key points about Least Square Model&lt;/p&gt;

&lt;!--break--&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\hat \beta_1 = Cor(Y, X)\frac{Sd(Y)}{Sd(X)}&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\hat \beta_0 = \bar Y - \hat \beta_1 \bar X&lt;/script&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\hat \beta_1&lt;/script&gt; has the unit of &lt;script type=&quot;math/tex&quot;&gt;\frac{Y}{X}&lt;/script&gt;, &lt;script type=&quot;math/tex&quot;&gt;\hat \beta_0&lt;/script&gt; has the unit of Y.&lt;/p&gt;

&lt;p&gt;The line passes through the point (&lt;script type=&quot;math/tex&quot;&gt;\bar X&lt;/script&gt;,&lt;script type=&quot;math/tex&quot;&gt;\bar Y&lt;/script&gt;)&lt;/p&gt;

&lt;p&gt;The slope of the regression line with X as the outcome and Y as the predictor is Cor(Y,X)Sd(X)/Sd(Y)&lt;/p&gt;

&lt;p&gt;The slope is the same one you would get if you centered the data&lt;script type=&quot;math/tex&quot;&gt;(X_i - \bar X, Y_i - \bar Y)&lt;/script&gt;, and did regression through the origin.&lt;/p&gt;

&lt;p&gt;If you normalized the data, &lt;script type=&quot;math/tex&quot;&gt;{\frac{X_i - \bar X}{Sd(X)} , \frac{Y_i-\bar Y}{Sd(Y)}}&lt;/script&gt;, the slope is Cor(Y,X) because Sd(X) = Sd(Y) = 1.&lt;/p&gt;

&lt;p&gt;R code examples&lt;/p&gt;

&lt;pre&gt;
 &lt;code class=&quot;r&quot;&gt;
library(UsingR)
data(galton)
library(dplyr); library(ggplot2)
y &amp;lt;- galton$child
x &amp;lt;- galton$parent
beta1 &amp;lt;- cor(y,x) * sd(y) / sd(x)
beta0 &amp;lt;- mean(y) - beta1 * mean(x)
rbind(c(beta0,beta1), coef(lm(y~x)))
  &lt;/code&gt;
&lt;/pre&gt;

&lt;pre&gt;
&lt;code&gt;
    (Intercept)         x
[1,]    23.94153 0.6462906
[2,]    23.94153 0.6462906	
&lt;/code&gt;
&lt;/pre&gt;

&lt;h2 id=&quot;derivation-of-regression-formula-through-calculus&quot;&gt;derivation of regression formula through calculus&lt;/h2&gt;
&lt;p&gt;&lt;a href=&quot;http://seismo.berkeley.edu/~kirchner/eps_120/Toolkits/Toolkit_10.pdf&quot;&gt;adapted from Berkeley&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\sum_{i=1}^n (\bar X^2 - X_i\bar X ) = 0&lt;/script&gt; and &lt;script type=&quot;math/tex&quot;&gt;\sum_{i=1}^n (\bar X \bar Y - Y_i \bar X) = 0&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;The following is simulation with R to prove the above terms are true.&lt;/p&gt;

&lt;pre&gt;
&lt;code class=&quot;r&quot;&gt;
x = c(3,2,4,5,3,2,4,3)
y = c(3,4,2,4,5,3,2,6)
sum((mean(d))^2-d*mean(d))
sum(mean(d)*mean(e)-e*mean(d))
&lt;/code&gt;
&lt;/pre&gt;

&lt;pre&gt;
&lt;code class=&quot;r&quot;&gt;
[1] 0
[1] 0
&lt;/code&gt;
&lt;/pre&gt;

</content>
 </entry>
 
 <entry>
   <title>block2 exam review</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/29/blcok-2-pathology-exam-review/"/>
   <updated>2015-09-29T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/29/blcok-2-pathology-exam-review</id>
   <content type="html">&lt;p&gt;Infectious Mononucleosis&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://library.med.utah.edu/WebPath/jpeg5/HEME045.jpg&quot;&gt;reed-sternberg cells&lt;/a&gt;
Reed-Sternberg cells, the hallmark of Hodgkin lymphoma, often are seen.&lt;/p&gt;

&lt;p&gt;(Monospot test)&lt;/p&gt;

&lt;!--break--&gt;

&lt;h2 id=&quot;keyword-with-pictures&quot;&gt;keyword with pictures&lt;/h2&gt;

&lt;p&gt;&lt;a href=&quot;https://www.med-ed.virginia.edu/courses/path/innes/wcd/lymphoma.cfm&quot;&gt;tingible body macrophages&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.medical-labs.net/wp-content/uploads/2014/03/Smudge-cells.jpg&quot;&gt;Smudge cell&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;video-temp&quot;&gt;video temp&lt;/h2&gt;

&lt;iframe width=&quot;420&quot; height=&quot;315&quot; src=&quot;https://www.youtube.com/embed/it0lwR3Fls0&quot; frameborder=&quot;0&quot; allowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;

&lt;p&gt;acute nonspecific lymphadenitis&lt;/p&gt;

&lt;p&gt;Sinus Histiocytosis. This reactive pattern is characterized by distention and prominence of the lymphatic sinusoids, owing to a marked hypertrophy of lining endothelial cells and an infiltrate of macrophages (histiocytes). It often is encountered in lymph nodes draining cancers and may represent an immune response to the tumor or its products.&lt;/p&gt;

&lt;h2 id=&quot;laboratory-findings&quot;&gt;Laboratory Findings&lt;/h2&gt;

&lt;p&gt;ALL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The white cell count is variable; it may be greater than 100,000 cells/μL but in about half of the patients is less than 10,000 cells/μL. Anemia is almost always present, and the platelet count usually is below 100,000/μL. Neutropenia is another common finding.&lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;genetic-features&quot;&gt;Genetic Features.&lt;/h2&gt;

&lt;p&gt;ALL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;non-random karyotypic abnormalities.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;common in child- hood pre-B cell tumors are hyperdiploidy&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a cryptic (12;21) translocation involving the TEL1 and AML1 genes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;25% of adult pre-B cell tumors harbor the (9;22) translocation involving the ABL and BCR genes&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Chronic lymphocytic leukemia (CLL) and small lympho- cytic lymphoma (SLL)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;exceeds 4000 cells/μL, the patient is diagnosed with CLL; if it does not, a diagnosis of SLL is made.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CLL/SLL is much less common in Asia.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CLL is more common than SLL in the west.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;immune dysregulation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;accumulation of CLL/SLL cells suppresses normal B cell function(unclear mechanism), -&amp;gt; hypogammaglobulinemia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;proliferation centers&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;chromosomal translocations are rare.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Approximately 50% of tumors have karyotypic abnormalities, the most common of which are trisomy 12 and deletions of chromosomes 11, 13, and 17.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Follicular l􏰎ym􏰁phom􏰁a&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Express BCL2&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;(14;18) translocation, fuses the BCL2 on chromosome 18 to IgH locus on chromosome 14.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;nodular proliferation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;predominant neoplastic cells are slightly larger than resting lymphocytes that have angular “cleaved” nuclei with prominent indentations and linear infoldings (Fig. 11–16, B). The nuclear chromatin is coarse and condensed, and nucleoli are indistinct. These small, cleaved cells are mixed with variable numbers of larger cells with vesicular chromatin, several nucleoli, and modest amounts of cytoplasm. In most tumors, large cells are a minor component of the &lt;strong&gt;overall cellularity&lt;/strong&gt;, mitoses are infrequent, and single necrotic cells (cells undergoing apoptosis) are not seen. These features help to distinguish follicular lymphoma from &lt;strong&gt;follicular hyperplasia&lt;/strong&gt;, in which mitoses and apoptosis are prominent.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mantle Cell l􏰎ym􏰁phom􏰁a&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Mantle cell lymphoma is composed of cells resembling the naive B cells found in the mantle zones of normal lymphoid follicles.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;lymphomatoid polyposis. (11;14) translocation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;that fuses the cyclin D1 gene to the IgH locus.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;distinguished from CLL/SLL by the absence of proliferation centers and the presence of cyclin D1 protein.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Diffuse 􏰂large B􏰀 Cell 􏰂lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;most common type of lymphoma in adults, 50% of NHLs.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;About one third of tumors have rearrangements of the BCL6 gene,located on 3q27, and an even higher fraction of tumors have activating point mutations in the BCL6 promotor. resulted in increased levels of BCL6 protein. transcriptional regulator of gene expression in germinal center B cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Another 30% of tumors have a (14,18) translocation involving the BCL2 gene that results in overexpression of BCL2 protein. loss-of-function mutations in genes encoding histone acetyl transferases.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Aneuploidy and high S phase&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Burkitt lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;highly associated with translocations involving the MYC gene on chromosome 8. Most translocations fuse MYC with the IgH gene on chromo- some 14, but variant translocations involving the κ and λ light chain loci on chromosomes 2 and 22, respectively, are also observed.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;“starry sky” pattern.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;usually is present in the jaw or abdomen&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Muliple Myeloma and Related Plasma Cell Tumors&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The plasma cell neoplasms can be divided into six major variants: (1) multiple myeloma, (2) solitary plasmacytoma, (3) lymphoplasmacytic lymphoma, (4) heavy-chain disease, (5) primary amyloidosis, and (6) MGUS. The focus here is on the most important of these disorders, multiple myeloma and lymphoplasmacytic lymphoma, with a brief discussion of the other disorders.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Multiple Myeloma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;It principally involves the bone marrow and usually is associated with lytic lesions throughout the skeletal system.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;M protein produced by myeloma cells is IgG (60%), followed by IgA (20% to 25%); only rarely are IgM, IgD, or IgE M proteins observed. In the remaining 15% to 20% of cases, the plasma cells produce only κ or λ light chains.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;dysregulation of D cyclins is common in multiple myeloma.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;cytokine interleukin 6 (IL-6) support proliferation of myeloma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Patients with myeloma are immunosuppressed.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;myeloma cells interfere with the function of normal plasma cells, leading to defects in antibody production.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Renal dysfunction is a common, serious problem in myeloma. Proteinaceous casts, formed in the distal convoluted tubules and the collecting ducts. 
The casts consist mostly of Bence Jones proteins along with variable amounts of complete immunoglobulins, Tamm-Horsfall protein, and albumin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;hypercalcemia&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Solitary Plasmacytoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;involving the skeleton or the soft tissues&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;occur in the same locations as does multiple myeloma and usually progress to full-blown multiple myeloma over a period of 5 to 10 years&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IL-LB and IL-6 stimulate RANK-ligand.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Monoclonal gammopathy of undetermined significance (MGUS)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;the term applied to an asymptomatic monoclonal gammopathy of undetermined significance(MGUS).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a precursor lesion with a tendency to evolve to multiple myeloma.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Lymphoplasmacytic Lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Waldenström macroglobulinemia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Heavy-Chain Disease&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;IgA heavy-chain disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a variant of extranodal marginal zone lymphoma&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Primary Amyloidosis&lt;/p&gt;

&lt;p&gt;Lymphoplasmacytic lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Waldenström macroglobulinemia, the size of macroglobulins cause the blood to become viscous.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Visual impairment&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cryoglobulinemia&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;hodgkin-lymphoma&quot;&gt;Hodgkin lymphoma&lt;/h3&gt;

&lt;p&gt;Basic facts&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;“classic” RS cells are common in the &lt;strong&gt;mixed-cellularity subtype&lt;/strong&gt;, uncommon in the &lt;strong&gt;nodular sclerosis subtype&lt;/strong&gt;, and rare in the lymphocyte- predominance subtype; in these latter two subtypes, other characteristic RS cell variants predominate.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://classconnection.s3.amazonaws.com/261/flashcards/663261/png/nodular_sclerosing_hodgkins_lymphoma1319950956443.png&quot;&gt;Nodular sclerosis Hodgkin lymphoma&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;striking propensity to involve the lower cervical, supraclavicular, and mediastinal lymph nodes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://library.med.utah.edu/WebPath/HEMEHTML/HEME110.html&quot;&gt;the lacunar cell&lt;/a&gt; which a single multilobate nucleus, multiple small nucleoli and abundant, pale-staining cytoplasm leaving the nucleus lying in an empty space (a lacune)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;also see &lt;strong&gt;Fig. 11–21&lt;/strong&gt; from text book.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://www.webpathology.com/slides-13/slides/LymphNode_HodgkinsLymphoma_MixedCellularity2.jpg&quot;&gt;Mixed-cellularity Hodgkin lymphoma&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;male predominance&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Classic RS cells, within a heterogeneous inflammatory infiltrate&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;small lymphocytes, eosinophils, plasma cells, and macrophages&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://upload.wikimedia.org/wikipedia/commons/5/55/Nodular_lymphocyte_predominant_Hodgkin_lymphoma_-_very_high_mag.jpg&quot;&gt;Lymphocyte-Predominance Hodgkin lymphoma&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;presence of lymphohistiocytic (L&amp;amp;H) variant RS cells that have a delicate multilobed, puffy nucleus resembling popped corn (“popcorn cell”)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;typical RS cells are rare&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://www.webpathology.com/slides-13/slides/Stomach_Lymphoma_MALToma1.jpg&quot;&gt;Extranodal Marginal Zone Lymphoma&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;tend to develop in the setting of autoimmune disorders(sjogren and Hashimoto thyroiditis) or chronic infection like H. pylori gastritis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;(11,18) translocation involving the MALT1 and IAP2 genes. it is predictive of the failure of gastric tumors to respond to antibiotic treatment.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathpedia.com/education/eatlas/histopathology/blood_cells/hairy_cell_leukemia_classic/hairy-cell-leukemia-%5B5-bl089-1%5D.jpeg?Width=600&amp;amp;Height=450&amp;amp;Format=4&quot;&gt;Hairy Cell Leukemia&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;activating mutations in the serine/threo- nine kinase BRAF&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;mainly in older males, infiltration of bone marrow and splenomegaly, Pancytopenia.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;rara lymph node involvement.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;pancytopenia and infections cause the major clinical problems.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;sensistive to chemotherapeutic agents, particularly purine nucleosides&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://media.tumblr.com/tumblr_mc01t2BA101r9he9m.jpg&quot;&gt;Mycosis Fungoides and Sézary Syndrome&lt;/a&gt; (also cutaneous T cell lymphoma)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Sézary syndrome is a clinical variant characterized by (1) a generalized exfoliative erythroderma (2) tumor cells( Sezary cells) in peripheral blood.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;circulating tumor cells present in 25 % of cases of plaque or tumor-phase mycosis fungoides.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;with mycosis fungoides, survival for many years, tumor-phase disease, visceral disease, or sezary syndrome, survival for 1 to 3 years.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://pathy.med.nagoya-u.ac.jp/atlas/img/t2/img0024.jpg&quot;&gt;Adult T Cell Leukemia/Lymphoma&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Neoplasm of CD4+ T cells, caused by a retrovirus, human T cell leukemia virus type 1 (HTLV-1).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;some patients develop a chronic course resembling that of mycosis fungoides.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;short survival time (8 months)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;&quot;&gt;Peripheral T Cell Lymphomas&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;immunotyping&quot;&gt;immunotyping&lt;/h2&gt;

&lt;p&gt;ALL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Terminal deoxynucleotidyl transferase (TdT), an enzyme specifically expressed in pre-B and pre-T cells, is present in more than 95% of cases. Further subtyping of ALL into pre-B and pre-T cell types relies on stains for lineage-specific markers, such as CD19 (B cell) and CD3 (T cell).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CLL/SLL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a neoplasm of mature B cells expressing the pan-B cell markers CD19, CD20, and CD23 and surface immunoglobulin heavy and light chains.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;tumor cells also express CD5&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Folicular Lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;These tumors express pan-B cell markers (CD19 and CD20), CD10, and BCL6, a transcription factor required for the generation of germinal center B cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Follicular lymphoma mainly occurs in adults older than 50 years of age and affects males and females equally.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mantle cell lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The tumor cells usually coexpress surface IgM and IgD, pan-B cell antigens (CD19 and CD20), and CD5.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Diffuse 􏰂large B􏰀 Cell 􏰂lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;These mature B cell tumors express pan-B cell antigens, such as CD19 and CD20. Many also express surface IgM and/or IgG. Other antigens (e.g., CD10, BCL2) are variably expressed.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Burkitt lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;These B cell tumors express surface IgM, the pan-B cell markers CD19 and CD20, and the germinal center B cell markers CD10 and BCL6.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hodgkin lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Typical RS cells and variants have a characteristic immunophenotype, as they express CD15 and CD30 and fail to express CD45(common leukocyte antigen)
The immunophenotype of lacunar variants is identical to that of other RS cells found in classical subtypes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;L&amp;amp;H variants express B cell markers (e.g., CD20) and usually fail to express CD15 and CD30.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hairy Cell leukemia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The tumor cells express pan-B cell markers (CD19 and CD20), surface immunoglobulin, and CD11c and CD103; the latter two antigens are not present on most other B cell tumors, making them diagnostically useful.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Adult T Cell Leukemia/Lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;In addition to CD4, the leukemic cells express high levels of CD25, the IL-2 receptor α chain.&lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;prognosis&quot;&gt;Prognosis&lt;/h2&gt;

&lt;p&gt;ALL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;2 to 10 years of age have the best prognosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;worse outcomes includes male gender; age younger than 2 or older than 10 years; a high leukocyte count at diagnosis; and molecular evidence of persistent disease on day 28 of treatment.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;good prognosis - chromosomal aberrations (such as the t[12;21] and hyperdiploidy) are common in the 2- to 10-year age group&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;bad prognosis - rearrangements of the gene MLL or the presence of a BCR-ABL fusion gene, both associated with poor outcomes in B cell tumors, are most common in children younger than 2 years of age and adult&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CLL/SLL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;lymphadenopathy and hepatosplenomegaly are present in 50% to 60% of patients.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;half has Hypogammaglobulinemia (susceptibility to bacterial infections)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;autoimmune hemolytic anemia and thrombocytopenia (less common)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Follicular lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;painless, generalized lymphadenopathy.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;not curable&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;therapy with cytotoxic drugs and rituximab (anti-CD20 antibody) is reserved for those with bulky, symptomatic disease.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Diffuse Large B Cell Lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Kaposi sarcoma herpesvirus (KSHV), also called human herpesvirus type 8 (HHV-8), is associated with rare primary effusion lym- phomas,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mediastinal large B cell lymphoma occurs most often in young women and shows a predilec- tion for spread to abdominal viscera and the central nervous system.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;cluster-of-differentiation&quot;&gt;cluster of differentiation&lt;/h2&gt;

&lt;p&gt;CD19 (B cell) 
CD3 (T cell).
pan-B cell markers CD19, CD20, and CD23
CLL/SLL and mantle cell lymphoma express CD5.
BCL6, a transcription factor required for the generation of germinal center B cells.
Typical RS cells express CD15 and CD30 and fail to express CD45 (common leukocyte antigen), B cell antigens, and T cell antigens
CD68 is a macrophage (histiocyte) marker
T-cell markers CD2 and CD7.
CLL/SLL has a distinctive immuno- phenotype. The tumor cells express the pan B-cell markers CD19 and CD20, as well as CD23 and CD5, the latter a marker that is found on a small subset of normal B cells.
Plasma cell tumors are positive for CD138, an adhesion molecule also known as syndecan-1, and often express CD56,
CD45 - leukocyte common antigen (LCA)
CD15 - expressed on granulocytes
Myeloperoxidase (MPO) – myeloid cells
CD34, CD117 - blast/stem cell marker
Hemoglobin - erythroid precursors
CD61, Factor VIII related antigen - megakaryocytic precursors&lt;/p&gt;

&lt;p&gt;Flow Cytometry
for AML
Myeloid markers:
Myeloperoxidase
CD13
CD33
CD117
Blast/stem cell marker:
CD34, CD117
Monocytic marker:
CD4, CD14, CD64
Megakaryocytic markers:
CD41
CD61
Erythroid markers:
CD71 (transferrin receptor)
glycophorin
Miscellaneous:
HLA-DR (early myeloid and B-cells)&lt;/p&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Hodgkin lymphoma&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Non-Hodgkin lymphoma&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;More often localized to a single More frequent involvement of axial group of nodes cervical, multiple peripheral nodes mediastinal, para-aortic&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;More frequent involvement of multiple peripheral nodes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;orderly spread by contiguity Noncontiguous spread&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Noncontiguous spread&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mesenteric nodes and Waldeyer Mesenteric nodes and Waldeyer ring rarely involved ring commonly involved&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mesenteric nodes and Waldeyer ring commonly involved&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Extranodal involvement uncommon&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Extranodal involvement common&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h2 id=&quot;screenshot-list&quot;&gt;screenshot list&lt;/h2&gt;

&lt;h3 id=&quot;robbins-basic-pathology&quot;&gt;Robbins Basic Pathology&lt;/h3&gt;

&lt;p&gt;Figure 11–14 Morphologic comparison of lymphoblasts and myeloblasts. A, Lymphoblastic leukemia/lymphoma. Lymphoblasts have condensed nuclear chromatin, small nucleoli, and scant agranular cytoplasm. B, Acute myeloid leukemia. Myeloblasts have delicate nuclear chromatin, prominent nucleoli, and fine azurophilic cytoplasmic granules. 433&lt;/p&gt;

&lt;p&gt;Figure 11–13 Origin of lymphoid neoplasms. Stages of B and T cell differentiation from which specific lymphoid and tumors emerge are shown. BLB, pre-B lymphoblast; CLP, common lymphoid progenitor; DN, CD4−/CD8− (double-negative) pro-T cell; DP, CD4+/CD8+ (double-positive) pre-T cell; GC, germinal center B cell; MC, mantle zone B cell; MZ, marginal zone B cell; NBC, naive B cell; PC, plasma cell; PTC, peripheral T cell.&lt;/p&gt;

&lt;p&gt;Figure 11–15 Small lymphocytic lymphoma/chronic lymphocytic leukemia—lymph node. A, Low-power view shows diffuse effacement of nodal architecture. B, At high power, a majority of the tumor cells have the appearance of small, round lymphocytes. A “prolymphocyte,” a larger cell with a centrally placed nucleolus, also is present in this field (arrow).    2&lt;/p&gt;

&lt;p&gt;Figure 11–16 Follicular lymphoma—lymph node. A, Nodular aggregates of lymphoma cells are present throughout. B, At high magnification, small lymphoid cells with condensed chromatin and irregular or cleaved nuclear outlines (centrocytes) are mixed with a population of larger cells with nucleoli (centroblasts).  2&lt;/p&gt;

&lt;p&gt;Figure 11–17 Diffuse large B cell lymphoma—lymph node. The tumor cells have large nuclei with open chromatin and prominent nucleoli.   1&lt;/p&gt;

&lt;p&gt;Figure 11–18 Burkitt lymphoma—lymph node. The tumor cells and their nuclei are fairly uniform, giving a monotonous appearance. Note the high level of mitotic activity (arrowheads) and prominent nucleoli. The “starry sky” pattern produced by interspersed, lightly staining, normal macrophages is better appreciated at a lower magnification.&lt;/p&gt;

&lt;p&gt;Figure 11–19 Multiple myeloma. A, Radiograph of the skull, lateral view. The sharply punched-out bone defects are most obvious in the calvaria. B, Bone marrow aspirate. Normal marrow cells are largely replaced by plasma cells, including atypical forms with multiple nuclei, prominent nucleoli, and cytoplasmic droplets containing immunoglobulin.		2&lt;/p&gt;

&lt;p&gt;Figure 11–20 Hodgkin lymphoma—lymph node. A binucleate Reed- Sternberg cell with large, inclusion-like nucleoli and abundant cytoplasm is surrounded by lymphocytes, macrophages, and an eosinophil. 1&lt;/p&gt;

&lt;p&gt;Figure 11–21 Hodgkin lymphoma, nodular sclerosis type—lymph node. A distinctive “lacunar cell” with a multilobed nucleus containing many small nucleoli is seen lying within a clear space created by retraction of its cytoplasm. It is surrounded by lymphocytes.&lt;/p&gt;

&lt;p&gt;Figure 11–22 Hodgkin lymphoma, nodular sclerosis type—lymph node. A low-power view shows well-defined bands of pink, acellular collagen that have subdivided the tumor cells into nodules. 1&lt;/p&gt;

&lt;h3 id=&quot;basis-of-disease&quot;&gt;Basis of Disease&lt;/h3&gt;

&lt;p&gt;Figure 13-2  Reactive changes in neutrophils. Neutrophils containing coarse  purple  cytoplasmic  granules  (toxic  granulations)  and  blue  cytoplasmic  patches of dilated endoplasmic reticulum (Döhle bodies, arrow) are observed  in this peripheral blood smear prepared from a patient with bacterial sepsis.&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Randomized complete blocked design</title>
   <link href="http://lanyon.getpoole.com/statistics/2015/09/29/Randomized-complete-block-design-stata/"/>
   <updated>2015-09-29T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/statistics/2015/09/29/Randomized-complete-block-design-stata</id>
   <content type="html">&lt;!---&gt;
## Randomized complete blocked design

### Question 2 

The nursing supervisor in a local health department is studying the influence of time of day on length of home visits (mins.) by the nursing staff. Individual differences among nurses might be large, so the nurse was used as a blocking factor. Does the time of day of the home visit influence the length of home visits?

&lt;!--break--&gt;

&lt;p&gt;&amp;lt;!–&amp;gt;
You can download the &lt;em&gt;do&lt;/em&gt; file &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/stata%20blog/ID740%20course%20material%20blog/module%203/doFiles/Daniel%20Ch_8_Ex_24_rcbd-2.do&quot;&gt;here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;You can download the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/stata%20blog/ID740%20course%20material%20blog/module%203/TwoWay%20Anova/Daniel%20Ch_8_Ex_24_rcbd-2.dta&quot;&gt;Daniel EX 8_3_4.dta here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;(Page 379 from Daniel 9th ed.) The aggression scores of 30 Lab animals reared under three different conditions. One animal from each of 10 litters were randomly assigned to each of the three rearing conditions (dataset Daniel Ch_8_Ex_24.dta).
Question: Do these data provide sufficient evidence to indicate that the level of crowding has an effect on aggression? Let alpha=0.05.
Solution: Step 1) Explore Data&lt;/p&gt;

&lt;h4 id=&quot;step-1&quot;&gt;Step 1&lt;/h4&gt;

&lt;p&gt;Exploratory data analysis&lt;/p&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;
. codebook

--------------------------------------------------------------------------------------------------------------------
litter                                                                                                        LITTER
--------------------------------------------------------------------------------------------------------------------

                  type:  numeric (byte)

                 range:  [1,10]                       units:  1
         unique values:  10                       missing .:  0/30

                  mean:       5.5
              std. dev:   2.92138

           percentiles:        10%       25%       50%       75%       90%
                               1.5         3       5.5         8       9.5

--------------------------------------------------------------------------------------------------------------------
scores                                                                                                        SCORES
--------------------------------------------------------------------------------------------------------------------

                  type:  numeric (byte)

                 range:  [10,35]                      units:  1
         unique values:  6                        missing .:  0/30

            tabulation:  Freq.  Value
                             8  10
                             1  15
                             9  20
                             4  25
                             7  30
                             1  35

--------------------------------------------------------------------------------------------------------------------
cond                                                                                                            COND
--------------------------------------------------------------------------------------------------------------------

                  type:  string (str3)

         unique values:  3                        missing &quot;&quot;:  0/30

            tabulation:  Freq.  Value
                            10  &quot;EXT&quot;
                            10  &quot;MOD&quot;
                            10  &quot;NOT&quot;

. 
end of do-file

. 
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
&lt;p&gt;Check dataset structure&lt;/p&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
 &lt;code&gt;
. describe

Contains data from https://dl.dropboxusercontent.com/u/49272502/stata%20blog/ID740%20course%20material%20blog/module
&amp;gt; %203/TwoWay%20Anova/Daniel%20Ch_8_Ex_24_rcbd-2.dta
  obs:            30                          
 vars:             3                          23 May 2012 16:46
 size:           150                          
--------------------------------------------------------------------------------------------------------------------
              storage   display    value
variable name   type    format     label      variable label
--------------------------------------------------------------------------------------------------------------------
litter          byte    %8.0g                 LITTER
scores          byte    %8.0g                 SCORES
cond            str3    %9s                   COND
--------------------------------------------------------------------------------------------------------------------
Sorted by: 

. 
end of do-file

. 
 &lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
&lt;p&gt;Data is sorted by “cond” so each litter are clumped by type of condition, it doesn’t matter the in which way its sorted, sometimes it good to sort in different ways to understand data structure.&lt;/p&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
	&lt;code&gt;
. by cond, sort : summarize scores, format

--------------------------------------------------------------------------------------------------------------------
-&amp;gt; cond = EXT

    Variable |        Obs        Mean    Std. Dev.       Min        Max
-------------+---------------------------------------------------------
      scores |         10        28.5    4.116363         20         35

--------------------------------------------------------------------------------------------------------------------
-&amp;gt; cond = MOD

    Variable |        Obs        Mean    Std. Dev.       Min        Max
-------------+---------------------------------------------------------
      scores |         10        20.5    5.502525         10         30

--------------------------------------------------------------------------------------------------------------------
-&amp;gt; cond = NOT

    Variable |        Obs        Mean    Std. Dev.       Min        Max
-------------+---------------------------------------------------------
      scores |         10          13    4.830459         10         20


. 

. tabstat scores, stat( mean sd) by(cond)

Summary for variables: scores
     by categories of: cond (COND)

  cond |      mean        sd
-------+--------------------
   EXT |      28.5  4.116363
   MOD |      20.5  5.502525
   NOT |        13  4.830459
-------+--------------------
 Total |  20.66667  7.958224
----------------------------

. 

	&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
&lt;p&gt;####Step 2&lt;/p&gt;

&lt;p&gt;Since “cond” is a string variable, there is a need to convert it to numeric&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
	&lt;code&gt;
. gen _cond=.
(30 missing values generated)

. replace _cond=2 if cond==&quot;EXT&quot; &amp;amp; !missing(cond)
(10 real changes made)

. replace _cond=1 if cond==&quot;MOD&quot; &amp;amp; !missing(cond)
(10 real changes made)

. replace _cond=0 if cond==&quot;NOT&quot; &amp;amp; !missing(cond)
(10 real changes made)

. 
end of do-file

. do &quot;/var/folders/nc/tpl2k1rx68d_xgzmz310w_fc0000gn/T//SD02136.000000&quot;

. label define cond 2 &quot;EXT&quot; 1 &quot;MOD&quot; 0 &quot;NOT&quot;

. label value  _cond cond

. 
end of do-file

	&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
&lt;p&gt;Double check the newly generated _cond variable aligns with the original cond&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
	&lt;code&gt;

 tab2 _cond cond //check your code

-&amp;gt; tabulation of _cond by cond  

           |               COND
     _cond |       EXT        MOD        NOT |     Total
-----------+---------------------------------+----------
       NOT |         0          0         10 |        10 
       MOD |         0         10          0 |        10 
       EXT |        10          0          0 |        10 
-----------+---------------------------------+----------
     Total |        10         10         10 |        30 


. 
end of do-file

. 
	&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
&lt;p&gt;drop the original cond variable and rename the _cond variable to cond&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
	&lt;code&gt;

. drop cond 

. 
. rename _cond cond 

. 
end of do-file

	&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
&lt;p&gt;Summary&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
	&lt;code&gt;
. by cond, sort : summarize scores, format //summary

--------------------------------------------------------------------------------------------------------------------
-&amp;gt; cond = NOT

    Variable |        Obs        Mean    Std. Dev.       Min        Max
-------------+---------------------------------------------------------
      scores |         10          13    4.830459         10         20

--------------------------------------------------------------------------------------------------------------------
-&amp;gt; cond = MOD

    Variable |        Obs        Mean    Std. Dev.       Min        Max
-------------+---------------------------------------------------------
      scores |         10        20.5    5.502525         10         30

--------------------------------------------------------------------------------------------------------------------
-&amp;gt; cond = EXT

    Variable |        Obs        Mean    Std. Dev.       Min        Max
-------------+---------------------------------------------------------
      scores |         10        28.5    4.116363         20         35


. 
end of do-file

	&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
&lt;p&gt;estimate means by condition and by litter&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
	&lt;code&gt;
. tabstat scores, stat( mean sd semean) by(cond) //means by condition

Summary for variables: scores
     by categories of: cond 

  cond |      mean        sd  se(mean)
-------+------------------------------
   NOT |        13  4.830459  1.527525
   MOD |      20.5  5.502525  1.740051
   EXT |      28.5  4.116363  1.301708
-------+------------------------------
 Total |  20.66667  7.958224  1.452966
--------------------------------------

. 
end of do-file

. do &quot;/var/folders/nc/tpl2k1rx68d_xgzmz310w_fc0000gn/T//SD02136.000000&quot;

. mean scores,over(cond) // Mean Estimation by condition

Mean estimation                   Number of obs   =         30

          NOT: cond = NOT
          MOD: cond = MOD
          EXT: cond = EXT

--------------------------------------------------------------
        Over |       Mean   Std. Err.     [95% Conf. Interval]
-------------+------------------------------------------------
scores       |
         NOT |         13   1.527525       9.87586    16.12414
         MOD |       20.5   1.740051       16.9412     24.0588
         EXT |       28.5   1.301708      25.83771    31.16229
--------------------------------------------------------------

. 
end of do-file

. do &quot;/var/folders/nc/tpl2k1rx68d_xgzmz310w_fc0000gn/T//SD02136.000000&quot;

. tabstat scores, stat( mean sd) by(litter) //means by litter

Summary for variables: scores
     by categories of: litter (LITTER)

  litter |      mean        sd
---------+--------------------
       1 |        20        10
       2 |        20        10
       3 |        20        10
       4 |  16.66667  7.637626
       5 |  26.66667  7.637626
       6 |        20        10
       7 |  16.66667  5.773503
       8 |  23.33333  11.54701
       9 |        20  8.660254
      10 |  23.33333  5.773503
---------+--------------------
   Total |  20.66667  7.958224
------------------------------

. mean scores,over(litter) //mean estimation by litter

Mean estimation                   Number of obs   =         30

            1: litter = 1
            2: litter = 2
            3: litter = 3
            4: litter = 4
            5: litter = 5
            6: litter = 6
            7: litter = 7
            8: litter = 8
            9: litter = 9
           10: litter = 10

--------------------------------------------------------------
        Over |       Mean   Std. Err.     [95% Conf. Interval]
-------------+------------------------------------------------
scores       |
           1 |         20   5.773503      8.191861    31.80814
           2 |         20   5.773503      8.191861    31.80814
           3 |         20   5.773503      8.191861    31.80814
           4 |   16.66667   4.409586      7.648052    25.68528
           5 |   26.66667   4.409586      17.64805    35.68528
           6 |         20   5.773503      8.191861    31.80814
           7 |   16.66667   3.333333      9.849235     23.4841
           8 |   23.33333   6.666667      9.698469     36.9682
           9 |         20          5      9.773852    30.22615
          10 |   23.33333   3.333333       16.5159    30.15077
--------------------------------------------------------------

. 
end of do-file

	
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
&lt;p&gt;####Step 3&lt;/p&gt;

&lt;p&gt;Plot a box Plot&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
	&lt;code&gt;
/*Box Plot */
graph box scores ///
    , over(cond) ///
	ytitle(Aggression Scores) ytitle(, size(large)) ///
	title(Distrubution of Aggression Scores by Living Condition Type, size(medlarge))
	&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
&lt;p&gt;&lt;img src=&quot;https://dl.dropboxusercontent.com/u/49272502/stata%20blog/ID740%20course%20material%20blog/module%203/graph/danielCh8Ex24Boxplot.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;h4 id=&quot;step-4&quot;&gt;Step 4&lt;/h4&gt;

&lt;p&gt;Before moving on to ANOVA: Check the assumption of model additivity&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
	&lt;code&gt;
findit nonadd // install this package

nonadd scores cond litter // code for checking the assumption

Tukey&#39;s test of nonadditivity (Ho: model is additive)
SS nonadd =   df = 1
F (1,17) = .04801813   Pr &amp;gt; F: .82915782

. 
end of do-file
	&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
&lt;p&gt;####Step 5&lt;/p&gt;

&lt;p&gt;Perform One Way ANOVA&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
	&lt;code&gt;
/* ANOVA model */
anova scores cond litter


                         Number of obs =         30    R-squared     =  0.7922
                         Root MSE      =    4.60475    Adj R-squared =  0.6652

                  Source | Partial SS         df         MS        F    Prob&amp;gt;F
              -----------+----------------------------------------------------
                   Model |       1455         11   132.27273      6.24  0.0003
                         |
                    cond |  1201.6667          2   600.83333     28.34  0.0000
                  litter |  253.33333          9   28.148148      1.33  0.2901
                         |
                Residual |  381.66667         18   21.203704  
              -----------+----------------------------------------------------
                   Total |  1836.6667         29   63.333333  

. 
end of do-file


	&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
&lt;p&gt;####Step 6&lt;/p&gt;

&lt;p&gt;Perform PostHoc test&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
	&lt;code&gt;
pwcompare cond, mcompare(tukey) effects

Pairwise comparisons of marginal linear predictions

Margins      : asbalanced

---------------------------
             |    Number of
             |  Comparisons
-------------+-------------
        cond |            3
---------------------------

------------------------------------------------------------------------------
             |                              Tukey                Tukey
             |   Contrast   Std. Err.      t    P&amp;gt;|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
        cond |
 MOD vs NOT  |        7.5   2.059306     3.64   0.005     2.244315    12.75568
 EXT vs NOT  |       15.5   2.059306     7.53   0.000     10.24432    20.75568
 EXT vs MOD  |          8   2.059306     3.88   0.003     2.744315    13.25568
------------------------------------------------------------------------------

. 
end of do-file

. 
	&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;
</content>
 </entry>
 
 <entry>
   <title>Assignment2 Running Your First Program</title>
   <link href="http://lanyon.getpoole.com/data%20science/2015/09/27/pythonhomework/"/>
   <updated>2015-09-27T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/data%20science/2015/09/27/pythonhomework</id>
   <content type="html">&lt;h3 id=&quot;i-have-completed-all-the-requirments-for-this-assignment&quot;&gt;I have completed all the requirments for this assignment.&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;Please check the result &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment2/index.html&quot;&gt;here&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;ul&gt;
  &lt;li&gt;And download the python script &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment2/firstPyProGapMinderAssign.py&quot;&gt;here&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;For codebook reference and other details, you can access my 1st assignment post &lt;a href=&quot;http://jizongl.github.io/data%20science/2015/09/19/Data-Management-Assignment1/&quot;&gt;here&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;review-criterialess&quot;&gt;Review Criterialess&lt;/h2&gt;

&lt;p&gt;Your assessment will be based on the evidence you provide that you have completed all of the steps. When relevant, gradients in the scoring will be available to reward clarity (for example, you will get one point for submitting output that is not understandable, but two points if it is understandable). In all cases, consider that the peer assessing your work is likely not an expert in the field you are analyzing. You will be assessed equally on your description of your frequency distributions.&lt;/p&gt;

&lt;p&gt;Specific rubric items, and their point values, are as follows:&lt;/p&gt;

&lt;p&gt;Was the program output interpretable (i.e. organized and labeled)? (1 point)
Does the program output display three data managed variables as frequency tables? (1 point)
Did the summary describe the frequency distributions in terms of the values the variables take, how often they take them, the presence of missing data, etc.? (2 points)&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>web crawling with python</title>
   <link href="http://lanyon.getpoole.com/python/2015/09/26/webcrawling/"/>
   <updated>2015-09-26T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/python/2015/09/26/webcrawling</id>
   <content type="html">&lt;h3 id=&quot;goals&quot;&gt;goals&lt;/h3&gt;
&lt;p&gt;Say we are shopping on this&lt;a href=&quot;http://www.ebay.ie/sch/Clothes-Shoes-Accessories-/11450/i.html?_catref=1&quot;&gt;eBay&lt;/a&gt;, we see numerous items and vast number of pages. We really do not have time to sort through the item one by one right away, but however we want to make a file with a list of all the links to all the items from all the pages, with specified title. How do we achieve this? Python and a 2 libraries will make this easy.&lt;/p&gt;

&lt;!--break--&gt;

&lt;h3 id=&quot;preparatory&quot;&gt;preparatory&lt;/h3&gt;

&lt;p&gt;In order to perform this task, you need to install &lt;a href=&quot;https://www.python.org/downloads/&quot;&gt;python 3.4&lt;/a&gt; or newer, and I recommand an &lt;a href=&quot;https://en.wikipedia.org/wiki/Integrated_development_environment&quot;&gt;IDE&lt;/a&gt; like &lt;a href=&quot;https://www.jetbrains.com/pycharm/&quot;&gt;PyCharm&lt;/a&gt;. If you are not familiar with those basic, you should learn them first. You will also need to install 2 python libraries.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://www.crummy.com/software/BeautifulSoup/bs4/doc/&quot;&gt;BeautifulSoup&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://www.python-requests.org/en/latest/&quot;&gt;requests&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-is-beautifulsoup&quot;&gt;What is “BeautifulSoup”?&lt;/h3&gt;

&lt;p&gt;Beautiful Soup is a Python library for pulling data out of HTML and XML files. It works with your favorite parser to provide 
idiomatic ways of navigating, searching, and modifying the parse tree. It commonly saves programmers hours or days of work. &lt;a href=&quot;http://www.crummy.com/software/BeautifulSoup/bs4/doc/&quot;&gt;Click for detail&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-requests-&quot;&gt;What is “requests” ?&lt;/h3&gt;
&lt;p&gt;Requests is an Apache2 Licensed HTTP library, written in Python, for human beings. &lt;a href=&quot;http://www.python-requests.org/en/latest/&quot;&gt;click for detail&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;procedure&quot;&gt;procedure&lt;/h3&gt;

&lt;p&gt;start a new .py file then copy and paste the following code&lt;/p&gt;

&lt;p&gt;this chunk is for importing the libraries&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;import requests
from bs4 import BeautifulSoup&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;this chunk is for building a “while loop” to crawl through the source code of the site.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;def trade_spider(max_pages):      ## build a helper function to enact the task
    page = 1
    while page &amp;lt;= max_pages:      ## set dummy variables to represent page numbers to be queried.
        url = &amp;quot;http://www.ebay.ie/sch/Clothes-Shoes-Accessories-/11450/i.html?_catref=&amp;quot; + str(page)
        source_code = requests.get(url)     ## machine for getting info from url
        plain_text = source_code.text       ## machine for storing info from url
        soup = BeautifulSoup(plain_text)    ## machine for converting text into soup format.
        for link in soup.findAll(&amp;#39;a&amp;#39;,{&amp;#39;class&amp;#39;:&amp;#39;vip&amp;#39;}):    ##  look for an item that is unique for that link.
            href = &amp;quot;https://www.thenewboston.com&amp;quot; + link.get(&amp;#39;href&amp;#39;)   ## paste the main url to the specific sublinks
            title = link.string   ## include titles by using link.string
            print(href)           ## print href
            print(title)          ## print title
        page += 1

trade_spider(1)    ## print only 1 page&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;
</content>
 </entry>
 
 <entry>
   <title>Include Mathematical notation in your Jekyll blog</title>
   <link href="http://lanyon.getpoole.com/jekyll/2015/09/26/test/"/>
   <updated>2015-09-26T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/jekyll/2015/09/26/test</id>
   <content type="html">&lt;p&gt;In order to use Mathjax with Jekyll markdown, you need to make change to the followings in your &lt;strong&gt;_layouts&lt;/strong&gt; folder&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;page.html&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;post.html&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;config.yml&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;first add the following into both your &lt;em&gt;page.html&lt;/em&gt; and &lt;em&gt;post.html&lt;/em&gt; files, this is to load the MathJax javascript for your blog posts and pages. 
see &lt;a href=&quot;https://docs.mathjax.org/en/latest/configuration.html&quot;&gt;MathJax&lt;/a&gt; Document for further details.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&amp;lt;script type=&amp;quot;text/javascript&amp;quot;
    src=&amp;quot;http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML&amp;quot;&amp;gt;
&amp;lt;/script&amp;gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;then add the following into your config.yml file. This is to make redcarpet behave like GitHub Flavored Markdown. &lt;strong&gt;note&lt;/strong&gt;, simply adding redcarpet is not enough, you must include the extensions as follow. See &lt;a href=&quot;http://sholsinger.com/2014/03/jekyll-github-flavored-markdown&quot;&gt;this link&lt;/a&gt; for further details.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;# Make redcarpet behave like GitHub Flavored Markdown 
redcarpet: 
extensions: [&amp;quot;no_intra_emphasis&amp;quot;, &amp;quot;fenced_code_blocks&amp;quot;, &amp;quot;autolink&amp;quot;, &amp;quot;strikethrough&amp;quot;, &amp;quot;superscript&amp;quot;, &amp;quot;with_toc_data&amp;quot;]&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;When this is done, you can begin writing your blog with mathematical notations. I personally find this &lt;a href=&quot;http://meta.math.stackexchange.com/questions/5020/mathjax-basic-tutorial-and-quick-reference&quot;&gt;link from Mathematics meta&lt;/a&gt; very helpful, it list many useful notation scripts for reference.&lt;/p&gt;

&lt;p&gt;good luck.&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Include Mathematical notation in your Jekyll blog</title>
   <link href="http://lanyon.getpoole.com/jekyll/2015/09/26/include-math-symbol-in-jekyllblog/"/>
   <updated>2015-09-26T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/jekyll/2015/09/26/include-math-symbol-in-jekyllblog</id>
   <content type="html">&lt;p&gt;In order to use Mathjax with Jekyll markdown, you need to make change to the followings in your &lt;strong&gt;_layouts&lt;/strong&gt; folder&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;page.html&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;post.html&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;config.yml&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;p&gt;first add the following into both your &lt;em&gt;page.html&lt;/em&gt; and &lt;em&gt;post.html&lt;/em&gt; files, this is to load the MathJax javascript for your blog posts and pages. 
see &lt;a href=&quot;https://docs.mathjax.org/en/latest/configuration.html&quot;&gt;MathJax&lt;/a&gt; Document for further details.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&amp;lt;script type=&amp;quot;text/javascript&amp;quot;
    src=&amp;quot;http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML&amp;quot;&amp;gt;
&amp;lt;/script&amp;gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;then add the following into your config.yml file. This is to make redcarpet behave like GitHub Flavored Markdown. &lt;strong&gt;note&lt;/strong&gt;, simply adding redcarpet is not enough, you must include the extensions as follow. See &lt;a href=&quot;http://sholsinger.com/2014/03/jekyll-github-flavored-markdown&quot;&gt;this link&lt;/a&gt; for further details.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;# Make redcarpet behave like GitHub Flavored Markdown 
redcarpet: 
extensions: [&amp;quot;no_intra_emphasis&amp;quot;, &amp;quot;fenced_code_blocks&amp;quot;, &amp;quot;autolink&amp;quot;, &amp;quot;strikethrough&amp;quot;, &amp;quot;superscript&amp;quot;, &amp;quot;with_toc_data&amp;quot;]&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;When this is done, you can begin writing your blog with mathematical notations. I personally find this &lt;a href=&quot;http://meta.math.stackexchange.com/questions/5020/mathjax-basic-tutorial-and-quick-reference&quot;&gt;link from Mathematics meta&lt;/a&gt; very helpful, it list many useful notation scripts for reference.&lt;/p&gt;

&lt;p&gt;good luck.&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>ANOVA indepth study and resource</title>
   <link href="http://lanyon.getpoole.com/statistics/2015/09/24/ANOVA-study/"/>
   <updated>2015-09-24T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/statistics/2015/09/24/ANOVA-study</id>
   <content type="html">&lt;h2 id=&quot;r-resources&quot;&gt;R resources&lt;/h2&gt;

&lt;p&gt;1: Pretty straightforward &lt;a href=&quot;http://www.stat.columbia.edu/~martin/W2024/R3.pdf&quot;&gt;One Way ANOVA with R&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;basic-and-advance-math-behind-anova&quot;&gt;basic and advance math behind ANOVA&lt;/h2&gt;

&lt;p&gt;1: The basic math behind &lt;a href=&quot;https://stat.ethz.ch/education/semesters/as2010/anova/ANOVA_how_to_do.pdf&quot;&gt;ANOVA&lt;/a&gt;&lt;/p&gt;

&lt;!--break--&gt;

&lt;h2 id=&quot;video-resources&quot;&gt;Video resources&lt;/h2&gt;

&lt;p&gt;One Way ANOVA with great explanation by Brandon Foltz. I encourage you to subscribe &lt;a href=&quot;https://www.youtube.com/channel/UCFrjdcImgcQVyFbK04MBEhA&quot;&gt;his channel&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;additional recource&lt;/p&gt;

&lt;p&gt;To understand the computational formula for Total sum of squares, see &lt;a href=&quot;http://www.psychology.emory.edu/clinical/mcdowell/PSYCH560/Basics/var.html&quot;&gt;Derivation of Computational Forumla for the Variance&lt;/a&gt;. Just pay attention to the numerator in the proof.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=R5KfO5HpzLE&quot;&gt;Complete Randomized Block Design&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;One way ANOVA&lt;/p&gt;

&lt;iframe width=&quot;560&quot; height=&quot;315&quot; src=&quot;https://www.youtube.com/embed/UrRYITjDOww&quot; frameborder=&quot;0&quot; allowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;

&lt;p&gt;Two way ANOVA&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/Statistics/PDF/ANOVAderivation.pdf&quot;&gt;Detail formula derivation&lt;/a&gt;
&lt;a href=&quot;/assets/Statistics/PDF/twoway.pdf&quot;&gt;TWO- AND THREE-FACTOR ANOVA&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;anova-table&quot;&gt;ANOVA table&lt;/h3&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Source&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;SS&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;df&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;MS&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;F&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;F table (5%)&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Regression&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;SSR&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;1&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;SSR&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;script type=&quot;math/tex&quot;&gt;F = \frac{Sd(Y)}{Sd(X)}\&lt;/script&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;qt(0.95,1,n-2)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Error&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;SSE&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;n-2&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;script type=&quot;math/tex&quot;&gt;s^2 \ = \frac{SSE}{n-2}\&lt;/script&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Total&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;SST&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;n-1&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

</content>
 </entry>
 
 <entry>
   <title>Exploratory Data Analysis through correlation in R</title>
   <link href="http://lanyon.getpoole.com/statistics/2015/09/19/correlation-exploratory-data-analysis/"/>
   <updated>2015-09-19T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/statistics/2015/09/19/correlation-exploratory-data-analysis</id>
   <content type="html">&lt;p&gt;This post introduces the procedure of performing basic correlation and exploratory data analysis. I will go through the steps on how to do some basic data cleaning, such as removing NA values and factors elements. How to conduct correlation analysis and form a correlation matrix. Finally, we will test if the correlation matrix is accurate by doing a pair of random selected identifier. You will also learn how to do basic subsetting of data and locating values from specific rows or columns.&lt;/p&gt;

&lt;!--break--&gt;
&lt;p&gt;House keeping&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;fileUrl &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; &lt;span class=&quot;s&quot;&gt;&amp;quot;https://raw.githubusercontent.com/JizongL/jizongL.github.io/master/assets/blog/Rblog/correlation/09192015correlation/gapminder.csv&amp;quot;&lt;/span&gt;

download.file&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;fileUrl&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; destfile &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;s&quot;&gt;&amp;quot;./gapminder.csv&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; method &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;s&quot;&gt;&amp;quot;curl&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;data &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; read.csv&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s&quot;&gt;&amp;quot;./gapminder.csv&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
data1 &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; na.omit&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
&lt;span class=&quot;kp&quot;&gt;names&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data1&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1] &amp;quot;country&amp;quot;              &amp;quot;incomeperperson&amp;quot;      &amp;quot;alcconsumption&amp;quot;      
##  [4] &amp;quot;armedforcesrate&amp;quot;      &amp;quot;breastcancerper100th&amp;quot; &amp;quot;co2emissions&amp;quot;        
##  [7] &amp;quot;femaleemployrate&amp;quot;     &amp;quot;hivrate&amp;quot;              &amp;quot;internetuserate&amp;quot;     
## [10] &amp;quot;lifeexpectancy&amp;quot;       &amp;quot;oilperperson&amp;quot;         &amp;quot;polityscore&amp;quot;         
## [13] &amp;quot;relectricperperson&amp;quot;   &amp;quot;suicideper100th&amp;quot;      &amp;quot;employrate&amp;quot;          
## [16] &amp;quot;urbanrate&amp;quot;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;setting-a-correlation-matrixremove-the-country-because-it-is-a-factor&quot;&gt;setting a correlation matrix,remove the country because it is a factor&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;&lt;span class=&quot;kn&quot;&gt;library&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;reshape&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
data2 &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; data1&lt;span class=&quot;p&quot;&gt;[,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;-1&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;]&lt;/span&gt;
&lt;span class=&quot;kp&quot;&gt;names&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data2&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1] &amp;quot;incomeperperson&amp;quot;      &amp;quot;alcconsumption&amp;quot;       &amp;quot;armedforcesrate&amp;quot;     
##  [4] &amp;quot;breastcancerper100th&amp;quot; &amp;quot;co2emissions&amp;quot;         &amp;quot;femaleemployrate&amp;quot;    
##  [7] &amp;quot;hivrate&amp;quot;              &amp;quot;internetuserate&amp;quot;      &amp;quot;lifeexpectancy&amp;quot;      
## [10] &amp;quot;oilperperson&amp;quot;         &amp;quot;polityscore&amp;quot;          &amp;quot;relectricperperson&amp;quot;  
## [13] &amp;quot;suicideper100th&amp;quot;      &amp;quot;employrate&amp;quot;           &amp;quot;urbanrate&amp;quot;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;d_cor &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; &lt;span class=&quot;kp&quot;&gt;as.matrix&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;cor&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data2&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
d_cor_melt &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; arrange&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;melt&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;d_cor&lt;span class=&quot;p&quot;&gt;),&lt;/span&gt; &lt;span class=&quot;o&quot;&gt;-&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;abs&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;value&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
d_cor_melt&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##                       X1                   X2       value
## 1        incomeperperson      incomeperperson  1.00000000
## 2         alcconsumption       alcconsumption  1.00000000
## 3        armedforcesrate      armedforcesrate  1.00000000
## 4   breastcancerper100th breastcancerper100th  1.00000000
## 5           co2emissions         co2emissions  1.00000000
## 6       femaleemployrate     femaleemployrate  1.00000000
## 7                hivrate              hivrate  1.00000000
## 8        internetuserate      internetuserate  1.00000000
## 9         lifeexpectancy       lifeexpectancy  1.00000000
## 10          oilperperson         oilperperson  1.00000000
## 11           polityscore          polityscore  1.00000000
## 12    relectricperperson   relectricperperson  1.00000000
## 13       suicideper100th      suicideper100th  1.00000000
## 14            employrate           employrate  1.00000000
## 15             urbanrate            urbanrate  1.00000000
## 16       internetuserate      incomeperperson  0.82300755
## 17       incomeperperson      internetuserate  0.82300755
## 18    relectricperperson      incomeperperson  0.80803700
## 19       incomeperperson   relectricperperson  0.80803700
## 20        lifeexpectancy      internetuserate  0.76916000
## 21       internetuserate       lifeexpectancy  0.76916000
## 22            employrate     femaleemployrate  0.75953615
## 23      femaleemployrate           employrate  0.75953615
## 24       internetuserate breastcancerper100th  0.74545445
## 25  breastcancerper100th      internetuserate  0.74545445
## 26        lifeexpectancy      incomeperperson  0.73245246
## 27       incomeperperson       lifeexpectancy  0.73245246
## 28    relectricperperson      internetuserate  0.71730923
## 29       internetuserate   relectricperperson  0.71730923
## 30  breastcancerper100th      incomeperperson  0.70870641
## 31       incomeperperson breastcancerper100th  0.70870641
## 32    relectricperperson breastcancerper100th  0.64073128
## 33  breastcancerper100th   relectricperperson  0.64073128
## 34             urbanrate      internetuserate  0.62837641
## 35       internetuserate            urbanrate  0.62837641
## 36        lifeexpectancy breastcancerper100th  0.58024660
## 37  breastcancerper100th       lifeexpectancy  0.58024660
## 38          oilperperson      incomeperperson  0.56832284
## 39       incomeperperson         oilperperson  0.56832284
## 40             urbanrate       lifeexpectancy  0.55208423
## 41        lifeexpectancy            urbanrate  0.55208423
## 42             urbanrate      incomeperperson  0.55175903
## 43       incomeperperson            urbanrate  0.55175903
## 44    relectricperperson       lifeexpectancy  0.55158140
## 45        lifeexpectancy   relectricperperson  0.55158140
## 46        lifeexpectancy              hivrate -0.54250579
## 47               hivrate       lifeexpectancy -0.54250579
## 48           polityscore breastcancerper100th  0.53192879
## 49  breastcancerper100th          polityscore  0.53192879
## 50             urbanrate breastcancerper100th  0.53106183
## 51  breastcancerper100th            urbanrate  0.53106183
## 52          oilperperson      armedforcesrate  0.52487245
## 53       armedforcesrate         oilperperson  0.52487245
## 54             urbanrate         oilperperson  0.50197420
## 55          oilperperson            urbanrate  0.50197420
## 56       internetuserate       alcconsumption  0.46509554
## 57        alcconsumption      internetuserate  0.46509554
## 58             urbanrate   relectricperperson  0.46251094
## 59    relectricperperson            urbanrate  0.46251094
## 60       suicideper100th       alcconsumption  0.45834251
## 61        alcconsumption      suicideper100th  0.45834251
## 62          oilperperson      internetuserate  0.44164454
## 63       internetuserate         oilperperson  0.44164454
## 64          oilperperson       lifeexpectancy  0.42291135
## 65        lifeexpectancy         oilperperson  0.42291135
## 66           polityscore      internetuserate  0.38803948
## 67       internetuserate          polityscore  0.38803948
## 68       internetuserate     femaleemployrate  0.38696564
## 69      femaleemployrate      internetuserate  0.38696564
## 70  breastcancerper100th       alcconsumption  0.38654294
## 71        alcconsumption breastcancerper100th  0.38654294
## 72    relectricperperson         oilperperson  0.38628947
## 73          oilperperson   relectricperperson  0.38628947
## 74           polityscore      armedforcesrate -0.37492095
## 75       armedforcesrate          polityscore -0.37492095
## 76           polityscore       alcconsumption  0.35133104
## 77        alcconsumption          polityscore  0.35133104
## 78           polityscore       lifeexpectancy  0.34484282
## 79        lifeexpectancy          polityscore  0.34484282
## 80      femaleemployrate       alcconsumption  0.34438970
## 81        alcconsumption     femaleemployrate  0.34438970
## 82      femaleemployrate      incomeperperson  0.32125406
## 83       incomeperperson     femaleemployrate  0.32125406
## 84    relectricperperson     femaleemployrate  0.31856727
## 85      femaleemployrate   relectricperperson  0.31856727
## 86      femaleemployrate breastcancerper100th  0.31717282
## 87  breastcancerper100th     femaleemployrate  0.31717282
## 88           polityscore      incomeperperson  0.29850030
## 89       incomeperperson          polityscore  0.29850030
## 90          co2emissions      incomeperperson  0.29424580
## 91       incomeperperson         co2emissions  0.29424580
## 92      femaleemployrate      armedforcesrate -0.28084508
## 93       armedforcesrate     femaleemployrate -0.28084508
## 94            employrate      incomeperperson  0.28000427
## 95       incomeperperson           employrate  0.28000427
## 96          co2emissions breastcancerper100th  0.27716789
## 97  breastcancerper100th         co2emissions  0.27716789
## 98            employrate   relectricperperson  0.27427813
## 99    relectricperperson           employrate  0.27427813
## 100           employrate              hivrate -0.27211131
## 101              hivrate           employrate -0.27211131
## 102            urbanrate       alcconsumption  0.27009139
## 103       alcconsumption            urbanrate  0.27009139
## 104 breastcancerper100th      armedforcesrate -0.26847241
## 105      armedforcesrate breastcancerper100th -0.26847241
## 106       lifeexpectancy     femaleemployrate  0.26812937
## 107     femaleemployrate       lifeexpectancy  0.26812937
## 108   relectricperperson         co2emissions  0.26331050
## 109         co2emissions   relectricperperson  0.26331050
## 110         oilperperson breastcancerper100th  0.25901913
## 111 breastcancerper100th         oilperperson  0.25901913
## 112           employrate      armedforcesrate -0.24247267
## 113      armedforcesrate           employrate -0.24247267
## 114           employrate         oilperperson  0.23037392
## 115         oilperperson           employrate  0.23037392
## 116            urbanrate          polityscore  0.23014522
## 117          polityscore            urbanrate  0.23014522
## 118      internetuserate              hivrate -0.22652361
## 119              hivrate      internetuserate -0.22652361
## 120       lifeexpectancy       alcconsumption  0.21854104
## 121       alcconsumption       lifeexpectancy  0.21854104
## 122      suicideper100th       lifeexpectancy -0.21833549
## 123       lifeexpectancy      suicideper100th -0.21833549
## 124           employrate       lifeexpectancy  0.21033357
## 125       lifeexpectancy           employrate  0.21033357
## 126   relectricperperson          polityscore  0.20908881
## 127          polityscore   relectricperperson  0.20908881
## 128           employrate      internetuserate  0.19051364
## 129      internetuserate           employrate  0.19051364
## 130      suicideper100th     femaleemployrate  0.18778683
## 131     femaleemployrate      suicideper100th  0.18778683
## 132           employrate          polityscore -0.18711922
## 133          polityscore           employrate -0.18711922
## 134            urbanrate     femaleemployrate  0.17822695
## 135     femaleemployrate            urbanrate  0.17822695
## 136     femaleemployrate         co2emissions  0.17238628
## 137         co2emissions     femaleemployrate  0.17238628
## 138   relectricperperson      armedforcesrate -0.16898440
## 139      armedforcesrate   relectricperperson -0.16898440
## 140         oilperperson     femaleemployrate  0.15953621
## 141     femaleemployrate         oilperperson  0.15953621
## 142           employrate       alcconsumption -0.14626247
## 143       alcconsumption           employrate -0.14626247
## 144      internetuserate         co2emissions  0.14309235
## 145         co2emissions      internetuserate  0.14309235
## 146       alcconsumption      incomeperperson  0.13723859
## 147      incomeperperson       alcconsumption  0.13723859
## 148              hivrate     femaleemployrate -0.13357235
## 149     femaleemployrate              hivrate -0.13357235
## 150         co2emissions      armedforcesrate -0.13055412
## 151      armedforcesrate         co2emissions -0.13055412
## 152            urbanrate      armedforcesrate  0.12937141
## 153      armedforcesrate            urbanrate  0.12937141
## 154            urbanrate           employrate  0.12523556
## 155           employrate            urbanrate  0.12523556
## 156   relectricperperson       alcconsumption  0.12292871
## 157       alcconsumption   relectricperperson  0.12292871
## 158              hivrate      armedforcesrate -0.12215132
## 159      armedforcesrate              hivrate -0.12215132
## 160           employrate         co2emissions  0.11792695
## 161         co2emissions           employrate  0.11792695
## 162      internetuserate      armedforcesrate -0.11644553
## 163      armedforcesrate      internetuserate -0.11644553
## 164              hivrate      incomeperperson -0.11500444
## 165      incomeperperson              hivrate -0.11500444
## 166            urbanrate      suicideper100th -0.11497281
## 167      suicideper100th            urbanrate -0.11497281
## 168      armedforcesrate       alcconsumption -0.10485225
## 169       alcconsumption      armedforcesrate -0.10485225
## 170          polityscore         oilperperson -0.10420992
## 171         oilperperson          polityscore -0.10420992
## 172       lifeexpectancy         co2emissions  0.10399038
## 173         co2emissions       lifeexpectancy  0.10399038
## 174         oilperperson       alcconsumption -0.10193469
## 175       alcconsumption         oilperperson -0.10193469
## 176      suicideper100th              hivrate  0.10098194
## 177              hivrate      suicideper100th  0.10098194
## 178              hivrate breastcancerper100th -0.08969369
## 179 breastcancerper100th              hivrate -0.08969369
## 180      armedforcesrate      incomeperperson -0.08854208
## 181      incomeperperson      armedforcesrate -0.08854208
## 182            urbanrate         co2emissions  0.08796496
## 183         co2emissions            urbanrate  0.08796496
## 184         oilperperson         co2emissions  0.08526168
## 185         co2emissions         oilperperson  0.08526168
## 186          polityscore              hivrate  0.07565524
## 187              hivrate          polityscore  0.07565524
## 188         oilperperson              hivrate -0.07406404
## 189              hivrate         oilperperson -0.07406404
## 190          polityscore         co2emissions  0.07308423
## 191         co2emissions          polityscore  0.07308423
## 192      suicideper100th      internetuserate  0.07286536
## 193      internetuserate      suicideper100th  0.07286536
## 194   relectricperperson              hivrate -0.06584784
## 195              hivrate   relectricperperson -0.06584784
## 196            urbanrate              hivrate -0.06106555
## 197              hivrate            urbanrate -0.06106555
## 198           employrate breastcancerper100th  0.06002107
## 199 breastcancerper100th           employrate  0.06002107
## 200      suicideper100th         oilperperson -0.05819842
## 201         oilperperson      suicideper100th -0.05819842
## 202      suicideper100th      incomeperperson -0.05759281
## 203      incomeperperson      suicideper100th -0.05759281
## 204          polityscore     femaleemployrate  0.04549128
## 205     femaleemployrate          polityscore  0.04549128
## 206           employrate      suicideper100th -0.04075238
## 207      suicideper100th           employrate -0.04075238
## 208      suicideper100th   relectricperperson -0.03981433
## 209   relectricperperson      suicideper100th -0.03981433
## 210      suicideper100th      armedforcesrate -0.03859743
## 211      armedforcesrate      suicideper100th -0.03859743
## 212              hivrate       alcconsumption  0.03580681
## 213       alcconsumption              hivrate  0.03580681
## 214      suicideper100th breastcancerper100th -0.03450769
## 215 breastcancerper100th      suicideper100th -0.03450769
## 216      suicideper100th          polityscore  0.03262108
## 217          polityscore      suicideper100th  0.03262108
## 218      suicideper100th         co2emissions  0.03116024
## 219         co2emissions      suicideper100th  0.03116024
## 220       lifeexpectancy      armedforcesrate  0.02364780
## 221      armedforcesrate       lifeexpectancy  0.02364780
## 222         co2emissions       alcconsumption  0.01656709
## 223       alcconsumption         co2emissions  0.01656709
## 224              hivrate         co2emissions  0.01004384
## 225         co2emissions              hivrate  0.01004384&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;looking-for-a-specific-values-from-columns-and-build-index&quot;&gt;looking for a specific values from columns and build index&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;index&lt;span class=&quot;o&quot;&gt;=&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;which&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;grepl&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s&quot;&gt;&amp;quot;polityscore&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;X1&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
index2&lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;kp&quot;&gt;which&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;grepl&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s&quot;&gt;&amp;quot;urbanrate&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt;d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;X2&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
index&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1]  11  48  66  74  76  78  88 117 127 133 170 186 190 204 217&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;index2&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1]  15  35  41  43  51  55  59 103 117 135 153 155 167 183 197&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;find-common-elements-by-intersect&quot;&gt;find common elements by intersect()&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;targetrow &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; &lt;span class=&quot;kp&quot;&gt;intersect&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;index&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt;index2&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
targetrow&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;## [1] 117&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;locate-the-target&quot;&gt;locate the target&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;d_cor_melt&lt;span class=&quot;p&quot;&gt;[&lt;/span&gt;targetrow&lt;span class=&quot;p&quot;&gt;,]&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##              X1        X2     value
## 117 polityscore urbanrate 0.2301452&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;To get those corrleations which are above 0.5 and less than 1.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;d_cor_melt&lt;span class=&quot;p&quot;&gt;[&lt;/span&gt;d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;value&lt;span class=&quot;o&quot;&gt;&amp;gt;=&lt;/span&gt;&lt;span class=&quot;m&quot;&gt;0.5&lt;/span&gt; &lt;span class=&quot;o&quot;&gt;&amp;amp;&lt;/span&gt; d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;value&lt;span class=&quot;o&quot;&gt;&amp;lt;&lt;/span&gt;&lt;span class=&quot;m&quot;&gt;1&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,])&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##                      X1                   X2     value
## 16      internetuserate      incomeperperson 0.8230076
## 17      incomeperperson      internetuserate 0.8230076
## 18   relectricperperson      incomeperperson 0.8080370
## 19      incomeperperson   relectricperperson 0.8080370
## 20       lifeexpectancy      internetuserate 0.7691600
## 21      internetuserate       lifeexpectancy 0.7691600
## 22           employrate     femaleemployrate 0.7595362
## 23     femaleemployrate           employrate 0.7595362
## 24      internetuserate breastcancerper100th 0.7454545
## 25 breastcancerper100th      internetuserate 0.7454545
## 26       lifeexpectancy      incomeperperson 0.7324525
## 27      incomeperperson       lifeexpectancy 0.7324525
## 28   relectricperperson      internetuserate 0.7173092
## 29      internetuserate   relectricperperson 0.7173092
## 30 breastcancerper100th      incomeperperson 0.7087064
## 31      incomeperperson breastcancerper100th 0.7087064
## 32   relectricperperson breastcancerper100th 0.6407313
## 33 breastcancerper100th   relectricperperson 0.6407313
## 34            urbanrate      internetuserate 0.6283764
## 35      internetuserate            urbanrate 0.6283764
## 36       lifeexpectancy breastcancerper100th 0.5802466
## 37 breastcancerper100th       lifeexpectancy 0.5802466
## 38         oilperperson      incomeperperson 0.5683228
## 39      incomeperperson         oilperperson 0.5683228
## 40            urbanrate       lifeexpectancy 0.5520842
## 41       lifeexpectancy            urbanrate 0.5520842
## 42            urbanrate      incomeperperson 0.5517590
## 43      incomeperperson            urbanrate 0.5517590
## 44   relectricperperson       lifeexpectancy 0.5515814
## 45       lifeexpectancy   relectricperperson 0.5515814
## 48          polityscore breastcancerper100th 0.5319288
## 49 breastcancerper100th          polityscore 0.5319288
## 50            urbanrate breastcancerper100th 0.5310618
## 51 breastcancerper100th            urbanrate 0.5310618
## 52         oilperperson      armedforcesrate 0.5248724
## 53      armedforcesrate         oilperperson 0.5248724
## 54            urbanrate         oilperperson 0.5019742
## 55         oilperperson            urbanrate 0.5019742&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

</content>
 </entry>
 
 <entry>
   <title>Assignment 1 Getting Your Research Project Started</title>
   <link href="http://lanyon.getpoole.com/data%20science/2015/09/19/Data-Management-Assignment1/"/>
   <updated>2015-09-19T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/data%20science/2015/09/19/Data-Management-Assignment1</id>
   <content type="html">&lt;h3 id=&quot;brief-summary-and-introduction&quot;&gt;Brief summary and introduction&lt;/h3&gt;

&lt;p&gt;My name is &lt;a href=&quot;https://www.linkedin.com/in/jizongliang&quot;&gt;Jizong Liang&lt;/a&gt; and you can call me &lt;a href=&quot;http://jizongl.github.io/&quot;&gt;TmmGeek&lt;/a&gt;, I am a PhD student in Pathology at the cancer research Institute at &lt;a href=&quot;https://www.umc.edu/&quot;&gt;University of Mississippi Medical Center&lt;/a&gt;, In addition, I am also a computer geek and extremely interested in statistical analysis and Data Science. As a result, anything related to diseases and data analysis would be my areas of interests.&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;Recently, I have done indepth study in HIV and AIDS and have developed a thorougly understanding of its pathology and molecular mechanism and I am quite facinated with this devilish disease which is by far one of the most clever viruses known to us. and as a biomedical scientist, I believe that my priority is to focus on bringing better health care to people and conduct innovative research to improve disease treatments, and I believe in the near future, the mystery of HIV and AIDS will be resolved and million of people will have their second chance to relive their life.&lt;/p&gt;

&lt;p&gt;Nevertheless, diseases, especially HIV and AIDS, could also be studied at different angles other than just biomedical research, such as their effects and ramifications woven into all levels of social strata, their influences on human behaviors in different cultures, economic status, how they may influence life expectancy in different countries, how different cultural practices would either promote or discourage them. All these different domains mentioned above along with numerous others, as I am strongly convinced, would provide unexpected additional evidence for scientists, medical professionals, social workers and many other related personnels to work together in order to understand disease epidemiology better and develop more effective personalized treatment plans.&lt;/p&gt;

&lt;p&gt;Here I want to say thank you to &lt;a href=&quot;https://www.coursera.org/&quot;&gt;Coursera&lt;/a&gt; which provides this amazing course &lt;a href=&quot;https://www.coursera.org/learn/data-visualization&quot;&gt;Data Management and Visualization&lt;/a&gt; by &lt;a href=&quot;http://www.wesleyan.edu/&quot;&gt;Wesleyan University&lt;/a&gt;. I am motivated by the structure of this course which gives me freedom and a mature guideline to venture into the unknowns of Data Science. The following contents are my effort to complete &lt;a href=&quot;https://www.coursera.org/learn/data-visualization/peer/ntBWz/getting-your-research-project-started&quot;&gt;the step by step guidelines&lt;/a&gt; to get my project started.&lt;/p&gt;

&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#brief-summary-and-introduction&quot; id=&quot;markdown-toc-brief-summary-and-introduction&quot;&gt;Brief summary and introduction&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#choose-a-data-set-that-you-would-like-to-work-with&quot; id=&quot;markdown-toc-choose-a-data-set-that-you-would-like-to-work-with&quot;&gt;1: Choose a data set that you would like to work with.&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#identify-a-specific-topic-of-interest&quot; id=&quot;markdown-toc-identify-a-specific-topic-of-interest&quot;&gt;2: identify a specific topic of interest&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#codebook&quot; id=&quot;markdown-toc-codebook&quot;&gt;3: Codebook&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#identify-a-second-topic-that-you-would-like-to-explore-in-terms-of-its-association-with-your-original-topic&quot; id=&quot;markdown-toc-identify-a-second-topic-that-you-would-like-to-explore-in-terms-of-its-association-with-your-original-topic&quot;&gt;4: Identify a second topic that you would like to explore in terms of its association with your original topic.&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#add-questionsitemsvariables-documenting-this-second-topic-to-your-personal-codebook&quot; id=&quot;markdown-toc-add-questionsitemsvariables-documenting-this-second-topic-to-your-personal-codebook&quot;&gt;5: Add questions/items/variables documenting this second topic to your personal codebook.&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#perform-a-literature-review-to-see-what-research-has-been-previously-done-on-this-topic&quot; id=&quot;markdown-toc-perform-a-literature-review-to-see-what-research-has-been-previously-done-on-this-topic&quot;&gt;6: Perform a literature review to see what research has been previously done on this topic.&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#hypothesis&quot; id=&quot;markdown-toc-hypothesis&quot;&gt;7: Hypothesis&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#reference&quot; id=&quot;markdown-toc-reference&quot;&gt;Reference&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#recourses&quot; id=&quot;markdown-toc-recourses&quot;&gt;Recourses&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#review-criteria&quot; id=&quot;markdown-toc-review-criteria&quot;&gt;Review Criteria&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;choose-a-data-set-that-you-would-like-to-work-with&quot;&gt;1: Choose a data set that you would like to work with.&lt;/h3&gt;
&lt;p&gt;After looking through all the datasets available, I have chosen the &lt;a href=&quot;https://d396qusza40orc.cloudfront.net/phoenixassets/data-management-visualization/GapMinder%20Codebook%20.pdf&quot;&gt;Gapminder&lt;/a&gt; dataset because it is closely related to my areas of interests. The dataset is availble &lt;a href=&quot;https://raw.githubusercontent.com/JizongL/jizongL.github.io/master/assets/blog/Rblog/correlation/09192015correlation/gapminder.csv&quot;&gt;here&lt;/a&gt;.&lt;/p&gt;

&lt;h3 id=&quot;identify-a-specific-topic-of-interest&quot;&gt;2: identify a specific topic of interest&lt;/h3&gt;

&lt;p&gt;After studying briefly on the Gapminder dataset, I found that there is an &lt;strong&gt;HIV&lt;/strong&gt; identifier that caught my attention, along with a few others related identifers that I am interested in, such as &lt;em&gt;life expectancy&lt;/em&gt;, &lt;em&gt;urban rate&lt;/em&gt;, &lt;em&gt;Internet user rate&lt;/em&gt; etc.(please see Codebook for further details)&lt;/p&gt;

&lt;p&gt;Intuitively, I would ask the question wheather &lt;strong&gt;HIV Prevalence&lt;/strong&gt; might more or less correlate with &lt;strong&gt;urbanization&lt;/strong&gt;, at least in the developed countries. Or perhaps there might be different patterns of HIV rate between developed and developing countries. Furthermore, would the patterns be different between the western and eastern worlds?&lt;/p&gt;

&lt;p&gt;Besides, I personally incline to believe that the &lt;strong&gt;Internet&lt;/strong&gt; might play a critical role in influencing people’s awareness on HIV infection and prevention. Or would the many misleading information people could have access from the web actually contribute to people making less informed decisions about their sexual orientation or behaviors, or rather not? I am excited to experiment on the data deeper as the course proceeds and to extract more insightful evidence to support my hypothesis and I believe that the journey will be fun.&lt;/p&gt;

&lt;p&gt;variables available from the &lt;a href=&quot;https://d396qusza40orc.cloudfront.net/phoenixassets/data-management-visualization/GapMinder%20Codebook%20.pdf&quot;&gt;Gapminder&lt;/a&gt; dataset for my primary topic are as followed.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;HIVrate&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;urbanrate&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Internetuserate&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;codebook&quot;&gt;3: Codebook&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;Note:&lt;/strong&gt; This extracted Codebook includes all the variables details for both my primary and secondary topics&lt;/p&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th&gt;Variable Name&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Description of Indicator&lt;/th&gt;
      &lt;th style=&quot;text-align: right&quot;&gt;Main Source&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;incomeperperson&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2010 Gross Domestic Product per capita in constant 2000 US$. The inflation but not the differences in the cost of living between countries has been taken into account.&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;World Bank Work Development Indicators&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;lifeexpectancy&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2011 life expectancy at birth (years) The average number of years a newborn child would live if current mortality patterns were to stay the same.&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;&lt;strong&gt;I&lt;/strong&gt; Human Mortality Database &lt;strong&gt;II&lt;/strong&gt; World Population Prospects &lt;strong&gt;III&lt;/strong&gt;* Publications and files by history prof. James C Riley &lt;strong&gt;IV&lt;/strong&gt; Human Lifetable Database&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;relectricperperson&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2008 residential electricity consumption, per person (kWh) The amount of residential electricity consumption per person during the given year, counted in kilowatt-hours (kWh).&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;International Energy Agency&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;urbanrate&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2008 urban population (% of total) Urban population refers to people living in urban areas as defined by national statistical offices (calculated using World Bank population estimates and urban ratios from the United Nations World UrbanizationProspects).&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;World Bank&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;Internetuserate&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2010 Internet users (per 100 people) Internet users are people with access to the worldwide network.&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;World Bank&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;HIVrate&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2009 estimated HIV Prevalence % - (Ages 15-49) Estimated number of people living with HIV per 100 population of age group 15-49.&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;UNAIDS online database&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;identify-a-second-topic-that-you-would-like-to-explore-in-terms-of-its-association-with-your-original-topic&quot;&gt;4: Identify a second topic that you would like to explore in terms of its association with your original topic.&lt;/h3&gt;

&lt;p&gt;After looking at the &lt;a href=&quot;https://d396qusza40orc.cloudfront.net/phoenixassets/data-management-visualization/GapMinder%20Codebook%20.pdf&quot;&gt;Gapminder&lt;/a&gt; Codebook again, I also think of the possiblity to explore the possible relationship between Socioeconomic status and life expectancy. My question to ask is that does income rate necessarily improve life expectancy in general, or the otherwise? As when people become more fiancially confident, they may or may not take better care of themselves. Of course, I would not jump into any conclusion until I could analytically draw more insight from the data along this course. It should be exciting.&lt;/p&gt;

&lt;h3 id=&quot;add-questionsitemsvariables-documenting-this-second-topic-to-your-personal-codebook&quot;&gt;5: Add questions/items/variables documenting this second topic to your personal codebook.&lt;/h3&gt;

&lt;p&gt;Please see Codebook above.&lt;/p&gt;

&lt;h3 id=&quot;perform-a-literature-review-to-see-what-research-has-been-previously-done-on-this-topic&quot;&gt;6: Perform a literature review to see what research has been previously done on this topic.&lt;/h3&gt;

&lt;p&gt;1: HIV/AIDs and Urbanization&lt;/p&gt;

&lt;p&gt;It is well known that levels of HIV prevalence tend to be appreciably higher inurban areas&lt;sup&gt;&lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1111/j.1728-4457.2003.00427.x/abstract&quot;&gt;1&lt;/a&gt;&lt;/sup&gt;(&lt;em&gt;Tim Dyson Et.al&lt;/em&gt;). Once in a city, the newly introduced infection would have the opportunity to spread locally among the population and could also spread further along highways and inter- urban transport routes and by airplane. HIV has been, and in Asia is becoming, the best known beneficiary of this dynamic, but many other diseases, such as dengue, stand to benefit.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2626828/pdf/8903148.pdf&quot;&gt;2&lt;/a&gt;&lt;/sup&gt;(&lt;em&gt;Stephen S. Morse et.al 1995&lt;/em&gt;)&lt;/p&gt;

&lt;p&gt;Netertheless, we must not easily jump into conclusion based on one side of the story. To look deeper, we must ask how should we effectively discern if there is bias in HIV/AIDS surveillance data collection practice both nationally and globally. For instance, Given the absence of recent and regularly updated census data for many countries in sub-Saharan Africa, global statistics on urban- ization on the subcontinent are often speculative and not particularly reliable&lt;sup&gt;&lt;a href=&quot;http://eau.sagepub.com/content/18/1/155.full.pdf+html&quot;&gt;3&lt;/a&gt;&lt;/sup&gt;(MIRJAM VAN DONK et.al,2015).&lt;/p&gt;

&lt;p&gt;In fact, global HIV/AIDS data are continuously adjusted in response to better HIV surveillance systems and improved software to model the HIV/AIDS epidemic.(6) Global HIV/AIDS data also tend to reflect an implicit urban bias, as sentinel surveillance sites are generally located in urban areas and in larger settle- ments in rural districts. For this reason UNAIDS prefers to use the term “outside major urban areas”, rather than “rural areas”. This distinction is again based on country distinctions, which complicates comparisons between countries.&lt;sup&gt;&lt;a href=&quot;http://eau.sagepub.com/content/18/1/155.full.pdf+html&quot;&gt;3&lt;/a&gt;&lt;/sup&gt;(MIRJAM VAN DONK et.al,2015).&lt;/p&gt;

&lt;p&gt;Though the true trace of HIV/AIDs development in both Urban and Rural areas around the world may indeed be too challenge to detect, we may argue that there could be specific factors that make the HIV/AIDs patterns of HIV/AIDs development distinctly different between Urban and Rural. For example, a Cross-sectional survey data were gathered from 995 respondents in northwest Ethiopia. The findings indicated that urban residents’ concern about and information needs on HIV/AIDS was greater than that of the rural populace. Urban and rural residents were also found to be significantly different in their preferences for specific types of HIV/AIDS-related information. While rurality was found to be associated with a preference for basic HIV transmission and prevention information, urbanity was associated with a preference for information on HIV/AIDS-related care and support&lt;sup&gt;&lt;a href=&quot;http://idv.sagepub.com/content/29/4/323.full.pdf+html?cited-by=yes&amp;amp;legid=spidv;29/4/323#cited-by&quot;&gt;4&lt;/a&gt;&lt;/sup&gt;(Mesfin Awoke Bekalu,2013)&lt;/p&gt;

&lt;p&gt;In 1990, James W.Curran and colleagues mentioned that there are three major epidemiological patterns of HIV infection have been previously described in the world. In pattern I, which occurs mainly in North America, Europe, and Australia, most cases occur in homosexual men and injecting drug users and their sex partners and offspring. Pattern II occurs mainly in sub-Saharan Africa, and increasingly in other parts of the world. Here most people acquire their infection heterosexually, perinatally from their mother, or through blood transfusion. Finally, pattern III includes the remaining countries where HIV was very recently introduced and where small numbers of cases have been infected in various ways.&lt;sup&gt;&lt;a href=&quot;http://journals.lwwcom/jaids/Citation/1990/04000/The_Global_Epidemiology_of_HIV_Infection_.16.aspx&quot;&gt;6&lt;/a&gt;&lt;/sup&gt;(Barney Cohen,2005)&lt;/p&gt;

&lt;p&gt;These findings again suggest the different patterns of HIV/AIDs development between Urban and Rural areas, moreover, the course of HIV/AIDs epidemic may have been further complicated by other factor such as the internet. It may influence people’s sexual behaviors and in term indirectly contribute to the development of HIV/AIDs. For example, Mary McFarlane and colleagues found that Young adults who seek sex on the Internet report substantially different sexual behavior patterns than young adults who do not seek sex on the Internet. Young adults with online partners reported sexual behaviors similar to older respondents who used the Internet to find sex partners; however, older respondents were more likely than young adults to have been tested for sexually transmitted diseases and HIV.&lt;sup&gt;&lt;a href=&quot;http://www.sciencedirect.com/science/article/pii/S1054139X02003737&quot;&gt;7&lt;/a&gt;&lt;/sup&gt;(Mary McFarlane et.al, 2002)&lt;/p&gt;

&lt;p&gt;The internet may also play a critial role in HIV/AIDs prevention and disease management for patients. Unfortunately, health information is not equally accessible, with less educated, economically disadvantaged, and socially marginalized persons least likely to access health information on the Internet (Bolt &amp;amp; Crawford, 2000), and the same demographic characteristics represent the fastest growing populations of people living with HIV/AIDS. In a previous study, we found that 49% of HIV-positive men and women had used the Internet and that 29% were currently using the Internet to access health information (Kalichman, Benotsch, Weinhardt, Austin, &amp;amp; Luke, 2002). We also found evidence of a digital divide in people with HIV/AIDS,with a history of Internet use more common among Whites (77%) than African Americans (42%). A gap therefore exists between persons who do and do not have access to the Internet, with the growing population of people living with HIV/AIDS being among those least likely to access information online.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/?term=Health-related+Internet+use%2C+coping%2C+social+support%2C+and+health+indicators+in+people+living+with+HIV%2FAIDS%3A+preliminary+results+from+a+community+survey.+Health+Psychol.+2003%3B22(1)%3A111-6.&quot;&gt;8&lt;/a&gt;&lt;/sup&gt;(Kalichman SC &amp;amp; Benotsch EG,2003)&lt;/p&gt;

&lt;p&gt;The same study also found that Internet use for health-related information was associated with health-related outcomes. Persons who used the Internet for health information were better informed about HIV disease and reported more use of active coping strategies and greater social support. We found that health-related Internet use was associated with information-seeking coping, a result that is consistent with research showing that information seeking as a coping style is associated with health benefits among some people with chronic medical conditions (Devins &amp;amp; Binik, 1996). These results support the use of interventions that increase active coping strategies, and we suggest including use of the Internet for health- related purposes among active coping strategies. It is likely that persons who seek information on the Internet are actively seeking health information through multiple other information sources as well. However, our cross-sectional study design precludes drawing causal interpretations of the observed associations. Thus, prospec- tive and experimental studies are needed to determine the direction of associations between Internet use, coping strategies, and health outcomes.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/?term=Health-related+Internet+use%2C+coping%2C+social+support%2C+and+health+indicators+in+people+living+with+HIV%2FAIDS%3A+preliminary+results+from+a+community+survey.+Health+Psychol.+2003%3B22(1)%3A111-6.&quot;&gt;8&lt;/a&gt;&lt;/sup&gt;(Kalichman SC &amp;amp; Benotsch EG,2003)&lt;/p&gt;

&lt;p&gt;Based on those studies mentioned above, there are still many potential correlations among the 3 identifiers, HIV/AIDs development rate, Urbanization, and Internet use yet to be discovered, therefore, it is worth looking further into these relationships.&lt;/p&gt;

&lt;p&gt;2: Income levels and life expectancy&lt;/p&gt;

&lt;p&gt;estimates of life expectancy according to education have been reported by Kitagawa and Hauser for white men and white women in the United States.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1403677/pdf/pubhealthrep00072-0091.pdf&quot;&gt;13&lt;/a&gt;&lt;/sup&gt;(Rogot E &amp;amp; Sorlie PD,1992) In the same study, Rogot E and colleagues found that Differences in lifeexpectancy at age 25 between the highest and the lowest levels of education completed were about 6 years for white men and aboutSyearsforwhitewomen. Forfamilyincome, differences between the highest and the lowest income groups were about 10 years for white men and4.3yearsforwhitewomen. Thelargestdifer- ences in lifeexpectancy were between employment categories. At age 25, white men in the laborforce lived on average about 12 more years than those notinthelaborforce,andwhitewomen livedon average about 9 more years. For those who were unable to work compared with those in the labor force,thedifferenceforwhitemen wasabout20 years;forwhitewomen, 29 years. &lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1403677/pdf/pubhealthrep00072-0091.pdf&quot;&gt;13&lt;/a&gt;&lt;/sup&gt;(Rogot E &amp;amp; Sorlie PD,1992)&lt;/p&gt;

&lt;p&gt;In 1992, the BMJ published a now famous paper showing a strong negative correlation between income inequality and life expectancy. Among nine Western industrialised countries those which had less income inequality seemed to have higher life expectancy.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1121932/pdf/1.pdf&quot;&gt;14&lt;/a&gt;&lt;/sup&gt;(Johan P Mackenbach,2002)&lt;/p&gt;

&lt;p&gt;Moreover, Muller shows that most of the correlation between income inequality and mortality at the aggregate level in the United States can be explained away by differences in average levels of formal education (p 23).21 This is not surprising in itself, because others have shown before that income inequality is strongly and negatively associated with measures of educational achievement in the United States.2 The main issue is whether we should see educational achievement as a confounder or an intermediary between income inequality and mortality.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC61654/pdf/23.pdf&quot;&gt;19&lt;/a&gt;&lt;/sup&gt;
(Andreas Muller,2002)&lt;/p&gt;

&lt;p&gt;Another possible explanation is that some of the possible pathways linking income inequality and mortality cannot be expected to operate at this low geographical level. Would individuals feel relatively deprived because of a comparison with others’ incomes in the same small area, or because of comparisons within a larger social environment? Would income inequality be associated with underinvestment in public resources within the same small area, or would this mechanism operate on a larger geographical scale? It would be useful to replicate these analyses with different geographical scales, and in different European countries.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1121932/pdf/1.pdf&quot;&gt;14&lt;/a&gt;&lt;/sup&gt;(Johan P Mackenbach,2002)&lt;/p&gt;

&lt;p&gt;Humerous studies have been conducted on this topic, but these studies only suggest that there are still more confounding factors or unknown correlations remained to be discovered. Or maybe such correlation between income inequality and the health of the population is slowly dissipating? at least in the U.S and who knows? Thereofore, it would be interesting to explore deeper into the unknown water of this study and in the hope of finding more convincing evidence to form better phypothesis in the near future, and as result, come up with more effecitve policies or plans to help improve the social balance of the world we live in.&lt;/p&gt;

&lt;h3 id=&quot;hypothesis&quot;&gt;7: Hypothesis&lt;/h3&gt;

&lt;p&gt;Primary hypothesis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;1: &lt;strong&gt;HIV/AIDs Prevalence&lt;/strong&gt; correlates with &lt;strong&gt;urbanization&lt;/strong&gt; in both the developed and developing nations and have different patterns of development.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;2: The &lt;strong&gt;Internet rate&lt;/strong&gt; plays a critical role in influencing people’s awareness on HIV infection and prevention across the globe.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Secondary hypothesis&lt;/p&gt;

&lt;p&gt;Socioeconomic status and income levels have a direct correlation with life expectancy globally.&lt;/p&gt;

&lt;h3 id=&quot;reference&quot;&gt;Reference&lt;/h3&gt;

&lt;p&gt;1: &lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1111/j.1728-4457.2003.00427.x/abstract&quot;&gt;Dyson, T. (2003), HIV/AIDS and Urbanization. Population and Development Review, 29: 427–442. doi: 10.1111/j.1728-4457.2003.00427.x&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;2: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2626828/pdf/8903148.pdf&quot;&gt;Morse SS. Factors in the emergence of infectious diseases. Emerging Infectious Diseases. 1995;1(1):7-15.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;3: &lt;a href=&quot;http://eau.sagepub.com/content/18/1/155.full.pdf+html&quot;&gt;Mirjam Van Donk “Positive” urban futures in sub-Saharan Africa: HIV/AIDS and the need for ABC (A Broader Conceptualization)Environment and Urbanization April 2006 18: 155-175, doi:10.1177/0956247806063971&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;4: &lt;a href=&quot;http://idv.sagepub.com/content/29/4/323.full.pdf+html?cited-by=yes&amp;amp;legid=spidv;29/4/323#cited-by&quot;&gt;HIV/AIDS-related information needs of urban and rural residents of northwest Ethiopia: Alerting the rural populace and meeting the progressive needs of the urban populace&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;5: &lt;a href=&quot;http://ac.els-cdn.com/S0160791X05000588/1-s2.0-S0160791X05000588-main.pdf?_tid=d268c95a-5f37-11e5-831c-00000aacb360&amp;amp;acdnat=1442713086_4283cba38630c5f1c45bc1c827ef4e70&quot;&gt;Barney Cohen. (2005),Urbanization in developing countries: Current trends, future projections, and key challenges for sustainability, Volume 28, Issues 1–2, January–April 2006, Pages 63–80&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;6: &lt;a href=&quot;http://journals.lww.com/jaids/Citation/1990/04000/The_Global_Epidemiology_of_HIV_Infection_.16.aspx&quot;&gt;Piot P, Laga M, Ryder R, et al. The global epidemiology of HIV infection: continuity, heterogeneity, and change. J Acquir Immune Defic Syndr. 1990;3(4):403-12.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;7: &lt;a href=&quot;http://www.sciencedirect.com/science/article/pii/S1054139X02003737&quot;&gt;Mcfarlane M, Bull SS, Rietmeijer CA. Young adults on the Internet: risk behaviors for sexually transmitted diseases and HIV(1). J Adolesc Health. 2002;31(1):11-6.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;8: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/?term=Health-related+Internet+use%2C+coping%2C+social+support%2C+and+health+indicators+in+people+living+with+HIV%2FAIDS%3A+preliminary+results+from+a+community+survey.+Health+Psychol.+2003%3B22(1)%3A111-6.&quot;&gt;Kalichman SC, Benotsch EG, Weinhardt L, Austin J, Luke W, Cherry C. Health-related Internet use, coping, social support, and health indicators in people living with HIV/AIDS: preliminary results from a community survey. Health Psychol. 2003;22(1):111-6.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;9: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/26357907&quot;&gt;Green SM, Lockhart E, Marhefka SL. Advantages and disadvantages for receiving Internet-based HIV/AIDS interventions at home or at community-based organizations. AIDS Care. 2015;:1-5.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;10: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/26369354&quot;&gt;Bucholz EM, Ma S, Normand ST, Krumholz HM. Race, Socioeconomic Status, and Life Expectancy After Acute Myocardial Infarction. Circulation. 2015;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;11: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/26297094&quot;&gt;Love-koh J, Asaria M, Cookson R, Griffin S. The Social Distribution of Health: Estimating Quality-Adjusted Life Expectancy in England. Value Health. 2015;18(5):655-62.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;12: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/26251226&quot;&gt;Arjun BY, Unnikrishnan B, Ramapuram JT, et al. Factors Influencing Quality of Life among People Living with HIV in Coastal South India. J Int Assoc Provid AIDS Care. 2015;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;13: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1403677/pdf/pubhealthrep00072-0091.pdf&quot;&gt;Rogot E, Sorlie PD, Johnson NJ. Life expectancy by employment status, income, and education in the National Longitudinal Mortality Study. Public Health Rep. 1992;107(4):457-61.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;14: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1121932/pdf/1.pdf&quot;&gt;Mackenbach JP. Income inequality and population health. BMJ. 2002;324(7328):1-2.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;15: &lt;a href=&quot;http://www.tandfonline.com/doi/abs/10.1080/00324728.1979.10410449&quot;&gt;Krasnova TN, Samokhodskaia LM, Ivaninitskiĭ LV, et al. [Impact of interleukin-10 and interleukin-28 gene polymorphisms on the development and course of lupus nephritis]. Ter Arkh. 2015;87(6):40-4.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;16: &lt;a href=&quot;http://ije.oxfordjournals.org/content/35/4/969.full.pdf+html&quot;&gt;Singh GK, Siahpush M. Widening socioeconomic inequalities in US life expectancy, 1980-2000. Int J Epidemiol. 2006;35(4):969-79.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;17: &lt;a href=&quot;http://www.nejm.org/doi/pdf/10.1056/NEJM199307083290208&quot;&gt;Guralnik JM, Land KC, Blazer D, Fillenbaum GG, Branch LG. Educational status and active life expectancy among older blacks and whites. N Engl J Med. 1993;329(2):110-6.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;18: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2551188/pdf/bmj00618-0048.pdf&quot;&gt;Judge K. Income distribution and life expectancy: a critical appraisal. BMJ. 1995;311(7015):1282-5.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;19: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC61654/pdf/23.pdf&quot;&gt;Muller A. Education, income inequality, and mortality: a multiple regression analysis. BMJ 2002;324:23-5.&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;recourses&quot;&gt;Recourses&lt;/h3&gt;

&lt;p&gt;1: Citation Machine &lt;a href=&quot;https://mickschroeder.com/citation/?q=2179527&quot;&gt;MICK SCHROEDER&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;2: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed&quot;&gt;Pubmed&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;3: &lt;a href=&quot;https://scholar.google.com/schhp?hl=en&amp;amp;as_sdt=0,25&quot;&gt;Google Scholar&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;review-criteria&quot;&gt;Review Criteria&lt;/h3&gt;

&lt;p&gt;Your assessment will be based on the evidence you provide that you have completed all of the steps. When relevant, gradients in the scoring will be available to reward clarity (for example, you will get one point for having a research question presented in an unclear fashion, but two points for being clear). In all cases, consider that the peer assessing your work is likely not an expert in the field you are analyzing. You will be assessed equally on your reflection of the literature you’ve discovered and the project you are proposing.&lt;/p&gt;

&lt;p&gt;Specific rubric items, and their point values, are as follows:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Has the learner selected a data set and indicated that selection? (1 point)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Has the learner clearly stated a research question and hypothesis? (2 points)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Does the literature review include clear information about search terms used? (1 point)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Does the literature review clearly identify references used? (2 points)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Does the literature review clearly present a summary of findings (e.g., variables considered, patterns of findings, etc.)? (2 points)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;
</content>
 </entry>
 
 <entry>
   <title>Slidify quiz recourse</title>
   <link href="http://lanyon.getpoole.com/slidify%20quiz/2015/09/14/slidify-quiz/"/>
   <updated>2015-09-14T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/slidify%20quiz/2015/09/14/slidify-quiz</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;http://ramnathv.github.io/user2014-idocs-slides/demos/widgets/quiz-all/#1&quot;&gt;Slidify quiz examples&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>How to gobally set images size in Slidify</title>
   <link href="http://lanyon.getpoole.com/web%20development/2015/09/14/setting-global-image-size-for-slidify/"/>
   <updated>2015-09-14T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/web%20development/2015/09/14/setting-global-image-size-for-slidify</id>
   <content type="html">&lt;p&gt;This issue can be addressed very easily.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;First, open the css folder in your slidify folder&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;then, open the ribbons.css file, where it stores information for your slidify slides’ style setting.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;ul&gt;
  &lt;li&gt;Finally, just add the following code at the end of the file. This is to specify a sepecific size for all the figures in your slide. 
For instance, width = 780 and height=520&lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;img {
  width: 780px;
  height: 520px;
}&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;Check out the [Figures review] that I made for my pathology exam review as an example.&lt;/p&gt;

&lt;p&gt;Hope this is helpful.&lt;/p&gt;

&lt;p&gt;Thank you for reading.&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Robbins and Cortran Review note</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/14/Robbin-Review-note/"/>
   <updated>2015-09-14T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/14/Robbin-Review-note</id>
   <content type="html">&lt;h2 id=&quot;robbins-and-cotran-review-note&quot;&gt;Robbins and Cotran REview note&lt;/h2&gt;

&lt;h3 id=&quot;acute-and-chronic-inflammation&quot;&gt;Acute and Chronic Inflammation&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Lymphocytes are a feature of chronic inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Nonhuman microbial substances such as double-stranded RNA of viruses, bacterial DNA, and bacterial endotoxin, can be recognized by Toll-like receptors (TLRs) on human cells as part of an innate defense mechanism against infection.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Lectins found on cell surfaces can bind a variety of substances, such as fungal polysaccharides, that trigger cellular defenses.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;T cell receptors respond to peptide antigens to trigger a cell-mediated immune response.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Complement C3a causes increased vascular permeability by releasing histamine from mast cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;This immunoglobulin deficiency prevents opsonization and phagocytosis of microbes. Deficiency of integrins and selectins, or a defect in microtubules, would prevent adhesion and locomotion of neutrophils.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Myeloperoxidase is present in the azurophilic granules of neutrophils. It converts H2O2 into HOCl–&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;NADPH oxidase, resulting in generation of superoxide that is converted by spontaneous dismutation to H2O2.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;This burst can be quantitated by flow cytometric analysis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Bacteria are opsonized by complement C3b and IgG, allowing the bacteria to be more readily phagocytosed.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Integrins have two chains, α and β. A genetic lack of β chains prevents firm adhesion of leukocytes to endothelial cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;c5a that bind to the neutrophil and activate phospholipase C to begin a series of events that culminate in the influx of calcium, which triggers contractile proteins.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;he respiratory burst to kill phagocytized organisms depends on NADPH oxidase, and a deficiency of this enzyme leads to chronic &lt;strong&gt;granulomatous disease.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Monocytes transforming to macrophages contain cytokine-inducible nitric oxide synthase (iNOS), which generates nitric oxide. Nitric oxide, by itself and on interaction with other reactive oxygen species, has antimicrobial activity.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 or CD8 lymphocytes can be the source for interferon-γ (IFN-γ), which stimulates macrophage production of NOS.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Interferon-γ also is important in transforming macrophages into epithelioid cells in a granulomatous inflammatory response&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Leukotriene B4, generated in the lipoxygenase pathway of arachidonic acid metabolism, is a potent neutrophil chemotactic factor.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Binding of agonists such as epinephrine, collagen, or thrombin to platelet surface receptors activates phospholipase C, which catalyzes the release of arachidonic acid from two of the major membrane phospholipids, phosphatidylinositol and phosphatidylcholine.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Bradykinin, generated from the kinin system on surface contact of Hageman factor with collagen and basement membrane from vascular injury, promotes vascular permeability, smooth muscle contraction, and pain&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;C3b may promote phagocytosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;C1q is generated in the initial stage of complement activation, which can eventually result in cell lysis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Leukotrienes are generated by the lipoxygenase pathway, which is not blocked by &lt;strong&gt;aspirin.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;important-pathways&quot;&gt;3 important pathways&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Activation of complement may occur via microbial cell wall components such as polysaccharides (alternative pathway) or&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;mannose (lectin pathway),&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;or antibody attached to surface antigens (classic pathway)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Plasmin is generated from plasminogen and helps lyse clots.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ongoing activation of coagulation generates an inflammatory response that further amplifies coagulation, creating a vicious cycle.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Protein C antagonizes coagulation factor V, which catalyzes activation of prothrombin to thrombin, thereby breaking the cycle of thrombin generation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Complement components can become activated by &lt;strong&gt;plasmin&lt;/strong&gt; (C3) and &lt;strong&gt;kallikrein&lt;/strong&gt; (C5), forming &lt;strong&gt;anaphylatoxins&lt;/strong&gt; (C3a and C5a) that promote inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;A protein-rich exudate results in fibrin accumulation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Granulomatous inflammation is characterized by collections of transformed macrophages called epithelioid cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Acute inflammatory cells, mainly neutrophils, exuded into a body cavity or space form a purulent (suppurative) exudate, typically associated with &lt;strong&gt;liquefactive necrosis.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;An abscess is a localized collection of neutrophils &lt;strong&gt;within tissues.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In fibrinous inflammation, exudation of blood proteins (including fibrinogen, which polymerizes to fibrin) gives a grossly shaggy appearance to surfaces overlying the inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Chronic inflammation occurs when there is a preponderance of mononuclear cells, such as lymphocytes, macrophages, and plasma cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Most bacterial pneumonias resolve, and progression to continued chronic inflammation is uncommon.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In acute inflammation, the healing process of fibrosis and angiogenesis has not begun.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Activated macrophages can secrete various cytokines that promote angiogenesis and fibrosis, including platelet-derived growth factor, fibroblast growth factor, interleukin-1 (IL-1), and tumor necrosis factor (TNF).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Plasmodium produces malaria, a parasitic infection without a significant degree of lung involvement.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The pyrogens stimulate prostaglandin synthesis in the hypothalamus to “reset the thermostat,” so that fever occurs as a sign of the acute inflammatory response&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hageman factor initiates the coagulation cascade.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Interleukin-12 (IL-12) released by macrophages &lt;strong&gt;stimulates T-cell responses&lt;/strong&gt;.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;nitric oxide produced in macrophages aids in microbial killing.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IL-1 and TNF can have autocrine, paracrine, and endocrine effects.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;C-reactive protein (CRP), fibrinogen, and serum amyloid A (SAA) protein. These proteins, particularly fibrinogen, and immunoglobulins increase RBC rouleaux formation to increase the erythrocyte sedimentation rate (ESR), which is a nonspecific indicator of inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CRP production is upregulated by interleukin-6 (IL-6), whereas fibrinogen and SAA are upregulated mainly by tumor necrosis factor (TNF) and interleukin-1 (IL-1).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hepatocytes are quiescent (stable) cells that can reenter the cell cycle and proliferate in response to hepatic injury, enabling the liver to regenerate partially.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Acute hepatitis results in hepatocyte necrosis, marked by elevations in AST and ALT.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Vitamin C deficiency leads to scurvy, with reduced lysyl oxidase enzyme activity that helps cross-link fibrillar collagens to provide tensile strength.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;final phase of wound healing, which is extensive by the end of the first month.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The inhibition of metalloproteinases leads to decreased degradation of collagen and impaired connective tissue remodeling in wound repair.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Platelet-derived growth factor (PDGF) can be produced by endothelium, macrophages, smooth muscle cells, and platelets&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;PDGF mediates migration and proliferation of fibroblasts and smooth muscle cells and &lt;strong&gt;migration of monocytes.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Glucocorticoids inhibit wound healing by impairing collagen synthesis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Serine proteinases are important in wound remodeling.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Organization occurs as granulation tissue is replaced by fibrous tissue&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;If normal tissue architecture is restored, resolution of inflammation has occurred.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Secondary union describes the process by which large wounds fill in and contract.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The elevated creatine kinase level indicates that myocardial necrosis has occurred(The elevation in the CK level is indicative of myocardial cell necrosis, because this intracellular enzyme does not leak in large quantities from intact myocardial cells.)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Coagulative necrosis is typical of myocardial infarction, but after 1 month, a scar would be present.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;cellular-injury&quot;&gt;cellular injury&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Nodular regeneration is typical of hepatocyte injury because hepatocytes are stable cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Accumulation of fat within cells is a common manifestation of sublethal cell injury or, uncommonly, of inborn errors in fat metabolism&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Nodular prostatic hyperplasia (also known as benign prostatic hyperplasia [BPH]) is a common condition in older men that results from proliferation of both prostatic glands and stroma.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Aplasia refers to lack of embryonic development;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hyaline change (hyalinosis) refers to a nonspecific, pink, glassy eosinophilic appearance of cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Steatosis (fatty change) can lead to hepatomegaly, but not as a regenerative process.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Irreversible cell injury is associated with loss of membrane integrity. This allows intracellular enzymes such as AST and ALT to leak into the serum.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Blunt trauma produces hemorrhage&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Gangrenous necrosis is mainly coagulative necrosis, but occurs over an extensive area of tissues.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Intestinal infarction is a form of coagulative necrosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Coagulative necrosis is the typical result of ischemia in most solid organs.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Fatty change is most often a feature of hepatocyte injury, and the cell integrity is maintained&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Reduction in oxidative phosphorylation leads to reduction in synthesis of ATP and diminished activity of the plasma membrane sodium pump, which maintains high intracellular potassium concentration. Loss of ATP leads to efflux of intracellular potassium, while net influx of sodium and water promote cell swelling. A marked rise in plasma potassium can indicate significant cell damage or death (such as skeletal muscle crush injury or hemolysis).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Decreased tissue perfusion from hypotensive shock leads to hypoxemia and depletion of ATP when cell metabolism shifts from aerobic to anaerobic glycolysis. This shift causes depletion of glycogen stores and increased production and accumulation of &lt;strong&gt;lactic acid&lt;/strong&gt;, reducing intracellular pH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Creatinine would increase with reduced renal function from decreased renal perfusion, but this would not explain the changes in other tissues.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;An increase in troponin I suggests irreversible myocardial injury.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Irreversible cellular injury is likely to occur when cytoplasmic calcium increases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The excess calcium activates ATPases, phospholipases, proteases, and endonucleases, which injure cell components.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mitochondrial permeability is increased to release cytochrome c, which activates caspases leading to apoptosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The drug acetaminophen can be converted to toxic metabolites in this manner. Glutathione in the cytosol helps to reduce cellular injury from many toxic metabolites and free radicals&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Glutathione peroxidase reduces such injury by catalyzing the breakdown of hydrogen peroxide&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Lactate dehydrogenase is present in a variety of cells, and its elevation in the serum is an indicator of cell injury and death.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Phospholipases decrease cellular phospholipids and promote cell membrane injury&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The free iron contributes to generation of cellular free radicals via the Fenton reaction.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hemosiderin is a storage form of iron from excess local or systemic accumulation of ferritin, and by itself does not cause cell injury until large amounts are present, as with hemochromatosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The onset of menstruation is orderly, programmed cell death (apoptosis) through hormonal stimuli, an example of the intrinsic (mitochondrial) apoptotic pathway&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The BCL2 gene product inhibits cellular apoptosis by binding to Apaf-1.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The BAX gene product promotes apoptosis,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The FAS gene encodes for a cellular receptor for Fas ligand that signals apoptosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Lipases are activated in enzymatic fat necrosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Granzyme B is a serine protease found in CTLs that can directly trigger apoptosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CTLs express Fas ligand on their surfaces, and when contacting Fas receptors on the target cell, the ligand can induce apoptosis by the &lt;strong&gt;extrinsic (death receptor–initiated) pathway.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Endonucleases are generated following caspase activation and lead to nuclear fragmentation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The RIP1-RIP3 complex is called a necrosome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Decreased serum albumin levels and increased prothrombin time suggest alcohol-induced hepatocyte damag&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hemosiderin is a storage form of iron that appears in tissues of the mononuclear phagocyte system (e.g., marrow, liver, spleen)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Lipofuscin is a golden brown pigment that increases with aging in cell cytoplasm, mainly in cardiac myocytes and in hepatocytes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Metastases are mass lesions that impart a tan-to-white appearance to tissues.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Amyloid is an abnormal protein derived from a variety of precursors, such as immunoglobulin light chains&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Steatosis usually occurs with ingestion of hepatotoxins, such as alcohol.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hypercalcemia can have a variety of causes, including primary and secondary hyperparathyroidism, bone destruction secondary&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Because the solubility product of calcium and phosphorus must be maintained, the serum calcium is depressed, triggering increased parathyroid hormone output to increase the calcium level, which promotes calcium deposition.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The granulomas of tuberculosis have caseous necrosis with dystrophic calcification.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The X chromosome transcribes XIST, a lncRNA that binds to and represses X chromosome expression.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;MicroRNAs (miRNAs) are noncoding RNA sequences that inhibit the translation of mRNAs&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Gene-silencing RNAs (small interfering RNAs [siRNAs]) have the same function as miRNAs, but they are produced synthetically for experimental purposes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Heterophagocytosis by macrophages requires that endocytosed vacuoles fuse with lysosomes to degrade the engulfed material.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Actin is a microfilament involved with cell movement&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cytokeratins form cytoskeletal elements of epithelial cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Desmin forms the scaffold in muscle cells on which actin and myosin contract.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Lamin is associated with the nuclear membrane.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;RAS proteins transduce signals from growth factor receptors, such as epidermal growth factor, that have intrinsic tyrosine kinase activity.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The MAP kinase cascade is involved in signaling from activation via cell surface receptors for growth factors. This pathway is particularly important for signaling of EGF and fibroblast growth factor.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;JAK/STAT pathways typically are recruited by cytokine receptors.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Basic fibroblast growth factor is a potent inducer of angiogenesis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Endostatin is an inhibitor of angiogenesis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Platelet-derived growth factor plays a role in vascular remodeling.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;TGF-β stimulates many steps in fibrogenesis, including fibroblast chemotaxis and production of collagen by fibroblasts, while inhibiting degradation of collagen.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hyaluronan (hyaluronic acid) is a large mucopolysaccharide, one form of proteoglycan, which forms a hydrated, compressible gel contributing to the shock-absorbing function of joint surfaces.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;immune-system-diseases&quot;&gt;immune System diseases&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;The NLR-inflammasome pathway plays a role in the innate immune system recognition of urate crystals and promoting the inflammation associated with gout.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Toll-like receptors (TLRs) in the plasma membrane and endosomal vesicles activate transcription factors that stimulate synthesis and secretion of cytokines and expression of adhesion molecules to recruit and activate leukocytes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Natural killer (NK) cells have CD16,an Fc receptor that allows them to bind to opsonized cells and lyse them. This is a form of type II hypersensitivity with antibody-mediated disease.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;B cells have surface immunoglobulin, are CD19 positive, and participate in humoral immunity&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4+ cells are T lymphocytes that are “helper” cells; they have T cell receptors and are CD3 positive.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dendritic cells elaborate type I interferons that up-regulate antiviral proteins in neighboring cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Because they survive selectively, the CD4+:CD8+ ratio is reversed so that it is typically less than 1 with advanced HIV infection.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Blood monocytes expressing MHC class II antigens can migrate into tissues and become longer-lived macrophages.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Methotrexate is useful in the treatment of graft-versus-host disease and for some malignancies&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Penicillin is an antibiotic that can induce a type I hypersensitivity reaction in sensitized persons.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anticardiolipin, along with anti–β2-glycoprotein “lupus anticoagulant,” are found with antiphospholipid syndrome, which may appear in systemic lupus erythematosus (SLE).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;antihistone antibodies are characteristic of drug-induced SLE&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti–SS-A antibody is seen in Sjögren syndrome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;anti–U1-ribonucleoprotein antibody is seen in mixed connective tissue disease (MCTD).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-Scl-70 (also called anti-topoisomerase I after the type I topoisomerase target[1]) is an anti-topoisomerase antibody-type of anti-nuclear autoantibodies, seen mainly in diffuse systemic scleroderma (with a sensitivity of 28–70%), but is also seen in 10–18% of cases of the more limited form of systemic scleroderma called CREST syndrome.[2] Anti Scl-70 antibodies are associated with more severe scleroderma disease.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Myasthenia gravis is a form of type II hypersensitivity reaction in which antibody is directed against cell surface receptors. Thymic hyperplasia or thymoma is likely to be present.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Immune complex–mediated injury is a feature of dermatomyositis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Muscle lysis by CD8+ T cells occurs in polymyositis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;When antibody is directed at a parasitic infection, there is Fc receptor–mediated inflammation and phagocytosis, characteristic for ADCC. IgG and IgE antibodies bearing Fc receptors coat the parasite. Macrophages, natural killer cells, and neutrophils can then recognize the Fc receptor and destroy the antibody-coated target cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4+ cells of the TH2 type are essential to the induction of type I hypersensitivity because they can secrete cytokines, such as interleukin (IL)-3, IL-4, IL-5, and
granulocyte-macrophage colony-stimulating factor, which are required for the growth, recruitment, and activation of mast cells and eosinophils&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The TH17 subset of CD4 cells plays a role in delayedtype hypersensitivity reactions. Many persons react to nickel, particularly with body piercing jewelry. IL-17 may also be useful in recruiting neutrophils to fight bacterial as well as fungal infections such as aspergillosis and candidiasis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IL-5 activates eosinophils as part of a TH2 response.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Perivascular accumulation of T cells, particularly CD4+ cells, is typical of delayed hypersensitivity skin reactions, driven by a TH1 response mediated largely by release of the cytokine interleukin-2.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Streptococcal M proteins cross-react with cardiac glycoproteins, resulting in rheumatic heart disease, a form of autoimmunity.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;This young woman has a classic picture of systemic lupus erythematosus (SLE)—the erythematous malar facial skin rash shown in the figure, and renal failure with proteinuria and hematuria from immune complex deposition in the glomeruli. Defective clearance and hence increased burden of nuclear apoptotic bodies in thymic lymphocyte development is considered a fundamental mechanism that underlies SLE&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Widespread and nonspecific activation of T cells by superantigens occurs in toxic shock syndrome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Patients with systemic lupus erythematosus (SLE) can develop anti-RBC antibodies, which can cause hemolytic anemia. Cytopenias, including leukopenia, thrombocytopenia, and anemia, also are common.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anticentromere antibody is seen most often with limited scleroderma, whereas anti–DNA topoisomerase I is found with diffuse scleroderma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cyclic citrullinated polypeptide and rheumatoid factor are found most often with rheumatoid arthritis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti–U1-RNP can be found with mixed connective tissue disease.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;A drug-induced systemic lupus erythematosus (SLE)– like condition may be caused by drugs such as isoniazid, procainamide, and hydralazine.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti–Jo-1 antibody has specificity for polymyositis/dermatomyositis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti–SS-A antibody is most characteristic of Sjögren syndrome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;discoid lupus erythematosus, with skin lesions similar to those of systemic lupus erythematosus (SLE), but with systemic involvement much less likely to occur. Self nucleic acids mimic their microbial counterparts, and in conjunction with TLRs, they incite type I interferon production to activate dendritic cells and B cells. (has &lt;strong&gt;follicular plugging&lt;/strong&gt;)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Sjögrensyndromeischaracterizedbyimmunologically mediated destruction of salivary and lacrimal glands and other exocrine glands lining the respiratory and gastrointestinal tracts. Dryness and crusting of the nose can lead to perforation of the nasal septum. In 25% of cases, extraglandular tissues, such as lung, skin, kidney, and muscles, may be involved. The immune dysregulation that accompanies autoimmune diseases increases the risk for B cell lymphoid malignancies, such as MALT lymphoma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Esophageal dysmotility is a feature of scleroderma.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Nongonococcal urethritis is seen in reactive arthritis, along with conjunctivitis and arthritis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Diffuse systemic sclerosis (scleroderma) initially has widespread skin involvement but rapidly progresses to visceral organ involvement, including the small arteries of the kidney. These are damaged by a hyperplastic arteriolosclerosis that can be complicated by very high blood pressure and renal failure.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ankylosing spondylitis is one of the spondyloarthropathies; it is characterized by low back pain from sacroiliitis and positive serology for &lt;strong&gt;HLA-B27&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In rheumatoid arthritis, there is often progressive joint deformity; the serologic tests likely to be positive include rheumatoid factor and antibodies to cyclic citrullinated peptide (anti-CCP).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dermatomyositis is a form of inflammatory myopathy in which capillaries are the primary target for antibody and complement-mediated injury. Anti–Jo-1 antibodies, although not present in most cases, are quite specific for inflammatory myopathies.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In reactive arthritis (with conjunctivitis, arthritis, and nongonococcal urethritis), there is often a positive serology for HLA-B27 and a history of either nongonoccocal urethritis with Chlamydia or gastrointestinal infection with Campylobacter, Salmonella, or Shigella organisms.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Endothelitis with intimal injury occurs with acute rejection, but this can be treated&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Fibrinoid necrosis and thrombosis are more typical of hyperacute rejection,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Amyloid derived from serum amyloid-associated protein can occur in chronic infections and inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Interstitial and glomerular fibrosis and blood vessel thickening occur in chronic rejection,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The localized apoptosis with GVHD does not produce significant substrate proteins for amyloid formation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Patients with the hyper-IgM syndrome produce normal (or even supranormal) levels of IgM antibodies to antigens but lack the ability to produce the IgG, IgA, and IgE isotypes; the underlying defect is an inability of T cells to induce B cell isotype switching. The most common genetic abnormality is mutation of the gene encoding CD40L.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;An absence of adenosine deaminase characterizes a form of severe combined immunodeficiency.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The deletion of chromosome 22q11 is a feature of the DiGeorge anomaly&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HIV infection can be accompanied by opportunistic infections, particularly Pneumocystis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;mutations in the gene encoding an adaptor molecule called SLAM-associated protein (SAP) that binds to a family of cell surface molecules involved in the activation of NK cells and T and B lymphocytes, and result in increased susceptibility to viral infections, particularly Epstein-Barr virus (EBV)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;These findings point to mutations in the gene encoding an adaptor molecule called SLAM-associated protein (SAP) that binds to a family of cell surface molecules involved in the activation of NK cells and T and B lymphocytes, and result in increased susceptibility to viral infections, particularly Epstein-Barr virus (EBV).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;When the family history indicates males are affected, then SCID is most likely X-linked and due to mutations in the common γ chain that is a part of many cytokine receptors, such as interleukin (IL)-2, IL-4, IL-7, and IL15.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;individuals lacking complement component C2 have some increase in infections, but mainly develop a disease resembling systemic lupus erythematosus.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hereditary angioedema is a rare autosomal-recessive disorder of the complement pathway in which there is a deficiency of antigenic or functional C1 inhibitor, resulting in recurrent episodes of edema.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;C3 deficiency is accompanied by recurrent infections with pyogenic bacteria.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;β2-Microglobulin is a component of MHC class I; it can be increased with HIV infection and can be a substrate for amyloid fibrils in patients receiving long- term hemodialysis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Individuals with a selective (isolated) IgA deficiency are bothered by minor recurrent sinopulmonary infections and by diarrhea. IgA is useful in innate immunity against bacterial organisms in the respiratory and gastrointestinal tracts.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Immune reactions against fungal and viral infection are me- diated mainly by T cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Pneumocystis infections are seen in patients with more severe acquired or inherited immunodeficiency disorders, particularly patients with AIDS, which affect cell-mediated immunity.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The X-linked disorder known as Wiskott-Aldrich syndrome (WAS) is characterized by thrombocytopenia, ec- zema, and &lt;strong&gt;decreased IgM&lt;/strong&gt;. there is an increased risk of non-Hodgkin lymphoma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hypocalcemia is seen in neonates with DiGeorge syndrome that affects parathyroid glands.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The most common neoplasms seen in association with AIDS are B cell non-Hodgkin lymphomas.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The reverse transcriptase gene of HIV undergoes mutation on average once per 2000 replications, a very high rate, which can account for the appearance of drug resistance.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The p24 antigen is a component of the HIV virion and is used to de- tect infection, but it is not a target of drug therapy&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Entry of HIV into cells requires binding to the CD4 molecule and co-receptor molecules, such as CCR5 and CXCR4. These HIV co-receptors are receptors for chemo- kines on the surface of T cells and macrophages.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Three types of cells are most likely to carry HIV: den- dritic cells (Langerhans cells in epithelium, follicular den- dritic cells in lymph nodes), monocyte-macrophages, and CD4+ T cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti–neutrophil cytoplasmic autoantibody (C-ANCA or P-ANCA) can be seen in some patients with vasculitis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The anti–streptolysin O (ASO) titer is elevated in patients with rheumatic fever, but there is no serious immunosuppres- sion.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Progression of HIV disease is monitored by levels of HIV-1 mRNA in the blood and by CD4+ cell counts&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Kaposi sarcoma is associated with a herpesvirus agent that is sexually transmitted: human her- pesvirus 8 (HHV-8), also called the Kaposi sarcoma herpesvirus.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HIV, although present in the lymphocytes and monocytes, is not detected in the spindle cells that proliferate in Kaposi sarcoma.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;the follicular dendritic cells and the macrophages are not destroyed in large numbers by the virus and can become a reservoir for infection&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Natural killer cells, CD19+ B cells, and plasma cells are not directly affected by HIV.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Amyloidosis is most often caused by excessive light chain production with plasma cell dyscrasias such as multiple myeloma (AL am- yloid). His spinal lesions are focal collections of neoplastic plasma cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Both rheumatoid factor (RF) and C-reactive protein (CRP) are markers for in- flammation, and the amyloid associated with chronic inflam- matory conditions is derived from serum amyloid associated (SAA) protein.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Pro- longed infection also stimulates production of colony- stimulating factors (CSFs), which increase the bone marrow output of leukocytes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Amyloid derived from β2-microglobulin occurs with hemo- dialysis-associated amyloidosis. Amyloid derived from light chains in association with multiple myeloma has AL fibrils. Cardiac and heredofamilial forms of amyloidosis have fibrils derived from prealbumin transthyretin (TTR).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;α-Fetoprotein is present during fetal life, but it is best known in adults as a serum tumor marker.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Calcitonin forms the precursor for amyloid deposited in thyroid medullary carcinomas.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;TGF-B also in the development of fibrosis in lung, liver, and kidneys that follows chronic inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;TGF-β is an anti-inflammatory cytokine that serves to limit and terminate inflammatory responses. It does so by inhibiting lymphocyte proliferation and the activity of other leukocytes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Medical Definition of HETEROPHAGY. : digestion in a fused vacuole and lysosome of material taken into a cell by phagocytosis or pinocytosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Microsatellite instability occurs with mutation in genes, such as hMSH2, that repair DNA damage.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;E This patient has clinical features of neurofibromatosis type 1. The NF1 gene encodes for a GTPase-activating protein that facilitates the conversion of active (GTP-bound) RAS to inactive (GDP-bound) RAS. Loss of NF1 prevents such con- version and traps RAS in the active signal-transmitting stage that drives cell proliferation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The p53 and c-MYC genes favor this metabolic change, whereas PTEN inhibits tumor cell autophagy, giving cancer cells an edge in growth.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;t(14,18) BCL2, t(8,14) Burkitt Lymphoma, Myc.  t(9,22) Philidelphia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD44 plays a role in cell adhesion and enables malignant cells to metastasize.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;A paraneoplastic syndrome results from ectopic secretion of a hormone by tumor (e.g., lung cancer cells producing corticotropin). Tumor heterogeneity does not refer to two separate kinds of neoplasms; it refers to heterogeneity with a given tumor or metastasis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;A The oncogenic potential of human papillomavirus (HPV), a sexually transmissible agent, is related to products of two early viral genes—E6 and E7. E7 protein binds to RB protein to cause displacement of normally sequestered transcription factors, which nullifies tumor suppressor activity of the RB protein. E6 protein binds to and inactivates the p53 gene product.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In- fection with Epstein-Barr virus is associated with various cancers, including Burkitt lymphoma and nasopharyngeal carcinoma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;intravenous immunoglobulin (IVIG) is a blood product administered intravenously&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;SOLU-MEDROL Sterile Powder is an anti-inflammatory glucocorticoid, which contains methylprednisolone sodium succinate as the active ingredient.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Reiter syndrome is characterized by conjunctivitis, arthritis, and nongonococcal urethritis, with a positive serology for HLA-B27.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In rheumatoid arthritis, there is often progressive joint deformity; the serologic tests likely to be positive include rheumatoid factor and antibodies to cyclic citrullinated peptide (anti-CCP).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Aortic dissection is more likely in Reiter syndrome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ankylosing spondylitis is marked by kyphosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dementia can be seen in patients with AIDS.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;B cells have surface immunoglobulin, are CD19 positive, and participate in humoral immunity&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4+ cells are T lymphocytes that are “helper” cells; they have T cell receptors and are CD3 positive.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Stem cells are CD34 positive and can give rise to the whole range of cells in the immune system and blood-forming cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;This patient has clinical features of neurofibromatosis type 1. The NF1 gene encodes a GTPase-activating protein that facilitates the conversion of active (GTP-bound) RAS to inactive (GDP-bound) RAS.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

</content>
 </entry>
 
 <entry>
   <title>Immunopathology figures and supplimentary</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/11/immunopathology-figures3/"/>
   <updated>2015-09-11T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/11/immunopathology-figures3</id>
   <content type="html">&lt;h3 id=&quot;injury-study&quot;&gt;Injury study&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image11.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image11.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;apotosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathpedia.com/education/eatlas/histopathology/liver_and_bile_ducts/chronic_hepatitis_c.aspx&quot;&gt;refine appearance of apototic cells-see slide 10&lt;/a&gt;&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/image13.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/image13.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The figure shows deep eosinophilic staining, loss of myocardial fiber nuclei, and loss of cell structure consis- tent with an early ischemic injury, resulting in coagulative necrosis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/image14.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/image14.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;An ischemic injury to most internal organs produces a pattern of cell death called coagulative necrosis. Note the faint outlines of renal tubules and glomerulus in the figure, but no cellular nuclei&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/image15.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/image15.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;There is an apoptotic cell (arrow) that is shrunken and has been converted into a dense eosinophilic mass. There is a surrounding inflammatory reaction with cytotoxic lymphocytes. This pattern is typical of apoptosis. Caspase activation is a universal feature of apoptosis, regardless of the initiating cause. Apoptosis induced in recipient cells from donor lymphocytes occurs with graft-versus-host disease.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/image16.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/image16.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The valve is stenotic because of nodular deposits of calcium. The process is “dystrophic” because calcium deposition occurs in damaged tissues. The damage in this patient is a result of excessive wear and tear with aging.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image19.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image19.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;notice the congested blood capillary&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathologyatlas.ro/pathology_atlas_imagini/cholesterolosis_02.jpg&quot;&gt;Cholesterolosis of the gallbladder&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image23.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image23.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://library.med.utah.edu/WebPath/CINJHTML/CINJ047.html&quot;&gt;dystrophic calcification with labeled explanation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image25.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image25.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;*Granulomatous Inflammation, Lung.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://edc2.healthtap.com/ht-staging/user_answer/avatars/913735/large/open-uri20130308-28336-dwqobc.jpeg?1386611344&quot;&gt;labeled explanation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/image17.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/image17.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image28.png&quot;&gt;&amp;lt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image28.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://library.med.utah.edu/WebPath/CINJHTML/CINJ026.html&quot;&gt;necrosis of the pancreas explanation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image29.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image29.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathologyatlas.ro/pathology_atlas_imagini/lobar_pneumonia_leukocytic_alveolitis.jpg&quot;&gt;Pneumonia&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;inflammation-and-repair&quot;&gt;Inflammation and Repair&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image5.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image5.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Hypertrophic Cardiac Myocytes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image9.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image9.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Hyperplasia of prostate glands&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image12.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image12.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image20.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image20.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Proximal renal tubules normal (L), hydropic change (R)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Karyolysis—fading of chromatin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Pyknosis—nuclear shrinkage, basophilia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Karyorrhexis—nuclear fragmentation&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image25.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image25.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Coagulative necrosis, kidney&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image31.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image31.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Fat Necrosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image35.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image35.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Polyarteritis Nodosa (fibrinoid necrosis)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image43.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image43.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Apoptotic cells show nuclear chromatin condensation with cellular shrinkage and formation of apoptotic bodies composed of membrane bound&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;vesicles of cytosol and organelles.&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image44.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image44.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Mechanisms of Apoptosis Death Receptor (Intrinsic) &amp;amp; (Extrinsic) Pathway&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image45.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image45.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;intracellular-accumulations&quot;&gt;Intracellular Accumulations&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Four pathways:&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Inadequate removal of normal substances&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Accumulation of abnormal endogenous substances&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Failure to degrade a metabolite&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Deposition /accumulation of exogenous substances&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Accumulation of  cholesterol within the gallbladder&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image46.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image46.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Cholesterol within an atheromatous plaque in a coronary artery&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image47.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image47.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Accumulation of  protein within liver cells (hepatocytes) The eosinophilic cytoplasmic inclusions seen above (in the middle) are Mallory-Denk bodies composed of intermediate filaments (cytokeratins) often seen in alcoholic liver diseas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image66.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image66.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Serous Inflammation in a Skin Blister&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image67.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image67.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Fibrinous Pericarditis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image68.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image68.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Fibrinous Pericarditis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image70.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image70.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Bronchopneumonia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image71.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image71.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Abscess&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image77.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image77.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;complement pathways&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/1.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image1.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/2.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/2.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image78.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image78.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Chronic gastritis The lamina propria is infiltrated by plasma cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Granulomatous Inflammation with Caseous Necrosis
A granuloma with central necrosis, surrounded by “epithelioid histiocytes,” giant cells, and a collar of lymphocytes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Aspiration Pneumonia&lt;/li&gt;
  &lt;li&gt;Aspiration pneumonia with abundant neutrophils and a foreign body giant cell reaction to a piece of aspirated plant material from gastric contents&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Caseating Granuloma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Notice&lt;/strong&gt; the prominent epithelioid histiocytes surrounding the necrosis&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Non-Caseating Granulomas Sarcoidosis involving the lung&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image87.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image87.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;A: Granulation tissue: Blood vessels (angiogenesis), tissue edema with loose extracellular matrix containing occasional inflammatory cells, mainly macrophages&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;B: Mature scar with dense collagen staining blue with a trichrome stain&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Glucocorticoids:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;May result in weakness of scar–inhibition of TGF-β&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-inflammatory properties may be desirable in some cases&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image91.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image91.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Keloid showing “keloidal collagen” (arrows&lt;/p&gt;

&lt;h3 id=&quot;immunopathology-study&quot;&gt;Immunopathology study&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image32.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.biomedcentral.com/1471-230X/11/36/figure/F4?highres=y&quot;&gt;diffuse Duodenal Nodular Lymphoid Hyperplasia&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image30.jpeg&quot;&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image30.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://www.mja.com.au/sites/default/files/issues/198_03_180213/war11518_fm-2.jpg&quot;&gt;see figure with label&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image29.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.jacobspublishers.com/images/micro_11.3.jpg&quot;&gt;Liver core biopsy with lymphocytic infiltration of the portal tract&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image27.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Histological examination of nodules shows that they consist of a shell of fibrous tissue surrounding a center of fibrinoid necrosis. Pea sized nodules have one centre. Larger nodules tend to be multilocular, with many separate shells or with connections between the necrotic centres. Individual necrotic centres may contain a cleft or several centres of necrosis may all open on to a large bursal pocket containing synovial fluid.&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image29.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathologystudent.com/wp-content/uploads/2009/04/hashimotos-follicle-thyroid-glands-2.jpg&quot;&gt;Hashimotos&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image6.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image38.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathologystudent.com/?p=3566&quot;&gt;explanation between pemphigus vulgaris and Bullous pemphigoid&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image8.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://library.med.utah.edu/WebPath/GIHTML/GI147.html&quot;&gt;pernicious anemia in gastritis&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;additonal-images-mentioned-from-lectures&quot;&gt;additonal images mentioned from lectures&lt;/h2&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/4.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/4.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
&lt;em&gt;Primary biliary cirrhosis&lt;/em&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/3.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/3.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
&lt;em&gt;close up&lt;/em&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;check &lt;a href=&quot;https://www.youtube.com/watch?v=Jj8ozr_IttM&quot;&gt;video explanation&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/1.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/1.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
&lt;em&gt;Chronic Active Hepatitis&lt;/em&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=CzKGvWZrUpU&quot;&gt;video explanation&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/2.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/2.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
&lt;em&gt;[piece meal necrosis&lt;/em&gt;
&lt;strong&gt;from slide 44 Autoimmune disease ppt&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/11.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/11.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Goodpasture epithelial crescent/type II/IF&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/8.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/8.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Farmer’s Lung/granulomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/9.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/9.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Granulomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/10.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/10.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Note&lt;/strong&gt; lack of necrosis of the vascular walls&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=805YGsF5jJ0&quot;&gt;Goodpasture syndrome video explanation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/12.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/12.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Lymphorrhage  associated with muscle atrophy in myasthenia gravis patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/13.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/13.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Dermatomyositis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;perivesicular inflammation, atrophy of muscle&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/14.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/14.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* Polymyositis&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Polymyositis showing extensive degeneration and focal necrosis of muscle fibers with phagocytosis and focal lymphocytic infiltration.
variation of muscle fiber sizes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;inflammatory myopathy IgG and C3&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/14.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/14.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;pancreas&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;note&lt;/strong&gt; : juvenle Diabetes is autoimmune/Adult is not*&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IgG4 Related Disease&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/15.jpg&quot;&gt;Polyarteritis  Nodosa&lt;/a&gt;
(/assets/pathology/test1/Immunopathologyfigures/media/lectures/16.jpg)&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/17.jpg&quot;&gt;Polyarteritis  Nodosa in pancreas&lt;/a&gt;
&lt;a href=&quot;http://www.proteinatlas.org/images_dictionary/pancreas__1__example_1__overview.jpg&quot;&gt;compare to normal pancrease&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;postulated as being associated with hepytitis B antigen&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=57s-GoqXSbs&quot;&gt;video explanation&lt;/a&gt;
&lt;em&gt;note: the fribinoid necrosis&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;&quot;&gt;Temporal Arteritis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/18.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/18.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* cross reactivity &lt;em&gt;note the middle figure&lt;/em&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;hyperacute-rejection&quot;&gt;Hyperacute rejection&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/19.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/19.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
Kidney Hyperacute Rejection: Note endothelium of lumen in artery&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/19.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/19.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/20.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/20.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
Kidney glomerulus in Hypercute Rejection – &lt;strong&gt;Note Fibrin Plugs&lt;/strong&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;note&lt;/strong&gt; major difference between hyperacute and acute rejection is that&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;hyperacute is more about glomerulus and fibrin plugs&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;acute is more about tubular infultration by lymphocytes&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h5 id=&quot;acute-rejection&quot;&gt;Acute Rejection&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/21.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/21.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute Rejection Kidney – Note: Pale, Swollen with Subcapsular Hemorrhage&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/22.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/22.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute Rejection Kidney – Note Hemorrhagic Medullary Areas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/23.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/23.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* Acute Rejection Kidney -  Note: Lymphocytic Infiltration in Interstitium Attacking Tubule Basement Membrane&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=e181JDaw8LM&quot;&gt;Acute Rejection video explanation&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/24.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/24.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute Rejection Kidney Glomerulus Spared – Note: Lymphocytic Infiltration in Interstitium attacking tubule basement membranes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/25.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/25.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/26.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/26.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/27.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/27.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute Rejection Kidney showing T-cells attacking Tubule Basement Membranes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/28.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/28.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute Rejection Kidney – Note: Numerous T-cells in Interstitium attacking tubules&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/29.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/29.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/31.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/31.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/32.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/32.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Positive C4d Staining of Peritubular Capillaries demonstrating Humoral Ab&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/33.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/33.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/34.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/34.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Vascular Rejection of Renal Artery – Note: Marked Proliferation of Endothelial Cells with Partial Occlusion of Lumen&lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;chronic-rejection&quot;&gt;Chronic rejection&lt;/h4&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/47.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/47.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/48.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/48.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Arteriosclerotic-type Lesion of Artery in Chronic Rejection&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/49.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/49.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Arteriosclerotic Type of Chronic Rejection with Intimal Proliferation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/50.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/50.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/51.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/51.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=qYQ6ynfY1_E&quot;&gt;Check video explanation&lt;/a&gt;&lt;/p&gt;

&lt;h4 id=&quot;graft-vs-host-disease&quot;&gt;Graft-vs-Host Disease&lt;/h4&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/40.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/40.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* Destruction of Basal Layer Cells in Skin during GVH Disease&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/41.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/41.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Crypts of Lieberkuhn of Gut demonstrating Infiltration of Transplanted T-Cells in GVH Disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/42.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/42.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Cross Section of Crypts being Destruction by T-Cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/43.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/43.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Normal Vessel in Liver – Note: Bile Duct Destruction by Donor T-Cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/44.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/44.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Portal Area of Liver with Extensive Donor T-Cells in GVH Disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/45.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/45.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Veno-Occlusive Disease of Central Vein in Liver – GVH Disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/46.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/46.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Hyperacute GVH Disease in Pediatric Case&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;autoimmune-diseases&quot;&gt;Autoimmune Diseases&lt;/h3&gt;

&lt;h5 id=&quot;systemic-lupus-erythematosus&quot;&gt;Systemic lupus erythematosus&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image11.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image11.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Discoid SLE(localized)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image22.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image22.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* the giant cell in middle is an LE cell. 
&lt;a href=&quot;https://en.wikipedia.org/wiki/LE_cell&quot;&gt;Check for further details&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image23.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image23.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/image39.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/image39.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;sjgrens-syndrome&quot;&gt;Sjögren’s syndrome&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image33.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image33.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;A, Enlargement of the salivary gland. B, Histopathologic findings include intense lymphocytic and plasma cell infiltration with ductal epithelial hyperplasia.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image35.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image35.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Salivary gland duct &lt;strong&gt;lining cell&lt;/strong&gt; staining for antibody in about 15% of Sjögren cases&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image38.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image38.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;wegener-granulomatosis&quot;&gt;Wegener granulomatosis&lt;/h5&gt;

&lt;ul&gt;
  &lt;li&gt;Extensive inflammatory cells in maxillary and ethmoid sinus bx in Wegener granulomatosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image42.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image42.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* Obliterative necrotizing arteritis of vasculature in Wegener granulamotosis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=-sNcAiRWLTU&quot;&gt;video explanation for WG&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image43.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image43.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Anti-neutrophil cytoplasmic antibody (ANCA) in systemic vasculitidies&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image44.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image44.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Necrotizing arteritis in Wegener granulomatosis.  Marked destruction of vessel wall with heavy lymphocytic infiltrate together with some polymorphonuclear leukocytes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image45.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image45.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Later phase of previous slide showing early fibroblastic proliferation and chronic inflammatory cells (lymphocytes) (Wegener granulamatosis)&lt;/li&gt;
&lt;/ul&gt;

&lt;h5 id=&quot;progressive--systemic--sclerosis&quot;&gt;Progressive  Systemic  Sclerosis&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image47.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image47.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image51.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image51.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Skin in scleroderma (progressive systemic sclerosis. Note prominent collagen deposition in the dermis yet skin appendages are still intact.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image52.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image52.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Extensive collagen deposition and disappearance of appendages, due to loss of their blood supply and thinning of the epidermis in scleroderma (PSS)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image53.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image53.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;mixed-connective-tissue-disease&quot;&gt;mixed connective tissue disease&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image60.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image60.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Mixed connective tissue disease: skin with collagenous thickening of papillary and reticular dermis, mild perivascular mononuclear cell infiltration and mild atrophy and hyperkeratosis of the epidermis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image62.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image62.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Speckled (other particulate) pattern of nuclear fluorescence of epidermal nuclei in mixed connective tissue disease&lt;/li&gt;
&lt;/ul&gt;

&lt;h5 id=&quot;rheumatoid-arthritis&quot;&gt;Rheumatoid Arthritis&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image67.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image67.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Aspirate of synovial joint in rheumatoid arthritis showing inflammatory cells and fibrin deposits&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image71.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image71.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image73.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image73.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* Histopathology of rheumatoid nodule showing central fibrinoid necrosis surrounded by macrophages rimmed by granulation tissue and lymphocytes&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image75.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image75.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* &lt;strong&gt;Pannus&lt;/strong&gt; formation with inflammatory destruction of articular cartilage followed by erosion of bone in rheumatoid arthritis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=ZcTi28aBY1s&quot;&gt;video explanation for RA&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;amyloidosis&quot;&gt;Amyloidosis&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image76.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image76.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image77.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image77.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image82.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image82.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Congo red stain of amyloid in vascular wall. (left)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Silver birefringence of same stain viewed by polarizing light microscopy. (right)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;primary-immunodeficiences&quot;&gt;Primary Immunodeficiences&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image4.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image4.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Interference at 12 weeks gestation leads to immunodeficiency with hypoparathyroidism&lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;digeorge-syndrome&quot;&gt;DiGeorge Syndrome&lt;/h4&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image5.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image5.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;DiGeorge syndrome thymus showing &lt;strong&gt;small Hassal’s corpuscles&lt;/strong&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image6.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image6.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Lymph node in DiGeorge syndrome showing depleted T cell-dependent areas, whereas B cell areas are intact&lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;x-linked-infantile-hypogammaglobulinemia&quot;&gt;X-linked Infantile Hypogammaglobulinemia&lt;/h4&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image9.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image9.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Barium Swallow Radiograph; Boy with malabsorption syndrome. &lt;strong&gt;Giardia lamblia&lt;/strong&gt; frequent cause&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image15.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image15.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Lymph node biopsy after Ag stimulation showing corticomedullary differentiation but absence of B cell dependent areas (lack of follicles). T cell areas are intact.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image16.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image16.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Thymus in Bruton’s showing normal architecture with Hassal’s corpuscles&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image21.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image21.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;SCID / Open lung biopsy showing Pneumosystis jiroveci microorganisms&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image22.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image22.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* SCID / Silver stain of Pneumocystis jiroveci&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image23.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image23.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The thymus in severe combined immunodeficiency (SCID) showing only reticulum cells and fatty tissue. Prior to this, the thymus was markedly hypoplastic with no corticomedullary differentiation and no Hassal’s corpuscles.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;chronic granulomatous disease&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;decreased oxidative burst.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Phagocytic disorders&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Chronic granulomatous disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Myeloperoxidase deficiency&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Job syndrome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Chédiak-Higashi syndrome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Disorders associated with chemotactic dysfunction&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image34.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image34.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Patient with hereditary angioedema due to C1 esterase inhibitor deficiency&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image32.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Pneumocystis jirovec in bronchial washings of AIDS patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image33.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image33.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Pneumocystis jiroveci in transbronchial biopsy of lung in AIDS patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image35.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image35.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Mycobacterium avium intercellulare infection of lung in AIDS&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image36.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image36.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;High power mag. Mycobacterium avium intercellulare in lung in AIDS&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image37.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image37.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Cryptosporidium, a protozoan parasite that causes severe diarrhea in AIDS patients (red stained in fecal contents)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image38.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image38.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;CMV inclusion bodies in rectal mucosa in AIDS patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image39.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image39.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;CMV inclusion bodies in rectal mucosa in AIDS patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image40.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image40.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Giardia lamblia (a protozoan) in the gut of AIDS patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image43.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image43.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Kaposi sarcoma histopathology in HIV infection&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=ZXk5k6k5-Ks&quot;&gt;video explanation for Kaposi Sarcoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/HIVlecture/image64.jpeg&quot;&gt;Immune reconstitution inflammatory syndrome (IRIS)/ Immune restoration disease (IRD)&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.who.int/topics/antiretroviral_therapy/en/&quot;&gt;HAART&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;flow-cytometry&quot;&gt;flow cytometry&lt;/h3&gt;

&lt;p&gt;cd45 leukocyte common antigen&lt;/p&gt;

&lt;p&gt;CD34 stem cell&lt;/p&gt;

&lt;p&gt;CD 33 myeloid cell marker&lt;/p&gt;

&lt;p&gt;CD 13 myeloid cell marker&lt;/p&gt;

&lt;h3 id=&quot;hiv&quot;&gt;HIV&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image19.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image19.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;neoplasia&quot;&gt;Neoplasia&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/neoplasiafigures/image16.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/neoplasiafigures/image18.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://patient.info/education/cervical-carcinoma&quot;&gt;Cervical intraepithelial neoplasia explanation&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Immunopathology figures review</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/10/immunopathology-figures2/"/>
   <updated>2015-09-10T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/10/immunopathology-figures2</id>
   <content type="html">&lt;style&gt;
div.img {
    margin: 5px;
    padding: 5px;
    border: 1px solid #cccccc;
    height: auto;
    width: auto;
    float: left;
    text-align: center;
}

div.img img {
    display: inline;
    margin: 5px;
    border: 1px solid #cccccc;
}

div.img a:hover img {
    border:1px solid #cccccc;
}

div.desc {
    text-align: center;
    font-weight: normal;
    font-size: 12px;
    width: 200px;
    margin: 5px;
}
&lt;/style&gt;

&lt;body&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image2.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image2.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Type I hypersensitivity reaction &lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image3.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image3.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Stomach, pernicious anemia&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image4.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image4.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Indirect Immunofluorescence: Anti-mitochondrial antibodies demonstrated in kidney proximal tubule cells&lt;/div&gt;
&lt;/div&gt;
&lt;!--break--&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image5.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image5.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin Biopsy, Pemphigus vulgaris&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image6.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image6.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Direct Immunofluorescence: Pemphigus vulgaris&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image7.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image7.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Systemic sclerosis with cutaneous fibrosis and ulcerations&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image8.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image8.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Indirect Immunofluorescence:  Anti-parietal cell antibodies&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image9.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image9.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Kidney, hyperacute rejection&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image10.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image10.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Transplanted kidney showing changes of antibody-mediated acute rejection within a blood vessel&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image11.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image11.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Type IV Hypersensitivity&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image12.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image12.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Patient with Lupus&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/bb.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/bb.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;skin biopsy showing a positive lupus band test at the dermal-epidermal junction&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image13.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image13.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Hashimoto Thyroiditis&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image14.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image14.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Kidney, hyperacute rejection&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/cc.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/cc.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Patient with Hashimoto Thyroiditis&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/dd.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/dd.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;normal thyroid (left) germinal center and tissue destruction (right)&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image18.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image18.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Kidney, acute rejection&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image19.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image19.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Glomerulus: PAS stain showing “wire loops” in patient with SLE&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image20.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image20.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin with Type IV hypersensitivity reaction&lt;/div&gt;
&lt;/div&gt;
&lt;/body&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image21.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image21.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin with Type IV hypersensitivity reaction&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image22.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image22.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Mast cells in Type I hypersensitivity reactions&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image23.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image23.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin rash: graft-versus-host disease&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image24.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image24.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Kaposi Sarcoma&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image25.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image25.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin biopsy showing graft-versus-host disease&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image26.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image26.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Graft-versus-host disease, colon&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image27.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image27.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Rheumatoid nodule&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image28.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image28.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Graft-versus-host disease, colon&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image29.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image29.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Graft-versus-host disease, liver&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image30.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image30.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin biopsy of SLE&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image31.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image31.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Lupus nephritis&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image32.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image32.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;diffuse prolifrative lupus nephritis&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image33.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image33.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Libman-Sacks endocarditis of the mitral valve in SLE&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image34.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image34.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;H&amp;amp;E stain of Salivary gland, Sjogren Syndrome&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image35.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image35.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Synovial histology in RA&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image36.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image36.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Pneumocystis jiroveci pneumonia, silver stain&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image37.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image37.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Lymphoid hyperplasia in HIV&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image38.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image38.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Direct Immunofluorescence: Bullous pemphigoid&lt;/div&gt;
&lt;/div&gt;
&lt;p style=&quot;clear: both;&quot;&gt;
&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>How to create a photo gallery with HTML and CSS</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/10/how-to-make-a-photo-gallery/"/>
   <updated>2015-09-10T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/10/how-to-make-a-photo-gallery</id>
   <content type="html">&lt;p&gt;This will work on platforms like Wordpress or Jekyll that let you minipulate “code” and input HTML directly. Although there are many web publishing tools included with photo gallery widgets or other plugins which can take care of this task for you, but knowing how to code it yourself is still something enjoyable to do!&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;Here is an example which I built for my pathology review.&lt;/p&gt;

&lt;p&gt;Before we start, we need to get some photos. To make thing easy for you, I have already prepare some lovely&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/blogimages/build%20a%20photo%20gallery/cat.zip&quot;&gt;cat&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;for you. Please go ahead and download them and unzip the files and place them into your Jekyll blog’s main directory. In my case, I created a folder “asset” which store all my media files there.&lt;/p&gt;

&lt;p&gt;Once you get the previous steps setup, it is time to create a new post. If you are a beginner and do not know Jekyll well you could certainly learn all the basic quickly by visitting &lt;a href=&quot;http://joshualande.com/jekyll-github-pages-poole/&quot;&gt;Joshua Lande’s&lt;/a&gt;blog, where you should find all the necessary information to help you get started.&lt;/p&gt;

&lt;p&gt;Once you created a new post, add the following chunk of code to the start, this is to set up the CSS style of the gallery layout.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&amp;lt;style&amp;gt;
div.img {
    margin: 5px;
    padding: 5px;
    border: 1px solid #cccccc;
    height: auto;
    width: auto;
    float: left;
    text-align: center;
}

div.img img {
    display: inline;
    margin: 5px;
    border: 1px solid #cccccc;
}

div.img a:hover img {
    border:1px solid #cccccc;
}

div.desc {
    text-align: center;
    font-weight: normal;
    font-size: 12px;
    width: 200px;
    margin: 5px;
}
&amp;lt;/style&amp;gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;
</content>
 </entry>
 
 <entry>
   <title>Pathology quiz 2 answer and explaination</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/06/pathology-quiz-2/"/>
   <updated>2015-09-06T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/06/pathology-quiz-2</id>
   <content type="html">&lt;h3 id=&quot;question-1&quot;&gt;Question 1&lt;/h3&gt;

&lt;p&gt;Within minutes after a bee sting, a 15 year-old girl suddenly has difficulty breathing. There is marked urticaria and marked edema of the hand that was stung. Which of the following is the best pharmacologic agent to treat these signs and symptoms?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Penicillin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Epinephrine&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Glucocorticoids&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Methotrexate&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cyclosporine&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;This girl has experienced a systemic anaphylactic reaction from a type I hypersensitivity reaction. Epinephrine is the fastest acting agent to treat this life-threatening condition. Cyclosporine is used to minimize transplant rejection. Penicillin is an antibiotic that often induces a type I hypersensitivity reaction. Glucocorticoids can reduce immune reactions, although this occurs over days to weeks, not minutes. Methotrexate is useful in the treatment of graft-versus-host disease.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-2&quot;&gt;Question 2&lt;/h3&gt;

&lt;p&gt;A 20 year-old man steps into an elevator full of people who are coughing and sneezing, all of whom appear to have colds or the flu. The influenza viral particles that he inhales attach to the respiratory epithelium, and viral transformation reduces the MHC class I molecules on these epithelial cells. Which of the following cells is most likely to respond to destroy these infected cells?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Natural killer cell&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dendritic cell&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 cell&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Neutrophil&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Macrophage&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Natural killer (NK) cells have the ability to respond without prior sensitization. They carry receptors for MHC class I molecules, which inhibit their lytic function. When expression of class I MHC molecules is reduced on a cell surface by viral interference, the inhibitory receptors on NK cells do not receive a negative signal, and the targeted cell is killed. NK cells are often the first line of defense against viral infection. CD4+ cells are helper T cells that assist other cells, such as NK cells, macrophages, and B cells, in the immune response. Dendritic cells aid in antigen presentation. Mac- rophages can phagocytize necrotic cells, then process and display any foreign antigens within those cells. Neutrophils provide a nonspecific immune response, primarily to bacte- rial infections and not to intracellular viral infections.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-3&quot;&gt;Question 3&lt;/h3&gt;

&lt;p&gt;A 30 year-old woman has had fever and arthralgia for the past two weeks. On physical examination, she has a temperature of 37.6 degrees C and an erythematous malar rash. Initial laboratory studies are also positive for ANAs at 1:1600 and anti-double-stranded DNA antibodies at 1:3200. Serum creatinine is markedly elevated, and serum complement levels are decreased. A VDRL test for syphilis is positive, and in vitro tests of coagulation (prothrombin time and partial thromboplastin time) are prolonged. Which of the following clinical features of her illness is most likely caused by antibodies that interfere with the coagulation tests?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Arthritis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Rash&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Renal failure&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Recurrent thrombosis&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Fever&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;This patient has clinical and serologic features of systemic lupus erythematosus (SLE). She also has a false-positive test result for syphilis, indicating the presence of anticardiolipin antibodies. These antibodies against phospholipid-protein complexes (antiphospholipid antibodies) also are called lupus anticoagulants because they interfere with in vitro clotting tests. In vivo, they are thrombogenic. Hence, these patients can have recurrent thrombosis. Lupus anticoagulants also can occur in the absence of SLE. The other listed options can occur in SLE, but they are not mediated by antiphospholipid antibodies.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-4&quot;&gt;Question 4&lt;/h3&gt;

&lt;p&gt;A 35 year-old man has a history of mild infections of the upper respiratory tract. He also has had diarrhea for most of his life, although it was not severe enough to cause malabsorption and weight loss. After an episode of trauma with blood loss, he receives a blood transfusion and has an anaphylactic reaction. Which of the following underlying conditions best explains these findings?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Selective IgA deficiency&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;DiGeorge syndrome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Severe combined immunodeficiency&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HIV infection&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Wiskott-Aldrich syndrome&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Patients with IgAD are at some increased risk of developing severe reactions after receiving blood products.[13, 14, 15] IgG anti-IgA antibodies may cause severe transfusion reactions if patients with IgAD are given whole blood; therefore, IgA-poor blood or washed red cells are preferred for those patients. IgA-deficient patients with immunoglobulin E (IgE)–class anti-IgA antibodies are at risk for anaphylaxis if they receive blood or intravenous immunoglobulin, but this situation is extremely rare. Individuals with such an unusual profile should receive only low IgA intravenous immunoglobulin preparations. However, caution must be used when administering IGIV to patients with IgAD if their anti-IgA status is unknown.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;a href=&quot;http://emedicine.medscape.com/article/136580-overview&quot;&gt;source of explanation&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;question-5&quot;&gt;Question 5&lt;/h3&gt;

&lt;p&gt;Laboratory tests are ordered for two hospitalized patients. During the phleobotomy procedure, the Vacutainer tubes drawn from these patients are mislabeled. One of the patients receives a blood transfusion later that day. Within one hour after the transfusion of RBCs begins, the patient becomes tachycardic and hypotensive and passes pink-colored urine. Which of the following statements best describes how the reaction is mediated?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Mast cell degranulation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Release of tumor necrosis factor alpha into the circulation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Antigen-antibody compex deposition in glomeruli&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Antibody-dependent cellular cytotoxicity by natural killer cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Complement-mediated lysis of RBCs&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;A major transfusion reaction results from a type II hypersensitivity reaction. The patient’s serum contains natu- rally occurring antibodies to the incompatible donor RBCs. They attach to the donor RBCs and induce complement activation that results in generation of the C5-9 membrane attack complex. Major transfusion reactions are rare, and&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-6&quot;&gt;Question 6&lt;/h3&gt;

&lt;p&gt;A 40 year-old laboratory technician accidentally injects a chemical into his skin. The next day, he notes that an area of erythematous, indurated skin is forming around the site of injection. Two days later, the induration measures 10mm in diameter. A microscopic section from this area, with immunostaining using an antibody to CD4, shows many positive lymphocytes. Which of the following immunologic reactions is most consistent with this appearance?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Systemic anaphylaxis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Delayed-type hypersensitivity&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Graft-versus-host disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Serum sickness&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Arthus reaction&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Perivascular accumulation of T cells, particularly CD4+ cells, is typical of delayed hypersensitivity skin reactions, driven by a TH1 response mediated largely by release of the cytokine interleukin-2. Systemic anaphylaxis typically occurs within minutes after an encounter with the antigen. Systemic and localized immune complex diseases (serum sickness and Arthus reactions) are type III hypersensitivity reactions; they often exhibit vasculitis. Graft-versus-host disease is characterized by epidermal apoptosis and rash.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-7&quot;&gt;Question 7&lt;/h3&gt;

&lt;p&gt;A 45 year-old woman has had a burning sensation with increasing blurring of vision for the past five years. On physical examination, she has keratoconjunctivitis. Atrophy of the oral mucosa, with buccal mucosal ulcerations, is also present. A biopsy specimen of the lip shows marked lymphocytic and plasma cell infiltration of the minor salivary glands. Which of the following antibodies is most likely to be identified on laboratory testing?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-double-standed DNA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-centromere&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Scl-70&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;SS-B&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Jo-1&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Sjogren syndrome primarily involves salivary and lacrimal glands. Antibodies to SS-B are found in the majority of these patients. Anti–double-stranded DNA is a specific autoantibody for systemic lupus erythematosus. Anticen- tromere antibody is seen most often in limited systemic sclerosis, whereas anti–DNA topoisomerase most often ap- pears with diffuse systemic sclerosis. U1-RNP is a marker for mixed connective tissue disease (MCTD).&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-8&quot;&gt;Question 8&lt;/h3&gt;

&lt;p&gt;A 22 year-old man has had a urethral discharge for the past week. A culture of the exudate from the urethra grows Neisseria gonorrhoeae. He is treated with penicillin G, but within minutes after injection, he develops itching and erythema of the skin. This is quickly followed by severe respiratory difficulty with wheezing and stridor. Which of the following immunoglobulins has most likely become attached to the penicillin G and mast cells to produce these symptoms?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;IgG&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IgD&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IgA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;IgE&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ig M&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;This patient is experiencing a systemic anaphylactic reaction, a form of type I hypersensitivity. IgE is bound to mast cells, after previous sensitization, so that a repeat encounter with the antigen results in mast cell degranulation and the release of mediators, such as histamine, which lead to anaphylaxis. IgE also is important in mediating more localized inflammatory reactions such as allergic rhinitis (hay fever). Other immunoglobulins do not bind so readily to mast cells.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-9&quot;&gt;Question 9&lt;/h3&gt;

&lt;p&gt;A 37 year-old man who is HIV positive has noticed multiple 0.5 to 1.2 cm plaque-like, reddish-purple skin lesions on his face, trunk, and extremities. Some of the larger lesions appear to be nodular. These lesions have appeared over the past six months and have slowly enlarged. Molecular analysis of the spindle cells found in these skin lesions is likely to reveal a genome of which of the following viruses?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Cytomegalovirus&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HIV-1&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Adenovirus&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Epstein-Barr virus&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Human herpesvirus-8&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Human herpesvirus-8 has been associated with Kaposi sarcoma and can be acquired as a sexually transmitted disease. Kaposi sarcoma is a complication of AIDS. Individuals with HIV infection can be infected with various viruses, including Epstein-Barr virus (EBV) and cytomegalovirus (CMV), but these have no etiologic association with Kaposi sarcoma. EBV is a factor in the development of non-Hodgkin lymphoma, and CMV can cause colitis or retinitis or can be disseminated. Hepatitis B virus can be seen in HIV-infected patients as well, particularly patients with a risk factor of injection drug use. Adenovirus, which, although rare, can be seen in HIV-infected individuals, tends to be a respiratory or gastrointestinal infection.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-10&quot;&gt;Question 10&lt;/h3&gt;

&lt;p&gt;A 31 year-old woman has had increasing edema, chest pain, and an erythematous rash for the past six months. Laboratory studies show increasing serum creatinine, and urinalysis shows proteinuria with RBC casts. If present, which of the following antibodies is most helpful in diagosing this patient’s condition?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Jo-1&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-HLA-B27&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-Sm&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-centromere&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Scl-70&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Anti-Sm and anti–double-stranded DNA are specific for systemic lupus erythematosus. Anti-Sm is present in only 25% of cases, however. Scl-70 is a marker for diffuse systemic sclerosis. Jo-1 is most specific for polymyositis. HLA-B27 is seen in ankylosing spondylitis. Anticentromere antibody is seen most often with limited scleroderma.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

</content>
 </entry>
 
 <entry>
   <title>Pathology quiz 1 answer and explaination</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/06/pathology-quiz-1/"/>
   <updated>2015-09-06T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/06/pathology-quiz-1</id>
   <content type="html">&lt;h3 id=&quot;question-1&quot;&gt;Question 1&lt;/h3&gt;

&lt;p&gt;At autopsy, the heart of a 63 year-old man weighs only 250 grams and has small right and left ventricles. The myocardium is firm, with a dark chocolate-brown color throughout. The coronary arteries show minimal atherosclerotic changes. An excessive amount of which of the following substances will be found in the myocardial fibers of this heart?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Lipofuscin&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Bilirubin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hemosiderin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Melanin&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Lipofuscin is a “wear-and-tear” pigment that in- creases with aging, particularly in liver and myocardium. This granular golden brown pigment seen adjacent to the myocyte nucleus in the figure has minimal effect on cellu- lar function in most cases. Rarely, there is marked lipofus- cin deposition in a small heart, a so-called brown atrophy. Bilirubin, another breakdown product of hemoglobin, im- parts a yellow appearance (icterus) to tissues. Hemosiderin is the breakdown product of hemoglobin that contains the iron. Hearts with excessive iron deposition tend to be large. Glycogen is increased in some inherited enzyme disorders, and when the heart is involved, heart size increases. Melanin pigment is responsible for skin tone: the more melanin, the darker the skin.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-2&quot;&gt;Question 2&lt;/h3&gt;

&lt;p&gt;A 40 year-old woman has had chronic congestive heart failure for the past three years. In the past two months, she developed a cough productive of rust-colored sputum. A sputum cytology specimen shows numerous hemosiderin-laden macrophages. Which of the following subcellular structures in macrophages is most important for the accumulation of this pigment?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Chromosome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ribosome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Endoplasmic reticulum&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Lysosome&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Golgi apparatus&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Heterophagocytosis by macrophages requires that endocytosed vacuoles fuse with lysosomes to degrade the engulfed material. With congestive heart failure, extravasation&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-3&quot;&gt;Question 3&lt;/h3&gt;

&lt;p&gt;A 38 year-old man has had headaches and nausea for the past 2 months. Laboratory findings show hypercalcemia and hypophosphatemia and normal serum albumin. Urine microscopic analysis shows deposition of calcium salts in the renal tubular epithelium. Which of the following processes has most likely produced this change in the kidney?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Cellular aging&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dystrophic calcification&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Autophagocytosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Metastatic calcification&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Renal tubular atrophy&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Metastatic calcification can occur widely throughout the body but principally affects the interstitial tissues of the vas- culature, kidneys, lungs, and gastric mucosa. The calcium deposits morphologically resemble those described in dys- trophic calcification&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-4&quot;&gt;Question 4&lt;/h3&gt;

&lt;p&gt;A 38 year-old man has had headaches and nausea for the past 2 months. Laboratory findings show hypercalcemia and hypophosphatemia and normal serum albumin. Urine microscopic analysis shows deposition of calcium salts in the renal tubular epithelium. Which of the following processes has most likely produced this change in the kidney?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Dystrophic calcification&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Autophagocytosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cellular aging&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Metastatic calcification&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Renal tubular atrophy&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Metastatic calcification can occur widely throughout the body but principally affects the interstitial tissues of the vas- culature, kidneys, lungs, and gastric mucosa. The calcium deposits morphologically resemble those described in dys- trophic calcification&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-5&quot;&gt;Question 5&lt;/h3&gt;

&lt;p&gt;An experiment introduces bacteria into a perfused tissue preparation. Leukocytes then leave the vasculature and migrate to the site of bacterial inoculation. The movement of these leukocytes is most likely to be mediated by which of the following substances?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Prostaglandins&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Bradykinin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Chemokines&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Histamine&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Complement C3a&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Chemokines include many molecules that are chemotactic for neutrophils, eosinophils, lymphocytes, monocytes, and basophils. Bradykinin causes pain and increased vascu- lar permeability. Complement C3a causes increased vascular permeability by releasing histamine from mast cells. Hista- mine causes vascular leakage. Prostaglandins have multiple actions, but they do not cause chemotaxis.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-6&quot;&gt;Question 6&lt;/h3&gt;

&lt;p&gt;An 18 year-old man lacerated his left hand and required sutures. The sutures were removed one week later. Wound healing continued, but the site became disfigured by a prominent raised, nodular scar that developed over the next two months. Which of the following terms best describes the process that occurred during this 2-month period?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Keloid formation&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dehiscence&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Secondary union&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Organization&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Resolution&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;The healing process sometimes results in an exuber- ant production of collagen, giving rise to a keloid, which is a prominent raised, nodular scar, as shown in the figure. This tendency may run in families. Dehiscence occurs when a wound pulls apart. Organization occurs as granulation tissue is replaced by fibrous tissue. If normal tissue architecture is restored, resolution of inflammation has occurred. Second- ary union describes the process by which large wounds fill in and contract.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-7&quot;&gt;Question 7&lt;/h3&gt;

&lt;p&gt;A 59 year-old man has had a cough and fever for the past week. On physical exam, his temperature is 38.5 degrees Celsius. On auscultation, he has decreased breath sounds and dullness to percussion over the right lung. A chest radiograph shows fluid in the right pleural cavity. Thoracentesis yields 500 mL of cloudy yellow fluid. Which of the following cell types is most likely to be abundant in this fluid?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Eosinophils&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 lymphocytes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Macrophages&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Plasma cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Neutrophils&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Bacterial infections often evoke an acute inflammatory response dominated by neutrophils. The extravasated neutro- phils attempt to phagocytose and kill the bacteria. In the pro- cess, some neutrophils die, and the release of their lysosomal enzymes can cause liquefactive necrosis of the tissue. This liquefied tissue debris and both live and dead neutrophils comprise pus, or purulent exudate. Such an exudate is typi- cal of bacterial infections that involve body cavities. Another term for purulent exudate in the pleural space is empyema.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-8&quot;&gt;Question 8&lt;/h3&gt;

&lt;p&gt;A 5 year-old child has a history of recurrent bacterial infections, inluding pneumonia and otitis media. Analysis of leukocytes collected from the peripheral blood shows a deficiency of myeloperoxidase. Which of the following is the most likely cause of this child’s increased susceptibility to infections?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Defective neutrophil degranulation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Defective production of prostaglandins&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Decreased oxygen consumption after phagocytosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Failure to produce hydroxy-halide radicals (HOCL-)&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Failure to produce hydrogen peroxide&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Myeloperoxidase is present in the azurophilic gran- ules of neutrophils. It converts H2O2 into HOCl–, a power- ful oxidant and antimicrobial agent. Degranulation occurs as phagolysosomes are formed with engulfed bacteria in phagocytic vacuoles within the neutrophil cytoplasm. Oxy- gen consumption with an oxidative or respiratory burst after phagocytosis is aided by glucose oxidation and activation of neutrophil NADPH oxidase, resulting in generation of superoxide that is converted by spontaneous dismutation to H2O2. In contrast, prostaglandin production depends on a functioning cyclooxygenase pathway of arachidonic acid metabolism.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-9&quot;&gt;Question 9&lt;/h3&gt;

&lt;p&gt;A 35 year-old woman takes acetysalicylic acid (aspirin) for arthritis. Although her joint pain is reduced with this therapy, the inflammation process continues. The aspirin therapy alleviates her pain mainly through reduction in the synthesis of which of the following mediators?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Leukotriene E4&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Complement C1q&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Prostaglandins&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Nitric Oxide&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Histamine&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Prostaglandins are produced through the cyclooxy- genase pathway of arachidonic acid metabolism. Aspirin and other nonsteroidal anti-inflammatory drugs block the synthesis of prostaglandins, which can produce pain. Com- plement C1q is generated in the initial stage of complement activation, which can eventually result in cell lysis. Hista- mine is mainly a vasodilator. Leukotrienes are generated by the lipoxygenase pathway, which is not blocked by aspirin. Nitric oxide released from endothelium is a vasodilator.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-10&quot;&gt;Question 10&lt;/h3&gt;

&lt;p&gt;On a routine visit to the physician, an otherwise healthy 51 year-old man has a blood pressure of 150/95 mmHg. If the patient’s hypertension remains untreated for years, which of the following cellular alterations will most likely be seen in the myocardium?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Hyperplasia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Hypertrophy&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Metaplasia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hemosiderosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Atrophy&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;The pressure load on the left ventricle results in an increase in myofilaments in the existing myofibers, so they enlarge. The result of continued stress from hypertension is eventual heart failure with decreased contractility. Apoptosis would lead to loss of cells and diminished size. Dysplasia is not a diagnosis made for the heart. Hemosiderin deposition in the heart is a pathologic process resulting from increased iron stores in the body. Though hyperplasia from prolifera- tion of myofibroblasts is possible, this does not contribute significantly to cardiac size. Metaplasia of muscle does not occur, although loss of muscle occurs with aging and ischemia as myofibers are replaced by fibrous tissue.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

</content>
 </entry>
 
 <entry>
   <title>Pathology reiew part IV Graphic recognication</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-4/"/>
   <updated>2015-09-04T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-4</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/1.png&quot;&gt;Figure 1&lt;/a&gt;
diffuse reticulonodular pulmonary densities&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/2.png&quot;&gt;Figure 2&lt;/a&gt;
hows noncaseating granulomas with many epithelioid cells and two prominent large Langhans gi- ant cells. If special stains and/or cultures for organisms (usu- ally mycobacteria or fungi) are negative, then this is likely sarcoidosis.
&lt;!--break--&gt;
&lt;a href=&quot;/assets/pathology/test1/3.png&quot;&gt;Figure 3&lt;/a&gt;
shows a subacute infarction with granu- lation tissue formation containing numerous capillaries stimulated by vascular endothelial growth factor, repre- senting a healing response.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/4.png&quot;&gt;Figure 4&lt;/a&gt;
 shows dense collagen with some remaining dilated blood vessels, typical of the final phase of wound healing, which is extensive by the end of the first month.&lt;/p&gt;

&lt;p&gt;&lt;em&gt;note&lt;/em&gt;
 * On day 1, the wound is filled only with fibrin and inflammatory cells. 
 * Macrophages and granulation tissue are seen 2 to 3 days postoperatively. 
 * Neovascularization is most prominent by days 4 and 5.
 * By week 2, collagen is prominent, and fewer vessels and inflammatory cells are seen.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/5.png&quot;&gt;Figure 5&lt;/a&gt;
 The figure shows the so-called wire loop glomeru- lar capillary lesions of lupus nephritis. Anti-Smith and anti– double-stranded DNA are more specific for systemic lupus erythematosus, but sensitivity is low: anti-Smith is present in only 25% of SLE cases.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/6.png&quot;&gt;Figure 6&lt;/a&gt;
 immune complex–mediated glomerulonephritis
 The immune complexes activate complement and result in acute inflammation&lt;/p&gt;

&lt;h3 id=&quot;neoplastic-diseases&quot;&gt;Neoplastic diseases&lt;/h3&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/7.png&quot;&gt;Figure 7&lt;/a&gt;
The figure shows an in situ carcinoma of the squamous cervical epithelium with neoplastic growth only above the basement membrane.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/8.png&quot;&gt;Figure 8&lt;/a&gt;
The cells shown in the figure show marked pleomorphism and hyperchromatism (anaplasia), and it is difficult to discern the cell of origin because no differentiation is noted. A bizarre tripolar mitotic figure is present. This de- gree of anaplasia is consistent with an aggressive, high-grade malignancy called anaplastic carcinoma.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/9.png&quot;&gt;Figure 9&lt;/a&gt;
In the figure the disorderly, atypical epithelial cells involve the entire thickness of the epithelium. They extend through the underlying basement membrane and into the underlying stroma as rounded nests at the right, a process known as invasion. The ectocervix and the squamous metaplasia of endocervix give rise to dysplasia from which squamous cell carcinoma can arise.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/10.png&quot;&gt;Figure 10&lt;/a&gt;
The figure shows the appearance of multiple vari- ably sized tan metastatic lesions in the liver from hematogenous spread of carcinoma&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/11.png&quot;&gt;Figure 11&lt;/a&gt; 
Infiltrating ductal and intraductal carcinoma are present in the figure. Increased expression of ERBB2 (HER2) can be detected immunohistochemically and by fluorescence in situ hybridization (FISH) in the biopsy specimen. One third of breast cancers may show this change. Such amplifi- cation is associated with a poorer prognosis.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/12.png&quot;&gt;Figure 12&lt;/a&gt; 
Thesmallcellshavescantcytoplasmbutmarkedhy- perchromatism, consistent with small cell anaplastic carcino- ma. This patient has Cushing syndrome resulting from ectopic corticotropin production by the tumor, a form of paraneoplas- tic syndrome common to small cell carcinomas of the lung. Such small cell carcinomas are of neuroendocrine derivation.&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Pathology reiew part III drugs</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-3/"/>
   <updated>2015-09-04T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-3</id>
   <content type="html">&lt;p&gt;NSAIDs
Naproxen&lt;/p&gt;

&lt;p&gt;Glucocorticoids&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;inhibit wound healing by impairing collagen synthesis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;can be used to treat acute cellular rejection&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Penicillin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;an antibiotic that can induce a type I hypersensitivity reaction in sensitized persons.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;isoniazid&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;prophylactic therapy, TB&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;drug-induced systemic lupus erythematosus (SLE)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;procainamide&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;drug-induced systemic lupus erythematosus (SLE)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hydralazine&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;drug-induced systemic lupus erythematosus (SLE)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;imatinib&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;chronic myelogenous leukemia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Agents that activate caspases&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;help in many cases, e.g. apoptosis is blocked as in tumors with BCL2 overexpression&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Antibodies to epithelial growth factor receptors&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;such as ERBB2 (HER2) receptors, are beneficial in certain breast tumors with amplification of this gene.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;methotrexate&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;treat graft-versus-host disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;penicillin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;antibiotics, and can induce type I hypersensitivity reaction in sensitized persons.&lt;/li&gt;
&lt;/ul&gt;

</content>
 </entry>
 
 <entry>
   <title>Pathology reiew part II diseases and symtoms</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-2/"/>
   <updated>2015-09-04T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-2</id>
   <content type="html">&lt;h3 id=&quot;inflammation-and-repair&quot;&gt;Inflammation and repair&lt;/h3&gt;

&lt;p&gt;Ankle swelling&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is most likely to result from peripheral edema secondary to congestive heart failure&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Increased susceptibility to bruising&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;prolonged glucocorticoid administration&lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;ul&gt;
  &lt;li&gt;also leukopenia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Asthma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;results from bronchoconstriction mediated by leukotrienes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Fever&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;prostaglandin release&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;chronic inflammation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;mononuclear cell infiltration&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;fibrosis and angiogenesis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;repair&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Serous inflammation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;exudation of fluid into the subcorneal or subepidermal space and the fluid is relatively protein-poor.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;fibrin accumulation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;protein-rich exudate&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Granulomatous inflammation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;collections of transformed macrophages called epithelioid cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Purulent inflammation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute inflammatory cells, mainly neutrophils, exuded into a body cavity or space form a purulent (suppurative) exudate, typically associated with liquefactive necrosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ulceration&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Loss of the epithelium&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Candida&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a commensal organism in the oropharyngeal region and rarely causes pneumonia in healthy &lt;strong&gt;(non-immunosuppressed)&lt;/strong&gt; individuals.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Cytomegalovirus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;produce a mononuclear interstitial inflammatory cell response&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Enterobacter aerogenes&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;produce acute inflammation.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Plasmodium falciparum&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;produces malaria, a parasitic infection without a significant degree of lung involvement.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mixed connective tissue disease&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;have some features of systemic lupus erythematosus (SLE), myo- sitis, rheumatoid arthritis, scleroderma, and Sjögren syn- drome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Staphylococcus aureus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;endocarditis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;endocarditis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Cardiac murmurs&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;nonbacterial thrombotic endocarditis&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Streptococcus pyogenes(strep throat)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;acute inflammation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;fever caused by bacterial organisms through release of pyrogen.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Acute hepatitis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;hepatocyte necrosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;elevations in AST and ALT&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;immune-diseases&quot;&gt;immune diseases&lt;/h3&gt;

&lt;p&gt;advanced HIV infection.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;the CD4+:CD8+ ratio is reversed so that it is typically less than 1&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;gout&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;urate crystals deposition&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Type I Hypersensisty&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;with antigen triggering mast cell–bound IgE with release of preformed mediators such as histamine.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Leukotriene C4&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mast cells degranulate with antigen attachment to IgE&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;In tuberculosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;macrophages further transform into epithelioid cells that can contribute to granulomatous inflammation.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Type II Hypersensisty&lt;/p&gt;

&lt;p&gt;Type III Hypersensisty&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Arthus reaction&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Type IV Hypersensisty&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Langhans giant cells are seen in granulomatous inflammation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;urticarial rash&lt;/p&gt;

&lt;p&gt;type I hypersensitivity&lt;/p&gt;

&lt;p&gt;Goodpasture syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;an autoantibody is directed against type IV collagen in basement membranes of the glomeruli (causing glomerulonephritis) and in the&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;lung. This is a form of type&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;microscopically shows glomerular dam- age and linear immunofluorescence with labeled complement C3 and anti-IgG antibody.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Urinalysis shows high hematuria, proteinuria, and no glucose&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;DiGeorge anomaly&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;deletion of chromosome 22q11 and it affects T cell differentiation and maturation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The size of the 22q11.2 deletion determines the severity of the disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;hypocalcemic tetany, as well as additional midline developmental abnormalities&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;II hypersensitivity reaction.&lt;/p&gt;

&lt;p&gt;lesions of lupus nephritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;wire loop glomerular capillary lesions of lupus nephritis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;severe combined immunodeficiency (SCID)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;deficient T cell and B cell arms of the immune system&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Absence of adenosine deaminase&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;X-linked SCID&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;due to mutations in the common γ chain that is a part of many cytokine receptors, such as interleukin (IL)-2, IL-4, IL-7, and IL- 15.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;A major transfusion reaction&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;results from a type II hypersensitivity reaction.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The patient’s serum contains naturally occurring antibodies to the incompatible donor RBCs.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;C5-9 membrane attack complex&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hyper-IgM syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;lack of isotype switching from IgM to other immunoglobulins&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mutation in the CD40 ligand&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Antigen-antibody complex formation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is typical of a type III hypersensitivity reaction.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;common variable immunodeficiency&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Impaired B cell maturation to plasma cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mast cells degranulate&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;with antigen attachment to IgE in type I hypersensitivity reactions.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hashimoto Thyroiditis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;caused by a breakdown in self- tolerance (Chapter 4) to thyroid autoantigens&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Myasthenia gravis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a form of type II hypersensitivity reaction in which antibody is directed against cell surface receptors.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Thymic hyperplasia or thymoma is likely to be present.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Antibodies to acetylcholine receptors impair skeletal muscle motor end plates function&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;dermatomyositis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Immune complex–mediated injury&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ewing sarcoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;t(11;22)(q24;12) translocation in that results in fusion of the EWS transcription factor with Fli-1&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;polymyositis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Muscle lysis by CD8+ T cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;criteria for SLE&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Delayed-type hypersensitivity&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;more likely in parasitic infestations of muscles.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Macrophages play an important role, associated with cell-mediated immunity&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;tuberculin skin test works through this pathway&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;perivascular accumulation of T cells, particularly CD4+ cells.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;parasitic infection&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;IgG and IgE antibodies bearing Fc receptors coat the parasite.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Antibody-mediated cellular cytotoxicity (ADCC) receptor–mediated inflammation and phagocytosis, characteristic for ADCC.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Macrophages, natural killer cells, neutrophils recognize the Fc receptor, then destroy the antibody-coated target cells.&lt;/p&gt;

&lt;p&gt;C3 deficiency&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;accompanied by recurrent infections with pyogenic bacteria.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hemolysis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Complement-mediated lysis, typical of immune destruction of RBCs&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IgA deficiency&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;leads to mild recurrent gastrointestinal and respiratory tract infections and predisposes to anaphylactic transfusion reaction.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;serum sickness&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;in response to the injected foreign protein&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;produced widespread antigen-antibody complex deposition, particularly in the kidneys.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;urticaria&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;A skin rash triggered by a reaction to food, medicine, or other irritants.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Thrombocytopenia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;thrombotic microangiopathy such as thrombotic thrombocytopenic purpura&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hereditary angioedema&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;autosomal-reces- sive disorder of the complement pathway in which there is a deficiency of antigenic or functional C1 inhibitor, resulting in recurrent episodes of edema.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hypocomplementemia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;In the localized immune complex reaction (Arthus reaction), activation and depletion of complement C3.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Arthus reaction&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;type III hypersensitivity reactions; they often exhibit vascu- litis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Systemic and localized immune complex diseases&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Graft-versus-host disease&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;characterized by epidermal apoptosis and rash in persons receiving an allogeneic hematopoietic stem cell transplant.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;rheumatic heart disease&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Streptococcal M proteins cross-react with cardiac glycoproteins, resulting in rheumatic heart disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a form of autoimmunity&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Molecular mimicry&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;occurs when a microbial antigen cross-reacts with a normal tissue&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;may follow an infec- tion and lead to polyclonal B cell activation&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;ophthalmia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Ophthalmia (also called ophthalmitis) is inflammation of the eye.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Prothrombin time (PT)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is a blood test that measures how long it takes blood to clot.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Breakdown of T cell anergy&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;localized tissue damage and inflammation -&amp;gt; up-regulation of co-stimulatory molecules on the target tissues.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;brain and in pancreatic islet β cells&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;thromboplastin time (PTT) or activated partial thromboplastin time ( aPTT or APTT)&lt;/p&gt;

&lt;p&gt;is a medical test that characterizes blood coagulation polyclonal lymphocyte activation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Microbial products such as endotoxin or bacterial superantigens&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Release of sequestered antigens&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;can cause autoimmunity&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;coagulopathy&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Antiphospholipid antibodies&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;rheumatic fever&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a microbial antigen cross-reacts with a normal tissue&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;toxic shock syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Widespread and non- specific activation of T cells by superantigens&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;glomerulonephritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;proteinuria with hematuria, renal failure.(SLE)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;scleroderma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Raynaud phenomenon&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Esophageal dysmotility&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Bronchoconstriction&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;bronchial asthma, allergies as type I hypersensitivity reaction&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Cerebral lymphomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;may occur in immunodeficient patients, patients with AIDS.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Keratoconjunctivitis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Sjögren syndrome -&amp;gt; decreased tear production (lacrimal gland inflammation.)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Sacroiliitis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;feature of many of the spondyloarthropathies, such as ankylosing spondylitis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Sclerodactyly&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;in scleroderma&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CREST syndrome(limited scleroderma)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;when it involves only a few areas of the skin (e.g., just the hands), it is more likely to indicate limited scleroderma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;anticentromere antibody&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;anti–DNA topoisomerase I is found with diffuse scleroderma&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;A drug-induced systemic lupus erythematosus (SLE)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Caused by drugs such as isoniazid, pro- cainamide, and hydralazine&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ANA are often positive&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;But anti–double-stranded DNA are negative&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Antibody-dependent cell-mediated cytotoxicity&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is initiated when IgG or IgE coats a target to attract cells that affect lysis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;discoid lupus erythematosus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;skin lesions similar to those of systemic lupus erythematosus (SLE), but with systemic involvement much less likely to occur.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Self nucleic acids mimic their microbial counterparts, and in conjunction with TLRs, they incite type I interferon production to activate dendritic cells and B cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;They also promote a TH1 response, which contributes to autoimmunity.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;immune complex deposition only in sun-exposed areas of the skin,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a positive ANA test result in a few cases,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;absence of anti-Smith or anti–double-stranded DNA antibodies&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;absence of serious renal disease.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;sympathetic ophthalmia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Release of sequestered antigens&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Non-Hodgkin lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;maybe triggered by Sjögren syndrome&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Libman-Sacks endocarditis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;SLE&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Nongonococcal urethritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;seen in reactive arthritis, along with conjunctivitis and arthritis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Diffuse systemic sclerosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;initially skin involvement&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;rapidly progresses to visceral organ involvement, including the small arteries of the kidney.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;These are damaged by a hyperplastic arteriolosclerosis, complicated by very high blood pressure and renal failure.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;esophageal squamous carcinoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;include smoking and alcohol abuse.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ankylosing spondylitis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;is one of the spondyloarthropathies&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;it is characterized by low back pain from sacroiliitis and positive serology for HLA-B27.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;sacroiliitis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;sacroiliitis is an inflammation of the sacroiliac joint&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;HLA-B27&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;present in ankylosing spondylitis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;rheumatoid arthritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;progressive joint deformity&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;rheumatoid factor and antibodies to cyclic citrullinated peptide (anti-CCP)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The antibody to cyclic citrullinated peptide is present&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Bony ankylosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a feature of progressive or recurrent joint inflammation with rheumatoid arthritis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Pericarditis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a feature of systemic lupus erythematosus or diffuse systemic sclerosis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Sjogren syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Xerophthalmia (usually with accompanying xerostomia)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;keratoconjunctivitis predominates, and antibodies to SS-A and SS-B are often present.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;fascicular myocyte necrosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The perivascular and perimysial inflammatory infiltrates result in peripheral muscle&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Dermatomyositis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a form of inflammatory myopathy in which capillaries are the primary target for antibody and complement-mediated injury&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;causes muscle pain, and the rash is typically a subtle heliotrope rash with a violaceous appearance to the eyelids&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The violaceous, or heliotrope, rash is a characteristic feature&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;reactive arthritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;(with conjunctivitis, arthritis, and nongonococcal urethritis)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;positive serology for HLA-B27&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a history of either nongonoccocal urethritis with Chlamydia or gastrointestinal infection with Campylobacter, Salmonella, or Shigella&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;organisms.&lt;/p&gt;

&lt;p&gt;Antibody-dependent cell-mediated cytotoxicity&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is initiated when IgG or IgE coats a target to attract cells that affect lysis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Complement- mediated cell lysis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;when antidonor antibodies are preformed in the host and lead to hyperacute rejection.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;peripheral muscle fascicular myocyte necrosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The perivascular and perimysial inflammatory infiltrates result.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;acute rejection&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;occurs weeks, months, or even years after transplantation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Endothelitis with intimal injury&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;infiltration with CD3+ T cells that include the CD4+ and CD8+ subsets.(acute cellular rejection)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Her graft-versus-host disease (GVHD)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;engrafted marrow is not completely matched for major histocompatibility loci and thus contains immunocompetent donor cells that can proliferate, recognize host cells as foreign, and attack host tissues.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hyperacute rejection&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Fibrinoid necrosis and thrombosis, occurs within minutes placement of the transplant into the recipient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Veno-Occlusive Disease of Central Vein in Liver&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;GVH Disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;chronic rejection&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Interstitial and glomerular fibrosis and blood vessel thickening (ireversible)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;X-linked agammaglobulinemia of Bruton&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a condition in which B cell maturation stops after the rearrangement of heavy-chain genes, and light chains are not produced.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IgA deficiency is marked by a more benign course&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mutations in the BTK gene&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;neopastic-diseases&quot;&gt;Neopastic diseases&lt;/h3&gt;

&lt;p&gt;adenocarcinoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;arise from a colonic adenoma, such malignant lesions tend to be larger and more irregular.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;endocervix or endometrium&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;choristoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a benign mass composed of tissues not found at the site of origin.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hamartoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a rare benign mass composed of tissues usually found at the site of origin.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;the lung is common site&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Bile duct hamartoma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Peutz-Jeghers (hamartomatous) polyp&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hyperplastic colonic lesion&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;tends to be small and flat.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;sarcoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a malignant neoplasm arising in mesenchymal tissues, not in epithelium&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;express TGFα and TGFα receptor&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Adenoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;small mass arise from epithelial surfaces.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;glandular tissues&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;An adnexal mass&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a lump in tissue of the adnexa of uterus&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;can be benign or cancerous&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;can be categorized as simple or complex.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;teratoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a neoplasm derived from totipotential germ cells that differentiate into tissues that represent all three germ layers: ectoderm,&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;endoderm, and mesoderm.&lt;/p&gt;

&lt;p&gt;Fibroadenomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a benign glandular and stromal component; common in the breast.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Gliomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;found in the central nervous system.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;mesothelioma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;arises from the lining of thoracic and abdominal body cavities.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;rhabdomyosarcoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;comprises cells that poorly resemble striated muscle; most arise in soft tissues.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Urothelial carcinomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;associated with smoking.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;papilloma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is a benign, localized mass that has an exophytic growth pattern.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hemangioma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a common benign lesion of the skin.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Leiomyomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;white, arise from smooth muscle and are most common in the uterus&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Lipomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;yellow fatty tumors that can occur beneath the epidermis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Melanomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;malignant, tend to increase in size quickly;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;darkly pigmented&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;nevus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;benign counterpart to the melanoma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;light to dark brown&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Well-differentiated neoplasms&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;tend to be less aggressive and slower growing and resemble the cell of origin.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Carcinoma in situ&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is confined to the epithelium&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;metaplasia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;human papillomavirus (HPV) and other inflammatory conditions&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;carcinoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Lymphatic spread, especially to regional lymph nodes draining from the primary site&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;breast abscess&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;can spread to the lymph nodes, resulting nodal enlargement is associated with pain&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hemoptysis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;coughing up of blood&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;cerebral metastases&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;arise from lung primary carcinomas half of the time.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Angiosarcomas(liver)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;linked to vinyl chloride exposure&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;chronic myelogenous leukemia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;t(9;22)translocation causes uncontrolled nonreceptor tyrosine kinase activity of the BCR-ABL fusion gene.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;imatinib that inhibit tyrosine kinases.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;colon cancers&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Translocation of β-catenin to the nucleus, when there is mutational loss of APC genes.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;non-Hodgkin lymphomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The BCL1 and BCL2 genes are mutated&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;T cell neoplasms&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The IL2 mutation may be present&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Melanoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;In melanomas, the implicated gene is called p16, or INK4a. The product of the p16 gene is an inhibitor of cyclin-dependent kinases.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Germline mutations in CDKN2A may also underlie familial melanomas. With loss of control over cyclin-dependent kinases, the cell cycle&lt;/p&gt;

&lt;p&gt;cannot be regulated, favoring neoplastic transformation.&lt;/p&gt;

&lt;p&gt;neurofibromatosis type 1&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The NF1 gene encodes for a GTPase-activating protein that facilitates the conversion of active (GTP-bound) RAS to inactive (GDP-bound) 
RAS. Loss of NF1 prevents such conversion and traps RAS in the active signal-transmitting stage that drives cell proliferation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;pheochromocytoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a small vascular tumor of the adrenal medulla, causing irregular secretion of epinephrine and norepinephrine, leading to attacks of&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;raised blood pressure, palpitations, and headache.&lt;/p&gt;

&lt;p&gt;Hemangioblastoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;are tumors of the central nervous system that originate from the vascular system usually during middle-age&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hepatosplenomegaly&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Resulted in storage of insoluble intermediates in the mononuclear phagocyte system&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Neuroblastoma (small round blue cell)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;HSRs and double minutes of N-myc&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;pediatric tumor&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;AIDS from HIV&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;B cell lymphomas of the brain are 1000-fold more common in HIV patients with infection than in the general population.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;amyloidosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;extracellular deposits of fibrillar proteins are responsible for tissue damage and functional compromise.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hereditary nonpolyposis colon carcinoma (HNPCC)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;inheritance of one defective copy of mismatch repair genes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Several human mismatch repair genes are involved in the development of HNPCC.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mismatch repair defects have microsatellite instability.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Microsatellites are tandem repeats found throughout the genome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;mutations of mismatch repair “proof reader” or “spell checker” genes MSH2 (2p16), MLH1 (3p21), MSH6, PMS, PMS2 as well as other&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;similar genes.&lt;/p&gt;

&lt;p&gt;xeroderma pigmentosum (XP)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;extreme photosensitivity, high risk of skin cancers.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;DNA damage is initiated by exposure to ultraviolet light and nucleotide excision repair cannot occur normally in XP because&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;inheritance of one of several XP genes is abnormal.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;autosomal recessive, because new mutations are unlikely to occur.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;paraneoplastic syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;results from ectopic secretion of a hormone by tumor (e.g., lung cancer cells producing corticotropin)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;symptoms that can not be explained by tumor spread.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hepatocellular carcinomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;can arise in cirrhosis caused by chronic alcoholism&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ataxia telangiectasia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is an inherited syndrome that carries an increased risk of development of leukemias and lymphomas.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;human T cell lymphotropic virus type 1&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;T cell leukemia.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Epstein-Barr virus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;associated with various cancers, including Burkitt lymphoma and nasopharyngeal carcinoma&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;H. pylori&lt;/p&gt;

&lt;p&gt;promotes chronic gastritis with increased risk for gastric adenocarcinomas and B cell lymphomas.&lt;/p&gt;

&lt;p&gt;Cachexia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;common in advanced cancers, and weight loss without dieting in an adult is a “red flag” for malignancy&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;increases in circulating factors such as tumor necrosis factor (TNF) may play a role.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Tympany&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;A low-pitched, resonant, drumlike note obtained by percussing the surface of a large air-containing space, such as the distended&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;abdomen or the thorax with or without pneumothorax.&lt;/p&gt;

&lt;p&gt;small cell carcinomas of the lung&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;inappropriate antidiuretic hormone (SIADH) secretion leads to hyponatremia as well as edema&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;renal cell carcinoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Erythropoietin production with polycythemia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;pulmonary squamous cell carcinomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Hypercalcemia from a parathyroid hormone-related peptide (PTHrP)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Glioblastomas (paracrine action)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;secrete PDGF and express PDGF receptor&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Microsatellites&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;repeated sequences of DNA, 1-6 bp in length&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;unique to each individual, “DNA fingerprint”&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Microsatellite instability (MSI)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;increased variation of microsatellites within an individual&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;an indicator of deficiency in DNA mismatch repair&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;confer an increased risk of neoplasia&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;desmoplasia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;the growth of fibrous or connective tissue. alled desmoplastic reaction –&amp;gt; secondary to an insult.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Desmoplasia may occur around a neoplasm, causing dense fibrosis around the tumor&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;EBV&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;nasopharyngeal cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;HPV&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;cervical cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;inappropriate antidiuretic hormone (SIADH) secretion&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;A syndrome from small cell carcinomas, and leads to hyponatremia as well as edema.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;cor pulmonale&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;abnormal enlargement of the right side of the heart as a result of disease of the lungs or the pulmonary blood vessels.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Wiskott-Aldrich syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;associated with eczema and thrombocytopenia.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;SLAM-associated protein (SAP)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;that binds to a family of cell surface molecules involved in the activation of NK cells and T and B lymphocytes, and result in&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;increased susceptibility to viral infections, particularly Epstein-Barr virus (EBV).&lt;/p&gt;

&lt;p&gt;rheumatoid arthritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;in some patients methotrexate treatment promotes nodule formation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;DMARDs - fundamental treatment for inflammatory arthritis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In any given patient, any of the DMARDs can be efficacious and well tolerated, but no one DMARD is efficacious and safe in every patient&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;MNEMONIC  DOPAMIN RASH&lt;/p&gt;

&lt;p&gt;DISCOID RASH
ORAL ULCERS
PHOTOSENSITIVITY
ANA
MALAR RASH
IMMUNOLOGICAL PHENOMENON(Le Cell, Ds DNA, Sm, APL ab, false + RPR, )
NEUROLOGICAL(Seizures,Psychosis)
RENAL(Nephrotic,Nephritic)
ARTHRITIS	
SEROSITIS
HEMATOLOGICAL(Leukopenia,Thrombocytopenia, anemia)&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Pathology reiew part I factors, cyctokines, cells</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-1/"/>
   <updated>2015-09-04T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-1</id>
   <content type="html">&lt;h3 id=&quot;inflammation-and-repair&quot;&gt;Inflammation and Repair&lt;/h3&gt;

&lt;p&gt;myeloperoxidase&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;present in neutrophils&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;converts H2O2 into HOCl–&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;antimicrobial agent.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;p&gt;lack of β2 integrin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Inadequate adhesion on cytokine-activated endothelium&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Natural killer cells&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Has Fc receptors, lyse IgG-coated target cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Monocytes&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;transform to macrophages, contain(iNOS), which generates NO, NO has antimicrobial activity.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Activated macrophages produces&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Interleukin-1 (IL-1)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;(TNF)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;neutrophils&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;NAPDH oxidase&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;prostaglandin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;promote vasodilation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;interferon-γ&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;transform Macrophage to epithelioid cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;stimulate monocyte&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Leukotriene B4&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;potent neutrophil chemotactic factor&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;generated by the lipoxygenase pathway of arachidonic acid metabolism&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Nitric oxide&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;mediates vasodilation, inhibits platelet&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;thromboxane A2&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;vasoconstrictive properties&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Plasmin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;from plasminogen&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;helps lyse clots&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Protein C&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;antagonizes coagulation factor V, in turn stop prothrombin to thrombin&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Kallikrein&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;generated by activation of Hageman factor (XII)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;generation of bradykinin and plasmin and C5a&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Thrombin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;coagulation cascade.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Fibrin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;end product of coagulation pathways&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;forms a meshwork entrapping platelets and creating a plug.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Tumor necrosis factor (TNF)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Produced by activated macrophages, mediates fever, metabolic wasting, and hypotension.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Bradykinin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;from the kinin system on surface contact of Hageman factor with collagen and basement membrane from vascular injury, vascular permeability, smooth muscle contraction, and pain.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Complement C5a&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;is chemotactic factor for neutrophils.&lt;/p&gt;

&lt;p&gt;complement C3b&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;an opsonin may promote phagocytosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;complement C5-9&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;membrane attack complex&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;complement C1q&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;generated in the initial stage of complement activation, eventually result in cell lysis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Interleukin-1 (IL-1)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;produced by activated macrophages&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;leukocyte release from bone marrow&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Tumor Necrosis factor (TNF)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;produced by activated macrophages&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;leukocyte release from bone marrow&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;upregulate fibrinogen and SAA&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Phospholipase C&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;from platelet activation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;release of arachidonic acid&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Histamine&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;vasodilator&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Commplement activation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;polysaccharides (alternative pathway)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;mannose (lectin pathway)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;antibody attached to surface antigens (classic pathway)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Fibroblasts&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;chronic inflammatory responses&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mononuclear infiltrates&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;typical of chronic inflammation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Epithelioid cells&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;granulomatous inflammation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;pyrogens&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;TNF&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IL 1&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hageman factor&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;initiates the coagulation cascade.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Immunoglobulin E&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;in response to inflammatory responses with allergens and with invasive parasites.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Interleukin-12 (IL-12)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;released by macrophages stimulates T-cell responses&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;SAA&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;serum amyloid A&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CRP&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;C-reactive protein&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Interleukin-2 (IL-2)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;mediates lymphocyte activation.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IL-5&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;activates eosinophils (part of a TH2 response.)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IL-6&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;interleukin-6&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IL-10&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;immunosuppressive cytokine -&amp;gt; diminishes lymphocyte activation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IL-17&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;delayed- type hypersensitivity reactions.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;recruiting neutrophils to fight bacterial and fungal infections (aspergillosis and candidiasis)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IL-12&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;stimulate NK cells to secrete interferon-γ&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;ALT&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Serum Glutamic-Pyruvic Transaminase&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;AST&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Serum Glutamic-Oxaloacetic Transaminase&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;fibronectin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;maintain a cellular scaffolding for growth and repair, and do not contract.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;metalloproteinases&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;degradation of collagen and connective tissue remodeling in wound repair&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Myofibroblast contraction&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Wound contraction&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Integrins&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;interact with the extracellular matrix proteins (e.g. fibronectin)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Platelet-drived growth factor (PDGF)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;mediates migration and proliferation of fibroblasts and smooth muscle cells and migration of monocytes.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Serine proteinases&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;are important in wound remodeling.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;creatine kinase&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;elevated level indicates that myocardial necrosis has occurred.&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;immune-system-diseases&quot;&gt;Immune System Diseases&lt;/h3&gt;

&lt;p&gt;HBsAg&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Surface antigen of the hepatitis B virus (HBV). It indicates current hepatitis B infection.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;D8+ T cells&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;binds to the complex of viral peptide and MHC class I mol- ecules displayed on the surface of the infected cell&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Natural killer (NK)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;recognize MHC class I molecules with self-peptides and self-recognition inhibits NK cell killing.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;NOD-like receptors (NLRs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The nucleotide-binding oligomerization domain receptors&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The NLR-inflammasome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;this pathway plays a role in the innate immune system recognition of urate crystals and promoting the inflammation associated with gout.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;These receptors may also contribute to inflammation of atherosclerosis.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;C-type lectin receptors (CLRs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;expressed on the plasma membrane of macrophages and dendritic cells detect fungal glycans and elicit inflammatory reactions to fungi.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mannose receptors&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;On phagocytes recognize microbial sugars with terminal mannose residues and induce microbial phagocytosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;RIG-like receptors (RLRs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;are located in the cytosol of most cell types and detect nucleic acids of viruses that replicate in the cytoplasm of infected cells to stimulate production of antiviral cytokines.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Toll-like receptors (TLRs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;in the plasma membrane and endosomal vesicles activate transcription factors that stimulate synthesis and secretion of cytokines and expression of adhesion molecules to recruit and activate leukocytes.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Neutrophils&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;provide a nonspecific immune response, primarily to bacterial infections and not to intracellular viral infections.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD16&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Natural killer(NK)cells haveCD16,and Fc receptor&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD19&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;B cells have surface immunoglobulin, are CD19 positive, and participate in humoral immunity&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD3&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;T lymphocytes, both CD4+ and CD8+.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD4&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;(TH2) essential to the induction of type I hypersensitivity with cytokines secretion e.g. interleukin (IL)-3, IL-4, IL-5 and macrophage colony-stimulating factor&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;macrophage colony-stimulating factor&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;the growth, recruitment, and activation of mast cells and eosinophils.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Dendritic cells&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;trap antigen and aid in antigen presentation.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;follicular dendritic cells (FDCs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The FDCs may become infected but not killed by HIV.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Blood monocytes&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;expressing MHC classII antigenscan migrate into tissues and become longer-lived macrophages.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anticardiolipin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;along with anti–β2-glycoprotein “lupus anticoagulant,”&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;found with antiphospholipid syndrome, which may appear in systemic lupus erythematosus (SLE).&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anti–double-stranded DNA antibodies&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;have specificity for SLE&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;antihistone antibodies&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;are characteristic of drug-induced SLE.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anti–SS-A antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is seen in Sjögren syndrome.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The anti–U1-ribonucleoprotein antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is seen in mixed connective tissue disease (MCTD).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Smith&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Anti-Smith, specific for SLE&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anti–Jo-1 antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;specificity for polymyositis/dermatomyositis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anti–U1-ribonucleotide protein&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;specificity for mixed connective tissue disease.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anticentromeric antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;limited scleroderma (CREST syndrome).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anti–SS-A antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;characteristic of Sjögren syndrome.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;TH17&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;may be present in chronic inflammatory conditions such as inflammatory bowel diseases with macrophage and neutrophilic infiltrates.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;SS-B&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;characteristic of Sjögren syndrome.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anticentromere antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is seen most often in limited systemic sclerosis,&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;anti–DNA topoisomerase&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;appears with diffuse systemic sclerosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Amyloid&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;derived from serum amyloid-associated protein can occur in chronic infections and inflammation.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Eosinophils&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;accumulate in acute interstitial nephritis owing to drug reactions.&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;neoplastic-diseases&quot;&gt;Neoplastic diseases&lt;/h3&gt;

&lt;p&gt;CA-125&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a tumor marker for ovarian cancer.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;MYC oncogene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;activated in Burkitt lymphoma because of a t(8;14) translocation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;binds DNA to cause transcriptional activation of growth-related genes (cyclin D1), resulting in activation of the cell cycle.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;EGF&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;(such as HER2 in breast cancers) encodes the epithelial growth factor receptor located on the cell surface&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;p53 and APC&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;tumor suppressor genes that are inactivated in many cancers, including colon cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;RAS oncogene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;encodes a GTP-binding protein that is located under the cell membrane.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;N-MYC gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Double minutes and homogeneously staining regions seen on a karyotype represent gene amplifications.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;K-RAS mutations&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;present in many cancers, but not typically childhood neoplasms.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Lyn mutation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;seen in some immunodeficiency states.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Epithelial dysplasias&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;can be precursors of carcinomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ovarian neoplasms&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;not related to cervical dysplasias or carcinomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;cervical cancers&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;not related to hereditary syndromes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;cervical dysplasias are not hereditary&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;mutant RB gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;lead to childhood retinoblastomas and osteosarcomas.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;EMA&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;many adenocarcinomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Carcinoembryonic antigen (CEA)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;colon cancers&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Alpha fetoprotein(AFP)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;germ cell tumors&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;liver cancers&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;A serum immunoglobulin level with protein electro- phoresis aids in the diagnosis of myeloma.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD 10 (CALLA)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;acute lymphoblastic leukemia (ALL)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;PSA&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;prostate cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Melanoma-associated antigen (MAGE)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Also normally present in the testis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;icterus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Jaundice&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;RAS oncogene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Mutations of the RAS oncogene reduce GTPase activity, and RAS is trapped in an activated GTP-bound state. RAS then signals the&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;not typically lymphoid malignancies.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;nucleus through cytoplasmic kinases.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The APC gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;can cause activation of the WNT signaling pathway&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The RET proto-oncogene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;encodes a receptor tyrosine kinase involved in neuroendocrine cells of the thyroid, adrenal medulla, and parathyroids.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;p16 (INK4a)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;In melanomas, the product of the p16 gene is an inhibitor of cyclin-dependent kinases. Germline mutations in CDKN2A may also underlie&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;familial melanomas. With loss of control over cyclin-dependent kinases, the cell cycle cannot be regulated, favoring neoplastic&lt;/p&gt;

&lt;p&gt;transformation.&lt;/p&gt;

&lt;p&gt;hMSH2 gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;is present in most cases of hereditary nonpolyposis colon cancer and functions in DNA repair.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Microsatellite instability&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;NF1 gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;acts as a tumor suppressor; this is a component of neurofibromatosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;appear at a later age.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;TGF-β&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;inhibits cell proliferation by activation of growth-inhibiting genes, such as the CDKIs.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;All pancreatic cancers and 83% of colon cancers have at least one mutational event in a TGF-β pathway.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;PTEN&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;inhibits tumor cell autophagy, giving cancer cells an edge in growth&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hypoxia-inducible factor 1-alpha (HIF-1-alpha)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Activation of this factor up-regulate VEGF for angiogensis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Von Hippel–Lindau (VHL) gene (3p25)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;acts as a tumor suppressor, and it normally produces a protein that binds to hypoxia-inducible factor 1-alpha so that it is cleared.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;VHL mutation leads to loss of this binding protein and activation of angiogenesis factors.&lt;/p&gt;

&lt;p&gt;CXCR4 chemokines&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Expressed by the carcinoma cells,in the case of breast cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;HSR&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;homogeneously staining regions&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD44&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;plays a role in cell adhesion and enables malignant cells to metastasize.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Solid tumors can express CD44 to enhance their spread to lymph nodes and other metastatic sites.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Vimentin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a protein expressed in mesenchymal neoplasms, such as sarcomas&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;also up-regulated in EMT.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Aspergillus flavus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;found on moldy peanuts and other foods, produces the potent hepatic carcinogen aflatoxin B1.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Human papillomavirus (HPV)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;is a sexually transmitted disease that is associated with the development of genital squamous cell carcinomas.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;produces E7 protein binds to RB protein to cause displacement of normally sequestered transcription factors, which nullifies tumor&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;suppressor activity of the RB protein&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;E6 protein binds to and inactivates the p53 gene product.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;HST1&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;mutation is seen in some gastric cancers.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;MicroRNAs (miRNAs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;5% of the human genome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;miRNAs do not encode for proteins, but bind and inactivate or cleave mRNA, preventing translation of proteins by mRNA.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Phorbol esters&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;examples of promoters of chemical carcinogenesis that cause tumor promotion by activating protein kinase C.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Vinyl chloride&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;rare cause of liver cancer.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Arsenic&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is a risk factor for skin cancer.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Asbestos&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;exposure is linked to pleural malignant mesothelioma and to bronchogenic carcinomas in smokers.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Benzene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;exposure is linked to leukemias&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Beryllium&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;exposure leads to interstitial lung disease and lung cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Nickel&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;exposure increases the risk of respiratory tract cancers.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;naphthalene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a risk factor for cancers of the urinary tract.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;HBx&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;disrupts normal growth of infected hepatocytes.&lt;/li&gt;
&lt;/ul&gt;

</content>
 </entry>
 
 <entry>
   <title>Correlation Exploratory Data Analysis</title>
   <link href="http://lanyon.getpoole.com/2015/09/04/correlation-exploratory-data-analysis/"/>
   <updated>2015-09-04T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/09/04/correlation-exploratory-data-analysis</id>
   <content type="html">&lt;p&gt;This post introduce the procedure of performing basic correlation and exploratory data analysis. I will go through the steps on how to do some basic data cleaning, such as removing NA values and factors elements. How to conduct correlation analysis and form a correlation matrix. Finally, we will test if the correlation matrix is accurate by doing a pair of random selected identifier. You will also learn how to do basic subsetting of data and locating values from specific rows or columns.&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;House keeping&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;fileUrl &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; &lt;span class=&quot;s&quot;&gt;&amp;quot;https://raw.githubusercontent.com/JizongL/jizongL.github.io/master/assets/blog/Rblog/correlation/09192015correlation/gapminder.csv&amp;quot;&lt;/span&gt;



download.file&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;fileUrl&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; destfile &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;s&quot;&gt;&amp;quot;./gapminder.csv&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; method &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;s&quot;&gt;&amp;quot;curl&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;data &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; read.csv&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s&quot;&gt;&amp;quot;./gapminder.csv&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
data1 &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; na.omit&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
&lt;span class=&quot;kp&quot;&gt;names&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data1&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1] &amp;quot;country&amp;quot;              &amp;quot;incomeperperson&amp;quot;      &amp;quot;alcconsumption&amp;quot;      
##  [4] &amp;quot;armedforcesrate&amp;quot;      &amp;quot;breastcancerper100th&amp;quot; &amp;quot;co2emissions&amp;quot;        
##  [7] &amp;quot;femaleemployrate&amp;quot;     &amp;quot;hivrate&amp;quot;              &amp;quot;internetuserate&amp;quot;     
## [10] &amp;quot;lifeexpectancy&amp;quot;       &amp;quot;oilperperson&amp;quot;         &amp;quot;polityscore&amp;quot;         
## [13] &amp;quot;relectricperperson&amp;quot;   &amp;quot;suicideper100th&amp;quot;      &amp;quot;employrate&amp;quot;          
## [16] &amp;quot;urbanrate&amp;quot;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;setting-a-correlation-matrixremove-the-country-because-it-is-a-factor&quot;&gt;setting a correlation matrix,remove the country because it is a factor&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;&lt;span class=&quot;kn&quot;&gt;library&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;reshape&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
data2 &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; data1&lt;span class=&quot;p&quot;&gt;[,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;-1&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;]&lt;/span&gt;
&lt;span class=&quot;kp&quot;&gt;names&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data2&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1] &amp;quot;incomeperperson&amp;quot;      &amp;quot;alcconsumption&amp;quot;       &amp;quot;armedforcesrate&amp;quot;     
##  [4] &amp;quot;breastcancerper100th&amp;quot; &amp;quot;co2emissions&amp;quot;         &amp;quot;femaleemployrate&amp;quot;    
##  [7] &amp;quot;hivrate&amp;quot;              &amp;quot;internetuserate&amp;quot;      &amp;quot;lifeexpectancy&amp;quot;      
## [10] &amp;quot;oilperperson&amp;quot;         &amp;quot;polityscore&amp;quot;          &amp;quot;relectricperperson&amp;quot;  
## [13] &amp;quot;suicideper100th&amp;quot;      &amp;quot;employrate&amp;quot;           &amp;quot;urbanrate&amp;quot;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;d_cor &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; &lt;span class=&quot;kp&quot;&gt;as.matrix&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;cor&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data2&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
d_cor_melt &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; arrange&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;melt&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;d_cor&lt;span class=&quot;p&quot;&gt;),&lt;/span&gt; &lt;span class=&quot;o&quot;&gt;-&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;abs&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;value&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
d_cor_melt&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##                       X1                   X2       value
## 1        incomeperperson      incomeperperson  1.00000000
## 2         alcconsumption       alcconsumption  1.00000000
## 3        armedforcesrate      armedforcesrate  1.00000000
## 4   breastcancerper100th breastcancerper100th  1.00000000
## 5           co2emissions         co2emissions  1.00000000
## 6       femaleemployrate     femaleemployrate  1.00000000
## 7                hivrate              hivrate  1.00000000
## 8        internetuserate      internetuserate  1.00000000
## 9         lifeexpectancy       lifeexpectancy  1.00000000
## 10          oilperperson         oilperperson  1.00000000
## 11           polityscore          polityscore  1.00000000
## 12    relectricperperson   relectricperperson  1.00000000
## 13       suicideper100th      suicideper100th  1.00000000
## 14            employrate           employrate  1.00000000
## 15             urbanrate            urbanrate  1.00000000
## 16       internetuserate      incomeperperson  0.82300755
## 17       incomeperperson      internetuserate  0.82300755
## 18    relectricperperson      incomeperperson  0.80803700
## 19       incomeperperson   relectricperperson  0.80803700
## 20        lifeexpectancy      internetuserate  0.76916000
## 21       internetuserate       lifeexpectancy  0.76916000
## 22            employrate     femaleemployrate  0.75953615
## 23      femaleemployrate           employrate  0.75953615
## 24       internetuserate breastcancerper100th  0.74545445
## 25  breastcancerper100th      internetuserate  0.74545445
## 26        lifeexpectancy      incomeperperson  0.73245246
## 27       incomeperperson       lifeexpectancy  0.73245246
## 28    relectricperperson      internetuserate  0.71730923
## 29       internetuserate   relectricperperson  0.71730923
## 30  breastcancerper100th      incomeperperson  0.70870641
## 31       incomeperperson breastcancerper100th  0.70870641
## 32    relectricperperson breastcancerper100th  0.64073128
## 33  breastcancerper100th   relectricperperson  0.64073128
## 34             urbanrate      internetuserate  0.62837641
## 35       internetuserate            urbanrate  0.62837641
## 36        lifeexpectancy breastcancerper100th  0.58024660
## 37  breastcancerper100th       lifeexpectancy  0.58024660
## 38          oilperperson      incomeperperson  0.56832284
## 39       incomeperperson         oilperperson  0.56832284
## 40             urbanrate       lifeexpectancy  0.55208423
## 41        lifeexpectancy            urbanrate  0.55208423
## 42             urbanrate      incomeperperson  0.55175903
## 43       incomeperperson            urbanrate  0.55175903
## 44    relectricperperson       lifeexpectancy  0.55158140
## 45        lifeexpectancy   relectricperperson  0.55158140
## 46        lifeexpectancy              hivrate -0.54250579
## 47               hivrate       lifeexpectancy -0.54250579
## 48           polityscore breastcancerper100th  0.53192879
## 49  breastcancerper100th          polityscore  0.53192879
## 50             urbanrate breastcancerper100th  0.53106183
## 51  breastcancerper100th            urbanrate  0.53106183
## 52          oilperperson      armedforcesrate  0.52487245
## 53       armedforcesrate         oilperperson  0.52487245
## 54             urbanrate         oilperperson  0.50197420
## 55          oilperperson            urbanrate  0.50197420
## 56       internetuserate       alcconsumption  0.46509554
## 57        alcconsumption      internetuserate  0.46509554
## 58             urbanrate   relectricperperson  0.46251094
## 59    relectricperperson            urbanrate  0.46251094
## 60       suicideper100th       alcconsumption  0.45834251
## 61        alcconsumption      suicideper100th  0.45834251
## 62          oilperperson      internetuserate  0.44164454
## 63       internetuserate         oilperperson  0.44164454
## 64          oilperperson       lifeexpectancy  0.42291135
## 65        lifeexpectancy         oilperperson  0.42291135
## 66           polityscore      internetuserate  0.38803948
## 67       internetuserate          polityscore  0.38803948
## 68       internetuserate     femaleemployrate  0.38696564
## 69      femaleemployrate      internetuserate  0.38696564
## 70  breastcancerper100th       alcconsumption  0.38654294
## 71        alcconsumption breastcancerper100th  0.38654294
## 72    relectricperperson         oilperperson  0.38628947
## 73          oilperperson   relectricperperson  0.38628947
## 74           polityscore      armedforcesrate -0.37492095
## 75       armedforcesrate          polityscore -0.37492095
## 76           polityscore       alcconsumption  0.35133104
## 77        alcconsumption          polityscore  0.35133104
## 78           polityscore       lifeexpectancy  0.34484282
## 79        lifeexpectancy          polityscore  0.34484282
## 80      femaleemployrate       alcconsumption  0.34438970
## 81        alcconsumption     femaleemployrate  0.34438970
## 82      femaleemployrate      incomeperperson  0.32125406
## 83       incomeperperson     femaleemployrate  0.32125406
## 84    relectricperperson     femaleemployrate  0.31856727
## 85      femaleemployrate   relectricperperson  0.31856727
## 86      femaleemployrate breastcancerper100th  0.31717282
## 87  breastcancerper100th     femaleemployrate  0.31717282
## 88           polityscore      incomeperperson  0.29850030
## 89       incomeperperson          polityscore  0.29850030
## 90          co2emissions      incomeperperson  0.29424580
## 91       incomeperperson         co2emissions  0.29424580
## 92      femaleemployrate      armedforcesrate -0.28084508
## 93       armedforcesrate     femaleemployrate -0.28084508
## 94            employrate      incomeperperson  0.28000427
## 95       incomeperperson           employrate  0.28000427
## 96          co2emissions breastcancerper100th  0.27716789
## 97  breastcancerper100th         co2emissions  0.27716789
## 98            employrate   relectricperperson  0.27427813
## 99    relectricperperson           employrate  0.27427813
## 100           employrate              hivrate -0.27211131
## 101              hivrate           employrate -0.27211131
## 102            urbanrate       alcconsumption  0.27009139
## 103       alcconsumption            urbanrate  0.27009139
## 104 breastcancerper100th      armedforcesrate -0.26847241
## 105      armedforcesrate breastcancerper100th -0.26847241
## 106       lifeexpectancy     femaleemployrate  0.26812937
## 107     femaleemployrate       lifeexpectancy  0.26812937
## 108   relectricperperson         co2emissions  0.26331050
## 109         co2emissions   relectricperperson  0.26331050
## 110         oilperperson breastcancerper100th  0.25901913
## 111 breastcancerper100th         oilperperson  0.25901913
## 112           employrate      armedforcesrate -0.24247267
## 113      armedforcesrate           employrate -0.24247267
## 114           employrate         oilperperson  0.23037392
## 115         oilperperson           employrate  0.23037392
## 116            urbanrate          polityscore  0.23014522
## 117          polityscore            urbanrate  0.23014522
## 118      internetuserate              hivrate -0.22652361
## 119              hivrate      internetuserate -0.22652361
## 120       lifeexpectancy       alcconsumption  0.21854104
## 121       alcconsumption       lifeexpectancy  0.21854104
## 122      suicideper100th       lifeexpectancy -0.21833549
## 123       lifeexpectancy      suicideper100th -0.21833549
## 124           employrate       lifeexpectancy  0.21033357
## 125       lifeexpectancy           employrate  0.21033357
## 126   relectricperperson          polityscore  0.20908881
## 127          polityscore   relectricperperson  0.20908881
## 128           employrate      internetuserate  0.19051364
## 129      internetuserate           employrate  0.19051364
## 130      suicideper100th     femaleemployrate  0.18778683
## 131     femaleemployrate      suicideper100th  0.18778683
## 132           employrate          polityscore -0.18711922
## 133          polityscore           employrate -0.18711922
## 134            urbanrate     femaleemployrate  0.17822695
## 135     femaleemployrate            urbanrate  0.17822695
## 136     femaleemployrate         co2emissions  0.17238628
## 137         co2emissions     femaleemployrate  0.17238628
## 138   relectricperperson      armedforcesrate -0.16898440
## 139      armedforcesrate   relectricperperson -0.16898440
## 140         oilperperson     femaleemployrate  0.15953621
## 141     femaleemployrate         oilperperson  0.15953621
## 142           employrate       alcconsumption -0.14626247
## 143       alcconsumption           employrate -0.14626247
## 144      internetuserate         co2emissions  0.14309235
## 145         co2emissions      internetuserate  0.14309235
## 146       alcconsumption      incomeperperson  0.13723859
## 147      incomeperperson       alcconsumption  0.13723859
## 148              hivrate     femaleemployrate -0.13357235
## 149     femaleemployrate              hivrate -0.13357235
## 150         co2emissions      armedforcesrate -0.13055412
## 151      armedforcesrate         co2emissions -0.13055412
## 152            urbanrate      armedforcesrate  0.12937141
## 153      armedforcesrate            urbanrate  0.12937141
## 154            urbanrate           employrate  0.12523556
## 155           employrate            urbanrate  0.12523556
## 156   relectricperperson       alcconsumption  0.12292871
## 157       alcconsumption   relectricperperson  0.12292871
## 158              hivrate      armedforcesrate -0.12215132
## 159      armedforcesrate              hivrate -0.12215132
## 160           employrate         co2emissions  0.11792695
## 161         co2emissions           employrate  0.11792695
## 162      internetuserate      armedforcesrate -0.11644553
## 163      armedforcesrate      internetuserate -0.11644553
## 164              hivrate      incomeperperson -0.11500444
## 165      incomeperperson              hivrate -0.11500444
## 166            urbanrate      suicideper100th -0.11497281
## 167      suicideper100th            urbanrate -0.11497281
## 168      armedforcesrate       alcconsumption -0.10485225
## 169       alcconsumption      armedforcesrate -0.10485225
## 170          polityscore         oilperperson -0.10420992
## 171         oilperperson          polityscore -0.10420992
## 172       lifeexpectancy         co2emissions  0.10399038
## 173         co2emissions       lifeexpectancy  0.10399038
## 174         oilperperson       alcconsumption -0.10193469
## 175       alcconsumption         oilperperson -0.10193469
## 176      suicideper100th              hivrate  0.10098194
## 177              hivrate      suicideper100th  0.10098194
## 178              hivrate breastcancerper100th -0.08969369
## 179 breastcancerper100th              hivrate -0.08969369
## 180      armedforcesrate      incomeperperson -0.08854208
## 181      incomeperperson      armedforcesrate -0.08854208
## 182            urbanrate         co2emissions  0.08796496
## 183         co2emissions            urbanrate  0.08796496
## 184         oilperperson         co2emissions  0.08526168
## 185         co2emissions         oilperperson  0.08526168
## 186          polityscore              hivrate  0.07565524
## 187              hivrate          polityscore  0.07565524
## 188         oilperperson              hivrate -0.07406404
## 189              hivrate         oilperperson -0.07406404
## 190          polityscore         co2emissions  0.07308423
## 191         co2emissions          polityscore  0.07308423
## 192      suicideper100th      internetuserate  0.07286536
## 193      internetuserate      suicideper100th  0.07286536
## 194   relectricperperson              hivrate -0.06584784
## 195              hivrate   relectricperperson -0.06584784
## 196            urbanrate              hivrate -0.06106555
## 197              hivrate            urbanrate -0.06106555
## 198           employrate breastcancerper100th  0.06002107
## 199 breastcancerper100th           employrate  0.06002107
## 200      suicideper100th         oilperperson -0.05819842
## 201         oilperperson      suicideper100th -0.05819842
## 202      suicideper100th      incomeperperson -0.05759281
## 203      incomeperperson      suicideper100th -0.05759281
## 204          polityscore     femaleemployrate  0.04549128
## 205     femaleemployrate          polityscore  0.04549128
## 206           employrate      suicideper100th -0.04075238
## 207      suicideper100th           employrate -0.04075238
## 208      suicideper100th   relectricperperson -0.03981433
## 209   relectricperperson      suicideper100th -0.03981433
## 210      suicideper100th      armedforcesrate -0.03859743
## 211      armedforcesrate      suicideper100th -0.03859743
## 212              hivrate       alcconsumption  0.03580681
## 213       alcconsumption              hivrate  0.03580681
## 214      suicideper100th breastcancerper100th -0.03450769
## 215 breastcancerper100th      suicideper100th -0.03450769
## 216      suicideper100th          polityscore  0.03262108
## 217          polityscore      suicideper100th  0.03262108
## 218      suicideper100th         co2emissions  0.03116024
## 219         co2emissions      suicideper100th  0.03116024
## 220       lifeexpectancy      armedforcesrate  0.02364780
## 221      armedforcesrate       lifeexpectancy  0.02364780
## 222         co2emissions       alcconsumption  0.01656709
## 223       alcconsumption         co2emissions  0.01656709
## 224              hivrate         co2emissions  0.01004384
## 225         co2emissions              hivrate  0.01004384&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;looking-for-a-specific-values-from-columns-and-build-index&quot;&gt;looking for a specific values from columns and build index&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;index&lt;span class=&quot;o&quot;&gt;=&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;which&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;grepl&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s&quot;&gt;&amp;quot;polityscore&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;X1&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
index2&lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;kp&quot;&gt;which&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;grepl&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s&quot;&gt;&amp;quot;urbanrate&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt;d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;X2&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
index&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1]  11  48  66  74  76  78  88 117 127 133 170 186 190 204 217&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;index2&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1]  15  35  41  43  51  55  59 103 117 135 153 155 167 183 197&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;find-common-elements-by-intersect&quot;&gt;find common elements by intersect()&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;targetrow &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; &lt;span class=&quot;kp&quot;&gt;intersect&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;index&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt;index2&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
targetrow&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;## [1] 117&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;locate-the-target&quot;&gt;locate the target&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;d_cor_melt&lt;span class=&quot;p&quot;&gt;[&lt;/span&gt;targetrow&lt;span class=&quot;p&quot;&gt;,]&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##              X1        X2     value
## 117 polityscore urbanrate 0.2301452&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;To get those corrleations which are above 0.5 and less than 1.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;d_cor_melt&lt;span class=&quot;p&quot;&gt;[&lt;/span&gt;d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;value&lt;span class=&quot;o&quot;&gt;&amp;gt;=&lt;/span&gt;&lt;span class=&quot;m&quot;&gt;0.5&lt;/span&gt; &lt;span class=&quot;o&quot;&gt;&amp;amp;&lt;/span&gt; d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;value&lt;span class=&quot;o&quot;&gt;&amp;lt;&lt;/span&gt;&lt;span class=&quot;m&quot;&gt;1&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,])&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##                      X1                   X2     value
## 16      internetuserate      incomeperperson 0.8230076
## 17      incomeperperson      internetuserate 0.8230076
## 18   relectricperperson      incomeperperson 0.8080370
## 19      incomeperperson   relectricperperson 0.8080370
## 20       lifeexpectancy      internetuserate 0.7691600
## 21      internetuserate       lifeexpectancy 0.7691600
## 22           employrate     femaleemployrate 0.7595362
## 23     femaleemployrate           employrate 0.7595362
## 24      internetuserate breastcancerper100th 0.7454545
## 25 breastcancerper100th      internetuserate 0.7454545
## 26       lifeexpectancy      incomeperperson 0.7324525
## 27      incomeperperson       lifeexpectancy 0.7324525
## 28   relectricperperson      internetuserate 0.7173092
## 29      internetuserate   relectricperperson 0.7173092
## 30 breastcancerper100th      incomeperperson 0.7087064
## 31      incomeperperson breastcancerper100th 0.7087064
## 32   relectricperperson breastcancerper100th 0.6407313
## 33 breastcancerper100th   relectricperperson 0.6407313
## 34            urbanrate      internetuserate 0.6283764
## 35      internetuserate            urbanrate 0.6283764
## 36       lifeexpectancy breastcancerper100th 0.5802466
## 37 breastcancerper100th       lifeexpectancy 0.5802466
## 38         oilperperson      incomeperperson 0.5683228
## 39      incomeperperson         oilperperson 0.5683228
## 40            urbanrate       lifeexpectancy 0.5520842
## 41       lifeexpectancy            urbanrate 0.5520842
## 42            urbanrate      incomeperperson 0.5517590
## 43      incomeperperson            urbanrate 0.5517590
## 44   relectricperperson       lifeexpectancy 0.5515814
## 45       lifeexpectancy   relectricperperson 0.5515814
## 48          polityscore breastcancerper100th 0.5319288
## 49 breastcancerper100th          polityscore 0.5319288
## 50            urbanrate breastcancerper100th 0.5310618
## 51 breastcancerper100th            urbanrate 0.5310618
## 52         oilperperson      armedforcesrate 0.5248724
## 53      armedforcesrate         oilperperson 0.5248724
## 54            urbanrate         oilperperson 0.5019742
## 55         oilperperson            urbanrate 0.5019742&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

</content>
 </entry>
 
 <entry>
   <title>Pathology cases study</title>
   <link href="http://lanyon.getpoole.com/2015/08/29/ddd/"/>
   <updated>2015-08-29T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/29/ddd</id>
   <content type="html">
&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;&lt;span class=&quot;kn&quot;&gt;library&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;biomaRt&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
mart &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; useMart&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s&quot;&gt;&amp;quot;ensembl&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
datasets &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; listDatasets&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;mart&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
par&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;mar &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;kt&quot;&gt;c&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;m&quot;&gt;4&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;4&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;0.1&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;0.1&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;),&lt;/span&gt; omi &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;kt&quot;&gt;c&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;m&quot;&gt;0&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;0&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;0&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;0&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
plot&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;cars&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/figs/dddddd/unnamed-chunk-1-1.png&quot; alt=&quot;center&quot; /&gt;&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Pathology cases study</title>
   <link href="http://lanyon.getpoole.com/2015/08/28/class-discussion/"/>
   <updated>2015-08-28T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/28/class-discussion</id>
   <content type="html">&lt;h2 id=&quot;case-1&quot;&gt;Case 1&lt;/h2&gt;

&lt;p&gt;Clinical History:&lt;/p&gt;

&lt;p&gt;A 30-year-old &lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;African American woman&lt;/a&gt; presented to her family physician with nonradiating chest pain, shortness of breath, fever, weight-loss, malaise, lethargy and arthralgia.  She exhibited an &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;erythematous skin rash&lt;/a&gt; involving areas of the body exposed to sunlight. She noticed hair loss during the months prior to seeking medical attention.  She was admitted to the hospital for observation and tests.&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;Laboratory Findings and X-Ray:&lt;br /&gt;
A chest X-ray revealed cardiomegaly and &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;pleural effusion&lt;/a&gt;.  A complete blood count (CBC) identified a normochromic, normocytic anemia.  Urinalysis revealed &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.27.33.png&quot;&gt;hematuria, proteinuria and erythrocyte and leukocyte casts&lt;/a&gt;.  Analysis of the blood serum revealed the presence of autoantibodies against double-stranded DNA (p127).  &lt;a href=&quot;http://images.rheumatology.org/viewphoto.php?albumId=75690&amp;amp;imageId=2862319&quot;&gt;Immunofluorescence staining&lt;/a&gt; for antinuclear antibodies showed a &lt;a href=&quot;http://www.thelupussite.com/lupus_diagnosis_tests/ana_antinuclear_antibody.html&quot;&gt;peripheral pattern&lt;/a&gt; using human leukocytes as the substrate.  The serum also contained &lt;a href=&quot;http://www.healthline.com/health-slideshow/lupus-and-ra#1&quot;&gt;rheumatoid factor&lt;/a&gt; and &lt;a href=&quot;http://www.cidjournal.com/article/0738-081X%2885%2990074-4/abstract&quot;&gt;anticytoplasmic antibodies&lt;/a&gt;.&lt;/p&gt;

&lt;p&gt;Clinical Course of Disease:
A renal biopsy was performed and revealed diffuse &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;proliferative glomerulonephritis&lt;/a&gt; characterized by extensive cellular proliferation in more than 50% of glomeruli.  Immune complexes were deposited mainly in a &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;subendothelial distribution&lt;/a&gt;.  Immunofluorescence microscopy revealed that the immune deposits stained positively for all three major immunoglobulin classes and complement indicating a polyclonal activation of the immune system.  &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;Electron microscopy&lt;/a&gt; confirmed the subendothelial as well as intramembranous deposition of immune deposits.&lt;/p&gt;

&lt;h3 id=&quot;what-information-provided-above-is-of-the-greatest-assistance-in-reaching-a-diagnosis-of-systemic-lupus-erythematosus-in-this-patient&quot;&gt;1. What information provided above is of the greatest 	assistance in reaching a diagnosis of systemic lupus erythematosus in this patient?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;erythematous skin rash&lt;/a&gt; 
􏰡&lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.31.43.png&quot;&gt;hematuria, proteinuria and erythrocyte and leukocyte casts&lt;/a&gt; 7th criterion&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;􏰞https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.31.43.png&quot;&gt;pleural effusion&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;autoantibodies against double-stranded DNA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;antinuclear antibodies showed a &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;peripheral pattern&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://www.cidjournal.com/article/0738-081X%2885%2990074-4/abstract&quot;&gt;anticytoplasmic antibodies&lt;/a&gt;.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;proliferative glomerulonephritis&lt;/a&gt; &lt;em&gt;class V&lt;/em&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;subendothelial distribution&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;Electron microscopy&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;why-did-this-patient-present-with-chest-pain&quot;&gt;2.	Why did this patient present with chest pain?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;perual efusion.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The patient may suffer &lt;a href=&quot;p 89 &amp;amp; p 130&quot;&gt;Libman-Sacks endocarditis&lt;/a&gt;, possiblely related Thrombi, which can develop anywhere in the cardiovascular system due to &lt;a href=&quot;http://www.hopkinslupus.org/lupus-tests/antiphospholipid-antibodies/&quot;&gt;lupus anticoagulant&lt;/a&gt; which increases the ability of the blood to clot.&lt;/p&gt;

&lt;h3 id=&quot;what-are-the-major-immunologic-features-of-systemic-lupus-erythematosus-sle&quot;&gt;3. What are the major immunologic features of systemic lupus erythematosus (SLE)?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-DNA. Antibody to native DNA, Anti-Sm. Presence of AB to &lt;strong&gt;Smith&lt;/strong&gt; nuclear antigen.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;depostion of immune complex&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;epidermal and dermal junction&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;3.	LUPUS SKIN BIOPSY, THICKENED BASEMENT MEMBRANE&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image4.jpeg&quot;&gt;4.	LUPUS BAND TEST, ANTI IgG STAIN&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;5. PERIPHERAL RIM PATTERN&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;LE test is no longer performed.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The patient may suffer Libman-Sacks endocarditis (p 89 &amp;amp; p 130) Note that this is not infected, it is just fribid, so it is&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;not sigificant.&lt;/p&gt;

&lt;h3 id=&quot;is-lupus-more-likely-to-occur-in-males-or-females-and-in-caucasians-or-african-americans&quot;&gt;4. Is lupus more likely to occur in males or females and in Caucasians or African Americans?&lt;/h3&gt;

&lt;p&gt;More likely to occur in &lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;females&lt;/a&gt; and in African Americans.&lt;/p&gt;

&lt;h3 id=&quot;what-are-lupus-anti-coagulants-and-anti-phospholipid-antibodies-and-what-role-do-they-play-in-the-pathogenesis-of-sle&quot;&gt;5.What are lupus anti-coagulants and anti-phospholipid antibodies and what role do they play in the pathogenesis of SLE?&lt;/h3&gt;

&lt;p&gt;Antiphospholipid antibodies are present in 40% to 50% of patients with lupus and react with a wide variety of proteins in complex with phospholipids. Some bind to cardiolipin antigen, used in serologic tests for syphilis, so patients with lupus may have a false-positive test result for syphilis. Antiphos- pholipid antibodies contribute to coagulation abnormalities (p127)&lt;/p&gt;

&lt;p&gt;patients prolong pt are at risk of bleeding. not have a risk of bleeding, but have a risk of thomboli.&lt;/p&gt;

&lt;p&gt;Paradoxically, these antibodies interfere with clotting tests and are actually called “lupus anticoagulants.” Autoantibodies are also produced against clotting factors such as thrombin, and these too may contribute to clotting disorders. the term Lupus -anti-coagulants are actually a &lt;a href=&quot;http://www.hopkinslupus.org/lupus-tests/antiphospholipid-antibodies/&quot;&gt;misnomer&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-does-a-biopsy-of-the-erythematous-skin-rash-involving-areas-of-the-body-exposed-to-sunlight-reveal&quot;&gt;6. What does a biopsy of the erythematous skin rash involving areas of the body exposed to sunlight reveal?&lt;/h3&gt;

&lt;p&gt;Histopathologic findings include &lt;strong&gt;liquefactive degeneration&lt;/strong&gt; of the basal layer of the epidermis, &lt;strong&gt;edema&lt;/strong&gt; at the dermoepidermal junction, and &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image2.jpeg&quot;&gt;mononuclear infiltrates&lt;/a&gt; around blood vessels and skin appendages. also see &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;figure&lt;/a&gt; Immunofluorescence microscopy reveals deposition of immunoglobulin and complement at the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2023.27.19.png&quot;&gt;dermoepidermal junction&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-percentage-of-patients-with-sle-has-renal-involvement&quot;&gt;7. What percentage of patients with SLE has renal involvement?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;75 %&lt;/p&gt;

&lt;p&gt;**from book **&lt;/p&gt;

&lt;p&gt;Although the kidney appears normal by light microscopy in 25% to 30% of cases, almost all cases of SLE show some renal abnormality if examined by immuno- fluorescence and electron microscopy.(p128)&lt;/p&gt;

&lt;h3 id=&quot;why-did-the-patient-develop-exacerbations-and-remissions&quot;&gt;8.	Why did the patient develop exacerbations and remissions?&lt;/h3&gt;

&lt;h3 id=&quot;why-does-a-sle-patient-have-rheumatoid-factors-in-the-serum&quot;&gt;9.	Why does a SLE patient have rheumatoid factors in the serum?&lt;/h3&gt;

&lt;p&gt;class answers&lt;/p&gt;

&lt;p&gt;a lot of autoimmune diseases have rheumatoid factors.&lt;/p&gt;

&lt;p&gt;polyarthritis does not destroy the joints.&lt;/p&gt;

&lt;p&gt;supplementary&lt;/p&gt;

&lt;p&gt;Because in lupus, the immune system attacks the body, including the joints. Rheumatoid factor is an antibody that becomes connected to another type of antibody called immunoglobulin. Together, these form an immune complex that can become involved in inflammation. 
&lt;a href=&quot;http://www.everydayhealth.com/rheumatoid-arthritis/testing-for-rheumatoid-factor.aspx&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-differential-diagnosis-of-sle&quot;&gt;10.	What is the differential diagnosis of SLE?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;MNEMONIC  DOPAMIN RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;DISCOID RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ORAL ULCERS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;PHOTOSENSITIVITY&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ANA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;MALAR RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IMMUNOLOGICAL PHENOMENON(Le Cell, Ds DNA, Sm, APL ab, false + RPR, )&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;NEUROLOGICAL(Seizures,Psychosis)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;RENAL(Nephrotic,Nephritic)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ARTHRITIS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;SEROSITIS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HEMATOLOGICAL(Leukopenia,Thrombocytopenia, anemia)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.38.42.png&quot;&gt;slide 16 from sle ppt&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-are-the-complications-and-prognosis-of-sle&quot;&gt;11. What are the complications and prognosis of SLE?&lt;/h3&gt;

&lt;p&gt;good outlook&lt;/p&gt;

&lt;p&gt;Prognosis&lt;/p&gt;

&lt;p&gt;A primary cause of death among patients with lupus is atherosclerosis and SLE is unpredictable and varies greatly form one individual to the next.&lt;/p&gt;

&lt;p&gt;Mild SLE.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;skin rashes of discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) with or without joint aches.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Widespread SLE.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;SLE is a chronic, life-long disease, alternating between periods of symptom relapse, (called flares), and remission. The disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;may begin in any of the various systems of the body and progress unpredictably to others.&lt;/p&gt;

&lt;p&gt;The following are typical patterns:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Symptom relapses, or flares, occur on the average of two or three times a year.&lt;/li&gt;
  &lt;li&gt;Between flares, most patients with SLE function at about 90% of normal capacity.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The degree of severity depends on different factors:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Severity of the inflammatory response&lt;/li&gt;
  &lt;li&gt;Frequency of episodes&lt;/li&gt;
  &lt;li&gt;The degree of organ or system involvement&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Vital organs or systems,joints, skin, and others are affected.&lt;/p&gt;

&lt;p&gt;Infections followed by kidney failure are the chief causes of death in patients with SLE.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.nytimes.com/health/guides/disease/systemic-lupus-erythematosus/prognosis.html&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-five-year-survival-rate-of-patients-with-sle&quot;&gt;12.	What is the five-year survival rate of patients with SLE?&lt;/h3&gt;

&lt;p&gt;About 95% in the US, see the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/Screenshot%202015-08-27%2014.20.33.png&quot;&gt;table&lt;/a&gt;
from the book&lt;a href=&quot;https://books.google.com/books?id=qqq450swSv0C&amp;amp;pg=PA685&amp;amp;lpg=PA685&amp;amp;dq=five-year+survival+rate+of+sle&amp;amp;source=bl&amp;amp;ots=sJPHBW-jv0&amp;amp;sig=w3asQB_Jsjymaz1pxhh4GLGRLmk&amp;amp;hl=en&amp;amp;sa=X&amp;amp;ved=0CDcQ6AEwBGoVChMI-LDk_fDJxwIVgVk-Ch2FwQII#v=onepage&amp;amp;q&amp;amp;f=false&quot;&gt;Systemic Lupus Erythematosus&lt;/a&gt; by Robert G. Lahita, George Tsokos&lt;/p&gt;

&lt;h3 id=&quot;figure-from-powerpoint-sides&quot;&gt;Figure from powerpoint sides&lt;/h3&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;1.	LUPUS BUTTERFLY RASH&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image2.jpeg&quot;&gt;2.	LUPUS SKIN BIOPSY&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;3.	LUPUS SKIN BIOPSY, THICKENED BASEMENT MEMBRANE&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image4.jpeg&quot;&gt;4.	LUPUS BAND TEST, ANTI IgG STAIN&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;5. PERIPHERAL RIM PATTERN&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image6.jpeg&quot;&gt;6.	DIFFUSE PROLIFERATIVE LUPUS NEPHRITIS&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image7.jpeg&quot;&gt;7.	L.E. CELL PREPARATION&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Picture%20clipping.pictClipping&quot;&gt;8.	LIBMAN-SACKS ENDOCARDITIS&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;case-2&quot;&gt;Case 2&lt;/h2&gt;

&lt;h3 id=&quot;clinical-history&quot;&gt;CLINICAL HISTORY:&lt;/h3&gt;

&lt;p&gt;A 45-year-old white male previously diagnosed with a T cell leukemia developed skin rash, severe diarrhea and jaundice after receiving repeated blood transfusions.  The skin exhibited a fine, diffuse, erythematous, macular rash that began on the palms, soles and head and spread to the entire trunk as well as to extremities.  The rash became desquamative and resembled an extensive second-degree burn.  There was watery diarrhea associated with malabsorption, cramps and gastrointestinal bleeding.  Blood chemistry analysis revealed &lt;a href=&quot;p139&quot;&gt;hyperbilirubinemia&lt;/a&gt; and an elevated serum alkaline phosphatase level.  There was only a mild elevation in the alanine aminotransferase (ALT) and aspartate aminotransferase levels (AST).&lt;/p&gt;

&lt;p&gt;those sites have vast proliferative of immune cells, espeically the basal layers of the skin.&lt;/p&gt;

&lt;p&gt;eradated the blood, so the lymphocyte will be deactivated.&lt;/p&gt;

&lt;p&gt;alkaline phosphatase level will rise if the kidney ducts are damaged.&lt;/p&gt;

&lt;h3 id=&quot;are-the-clinical-events-described-above-attributable-to-the-leukemia-process-or-to-some-other-factor&quot;&gt;1.	Are the clinical events described above attributable to the leukemia process or to some other factor?&lt;/h3&gt;
&lt;p&gt;To some other factor.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-most-likely-cause-of-the-signs-and-symptoms-described-in-this-patient&quot;&gt;2.	What is the most likely cause of the signs and symptoms described in this patient?&lt;/h3&gt;

&lt;p&gt;graft-versus-host diseases&lt;/p&gt;

&lt;h3 id=&quot;how-could-a-leukemia-patient-in-hospital-develop-signs-and-symptoms-of-graft-versus-host-disease&quot;&gt;3. How could a leukemia patient in hospital develop signs and symptoms of graft-versus-host disease?&lt;/h3&gt;

&lt;p&gt;GVHD occurs when immunologically competent cells are introduced into an immunoincompetent host. GVHD refers to the immunologic insult and to the consequences to the organism. The patient must have had a Hematopoietic cell transplation, Solid organ transplants, or blood transfusions.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-mechanism-of-the-skin-rash&quot;&gt;4. What is the mechanism of the skin rash?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;from textbook&lt;/strong&gt;
It resemble those of SS (p139), In the early stages, affected skin areas are somewhat edematous and have a doughy consistency. Capillaries and small arteries (as large as 500 μm in diameter) may show thickening of the basal lamina, endothelial cell damage, and partial occlusion. With progression, the edema- tous phase is replaced by progressive fibrosis of the dermis, which becomes tightly bound to the subcutaneous structures. There is marked increase of compact collagen in the dermis along with thinning of the epidermis, atrophy of the dermal appendages, and hyaline thickening of the walls of dermal arterioles and capillaries (P133)&lt;/p&gt;

&lt;p&gt;or&lt;/p&gt;

&lt;p&gt;Skin — In most patients, the first (and most common) clinical manifestation of acute GVHD is a maculopapular rash, usually occurring at or near the time of the white blood cell engraftment (picture 1). The rash initially involves the nape of the neck, ears, shoulders, the palms of the hands (picture 2), and the soles of the feet. It can be described as a sunburn and may be pruritic or painful (picture 3). From these initial areas of presentation, the rash may spread to involve the whole integument, eventually becoming confluent. In severe GVHD, the maculopapular rash forms bullous lesions with toxic epidermal necrolysis mimicking Stevens-Johnson syndrome
&lt;a href=&quot;http://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-cause-of-the-hyperbilirubinemia&quot;&gt;5. What is the cause of the hyperbilirubinemia&lt;/h3&gt;

&lt;p&gt;Destruction of small bile ducts gives rise to jaundice, thus resulted in hyperbilirubinemia&lt;/p&gt;

&lt;h3 id=&quot;what-subset-of-t-lymphocytes-is-found-in-biopsies-of-skin-intestine-and-liver&quot;&gt;6. What subset of T lymphocytes is found in biopsies of skin, intestine and liver?&lt;/h3&gt;

&lt;p&gt;CD 4+ and CD 8+&lt;/p&gt;

&lt;h3 id=&quot;how-could-graft-versus-host-disease-be-prevented-in-patients-receiving-blood-transfusions&quot;&gt;7. How could graft-versus-host disease be prevented in patients receiving blood transfusions?&lt;/h3&gt;

&lt;p&gt;GVHD is a potentially lethal complication that can be minimized but not eliminated by HLA matching. As another potential solution, donor T cells can be depleted before marrow transplant.&lt;/p&gt;

&lt;h3 id=&quot;when-is-graft-versus-host-disease-most-often-observed&quot;&gt;8. When is graft-versus-host disease most often observed?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;Degree of mismatch between HLA types&lt;/li&gt;
  &lt;li&gt;“minor” histocompatibility antigens&lt;/li&gt;
  &lt;li&gt;Age – possible thymic influence&lt;/li&gt;
  &lt;li&gt;Germ free environment&lt;/li&gt;
  &lt;li&gt;Pre-treatment with cytotoxic drugs&lt;/li&gt;
  &lt;li&gt;Sex mismatch&lt;/li&gt;
  &lt;li&gt;Transfusion presensitization&lt;/li&gt;
&lt;/ul&gt;

&lt;ol&gt;
  &lt;li&gt;What types of GVH disease follow bone marrow transplantation?
The small bowel and colon are involved in most cases. Intestinal graft-versus-host disease often manifests as a watery diarrhea.&lt;/li&gt;
&lt;/ol&gt;

&lt;h3 id=&quot;figures&quot;&gt;figures&lt;/h3&gt;
&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.44.57.png&quot;&gt;1.	List of target tissues of acute G-V-H disease&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image9.jpeg&quot;&gt;2.	Baby with maculopapular rash of  G-V-H 	disease&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image10.jpeg&quot;&gt;3. 	Adult with acute G-V-H skin reaction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image11.jpeg&quot;&gt;4.	Micro–skin interface dermatitis with basal cell destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image12.jpeg&quot;&gt;5.	Micro–skin interface dermatitis with basal cell destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image13.jpeg&quot;&gt;6.	Micro–liver G-V-H with bile-duct injury and early cell infiltrate&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image14.jpeg&quot;&gt;7.	Micro-liver G-V-H, chronic with inflammation and fibrosis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image15.jpeg&quot;&gt;8.	Micro–enteritis in G-V-H in lower 1/3 of crypt, early&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image16.jpeg&quot;&gt;9.	Micro–enterocyte necrosis and crypt destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image17.jpeg&quot;&gt;10. Gross–intestinal G-V-H with bleeding and superinfection&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image18.jpeg&quot;&gt;11. Gross–intestinal G-V-H with intermittent involved areas&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image19.jpeg&quot;&gt;12. Gross–intestinal G-V-H with bleeding and 	superinfection&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image20.jpeg&quot;&gt;13. Gross–intestinal G-V-H with mucosal sloughing and scarring&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;case-3&quot;&gt;Case 3&lt;/h2&gt;

&lt;h3 id=&quot;clinical-history-1&quot;&gt;CLINICAL HISTORY:&lt;/h3&gt;

&lt;p&gt;A 60-year-old white male presented to his family physician with complaints of weakness, anorexia, weight loss and severe back pain.&lt;/p&gt;

&lt;h3 id=&quot;laboratory-and-x-ray-findings&quot;&gt;LABORATORY AND X-RAY FINDINGS:&lt;/h3&gt;

&lt;p&gt;Radiologic examination revealed  “punched out” &lt;a href=&quot;&quot;&gt;skeletal lesions&lt;/a&gt; with sharply demarcated margins in vertebral bodies, skull, ribs, and pelvis.  Blood chemistry showed hypercalcemia and hyperglobulinemia.  The serum globulin concentration was &lt;a href=&quot;http://www.drstandley.com/labvalues_proteins.shtml&quot;&gt;6.0 g/dl&lt;/a&gt;.  Both the serum and urine revealed a homogeneous protein by electrophoresis, which was identified as &lt;a href=&quot;p437&quot;&gt;IgA&lt;/a&gt;.  The urine contained free light chains.  The urinary protein was insoluble at acid pH between &lt;a href=&quot;http://basicprotein.blogspot.com/2012/11/tests-for-detection-of-bence-jones.html&quot;&gt;40º and 60ºC but redissolved at 95ºC.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Hematologic examination revealed a normochromic normocytic anemia with leukopenia and thrombocytopenia.  The blood smear revealed rouleaux formation of red cells.  There was an elevated sedimentation rate and marked plasma cell proliferation in the bone marrow.   Flow cytometric analysis of the bone marrow revealed an abnormal CD45 negative cell population that expressed CD38, CD56 and CD138 with cytoplasmic kappa light chain restriction.  This cell population was negative for CD19, CD20 and surface immunoglobulin.&lt;/p&gt;

&lt;p&gt;A renal biopsy was performed and revealed large numbers of eosinophilic lamellated casts in the renal tubules.  The tubular cells were markedly atrophic and contained hyaline droplets and some crystalline material. The glomeruli appeared normal, yet they were surrounded by interstitial fibrosis as a result of tubular destruction.  The patient received supportive therapy including local radiation therapy to relieve pain.  He experienced repeated bouts of respiratory infection with Streptococcus pneumoniae.  After reaching a diagnosis, cytotoxic therapy was instituted, yet the patient died within 12 months of diagnosis.&lt;/p&gt;

&lt;p&gt;cd 138 is specific for plasma cells
cd 19 is B cell marker
kappa or lambda restricted&lt;/p&gt;

&lt;h3 id=&quot;what-information-provided-above-is-of-the-greatest-assistance-in-reaching-a-diagnosis-of-plasma-cell-multiple-myeloma-in-this-patient&quot;&gt;1. What information provided above is of the greatest assistance in reaching a diagnosis of plasma cell 	(multiple) myeloma in this patient?&lt;/h3&gt;

&lt;h3 id=&quot;why-did-this-patient-present-with-severe-back-pain&quot;&gt;2. Why did this patient present with severe back pain?&lt;/h3&gt;
&lt;p&gt;It is due to pathologic fractures. Pathologic fractures of vertebrae may lead to spinal cord impingement, an oncologic emergency.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-cause-of-the-punched-out-osteolytic-lesions&quot;&gt;3. What is the cause of the “punched out” osteolytic lesions?&lt;/h3&gt;

&lt;p&gt;Bone destruction by osteolytic lesions is caused by two separate events. Rapid growth of myeloma cells inhibits normal bone-forming cells, damaging bone. In addition, production of substances that activate the cells that resorb bone, called osteoclasts, is increased.&lt;/p&gt;

&lt;p&gt;The lesions generally arise in the medullary cavity, erode cancellous bone, and progressively destroy the cortical bone.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-significance-of-the-light-chain-proteinuria-described-in-this-patient&quot;&gt;4. What is the significance of the light chain proteinuria described in this patient.&lt;/h3&gt;
&lt;p&gt;Light chain deposition in the glomeruli or the interstitium, either as amyloid or linear deposits, also may contribute to renal dysfunction.&lt;/p&gt;

&lt;h3 id=&quot;since-the-patient-was-hypergammaglobulinemic-why-did-he-suffer-repeated-bouts-of-pneumococcal-infection&quot;&gt;5. Since the patient was hypergammaglobulinemic, why did he suffer repeated bouts of pneumococcal infection?&lt;/h3&gt;

&lt;p&gt;Patients with myeloma are immunosuppressed. Through uncertain mechanisms, myeloma cells interfere with the function of normal plasma cells, leading to defects in antibody production. Thus, although the plasma usually contains increased immunoglobulin owing to the pres- ence of an M protein, the levels of functional antibodies often are profoundly depressed, leaving patients at high risk for bacterial infections. (p438)&lt;/p&gt;

&lt;h3 id=&quot;which-part-of-the-skeletal-system-is-most-frequently-affected-in-plasma-cell-myeloma&quot;&gt;6. Which part of the skeletal system is most frequently affected in plasma cell myeloma?&lt;/h3&gt;

&lt;p&gt;Multiple myeloma usually manifests with multifocal destructive skeletal lesions, which most commonly involve the vertebral column, ribs, skull, pelvis, femur, clavicle, and scapula. The lesions generally arise in the medullary cavity, erode cancellous bone, and progressively destroy the cortical bone.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-differential-diagnosis-of-plasma-cell-myeloma&quot;&gt;7. What is the differential diagnosis of plasma cell 	myeloma?&lt;/h3&gt;
&lt;p&gt;we
The main differential is that of widespread bony metastases. Findings that favour the diagnosis of bony metastases over that of multiple myeloma include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;more commonly affect the vertebral pedicles rather than vertebral bodies&lt;/li&gt;
  &lt;li&gt;rarely involve mandible, distal axial skeleton&lt;/li&gt;
  &lt;li&gt;although both entities have variable bone scan appearances (both hot and cold) unlike myeloma, extensive bony metastases rarely have a normal appearance&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Other rare entities include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Waldenstrom macroglonulinaemia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://radiopaedia.org/articles/multiple-myeloma-1&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;which-immunoglobulins-may-be-increased-in-plasma-cell-myeloma&quot;&gt;8. Which immunoglobulins may be increased in plasma cell myeloma?&lt;/h3&gt;

&lt;p&gt;he most frequent M protein produced by myeloma cells is IgG (60%), followed by IgA (20% to 25%); only rarely are IgM, IgD, or IgE M proteins observed.&lt;/p&gt;

&lt;h3 id=&quot;do-all-cases-of-plasma-cell-myeloma-have-the-monoclonal-serum-paraprotein-identifiable-electrophoresis&quot;&gt;9. Do all cases of plasma cell myeloma have the monoclonal serum paraprotein identifiable 	electrophoresis?&lt;/h3&gt;

&lt;p&gt;Electrophoresis of the serum and urine is an important diagnostic tool. In 99% of cases, either a monoclonal com- plete immunoglobulin or a monoclonal free immunoglobu- lin light chain is present in the serum, the urine, or both&lt;/p&gt;

&lt;p&gt;Because these immunoglobulins can be detected in the serum, these disorders are also referred to as monoclonal gammopathies, and the associated immuno- globulin is often referred to as an M protein&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;What is the meaning of the results of flow cytometric analysis of the bone marrow.&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;figures&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image21.jpeg&quot;&gt;1.	Plasma cell in smear&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image22.jpeg&quot;&gt;2.	Plasma cell (drawing)&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image23.jpeg&quot;&gt;3.	Plasma cell cluster in smear&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image24.jpeg&quot;&gt;4.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image25.jpeg&quot;&gt;5.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image26.jpeg&quot;&gt;6.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image27.jpeg&quot;&gt;7.	Gross of rib with protruding plasma cell proliferation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image28.jpeg&quot;&gt;8.	Gross of osteolytic lesions of skull in plasma cell myeloma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image29.jpeg&quot;&gt;9.	X-rays of osteolytic lesions of skull in plasma cell myeloma&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Pathology cases study</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/08/27/pathology-cases/"/>
   <updated>2015-08-27T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/08/27/pathology-cases</id>
   <content type="html">&lt;h2 id=&quot;case-1&quot;&gt;Case 1&lt;/h2&gt;

&lt;p&gt;Clinical History:&lt;/p&gt;

&lt;p&gt;A 30-year-old &lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;African American woman&lt;/a&gt; presented to her family physician with nonradiating chest pain, shortness of breath, fever, weight-loss, malaise, lethargy and arthralgia.  She exhibited an &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;erythematous skin rash&lt;/a&gt; involving areas of the body exposed to sunlight. She noticed hair loss during the months prior to seeking medical attention.  She was admitted to the hospital for observation and tests.&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;Laboratory Findings and X-Ray:&lt;br /&gt;
A chest X-ray revealed cardiomegaly and &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;pleural effusion&lt;/a&gt;.  A complete blood count (CBC) identified a normochromic, normocytic anemia.  Urinalysis revealed &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.27.33.png&quot;&gt;hematuria, proteinuria and erythrocyte and leukocyte casts&lt;/a&gt;.  Analysis of the blood serum revealed the presence of autoantibodies against double-stranded DNA (p127).  &lt;a href=&quot;http://images.rheumatology.org/viewphoto.php?albumId=75690&amp;amp;imageId=2862319&quot;&gt;Immunofluorescence staining&lt;/a&gt; for antinuclear antibodies showed a &lt;a href=&quot;http://www.thelupussite.com/lupus_diagnosis_tests/ana_antinuclear_antibody.html&quot;&gt;peripheral pattern&lt;/a&gt; using human leukocytes as the substrate.  The serum also contained &lt;a href=&quot;http://www.healthline.com/health-slideshow/lupus-and-ra#1&quot;&gt;rheumatoid factor&lt;/a&gt; and &lt;a href=&quot;http://www.cidjournal.com/article/0738-081X%2885%2990074-4/abstract&quot;&gt;anticytoplasmic antibodies&lt;/a&gt;.&lt;/p&gt;

&lt;p&gt;Clinical Course of Disease:
A renal biopsy was performed and revealed diffuse &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;proliferative glomerulonephritis&lt;/a&gt; characterized by extensive cellular proliferation in more than 50% of glomeruli.  Immune complexes were deposited mainly in a &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;subendothelial distribution&lt;/a&gt;.  Immunofluorescence microscopy revealed that the immune deposits stained positively for all three major immunoglobulin classes and complement indicating a polyclonal activation of the immune system.  &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;Electron microscopy&lt;/a&gt; confirmed the subendothelial as well as intramembranous deposition of immune deposits.&lt;/p&gt;

&lt;h3 id=&quot;what-information-provided-above-is-of-the-greatest-assistance-in-reaching-a-diagnosis-of-systemic-lupus-erythematosus-in-this-patient&quot;&gt;1. What information provided above is of the greatest 	assistance in reaching a diagnosis of systemic lupus erythematosus in this patient?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;American woman&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;erythematous skin rash&lt;/a&gt; 
􏰡&lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.31.43.png&quot;&gt;hematuria, proteinuria and erythrocyte and leukocyte casts&lt;/a&gt; 7th criterion&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;􏰞https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.31.43.png&quot;&gt;pleural effusion&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;autoantibodies against double-stranded DNA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;antinuclear antibodies showed a &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;peripheral pattern&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://www.cidjournal.com/article/0738-081X%2885%2990074-4/abstract&quot;&gt;anticytoplasmic antibodies&lt;/a&gt;.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;proliferative glomerulonephritis&lt;/a&gt; &lt;em&gt;class V&lt;/em&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;subendothelial distribution&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;Electron microscopy&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;why-did-this-patient-present-with-chest-pain&quot;&gt;2.	Why did this patient present with chest pain?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;perual efusion.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The patient may suffer &lt;a href=&quot;p 89 &amp;amp; p 130&quot;&gt;Libman-Sacks endocarditis&lt;/a&gt;, possiblely related Thrombi, which can develop anywhere in the cardiovascular system due to &lt;a href=&quot;http://www.hopkinslupus.org/lupus-tests/antiphospholipid-antibodies/&quot;&gt;lupus anticoagulant&lt;/a&gt; which increases the ability of the blood to clot.&lt;/p&gt;

&lt;h3 id=&quot;what-are-the-major-immunologic-features-of-systemic-lupus-erythematosus-sle&quot;&gt;3. What are the major immunologic features of systemic lupus erythematosus (SLE)?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-DNA. Antibody to native DNA, Anti-Sm. Presence of AB to &lt;strong&gt;Smith&lt;/strong&gt; nuclear antigen.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;depostion of immune complex&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;epidermal and dermal junction&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;3.	LUPUS SKIN BIOPSY, THICKENED BASEMENT MEMBRANE&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image4.jpeg&quot;&gt;4.	LUPUS BAND TEST, ANTI IgG STAIN&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;5. PERIPHERAL RIM PATTERN&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;LE test is no longer performed.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The patient may suffer Libman-Sacks endocarditis (p 89 &amp;amp; p 130) Note that this is not infected, it is just fribid, so it is&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;not sigificant.&lt;/p&gt;

&lt;h3 id=&quot;is-lupus-more-likely-to-occur-in-males-or-females-and-in-caucasians-or-african-americans&quot;&gt;4. Is lupus more likely to occur in males or females and in Caucasians or African Americans?&lt;/h3&gt;

&lt;p&gt;More likely to occur in &lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;females&lt;/a&gt; and in African Americans.&lt;/p&gt;

&lt;h3 id=&quot;what-are-lupus-anti-coagulants-and-anti-phospholipid-antibodies-and-what-role-do-they-play-in-the-pathogenesis-of-sle&quot;&gt;5.What are lupus anti-coagulants and anti-phospholipid antibodies and what role do they play in the pathogenesis of SLE?&lt;/h3&gt;

&lt;p&gt;Antiphospholipid antibodies are present in 40% to 50% of patients with lupus and react with a wide variety of proteins in complex with phospholipids. Some bind to cardiolipin antigen, used in serologic tests for syphilis, so patients with lupus may have a false-positive test result for syphilis. Antiphos- pholipid antibodies contribute to coagulation abnormalities (p127)&lt;/p&gt;

&lt;p&gt;patients prolong pt are at risk of bleeding. not have a risk of bleeding, but have a risk of thomboli.&lt;/p&gt;

&lt;p&gt;Paradoxically, these antibodies interfere with clotting tests and are actually called “lupus anticoagulants.” Autoantibodies are also produced against clotting factors such as thrombin, and these too may contribute to clotting disorders. the term Lupus -anti-coagulants are actually a &lt;a href=&quot;http://www.hopkinslupus.org/lupus-tests/antiphospholipid-antibodies/&quot;&gt;misnomer&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-does-a-biopsy-of-the-erythematous-skin-rash-involving-areas-of-the-body-exposed-to-sunlight-reveal&quot;&gt;6. What does a biopsy of the erythematous skin rash involving areas of the body exposed to sunlight reveal?&lt;/h3&gt;

&lt;p&gt;Histopathologic findings include &lt;strong&gt;liquefactive degeneration&lt;/strong&gt; of the basal layer of the epidermis, &lt;strong&gt;edema&lt;/strong&gt; at the dermoepidermal junction, and &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image2.jpeg&quot;&gt;mononuclear infiltrates&lt;/a&gt; around blood vessels and skin appendages. also see &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;figure&lt;/a&gt; Immunofluorescence microscopy reveals deposition of immunoglobulin and complement at the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2023.27.19.png&quot;&gt;dermoepidermal junction&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-percentage-of-patients-with-sle-has-renal-involvement&quot;&gt;7. What percentage of patients with SLE has renal involvement?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;75 %&lt;/p&gt;

&lt;p&gt;**from book **&lt;/p&gt;

&lt;p&gt;Although the kidney appears normal by light microscopy in 25% to 30% of cases, almost all cases of SLE show some renal abnormality if examined by immuno- fluorescence and electron microscopy.(p128)&lt;/p&gt;

&lt;h3 id=&quot;why-did-the-patient-develop-exacerbations-and-remissions&quot;&gt;8.	Why did the patient develop exacerbations and remissions?&lt;/h3&gt;

&lt;h3 id=&quot;why-does-a-sle-patient-have-rheumatoid-factors-in-the-serum&quot;&gt;9.	Why does a SLE patient have rheumatoid factors in the serum?&lt;/h3&gt;

&lt;p&gt;class answers&lt;/p&gt;

&lt;p&gt;a lot of autoimmune diseases have rheumatoid factors.&lt;/p&gt;

&lt;p&gt;polyarthritis does not destroy the joints.&lt;/p&gt;

&lt;p&gt;supplementary&lt;/p&gt;

&lt;p&gt;Because in lupus, the immune system attacks the body, including the joints. Rheumatoid factor is an antibody that becomes connected to another type of antibody called immunoglobulin. Together, these form an immune complex that can become involved in inflammation. 
&lt;a href=&quot;http://www.everydayhealth.com/rheumatoid-arthritis/testing-for-rheumatoid-factor.aspx&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-differential-diagnosis-of-sle&quot;&gt;10.	What is the differential diagnosis of SLE?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;MNEMONIC  DOPAMIN RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;DISCOID RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ORAL ULCERS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;PHOTOSENSITIVITY&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ANA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;MALAR RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IMMUNOLOGICAL PHENOMENON(Le Cell, Ds DNA, Sm, APL ab, false + RPR, )&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;NEUROLOGICAL(Seizures,Psychosis)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;RENAL(Nephrotic,Nephritic)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ARTHRITIS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;SEROSITIS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HEMATOLOGICAL(Leukopenia,Thrombocytopenia, anemia)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.38.42.png&quot;&gt;slide 16 from sle ppt&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-are-the-complications-and-prognosis-of-sle&quot;&gt;11. What are the complications and prognosis of SLE?&lt;/h3&gt;

&lt;p&gt;Prognosis&lt;/p&gt;

&lt;p&gt;A primary cause of death among patients with lupus is atherosclerosis and SLE is unpredictable and varies greatly form one individual to the next.&lt;/p&gt;

&lt;p&gt;Mild SLE.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;skin rashes of discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) with or without joint aches.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Widespread SLE.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;SLE is a chronic, life-long disease, alternating between periods of symptom relapse, (called flares), and remission. The disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;may begin in any of the various systems of the body and progress unpredictably to others.&lt;/p&gt;

&lt;p&gt;The following are typical patterns:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Symptom relapses, or flares, occur on the average of two or three times a year.&lt;/li&gt;
  &lt;li&gt;Between flares, most patients with SLE function at about 90% of normal capacity.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The degree of severity depends on different factors:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Severity of the inflammatory response&lt;/li&gt;
  &lt;li&gt;Frequency of episodes&lt;/li&gt;
  &lt;li&gt;The degree of organ or system involvement&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Vital organs or systems,joints, skin, and others are affected.&lt;/p&gt;

&lt;p&gt;Infections followed by kidney failure are the chief causes of death in patients with SLE.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.nytimes.com/health/guides/disease/systemic-lupus-erythematosus/prognosis.html&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-five-year-survival-rate-of-patients-with-sle&quot;&gt;12.	What is the five-year survival rate of patients with SLE?&lt;/h3&gt;

&lt;p&gt;About 95% in the US, see the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/Screenshot%202015-08-27%2014.20.33.png&quot;&gt;table&lt;/a&gt;
from the book&lt;a href=&quot;https://books.google.com/books?id=qqq450swSv0C&amp;amp;pg=PA685&amp;amp;lpg=PA685&amp;amp;dq=five-year+survival+rate+of+sle&amp;amp;source=bl&amp;amp;ots=sJPHBW-jv0&amp;amp;sig=w3asQB_Jsjymaz1pxhh4GLGRLmk&amp;amp;hl=en&amp;amp;sa=X&amp;amp;ved=0CDcQ6AEwBGoVChMI-LDk_fDJxwIVgVk-Ch2FwQII#v=onepage&amp;amp;q&amp;amp;f=false&quot;&gt;Systemic Lupus Erythematosus&lt;/a&gt; by Robert G. Lahita, George Tsokos&lt;/p&gt;

&lt;h3 id=&quot;figure-from-powerpoint-sides&quot;&gt;Figure from powerpoint sides&lt;/h3&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;1.	LUPUS BUTTERFLY RASH&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image2.jpeg&quot;&gt;2.	LUPUS SKIN BIOPSY&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;3.	LUPUS SKIN BIOPSY, THICKENED BASEMENT MEMBRANE&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image4.jpeg&quot;&gt;4.	LUPUS BAND TEST, ANTI IgG STAIN&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;5. PERIPHERAL RIM PATTERN&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image6.jpeg&quot;&gt;6.	DIFFUSE PROLIFERATIVE LUPUS NEPHRITIS&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image7.jpeg&quot;&gt;7.	L.E. CELL PREPARATION&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Picture%20clipping.pictClipping&quot;&gt;8.	LIBMAN-SACKS ENDOCARDITIS&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;case-2&quot;&gt;Case 2&lt;/h2&gt;

&lt;h3 id=&quot;clinical-history&quot;&gt;CLINICAL HISTORY:&lt;/h3&gt;

&lt;p&gt;A 45-year-old white male previously diagnosed with a T cell leukemia developed skin rash, severe diarrhea and jaundice after receiving repeated blood transfusions.  The skin exhibited a fine, diffuse, erythematous, macular rash that began on the palms, soles and head and spread to the entire trunk as well as to extremities.  The rash became desquamative and resembled an extensive second-degree burn.  There was watery diarrhea associated with malabsorption, cramps and gastrointestinal bleeding.  Blood chemistry analysis revealed &lt;a href=&quot;p139&quot;&gt;hyperbilirubinemia&lt;/a&gt; and an elevated serum alkaline phosphatase level.  There was only a mild elevation in the alanine aminotransferase (ALT) and aspartate aminotransferase levels (AST).&lt;/p&gt;

&lt;h3 id=&quot;are-the-clinical-events-described-above-attributable-to-the-leukemia-process-or-to-some-other-factor&quot;&gt;1.	Are the clinical events described above attributable to the leukemia process or to some other factor?&lt;/h3&gt;
&lt;p&gt;To some other factor.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-most-likely-cause-of-the-signs-and-symptoms-described-in-this-patient&quot;&gt;2.	What is the most likely cause of the signs and symptoms described in this patient?&lt;/h3&gt;
&lt;p&gt;graft-versus-host diseases&lt;/p&gt;

&lt;h3 id=&quot;how-could-a-leukemia-patient-in-hospital-develop-signs-and-symptoms-of-graft-versus-host-disease&quot;&gt;3. How could a leukemia patient in hospital develop signs and symptoms of graft-versus-host disease?&lt;/h3&gt;
&lt;p&gt;GVHD occurs when immunologically competent cells are introduced into an immunoincompetent host. GVHD refers to the immunologic insult and to the consequences to the organism. The patient must have had a Hematopoietic cell transplation, Solid organ transplants, or blood transfusions.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-mechanism-of-the-skin-rash&quot;&gt;4. What is the mechanism of the skin rash?&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;from textbook&lt;/strong&gt;
It resemble those of SS (p139), In the early stages, affected skin areas are somewhat edematous and have a doughy consistency. Capillaries and small arteries (as large as 500 μm in diameter) may show thickening of the basal lamina, endothelial cell damage, and partial occlusion. With progression, the edema- tous phase is replaced by progressive fibrosis of the dermis, which becomes tightly bound to the subcutaneous structures. There is marked increase of compact collagen in the dermis along with thinning of the epidermis, atrophy of the dermal appendages, and hyaline thickening of the walls of dermal arterioles and capillaries (P133)&lt;/p&gt;

&lt;p&gt;or&lt;/p&gt;

&lt;p&gt;Skin — In most patients, the first (and most common) clinical manifestation of acute GVHD is a maculopapular rash, usually occurring at or near the time of the white blood cell engraftment (picture 1). The rash initially involves the nape of the neck, ears, shoulders, the palms of the hands (picture 2), and the soles of the feet. It can be described as a sunburn and may be pruritic or painful (picture 3). From these initial areas of presentation, the rash may spread to involve the whole integument, eventually becoming confluent. In severe GVHD, the maculopapular rash forms bullous lesions with toxic epidermal necrolysis mimicking Stevens-Johnson syndrome
&lt;a href=&quot;http://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-cause-of-the-hyperbilirubinemia&quot;&gt;5. What is the cause of the hyperbilirubinemia&lt;/h3&gt;
&lt;p&gt;Destruction of small bile ducts gives rise to jaundice, thus resulted in hyperbilirubinemia&lt;/p&gt;

&lt;h3 id=&quot;what-subset-of-t-lymphocytes-is-found-in-biopsies-of-skin-intestine-and-liver&quot;&gt;6. What subset of T lymphocytes is found in biopsies of skin, intestine and liver?&lt;/h3&gt;
&lt;p&gt;CD 4+ and CD 8+&lt;/p&gt;

&lt;h3 id=&quot;how-could-graft-versus-host-disease-be-prevented-in-patients-receiving-blood-transfusions&quot;&gt;7. How could graft-versus-host disease be prevented in patients receiving blood transfusions?&lt;/h3&gt;
&lt;p&gt;GVHD is a potentially lethal complication that can be minimized but not eliminated by HLA matching. As another potential solution, donor T cells can be depleted before marrow transplant.&lt;/p&gt;

&lt;h3 id=&quot;when-is-graft-versus-host-disease-most-often-observed&quot;&gt;8. When is graft-versus-host disease most often observed?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;Degree of mismatch between HLA types&lt;/li&gt;
  &lt;li&gt;“minor” histocompatibility antigens&lt;/li&gt;
  &lt;li&gt;Age – possible thymic influence&lt;/li&gt;
  &lt;li&gt;Germ free environment&lt;/li&gt;
  &lt;li&gt;Pre-treatment with cytotoxic drugs&lt;/li&gt;
  &lt;li&gt;Sex mismatch&lt;/li&gt;
  &lt;li&gt;Transfusion presensitization&lt;/li&gt;
&lt;/ul&gt;

&lt;ol&gt;
  &lt;li&gt;What types of GVH disease follow bone marrow transplantation?
The small bowel and colon are involved in most cases. Intestinal graft-versus-host disease often manifests as a watery diarrhea.&lt;/li&gt;
&lt;/ol&gt;

&lt;h3 id=&quot;figures&quot;&gt;figures&lt;/h3&gt;
&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.44.57.png&quot;&gt;1.	List of target tissues of acute G-V-H disease&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image9.jpeg&quot;&gt;2.	Baby with maculopapular rash of  G-V-H 	disease&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image10.jpeg&quot;&gt;3. 	Adult with acute G-V-H skin reaction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image11.jpeg&quot;&gt;4.	Micro–skin interface dermatitis with basal cell destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image12.jpeg&quot;&gt;5.	Micro–skin interface dermatitis with basal cell destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image13.jpeg&quot;&gt;6.	Micro–liver G-V-H with bile-duct injury and early cell infiltrate&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image14.jpeg&quot;&gt;7.	Micro-liver G-V-H, chronic with inflammation and fibrosis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image15.jpeg&quot;&gt;8.	Micro–enteritis in G-V-H in lower 1/3 of crypt, early&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image16.jpeg&quot;&gt;9.	Micro–enterocyte necrosis and crypt destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image17.jpeg&quot;&gt;10. Gross–intestinal G-V-H with bleeding and superinfection&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image18.jpeg&quot;&gt;11. Gross–intestinal G-V-H with intermittent involved areas&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image19.jpeg&quot;&gt;12. Gross–intestinal G-V-H with bleeding and 	superinfection&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image20.jpeg&quot;&gt;13. Gross–intestinal G-V-H with mucosal sloughing and scarring&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;case-3&quot;&gt;Case 3&lt;/h2&gt;

&lt;h3 id=&quot;clinical-history-1&quot;&gt;CLINICAL HISTORY:&lt;/h3&gt;

&lt;p&gt;A 60-year-old white male presented to his family physician with complaints of weakness, anorexia, weight loss and severe back pain.&lt;/p&gt;

&lt;h3 id=&quot;laboratory-and-x-ray-findings&quot;&gt;LABORATORY AND X-RAY FINDINGS:&lt;/h3&gt;

&lt;p&gt;Radiologic examination revealed  “punched out” &lt;a href=&quot;&quot;&gt;skeletal lesions&lt;/a&gt; with sharply demarcated margins in vertebral bodies, skull, ribs, and pelvis.  Blood chemistry showed hypercalcemia and hyperglobulinemia.  The serum globulin concentration was &lt;a href=&quot;http://www.drstandley.com/labvalues_proteins.shtml&quot;&gt;6.0 g/dl&lt;/a&gt;.  Both the serum and urine revealed a homogeneous protein by electrophoresis, which was identified as &lt;a href=&quot;p437&quot;&gt;IgA&lt;/a&gt;.  The urine contained free light chains.  The urinary protein was insoluble at acid pH between &lt;a href=&quot;http://basicprotein.blogspot.com/2012/11/tests-for-detection-of-bence-jones.html&quot;&gt;40º and 60ºC but redissolved at 95ºC.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Hematologic examination revealed a normochromic normocytic anemia with leukopenia and thrombocytopenia.  The blood smear revealed rouleaux formation of red cells.  There was an elevated sedimentation rate and marked plasma cell proliferation in the bone marrow.   Flow cytometric analysis of the bone marrow revealed an abnormal CD45 negative cell population that expressed CD38, CD56 and CD138 with cytoplasmic kappa light chain restriction.  This cell population was negative for CD19, CD20 and surface immunoglobulin.&lt;/p&gt;

&lt;p&gt;A renal biopsy was performed and revealed large numbers of eosinophilic lamellated casts in the renal tubules.  The tubular cells were markedly atrophic and contained hyaline droplets and some crystalline material. The glomeruli appeared normal, yet they were surrounded by interstitial fibrosis as a result of tubular destruction.  The patient received supportive therapy including local radiation therapy to relieve pain.  He experienced repeated bouts of respiratory infection with Streptococcus pneumoniae.  After reaching a diagnosis, cytotoxic therapy was instituted, yet the patient died within 12 months of diagnosis.&lt;/p&gt;

&lt;h3 id=&quot;what-information-provided-above-is-of-the-greatest-assistance-in-reaching-a-diagnosis-of-plasma-cell-multiple-myeloma-in-this-patient&quot;&gt;1. What information provided above is of the greatest assistance in reaching a diagnosis of plasma cell 	(multiple) myeloma in this patient?&lt;/h3&gt;

&lt;h3 id=&quot;why-did-this-patient-present-with-severe-back-pain&quot;&gt;2. Why did this patient present with severe back pain?&lt;/h3&gt;
&lt;p&gt;It is due to pathologic fractures. Pathologic fractures of vertebrae may lead to spinal cord impingement, an oncologic emergency.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-cause-of-the-punched-out-osteolytic-lesions&quot;&gt;3. What is the cause of the “punched out” osteolytic lesions?&lt;/h3&gt;

&lt;p&gt;Bone destruction by osteolytic lesions is caused by two separate events. Rapid growth of myeloma cells inhibits normal bone-forming cells, damaging bone. In addition, production of substances that activate the cells that resorb bone, called osteoclasts, is increased.&lt;/p&gt;

&lt;p&gt;The lesions generally arise in the medullary cavity, erode cancellous bone, and progressively destroy the cortical bone.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-significance-of-the-light-chain-proteinuria-described-in-this-patient&quot;&gt;4. What is the significance of the light chain proteinuria described in this patient.&lt;/h3&gt;
&lt;p&gt;Light chain deposition in the glomeruli or the interstitium, either as amyloid or linear deposits, also may contribute to renal dysfunction.&lt;/p&gt;

&lt;h3 id=&quot;since-the-patient-was-hypergammaglobulinemic-why-did-he-suffer-repeated-bouts-of-pneumococcal-infection&quot;&gt;5. Since the patient was hypergammaglobulinemic, why did he suffer repeated bouts of pneumococcal infection?&lt;/h3&gt;

&lt;p&gt;Patients with myeloma are immunosuppressed. Through uncertain mechanisms, myeloma cells interfere with the function of normal plasma cells, leading to defects in antibody production. Thus, although the plasma usually contains increased immunoglobulin owing to the pres- ence of an M protein, the levels of functional antibodies often are profoundly depressed, leaving patients at high risk for bacterial infections. (p438)&lt;/p&gt;

&lt;h3 id=&quot;which-part-of-the-skeletal-system-is-most-frequently-affected-in-plasma-cell-myeloma&quot;&gt;6. Which part of the skeletal system is most frequently affected in plasma cell myeloma?&lt;/h3&gt;

&lt;p&gt;Multiple myeloma usually manifests with multifocal destructive skeletal lesions, which most commonly involve the vertebral column, ribs, skull, pelvis, femur, clavicle, and scapula. The lesions generally arise in the medullary cavity, erode cancellous bone, and progressively destroy the cortical bone.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-differential-diagnosis-of-plasma-cell-myeloma&quot;&gt;7. What is the differential diagnosis of plasma cell 	myeloma?&lt;/h3&gt;

&lt;p&gt;The main differential is that of widespread bony metastases. Findings that favour the diagnosis of bony metastases over that of multiple myeloma include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;more commonly affect the vertebral pedicles rather than vertebral bodies&lt;/li&gt;
  &lt;li&gt;rarely involve mandible, distal axial skeleton&lt;/li&gt;
  &lt;li&gt;although both entities have variable bone scan appearances (both hot and cold) unlike myeloma, extensive bony metastases rarely have a normal appearance&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Other rare entities include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Waldenstrom macroglonulinaemia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://radiopaedia.org/articles/multiple-myeloma-1&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;which-immunoglobulins-may-be-increased-in-plasma-cell-myeloma&quot;&gt;8. Which immunoglobulins may be increased in plasma cell myeloma?&lt;/h3&gt;

&lt;p&gt;he most frequent M protein produced by myeloma cells is IgG (60%), followed by IgA (20% to 25%); only rarely are IgM, IgD, or IgE M proteins observed.&lt;/p&gt;

&lt;h3 id=&quot;do-all-cases-of-plasma-cell-myeloma-have-the-monoclonal-serum-paraprotein-identifiable-electrophoresis&quot;&gt;9. Do all cases of plasma cell myeloma have the monoclonal serum paraprotein identifiable 	electrophoresis?&lt;/h3&gt;

&lt;p&gt;Electrophoresis of the serum and urine is an important diagnostic tool. In 99% of cases, either a monoclonal com- plete immunoglobulin or a monoclonal free immunoglobu- lin light chain is present in the serum, the urine, or both&lt;/p&gt;

&lt;p&gt;Because these immunoglobulins can be detected in the serum, these disorders are also referred to as monoclonal gammopathies, and the associated immuno- globulin is often referred to as an M protein&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;What is the meaning of the results of flow cytometric analysis of the bone marrow.&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;figures&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image21.jpeg&quot;&gt;1.	Plasma cell in smear&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image22.jpeg&quot;&gt;2.	Plasma cell (drawing)&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image23.jpeg&quot;&gt;3.	Plasma cell cluster in smear&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image24.jpeg&quot;&gt;4.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image25.jpeg&quot;&gt;5.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image26.jpeg&quot;&gt;6.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image27.jpeg&quot;&gt;7.	Gross of rib with protruding plasma cell proliferation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image28.jpeg&quot;&gt;8.	Gross of osteolytic lesions of skull in plasma cell myeloma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image29.jpeg&quot;&gt;9.	X-rays of osteolytic lesions of skull in plasma cell myeloma&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Graphing with Stata Part I</title>
   <link href="http://lanyon.getpoole.com/2015/08/24/graphing_with_stata/"/>
   <updated>2015-08-24T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/24/graphing_with_stata</id>
   <content type="html">&lt;p&gt;Analytical graphics have always been one of Stata’s strengths, and reason enough for many users to choose Stata over other packages. Attractive and publishable basic graphs are easy to draw, using commands or choices from the menus under Graphics. Users who imagine more elaborate or creative graphs will find their efforts supported by an impressive array of tools and options, described in the Graphics Reference Manual, and illustrated by many examples in A Visual Guide to Stata Graphics (Mitchell 2012).
&lt;!--break--&gt;
 The above statement was taken from&lt;a href=&quot;http://www.stata.com/bookstore/statistics-with-stata/&quot;&gt;2012 Statistics with Stata 12-8&lt;/a&gt;
 by Lawrence C. Hamilton and it shows how important it is to develop good statistical graphing skills as a statistican. In this tutorial series, I will share how to use some of the most useful graphing techinques with Stata and I hope it is helpful to you. Let’s get started and go through some examples one by one and you can also download the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/stata%20blog/log/graphing.do&quot;&gt;do file&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;import-and-explore-the-data-set&quot;&gt;Import and explore the data set&lt;/h2&gt;
&lt;p&gt;We use the data set &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/stata%20blog/Nations2.dta&quot;&gt;Nations2.dta&lt;/a&gt; in this tutorial, you could either download it and manually import it to Stata or you can simply use the following code to import the data set.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;use https://dl.dropboxusercontent.com/u/49272502/stata%20blog/Nations2.dta, clear&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;Next, use describe have an idea how the data looks like.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;describe&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;histogram&quot;&gt;Histogram&lt;/h3&gt;

&lt;p&gt;First, let’s plot a basic histogram for the variable adfert, which stands for adolescent fertility rate.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;histogram adfert, percent&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/hist1.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Looking at the result, we can tell that the distribution is positively skew, with a mode not far above 0 and upper limit around 200. However, it is hard to describe the graph more specifically because the bars do not line up with the x axis tick marks. We can do a little improvement with the &lt;em&gt;options&lt;/em&gt; , for example&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;frequency&lt;/strong&gt; 	Frequencies are shown on the vertical (y) axis.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;start(0)&lt;/strong&gt;	The histogram’s first bar (bin) starts at 0.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;width(10)&lt;/strong&gt;	The width of each bar (bin) is 10.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;xlabel(0(20)200)&lt;/strong&gt;	The x axis is labeled from 0 to 200, in increments of 20.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;xtick(10(20)210)&lt;/strong&gt;	The x axis has tick marks from 10 to 210, in increments of 20.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;ylabel(0(5)35, grid gmax)&lt;/strong&gt; The y axis is labeled from 0 to 35, in increments of 5. A grid of horizontal lines is drawn, including a * line at the maximum value.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;title(“Adolescent fertility rate in 194 nations”)&lt;/strong&gt; 	The graph has a title at top.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;You can put all of the above items together in the following fashion&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;histogram adfert, frequency start(0) width(10) xlabel(0(20)200) xtick(10(20)210)
ylabel(0(5)35, grid gmax)
title(&amp;quot;Adolescent fertility rate in 194 nations&amp;quot;)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/hist2.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;How, we can see the improved result describes the distribution more specifically. For example, we now see that in 34 nations, the adolescent fertility rates are between 10 and 20. You can type &lt;strong&gt;help histogram&lt;/strong&gt; in stata console to learn more about histogram plotting.&lt;/p&gt;

&lt;p&gt;To explore the variable &lt;em&gt;adfert&lt;/em&gt; further, we can use a &lt;strong&gt;by&lt;/strong&gt;(varname) option. For example, if we want to illustrate with histograms of &lt;em&gt;adfert&lt;/em&gt; for each of the five regions, along with a sixth &lt;strong&gt;(total)&lt;/strong&gt; histogram showing the distribution for all nations. We can use the following code&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;histogram adfert, percent start(0) width(10) by(region, total)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/hist3.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Next, we explore the Box Plots&lt;/p&gt;

&lt;h3 id=&quot;box-plots&quot;&gt;Box Plots&lt;/h3&gt;

&lt;p&gt;Box plots convey information about center, spread, symmetry and outliers at a glance. For example&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph box adfert&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/box1.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;The result confirms the positive skew of this distribution, and shows five high outliers. The box plot extends from approximately 1st to third quartiles, a distance called the interquartile range (IQR).&lt;/p&gt;

&lt;p&gt;If we want to identify the adfert outliers by with labels, we can add a &lt;strong&gt;marker&lt;/strong&gt; option as follow.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph box adfert, marker(1, mlabel(country)) ytitle(&amp;quot;Births per 1,000 females 15-19&amp;quot;)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/box2.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Now, if we want to compare the distributions of &lt;em&gt;adfert&lt;/em&gt; from all 5 regions with a baseline, for instance 40, as well as labelling the outliers with their country names. We can use the option &lt;strong&gt;over&lt;/strong&gt; and the &lt;strong&gt;yline()&lt;/strong&gt; as following.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph box adfert, marker(1, mlabel(country)) yline(39.3) over(region)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/box3.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;We can also plot the boxplots horizontally by using the command &lt;strong&gt;hbox&lt;/strong&gt;&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph hbox co2, over(region)
note(&amp;quot;note: {bf:Statistics with Stata}, version 12&amp;quot;) caption(&amp;quot;caption: United Nations Human Development Report 2011&amp;quot;) title(&amp;quot;title: {it:Example of horizontal box plots}&amp;quot;) ytitle(&amp;quot;ytitle: Tons of CO{subscript:2} emitted per capita&amp;quot;)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/box4.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Note that individual outliers are not labeled in the figure because they would be hard to read in the horizontal format. To explore more about boxplot you can type &lt;strong&gt;help graph box&lt;/strong&gt; in the console. Now, we are going to explore Scatterplots and Overlays&lt;/p&gt;

&lt;h3 id=&quot;scatterplots-and-overlays&quot;&gt;Scatterplots and Overlays&lt;/h3&gt;

&lt;p&gt;Stata’s basic scatterplot command has the form&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph twoway scatter y x&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;Now, let’s make a twoway scatterplot with the variable &lt;strong&gt;life&lt;/strong&gt; and &lt;strong&gt;school&lt;/strong&gt;&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph twoway scatter life school&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter1.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;To make thing more interesting, we can manipulate the &lt;strong&gt;frequency weight feature&lt;/strong&gt; with &lt;strong&gt;[fweight = varname]&lt;/strong&gt; as follow&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph twoway scatter life school [fweight=pop], msymbol(Oh)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter2.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;The result is simply a redrawn scatterplot of &lt;em&gt;life&lt;/em&gt; againist &lt;em&gt;school&lt;/em&gt;, but make the symbol size reflect each country’s population &lt;em&gt;pop&lt;/em&gt;. Note that it also include &lt;strong&gt;msymbol(Oh)&lt;/strong&gt; to change the default dot from the previous scatterplot into &lt;em&gt;hollow circle&lt;/em&gt;.&lt;/p&gt;

&lt;p&gt;Now, let’s explore a key feature of Stata’s graph twoway family, that is we can overlay two or more graphs to build a more complex images. For example, we can plot a regression lines **lfit) on top of the scatter plot.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;twoway (scatter life school, msymbol(Oh))(lfit life school, lwidth(medthick))&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter3.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;We can also add x and y labels and tick mark as well as legend, for example&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;twoway (scatter life school, msymbol(Oh))(lfit life school, lwidth(medthick)ylabel(45(5)85) xlabel(2(2)12) xtick(1(2)13) legend(col(1) ring(0) position(11)))&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter4.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;note
The &lt;em&gt;legend option&lt;/em&gt; in the figure specifies three things:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;col(1)&lt;/strong&gt; The legend should have just one column, and hence two rows.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;ring(0)&lt;/strong&gt; The legend is placed within the plot region, instead of outside it.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;position(11)&lt;/strong&gt; The legend goes at the &lt;em&gt;11 o’clock position&lt;/em&gt;, which in this graph happens to
be empty of data.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Finally, let’s try to graph a more advanced regression scatterplot shows also the confident bands for the &lt;em&gt;conditonal mean of y&lt;/em&gt;.  We can do so with the command &lt;strong&gt;lfitci&lt;/strong&gt; and &lt;strong&gt;stdp&lt;/strong&gt;. note that the &lt;em&gt;ci&lt;/em&gt; in &lt;strong&gt;lfitci&lt;/strong&gt; refers to &lt;em&gt;confident interval&lt;/em&gt; and &lt;strong&gt;stdp&lt;/strong&gt; refers to standard erors for the conditional mean as “standard deviation of prediction”&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;twoway (lfitci life school, stdp)(scatter life school, msymbol(Th))(scatter life school if school &amp;gt; 8 &amp;amp; life &amp;lt; 55, msymbol(S) mlabel(country)legend(col(1) ring(0) position(11) label(3 &amp;quot;Life expectancy&amp;quot;)order(3 2 1)))&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter5.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;From the result, we see that normal data points are plotted as hollow triangles and the two outliers are solid squares. This can be accomplished by the option &lt;strong&gt;msymbol(Th)&lt;/strong&gt; and &lt;strong&gt;msymbol(S)&lt;/strong&gt; and you can type &lt;strong&gt;help scatter&lt;/strong&gt; to learn more about the other options.&lt;/p&gt;

&lt;p&gt;Lastly, we wrap up this tutorial with introducing the &lt;strong&gt;scatterplot matrices&lt;/strong&gt;. Scatterplot matrices are different from other twoway plots types that it can not be overlaid. Nevertheless, it is possible to include multiple plots in a single plot and it follows the same marker symbol conventions. Let’s create an example.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph matrix gdp school adfert chldmort life, half msymbol(oh)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter6.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;From the result, we see that scatterplot mattrix is the visual counterpart to a correlation mattrix, which is very helpful tool for multivariate analysis. It shows the relationships between variables pairs and thus helpful for the detection of &lt;strong&gt;nonlinear relationships&lt;/strong&gt;. For instance, the scatterplot matrix above shows that &lt;em&gt;gdp&lt;/em&gt; (per capita Gross Domestic Product) seems to be nonlinearly distributed and we could not have detected this pattern through correlation matrix alone. You can type &lt;strong&gt;help graph matrix&lt;/strong&gt; to learn more about scatterplot mattrix.&lt;/p&gt;

&lt;p&gt;Congradulation, now you have completed part I of this tutorial and in part II we will explore &lt;strong&gt;Line Plots and Connected-Line Plots&lt;/strong&gt;. Thank you for sticking around and please leave your comment and advise so that I can imporve it.&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Use Slidify to create cool slides</title>
   <link href="http://lanyon.getpoole.com/2015/08/21/using-slidify/"/>
   <updated>2015-08-21T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/21/using-slidify</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;https://github.com/ramnathv/slidify/issues/407&quot;&gt;Slidify error with update to stringr&lt;/a&gt;
install_github(‘ramnathv/slidify’, ref = github_pull(425))&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>How to create your web Gravatar</title>
   <link href="http://lanyon.getpoole.com/2015/08/20/making-your-gravatar/"/>
   <updated>2015-08-20T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/20/making-your-gravatar</id>
   <content type="html">&lt;p&gt;Gravatar is such a handy tool that has many applications and can save you a lot of time and make things pretty. You can check out &lt;a href=&quot;https://en.gravatar.com/&quot;&gt;Gravatar&lt;/a&gt; to learn all the details. The objective of this post is to show you how you can use your gravatar ID for your blog or website built by &lt;a href=&quot;http://jekyllrb.com/&quot;&gt;Jekyll&lt;/a&gt; the static site generator, in order to show your ownership of your site. &lt;!--break--&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;First, register a &lt;a href=&quot;https://en.gravatar.com/&quot;&gt;Gravatar&lt;/a&gt; account and following all the instruction to set up your account.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In order for Gravatar to work on your blog, you need to create a Hash for your Gravatar ID, and you can learn more about this from &lt;a href=&quot;http://en.gravatar.com/site/implement/hash/&quot;&gt;Create the Hash&lt;/a&gt;. But if you do not know PHP and want to speed thing up, you can use this trick I will show you here. First, you need to use &lt;a href=&quot;https://en.wikipedia.org/wiki/MD5&quot;&gt;a MD5 Encoder&lt;/a&gt; to encode your gravatar email account address. To do so go to &lt;a href=&quot;http://7thspace.com/webmaster_tools/online_md5_encoder.html&quot;&gt;7th Space&lt;/a&gt; and key in your registered email for Gravatar to get your MD5 Hash. It should look something like this&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;{&amp;quot;f9879d71855b5ff21e4963273a886bfc&amp;quot;}&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

</content>
 </entry>
 
 <entry>
   <title>Step by Step of building a Jekyll blog</title>
   <link href="http://lanyon.getpoole.com/2015/08/19/Jekyll-tutorial/"/>
   <updated>2015-08-19T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/19/Jekyll-tutorial</id>
   <content type="html">&lt;p&gt;So when I learned about Jekyll, it seemed like a great alternative. I like the idea that my entire blog is a set of static files. Besides its simplicity, it makes backups so much easier and avoids most common security concerns caused by running dynamic websites. I could write my posts in Markdown which I know from Confluence and GitHub. Also, Jekyll allows for code examples to be very nicely embedded in the website. Finally, Jekyll is very lightweight and allows for very minimal websites without any bloat.
&lt;!--break--&gt;
The fact that GitHub provides free hosting for Jekyll blogs is just icing on the cake. It will save me ~$50 per year in hosting. GitHub provides automatic version control of my blog. I can use GitHub’s web editor to write blog posts online. And I can still connect it to my custom domain (joshualande.com).&lt;/p&gt;

&lt;h2 id=&quot;set-up-disqus-comments&quot;&gt;Set up Disqus Comments&lt;/h2&gt;
&lt;p&gt;If you want to add a comment function to you blog, you can following the following steps&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;1: Go to&lt;a href=&quot;https://disqus.com&quot;&gt;DISQUS&lt;/a&gt; and register an account, then following the instuction there to add Disqus to your site and it will give you unique code to use for your site, save the code for later use.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;2: Modify the file&lt;a href=&quot;https://github.com/JizongL/jizongL.github.io/blob/master/_layouts/default.html&quot;&gt;_layouts/default.html&lt;/a&gt; in your 
layouts folder by including the following line after &lt;strong&gt;comment&lt;/strong&gt; in the default code.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&lt;span class=&quot;p&quot;&gt;{{&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;content&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;}}&lt;/span&gt;
&lt;span class=&quot;p&quot;&gt;{%&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nt&quot;&gt;include&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;comments.html&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;%}&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;ul&gt;
  &lt;li&gt;3: Next create a file &lt;a href=&quot;https://github.com/JizongL/jizongL.github.io/blob/master/_includes/comments.html&quot;&gt;_includes/comments.html&lt;/a&gt;     and paste the code given to me by Disqus as follow:&lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&lt;span class=&quot;p&quot;&gt;{%&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;kr&quot;&gt;if&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;page&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;.&lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;comments&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;%}&lt;/span&gt;
&amp;lt;!-- Add Disqus comments. --&amp;gt;
&amp;lt;div id=&amp;quot;disqus_thread&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;
&amp;lt;script type=&amp;quot;text/javascript&amp;quot;&amp;gt;
  /* * * CONFIGURATION VARIABLES: EDIT BEFORE PASTING INTO YOUR WEBPAGE * * */
  var disqus_shortname = &amp;#39;&amp;lt;USERNAME&amp;gt;&amp;#39;; // required: replace example with your forum shortname
  var disqus_identifier = &amp;quot;&lt;span class=&quot;p&quot;&gt;{{&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;site&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;.&lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;disqusid&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;}}{{&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;page&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;.&lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;url&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;|&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nf&quot;&gt;replace&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;:&lt;/span&gt;&lt;span class=&quot;s1&quot;&gt;&amp;#39;index.html&amp;#39;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt;&lt;span class=&quot;s1&quot;&gt;&amp;#39;&amp;#39;&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;}}&lt;/span&gt;&lt;span class=&quot;nf&quot;&gt;&amp;quot;;&lt;/span&gt;&lt;span class=&quot;w&quot;&gt;&lt;/span&gt;

&lt;span class=&quot;w&quot;&gt;  &lt;/span&gt;/*&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;*&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;*&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;DON&lt;span class=&quot;s1&quot;&gt;&amp;#39;T EDIT BELOW THIS LINE * * */&lt;/span&gt;
&lt;span class=&quot;s1&quot;&gt;  (function() {&lt;/span&gt;
&lt;span class=&quot;s1&quot;&gt;    var dsq = document.createElement(&amp;#39;&lt;/span&gt;script&lt;span class=&quot;s1&quot;&gt;&amp;#39;); dsq.type = &amp;#39;&lt;/span&gt;text/javascript&lt;span class=&quot;s1&quot;&gt;&amp;#39;; dsq.async = true;&lt;/span&gt;
&lt;span class=&quot;s1&quot;&gt;    dsq.src = &amp;#39;&lt;/span&gt;//&lt;span class=&quot;s1&quot;&gt;&amp;#39; + disqus_shortname + &amp;#39;&lt;/span&gt;.disqus.com/embed.js&lt;span class=&quot;s1&quot;&gt;&amp;#39;;&lt;/span&gt;
&lt;span class=&quot;s1&quot;&gt;    (document.getElementsByTagName(&amp;#39;&lt;/span&gt;head&lt;span class=&quot;s1&quot;&gt;&amp;#39;)[0] || document.getElementsByTagName(&amp;#39;&lt;/span&gt;body&amp;#39;)[&lt;span class=&quot;mi&quot;&gt;0&lt;/span&gt;]).appendChild(dsq);
  })();
&amp;lt;/script&amp;gt;
&amp;lt;noscript&amp;gt;Please enable JavaScript to view the &amp;lt;a href=&amp;quot;http://disqus.com/?ref_noscript&amp;quot;&amp;gt;comments powered by Disqus.&amp;lt;/a&amp;gt;&amp;lt;/noscript&amp;gt;
&amp;lt;a href=&amp;quot;http://disqus.com&amp;quot; class=&amp;quot;dsq-brlink&amp;quot;&amp;gt;comments powered by &amp;lt;span class=&amp;quot;logo-disqus&amp;quot;&amp;gt;Disqus&amp;lt;/span&amp;gt;&amp;lt;/a&amp;gt;
&lt;span class=&quot;p&quot;&gt;{%&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;kr&quot;&gt;endif&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;%}&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;enabling-google-analytics&quot;&gt;Enabling Google Analytics&lt;/h2&gt;

&lt;p&gt;This is very straightforward and follows the same pattern as setting up the Disqus comments. Go to the &lt;a href=&quot;http://www.google.com/analytics/&quot;&gt;Google Analytics&lt;/a&gt; sign up for an account if you don’t have one already, use universal tracking and copy the code that they provide. Create a file in the &lt;code&gt;_includes&lt;/code&gt; folder and name it something like &lt;code&gt;google_analytics.html&lt;/code&gt;. &lt;!--break--&gt;
Paste in the code Google gave you and save the file. Now all that’s left is to open &lt;code&gt;layouts/default.html&lt;/code&gt; and add the following line:&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&lt;span class=&quot;p&quot;&gt;{%&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nt&quot;&gt;include&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;google_analytics.html&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;%}&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;a href=&quot;https://truongtx.me/2013/04/05/google-analytics-for-jekyll-bootstrap/&quot;&gt;Google Analytics&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Example content</title>
   <link href="http://lanyon.getpoole.com/2014/01/01/example-content/"/>
   <updated>2014-01-01T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/2014/01/01/example-content</id>
   <content type="html">&lt;div class=&quot;message&quot;&gt;
  Howdy! This is an example blog post that shows several types of HTML content supported in this theme.
&lt;/div&gt;

&lt;p&gt;Cum sociis natoque penatibus et magnis &lt;a href=&quot;#&quot;&gt;dis parturient montes&lt;/a&gt;, nascetur ridiculus mus. &lt;em&gt;Aenean eu leo quam.&lt;/em&gt; Pellentesque ornare sem lacinia quam venenatis vestibulum. Sed posuere consectetur est at lobortis. Cras mattis consectetur purus sit amet fermentum.&lt;/p&gt;

&lt;blockquote&gt;
  &lt;p&gt;Curabitur blandit tempus porttitor. Nullam quis risus eget urna mollis ornare vel eu leo. Nullam id dolor id nibh ultricies vehicula ut id elit.&lt;/p&gt;
&lt;/blockquote&gt;

&lt;!--break--&gt;

&lt;p&gt;Etiam porta &lt;strong&gt;sem malesuada magna&lt;/strong&gt; mollis euismod. Cras mattis consectetur purus sit amet fermentum. Aenean lacinia bibendum nulla sed consectetur.&lt;/p&gt;

&lt;h2 id=&quot;inline-html-elements&quot;&gt;Inline HTML elements&lt;/h2&gt;

&lt;p&gt;HTML defines a long list of available inline tags, a complete list of which can be found on the &lt;a href=&quot;https://developer.mozilla.org/en-US/docs/Web/HTML/Element&quot;&gt;Mozilla Developer Network&lt;/a&gt;.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;To bold text&lt;/strong&gt;, use &lt;code&gt;&amp;lt;strong&amp;gt;&lt;/code&gt;.&lt;/li&gt;
  &lt;li&gt;&lt;em&gt;To italicize text&lt;/em&gt;, use &lt;code&gt;&amp;lt;em&amp;gt;&lt;/code&gt;.&lt;/li&gt;
  &lt;li&gt;Abbreviations, like &lt;abbr title=&quot;HyperText Markup Langage&quot;&gt;HTML&lt;/abbr&gt; should use &lt;code&gt;&amp;lt;abbr&amp;gt;&lt;/code&gt;, with an optional &lt;code&gt;title&lt;/code&gt; attribute for the full phrase.&lt;/li&gt;
  &lt;li&gt;Citations, like &lt;cite&gt;— Mark otto&lt;/cite&gt;, should use &lt;code&gt;&amp;lt;cite&amp;gt;&lt;/code&gt;.&lt;/li&gt;
  &lt;li&gt;&lt;del&gt;Deleted&lt;/del&gt; text should use &lt;code&gt;&amp;lt;del&amp;gt;&lt;/code&gt; and &lt;ins&gt;inserted&lt;/ins&gt; text should use &lt;code&gt;&amp;lt;ins&amp;gt;&lt;/code&gt;.&lt;/li&gt;
  &lt;li&gt;Superscript &lt;sup&gt;text&lt;/sup&gt; uses &lt;code&gt;&amp;lt;sup&amp;gt;&lt;/code&gt; and subscript &lt;sub&gt;text&lt;/sub&gt; uses &lt;code&gt;&amp;lt;sub&amp;gt;&lt;/code&gt;.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Most of these elements are styled by browsers with few modifications on our part.&lt;/p&gt;

&lt;h2 id=&quot;heading&quot;&gt;Heading&lt;/h2&gt;

&lt;p&gt;Vivamus sagittis lacus vel augue rutrum faucibus dolor auctor. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Morbi leo risus, porta ac consectetur ac, vestibulum at eros.&lt;/p&gt;

&lt;h3 id=&quot;code&quot;&gt;Code&lt;/h3&gt;

&lt;p&gt;Cum sociis natoque penatibus et magnis dis &lt;code&gt;code element&lt;/code&gt; montes, nascetur ridiculus mus.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-js&quot; data-lang=&quot;js&quot;&gt;&lt;span class=&quot;c1&quot;&gt;// Example can be run directly in your JavaScript console&lt;/span&gt;

&lt;span class=&quot;c1&quot;&gt;// Create a function that takes two arguments and returns the sum of those arguments&lt;/span&gt;
&lt;span class=&quot;kd&quot;&gt;var&lt;/span&gt; &lt;span class=&quot;nx&quot;&gt;adder&lt;/span&gt; &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;k&quot;&gt;new&lt;/span&gt; &lt;span class=&quot;nb&quot;&gt;Function&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s2&quot;&gt;&amp;quot;a&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;s2&quot;&gt;&amp;quot;b&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;s2&quot;&gt;&amp;quot;return a + b&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;);&lt;/span&gt;

&lt;span class=&quot;c1&quot;&gt;// Call the function&lt;/span&gt;
&lt;span class=&quot;nx&quot;&gt;adder&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;mi&quot;&gt;2&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;mi&quot;&gt;6&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;);&lt;/span&gt;
&lt;span class=&quot;c1&quot;&gt;// &amp;gt; 8&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;Aenean lacinia bibendum nulla sed consectetur. Etiam porta sem malesuada magna mollis euismod. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa.&lt;/p&gt;

&lt;h3 id=&quot;lists&quot;&gt;Lists&lt;/h3&gt;

&lt;p&gt;Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Aenean lacinia bibendum nulla sed consectetur. Etiam porta sem malesuada magna mollis euismod. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Praesent commodo cursus magna, vel scelerisque nisl consectetur et.&lt;/li&gt;
  &lt;li&gt;Donec id elit non mi porta gravida at eget metus.&lt;/li&gt;
  &lt;li&gt;Nulla vitae elit libero, a pharetra augue.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Donec ullamcorper nulla non metus auctor fringilla. Nulla vitae elit libero, a pharetra augue.&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;Vestibulum id ligula porta felis euismod semper.&lt;/li&gt;
  &lt;li&gt;Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.&lt;/li&gt;
  &lt;li&gt;Maecenas sed diam eget risus varius blandit sit amet non magna.&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;Cras mattis consectetur purus sit amet fermentum. Sed posuere consectetur est at lobortis.&lt;/p&gt;

&lt;dl&gt;
  &lt;dt&gt;HyperText Markup Language (HTML)&lt;/dt&gt;
  &lt;dd&gt;The language used to describe and define the content of a Web page&lt;/dd&gt;

  &lt;dt&gt;Cascading Style Sheets (CSS)&lt;/dt&gt;
  &lt;dd&gt;Used to describe the appearance of Web content&lt;/dd&gt;

  &lt;dt&gt;JavaScript (JS)&lt;/dt&gt;
  &lt;dd&gt;The programming language used to build advanced Web sites and applications&lt;/dd&gt;
&lt;/dl&gt;

&lt;p&gt;Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Nullam quis risus eget urna mollis ornare vel eu leo.&lt;/p&gt;

&lt;h3 id=&quot;tables&quot;&gt;Tables&lt;/h3&gt;

&lt;p&gt;Aenean lacinia bibendum nulla sed consectetur. Lorem ipsum dolor sit amet, consectetur adipiscing elit.&lt;/p&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th&gt;Name&lt;/th&gt;
      &lt;th&gt;Upvotes&lt;/th&gt;
      &lt;th&gt;Downvotes&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tfoot&gt;
    &lt;tr&gt;
      &lt;td&gt;Totals&lt;/td&gt;
      &lt;td&gt;21&lt;/td&gt;
      &lt;td&gt;23&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tfoot&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Alice&lt;/td&gt;
      &lt;td&gt;10&lt;/td&gt;
      &lt;td&gt;11&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Bob&lt;/td&gt;
      &lt;td&gt;4&lt;/td&gt;
      &lt;td&gt;3&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Charlie&lt;/td&gt;
      &lt;td&gt;7&lt;/td&gt;
      &lt;td&gt;9&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;Nullam id dolor id nibh ultricies vehicula ut id elit. Sed posuere consectetur est at lobortis. Nullam quis risus eget urna mollis ornare vel eu leo.&lt;/p&gt;

&lt;hr /&gt;

&lt;p&gt;Want to see something else added? &lt;a href=&quot;https://github.com/poole/poole/issues/new&quot;&gt;Open an issue.&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Introducing Lanyon</title>
   <link href="http://lanyon.getpoole.com/2014/01/01/Introducing-Lanyon/"/>
   <updated>2014-01-01T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/2014/01/01/Introducing-Lanyon</id>
   <content type="html">&lt;p&gt;Lanyon is an unassuming &lt;a href=&quot;http://jekyllrb.com&quot;&gt;Jekyll&lt;/a&gt; theme that places content first by tucking away navigation in a hidden drawer. It’s based on &lt;a href=&quot;http://getpoole.com&quot;&gt;Poole&lt;/a&gt;, the Jekyll butler.&lt;/p&gt;

&lt;h3 id=&quot;built-on-poole&quot;&gt;Built on Poole&lt;/h3&gt;

&lt;p&gt;Poole is the Jekyll Butler, serving as an upstanding and effective foundation for Jekyll themes by &lt;a href=&quot;https://twitter.com/mdo&quot;&gt;@mdo&lt;/a&gt;. Poole, and every theme built on it (like Lanyon here) includes the following:&lt;/p&gt;

&lt;!--break--&gt;

&lt;ul&gt;
  &lt;li&gt;Complete Jekyll setup included (layouts, config, &lt;a href=&quot;/404&quot;&gt;404&lt;/a&gt;, &lt;a href=&quot;/atom.xml&quot;&gt;RSS feed&lt;/a&gt;, posts, and &lt;a href=&quot;/about&quot;&gt;example page&lt;/a&gt;)&lt;/li&gt;
  &lt;li&gt;Mobile friendly design and development&lt;/li&gt;
  &lt;li&gt;Easily scalable text and component sizing with &lt;code&gt;rem&lt;/code&gt; units in the CSS&lt;/li&gt;
  &lt;li&gt;Support for a wide gamut of HTML elements&lt;/li&gt;
  &lt;li&gt;Related posts (time-based, because Jekyll) below each post&lt;/li&gt;
  &lt;li&gt;Syntax highlighting, courtesy Pygments (the Python-based code snippet highlighter)&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;lanyon-features&quot;&gt;Lanyon features&lt;/h3&gt;

&lt;p&gt;In addition to the features of Poole, Lanyon adds the following:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Toggleable sliding sidebar (built with only CSS) via &lt;strong&gt;☰&lt;/strong&gt; link in top corner&lt;/li&gt;
  &lt;li&gt;Sidebar includes support for textual modules and a dynamically generated navigation with active link support&lt;/li&gt;
  &lt;li&gt;Two orientations for content and sidebar, default (left sidebar) and &lt;a href=&quot;https://github.com/poole/lanyon#reverse-layout&quot;&gt;reverse&lt;/a&gt; (right sidebar), available via &lt;code&gt;&amp;lt;body&amp;gt;&lt;/code&gt; classes&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;https://github.com/poole/lanyon#themes&quot;&gt;Eight optional color schemes&lt;/a&gt;, available via &lt;code&gt;&amp;lt;body&amp;gt;&lt;/code&gt; classes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://github.com/poole/lanyon#readme&quot;&gt;Head to the readme&lt;/a&gt; to learn more.&lt;/p&gt;

&lt;h3 id=&quot;browser-support&quot;&gt;Browser support&lt;/h3&gt;

&lt;p&gt;Lanyon is by preference a forward-thinking project. In addition to the latest versions of Chrome, Safari (mobile and desktop), and Firefox, it is only compatible with Internet Explorer 9 and above.&lt;/p&gt;

&lt;h3 id=&quot;download&quot;&gt;Download&lt;/h3&gt;

&lt;p&gt;Lanyon is developed on and hosted with GitHub. Head to the &lt;a href=&quot;https://github.com/poole/lanyon&quot;&gt;GitHub repository&lt;/a&gt; for downloads, bug reports, and features requests.&lt;/p&gt;

&lt;p&gt;Thanks!&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>What's Jekyll?</title>
   <link href="http://lanyon.getpoole.com/2013/12/31/whats-jekyll/"/>
   <updated>2013-12-31T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/2013/12/31/whats-jekyll</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;http://jekyllrb.com&quot;&gt;Jekyll&lt;/a&gt; is a static site generator, an open-source tool for creating simple yet powerful websites of all shapes and sizes. From &lt;a href=&quot;https://github.com/mojombo/jekyll/blob/master/README.markdown&quot;&gt;the project’s readme&lt;/a&gt;:&lt;/p&gt;

&lt;!--break--&gt;

&lt;blockquote&gt;
  &lt;p&gt;Jekyll is a simple, blog aware, static site generator. It takes a template directory […] and spits out a complete, static website suitable for serving with Apache or your favorite web server. This is also the engine behind GitHub Pages, which you can use to host your project’s page or blog right here from GitHub.&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt;It’s an immensely useful tool and one we encourage you to use here with Lanyon.&lt;/p&gt;

&lt;p&gt;Find out more by &lt;a href=&quot;https://github.com/mojombo/jekyll&quot;&gt;visiting the project on GitHub&lt;/a&gt;.&lt;/p&gt;
</content>
 </entry>
 

</feed>
